MDR_REPORT_KEY|MDR_TEXT_KEY|TEXT_TYPE_CODE|PATIENT_SEQUENCE_NUMBER|DATE_REPORT|FOI_TEXT|BRAND_NAME|CATALOG_NUMBER|DATE_RECEIVED|DATE_REMOVED_FLAG|DATE_RETURNED_TO_MANUFACTURER|DEVICE_AGE_TEXT|DEVICE_AVAILABILITY|DEVICE_EVALUATED_BY_MANUFACTUR|DEVICE_EVENT_KEY|DEVICE_OPERATOR|DEVICE_REPORT_PRODUCT_CODE|DEVICE_SEQUENCE_NO|EXPIRATION_DATE_OF_DEVICE|GENERIC_NAME|IMPLANT_FLAG|LOT_NUMBER|MANUFACTURER_D_ADDRESS_1|MANUFACTURER_D_ADDRESS_2|MANUFACTURER_D_CITY|MANUFACTURER_D_COUNTRY_CODE|MANUFACTURER_D_NAME|MANUFACTURER_D_POSTAL_CODE|MANUFACTURER_D_STATE_CODE|MANUFACTURER_D_ZIP_CODE|MANUFACTURER_D_ZIP_CODE_EXT|MODEL_NUMBER|OTHER_ID_NUMBER|filter
6315557|66927053|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/09/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6540530|74301792|N|1||THE EVENTS OF LYMPHOMA ALCL AND SEROMA ARE A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE HISTORY RECORD DHR PROVIDES REVIEW OF DHR FOR B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES THAT MAY BE ASSOCIATED WITH THE REPORTED DEVICE EVENT ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM SAP WAS VERIFIED AND THERE WAS NO SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY |STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-401|05/03/2017||||N|R||0HP|FTR|1.0|07/27/2015|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2010555|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6247187|66742201|N|1||THE EVENTS OF LYMPHOMA-ALCL LATE SEROMA AND INFLAMMATION ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE HISTORY RECORD DHR SUMMARY REVIEW OF DHR FOR WORK ORDER 1321464 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT WAS VERIFIED AND THERE WAS NOT ANY SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER 1321464 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MX115-290|01/12/2017|||DA|N|R||0HP|FTR|1.0|09/04/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1321464|KILBRIDE INDUSTRIAL ESTATE||ARKLOW, COUNTY WICKLOW||ALLERGAN (ARKLOW)|||||||True
6247187|66742202|D|1||ADDITIONAL INFORMATION RECEIVED FROM THE HEALTH PROFESSIONAL REGARDING THE EVENT IN THE MRI REPORT DATED B6 2016 ADDITIONAL REPORTED EVENT OF IMPLANT SURROUNDED BY A LARGE COLLECTION OF FLUID PATHOLOGY RESULTS FROM B6 2016 REVEALED LEFT PERIPROSTHETIC CAPSULE ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH BREAST IMPLANT PATHOLOGY SHOWS ALCL MARKERS OF CD30+ AND ALK- PHYSICIAN ADDITIONALLY REPORTED EVENTS OF PAIN AND A FEELING OF LOCALIZED INFLAMMATION AROUND THE IMPLANT THE EVENT OF PAIN WILL BE NOT DEVICE RELATED AS IT IS A SECONDARY SYMPTOM TO OTHER REPORTED EVENTS|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MX115-290|01/12/2017|||DA|N|R||0HP|FTR|1.0|09/04/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1321464|KILBRIDE INDUSTRIAL ESTATE||ARKLOW, COUNTY WICKLOW||ALLERGAN (ARKLOW)|||||||True
6751756|81359983|N|1||FOLLOW-UP IS COMPLETE AS REPORTING COMPETENT AUTHORITY WILL NOT PROVIDE ANY FURTHER INFORMATION TO SAFEGUARD THE PRIVACY OF THE INVOLVED PATIENTSÂ¿ THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE LABELING ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|FX-410495|07/28/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6751766|81359644|N|1||FOLLOW-UP IS COMPLETE AS REPORTING COMPETENT AUTHORITY WILL NOT PROVIDE ANY FURTHER INFORMATION TO SAFEGUARD THE PRIVACY OF THE INVOLVED PATIENTSÂ¿ THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE LABELING ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410FX|07/28/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6378780|69092151|N|1||IN RESPONSE TO FDA REPORT NUMBER MW5067421 THE EVENTS OF LYMPHOMA ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE HISTORY RECORD DHR REPORTS BASED ON THE RISK ANALYSIS PERFORMED THE AE TERM CODE LYMPHOMA-ALCL WAS SELECTED FOR ANALYSIS AS IT REPRESENTS THE HIGHEST RISK FALLING ON THE MONITOR RISK REGION WITH AN APPLICABLE INVESTIGATION LEVEL OF 3 REVIEW OF DHR FOR WORK ORDER 1157904 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES THAT MAY BE ASSOCIATED WITH THE REPORTED DEVICE EVENT ALL SALINE BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM ORACLE WAS VERIFIED AND THERE WAS NO SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS THE QMS LISTING REPORT INDICATES THAT THERE WERE ANY NCMRS OR ERS FOR UNITS MANUFACTURED ON WORK ORDER 1157904 ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER 1157904 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL HEMATOMASEROMA AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA|STYLE 363 SALINE FILLED BREAST IMPLANT|363LF-300|03/04/2017||||Y|*||0HP|FWM|1.0|09/24/2009|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||1157904|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6257136|64954240|D|1||PHYSICIAN REPORTED RIGHT SIDE LATE SEROMA WITH POSITIVE CYTOLOGY FOR ANAPLASTIC LARGE CELL LYMPHOMA AS CYTOLOGICAL MARKERS NECESSARY FOR DIAGNOSIS ARE NOT CONFIRMED THIS EVENT OF ALCL WILL BE CAPTURED AS LYMPHOMA AT THIS TIME THERE IS NO MENTION OF EXPLANT|STYLE 150 EXPANDABLE BREAST IMPLANT|N-27-150386|01/17/2017||||N|R||0HP|FTR|1.0|03/26/2017|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2262674|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6559362|74887820|N|1||B4 THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE HISTORY RECORD REVIEW REVIEW OF DHR FOR WORK ORDER 2183997 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM SAP WAS VERIFIED AND THERE WAS NO SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER 2183997 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS REPORTED EVENTS ARE ADDRESSED IN THE LABELING PATIENTS SHOULD BE ADVISED THAT CAPSULAR CONTRACTURE MAY BE MORE COMMON FOLLOWING INFECTION HEMATOMA AND SEROMA AND THE CHANCE OF IT HAPPENING MAY INCREASE OVER TIME CAPSULAR CONTRACTURE OCCURS MORE COMMONLY IN REVISION PATIENTS THAN IN PRIMARY AUGMENTATION OR RECONSTRUCTION PATIENT CAPSULAR CONTRACTURE IS ALSO A RISK FACTOR FOR IMPLANT RUPTURE AND IT IS ONE OF THE MOST COMMON REASONS FOR REOPERATION ALLERGAN HAS NOT TESTED THE EFFECTS OF RADIATION THERAPY IN PATIENTS WHO HAVE BREAST IMPLANTS THE LITERATURE SUGGESTS THAT RADIATION THERAPY MAY INCREASE THE LIKELIHOOD OF CAPSULAR CONTRACTURE NECROSIS AND IMPLANT EXTRUSION POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY SIMILAR TO A BRUISE A SEROMA OCCURS WHEN THE WATERY PORTION OF THE BLOOD COLLECTS AROUND A SURGICAL INCISION OR AROUND A BREAST IMPLANT YOU SHOULD PERFORM SELF-EXAMINATION OF YOUR BREASTS EVERY MONTH FOR CANCER SCREENING HOWEVER THIS MAY BE MORE DIFFICULT WITH IMPLANTS YOU SHOULD ASK YOUR SURGEON TO HELP YOU DISTINGUISH THE IMPLANT FROM YOUR BREAST TISSUE THE PRESENCE OF LUMPS PERSISTENT PAIN SWELLING HARDENING OR CHANGES IN IMPLANT SHAPE MAY BE SIGNS OF A RUPTURE OF THE IMPLANT THESE SIGNS SHOULD BE REPORTED TO YOUR SURGEON AND POSSIBLY EVALUATED WITH AN MRI AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHY CHEST WALL DEFORMITY ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|N-TRM445|05/10/2017||||N|R||0HP|FTR|1.0|10/11/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2183997|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6576687|75473262|N|1||THE EVENTS OF LYMPHOMA ALCL CAPSULAR CONTRACTURE AND EDEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE LABELING ADDRESSES NATRELLEÂ® SILICONE-FILLED BREAST IMPLANTS AND NATRELLE INSPIRAÂ¿ BREAST IMPLANTS ARE INDICATED FOR WOMEN FOR THE FOLLOWING BREAST AUGMENTATION FOR WOMEN AT LEAST 22 YEARS OLD BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL PATIENTS SHOULD BE ADVISED THAT CAPSULAR CONTRACTURE MAY BE MORE COMMON FOLLOWING INFECTION HEMATOMA AND SEROMA AND THE CHANCE OF IT HAPPENING MAY INCREASE OVER TIME CAPSULAR CONTRACTURE OCCURS MORE COMMONLY IN REVISION PATIENTS THAN IN PRIMARY AUGMENTATION OR RECONSTRUCTION PATIENTS CAPSULAR CONTRACTURE IS ALSO A RISK FACTOR FOR IMPLANT RUPTURE AND IT IS ONE OF THE MOST COMMON REASONS FOR REOPERATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|05/18/2017|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6567317|75169544|D|1||REPORTED EVENT OF A PATIENT WITH A LEFT SIDE Â¿INAMED BIOCELL TEXTURED SALINE IMPLANTÂ¿ EXPERIENCING A Â¿DEFLATIONÂ¿ WAS NOTED IN THE ARTICLE Â¿CD30+ T CELLS IN LATE SEROMA MAY NOT BE DIAGNOSTIC OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ PUBLISHED IN AESTHETIC SURGERY JOURNAL 11APR2017 PP 1-5 THE DEVICE WAS EXPLANTED AND REPLACED WITH A Â¿NATRELLE STYLE 410 HIGHLY COHESIVE TEXTURED SILICONE GEL IMPLANTÂ¿|UNK SALINE IMPLANT|UNK SALINE IMPLANT|05/15/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6567317|75169503|N|1||ARTICLE CITATION Â¿CD30+ T CELLS IN LATE SEROMA MAY NOT BE DIAGNOSTIC OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ BY MARSHALL E KADIN MD JOHN MORGAN PHD HAIYING XU BS AND CAROLINE A GLICKSMAN MD PUBLISHED IN AESTHETIC SURGERY JOURNAL 11APR2017 PP 1-5 A REQUEST FOR FURTHER INFORMATION WAS MADE TO THE REPORTING PHYSICIAN NO ADDITIONAL INFORMATION WILL BE PROVIDED AS FURTHER FOLLOW UP IS NOT POSSIBLE AS THE DOCTOR IS NOT AVAILABLE FOR ADDITIONAL QUESTIONING DEVICE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY DEFLATION Â¿ BREAST IMPLANTS ARE NOT LIFETIME DEVICES SALINE BREAST IMPLANTS DEFLATE WHEN THE SHELL DEVELOPS A TEAR OR HOLE DEFLATION CAN OCCUR AT ANY TIME AFTER IMPLANTATION BUT THEY ARE MORE LIKELY TO OCCUR THE LONGER THE IMPLANT IS IMPLANTED THE FOLLOWING THINGS MAY CAUSE IMPLANTS TO DEFLATE DAMAGE BY SURGICAL INSTRUMENTS FOLDING OR WRINKLING OF THE IMPLANT SHELL EXCESSIVE FORCE TO THE CHEST EG DURING CLOSED CAPSULOTOMY WHICH IS CONTRAINDICATED TRAUMA COMPRESSION DURING MAMMOGRAPHIC IMAGING AND SEVERE CAPSULAR CONTRACTURE BREAST IMPLANTS MAY ALSO SIMPLY WEAR OUT OVER TIME LABORATORY STUDIES HAVE IDENTIFIED SOME OF THE CAUSES OF DEFLATION FOR ALLERGANÂ¿S PRODUCT HOWEVER IT IS NOT CONCLUSIVELY KNOWN WHETHER THESE TESTS HAVE IDENTIFIED ALL CAUSES OF DEFLATION -|UNK SALINE IMPLANT|UNK SALINE IMPLANT|05/15/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6730693|80619152|D|1||THIS EVENT IS FROM A LITERATURE SOURCE IT WAS REPORTED THAT A PATIENT UNDERWENT AXILLARY LYMPH NODE DISSECTION ALND AND IMMEDIATE BREAST RECONSTRUCTION IBR WITH A LATISSIMUS DORSI LD FLAP RECONSTRUCTION IN 2005 MENTOR MEMORY SHAPE BREAST IMPLANT MEDIUM HEIGHT MODERATE PROFILE 355CC  CATALOG  354-1308 WAS IMPLANTED DURING THIS PROCEDURE PATIENT HAD RECEIVED ADJUVANT CHEMOTHERAPY CHEST WALL RADIOTHERAPY AND ENDOCRINE THERAPY WITH TAMOXIFEN MCGHAN 150 TISSUE EXPANDER WAS USED IN 2006 PATIENT HAD A DEVICE REPLACEMENT WITH ALLERGAN N27-FX155-775 FOR UNKNOWN REASON IN 2013 PATIENT PRESENTED SEROMA AND WAS DIAGNOSED WITH STAGE I DISEASE IN 2016 THIS PATIENT WAS TREATED SUCCESSFULLY WITH IMPLANT REMOVAL AND COMPLETE UNILATERAL CAPSULECTOMY AND HAVE A FOLLOW UP OF 8 MONTHS TITLE BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA THE UK EXPERIENCE RECOMMENDATIONS ON ITS MANAGEMENT AND IMPLICATIONS FOR INFORMED CONSENT|nan|354-1308|07/20/2017||||N|R||0HP|FTR|1.0||BREAST IMPLANT||UNK|3041 SKYWAY CIRCLE||NORTH IRVING|US|MENTOR WORLDWIDE LLC|750383540|TX|75038|3540||354-1308|True
6460137|71714491|N|1||ARTICLE CITATION Â¿A CASE OF SUSPECTED LATE-STAGE RECURRENCE OF ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA AT BREAST IMPLANT INSERTION SITEÂ¿ BY BY Y FUKUSHIMA M ISHII T INOUE T SAKURAI PUBLISHED IN THE JOURNAL OF JAPANESE PATHOLOGY ASSOCIATION VOL 102 NUMBER 1 PG 137 APR 2013 THE EVENTS OF LYMPHOMA AND LUMPNODULE ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING THE EVENT PRODUCT ANDOR PATIENT DETAILS WAS REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|04/05/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6460137|71714494|D|1||REPORTED EVENT OF A PATIENT THAT WAS DIAGNOSED WITH Â¿ALCLÂ¿ AND Â¿SUBCUTANEOUS TUMORÂ¿ WAS FOUND IN Â¿A CASE OF SUSPECTED LATE-STAGE RECURRENCE OF ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA AT BREAST IMPLANT INSERTION SITE PUBLISHED IN THE JOURNAL OF JAPANESE PATHOLOGY ASSOCIATION VOL 102 NUMBER 1 PG 137 APR 2013 TREATMENT OF Â¿ANTIBIOTICSÂ¿ WAS PROVIDED AND THE DEVICE WAS LATER EXPLANTED THE MANUFACTURER OF THE DEVICE IS UNKNOWN THIS MEDWATCH REPRESENTS THE LEFT SIDE SEE MFR 9617229-2017-00129 FOR THE RIGHT SIDE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|04/05/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6654587|78019287|N|1||B4 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE HISTORY REVIEW DHR REPORTS REVIEW OF DHR FOR B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM SAP WAS VERIFIED AND THERE WAS NOT ANY SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|120-300|06/20/2017||||N|R||0HP|FTR|1.0|12/27/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2232205|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6323445|67166355|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/10/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6744780|81082639|N|1||THE EVENTS OF LYMPHOMA AND LATE SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|N-TSM520|07/26/2017||||N|R||0HP|FTR|1.0|10/04/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2180982|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6745299|81111775|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|07/26/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6331755|67482135|N|1||FURTHER CLARIFICATION REGARDING THE EVENT THE EVENT OF A CASE IS BEING CONSIDERED AS LYMPHOMA AS THE EVENT WAS STATED AS TO HAVE BEEN RECEIVED FROM THE PROFILE REGISTRY WHICH IS A DATABASE DEDICATED TO CAPTURING REPORTS OF ALCL THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLAINT AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING THE EVENT PRODUCT ANDOR PATIENT DETAILS WAS REQUESTED UPON ADDITIONAL FOLLOW UP WITH THE PHYSICIAN IT WAS DETERMINED THAT THERE WAS NO ADDITIONAL INFORMATION AVAILABLE DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/15/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6331760|67507919|N|1||FURTHER CLARIFICATION REGARDING THE EVENT THE EVENT OF A CASE IS BEING CONSIDERED AS LYMPHOMA AS THE EVENT WAS STATED AS TO HAVE BEEN RECEIVED FROM THE PROFILE REGISTRY WHICH IS A DATABASE DEDICATED TO CAPTURING REPORTS OF ALCL THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLAINT AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING THE EVENT PRODUCT ANDOR PATIENT DETAILS WAS REQUESTED UPON ADDITIONAL FOLLOW UP WITH THE PHYSICIAN IT WAS DETERMINED THAT THERE WAS NO ADDITIONAL INFORMATION AVAILABLE DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/15/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6497135|72921040|D|1||PATIENT REPORTED LEFT SIDE MASSIVE SWELLING AND LEFT BREAST HAD DOUBLED IN SIZE PATIENT ADDITIONALLY REPORTED GETTING REALLY SICK AND WAS DIAGNOSED WITH BREAST IMPLANT ANAPLASTIC LARGE CELL LYMPHOMA ON B6 2016 PATIENT ADDITIONALLY REPORTED PATHOLOGY SHOWED LEFT SIDE MASS HAD SPREAD OUTSIDE OF THE CAPSULE HEALTHCARE PROFESSIONAL CONFIRMED THE REPORTED EVENTS HEALTHCARE PROFESSIONAL ADDITIONALLY REPORTED LEFT SIDE Â¿PERIPROSTHETIC FLUID AT TIME OF DIAGNOSISÂ¿ AND SPONTANEOUS LARGE LEFT SIDED SEROMA A TOTAL CAPSULECTOMY AND EXPLANTATION WAS PERFORMED PATHOLOGY RESULTS SHOWED ALCL WITHIN THE LEFT CAPSULE AND SMALL LEFT BREAST MASS|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|N-TRF415|04/17/2017||||N|R||0HP|FTR|1.0|04/29/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2109766|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6497135|72921039|N|1||B4 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE HISTORY RECORD DHR REPORTS BASED ON THE RISK ANALYSIS PERFORMED THE AE TERM CODE LYMPHOMA ALCL WAS SELECTED FOR ANALYSIS AS IT REPRESENTS THE HIGHEST RISK FALLING ON THE MONITOR RISK REGION WITH AN APPLICABLE INVESTIGATION LEVEL OF THREE REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM SAP WAS VERIFIED AND THERE WAS NOT ANY SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS A QUERY WAS PERFORMED IN THE QMS SYSTEM AND NO DEVIATIONS OR NON-CONFORMANCES WERE FOUND TO BE RELATED TO WORK ORDER B4  ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|N-TRF415|04/17/2017||||N|R||0HP|FTR|1.0|04/29/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2109766|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6634993|77375388|N|1||B4 CLARIFICATION TO PATIENTS EXACT DATE OF DEATH WAS NOT PROVIDED THE ONLY KNOWN INFORMATION IS THE YEAR 2012 ARTICLE CITATION A SHOCKING DIAGNOSIS BREAST IMPLANTS GAVE ME CANCER DENISE GRADY THE NEW YORK TIMES MAY 14 2017 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT AND PRODUCT DETAILS CANNOT BE OBTAINED AS PATIENT AND EXPLANTING PHYSICIAN CONTACT INFORMATION WAS NOT PROVIDED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT MISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|06/12/2017|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6498449|72963713|N|1||THIS REPORT IS SUBMITTED IN RESPONSE TO FDA NOTICE TITLED BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCL PROVIDED ON 21MAR2017 THE TOTAL NUMBER OF CASES REFERENCED IN THE NOTICE IS 359 INCLUDING 9 DEATHS THE INFORMATION PROVIDED IN THE NOTICE CLASSIFIES THE ALCL EVENTS IN DIFFERENT CATEGORIES INCLUDING TYPES OF DEVICE ASSOCIATED ADVERSE EVENTS PRESENTATION AND DIAGNOSIS DETAILS BUT DOES NOT IDENTIFY SPECIFIC DEVICES OR PATIENTS IT IS NOT POSSIBLE TO INDIVIDUALIZE THIS INFORMATION INTO SPECIFIC REPORTS AND BY DEFINITION ALREADY INCLUDES EVENTS REPORTED BY ALLERGAN IN THE PAST THEREFORE IN ACCORDANCE WITH 21 CFR 803 THIS REPORT WILL REPRESENT ACKNOWLEDGEMENT OF RECEIPT OF THE NOTICE AND DOCUMENTATION OF ALLERGANS ATTEMPT TO INVESTIGATE ADVERSE EVENTS IDENTIFIED IN THAT NOTICE THIS REPORT WILL NOT SUBSTITUTE FOR ANY INVESTIGATION INTO COMPLAINTS RECEIVED WHERE INDIVIDUAL PATIENTS OR ALLERGAN DEVICES ARE IDENTIFIED INCLUSIVE OR EXCLUSIVE OF THE 359 CASES MENTIONED IN THE NOTICE B4 THE EVENTS OF DEATH LYMPHOMA-ALCL LYMPHOMA SEROMA CAPSULAR CONTRACTURE AND BREAST LUMPS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS SALINE DEVICE LABELING RADIATION TO THE BREAST Â¿ ALLERGAN HAS NOT TESTED THE IN VIVO EFFECTS OF RADIATION THERAPY IN PATIENTS WHO HAVE BREAST IMPLANTS THE LITERATURE SUGGESTS THAT RADIATION THERAPY MAY INCREASE THE LIKELIHOOD OF CAPSULAR CONTRACTURE NECROSIS AND IMPLANT EXTRUSION POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY CAPSULAR CONTRACTURE Â¿ PATIENTS SHOULD BE ADVISED THAT CAPSULAR CONTRACTURE MAY BE MORE COMMON FOLLOWING INFECTION HEMATOMA AND SEROMA AND THE CHANCE OF IT HAPPENING MAY INCREASE OVER TIME CAPSULAR CONTRACTURE OCCURS MORE COMMONLY IN REVISION PATIENTS THAN IN PRIMARY AUGMENTATION OR RECONSTRUCTION PATIENTS CAPSULAR CONTRACTURE IS ALSO A RISK FACTOR FOR IMPLANT DEFLATION AND IT IS ONE OF THE MOST COMMON REASONS FOR REOPERATION PATIENTS SHOULD ALSO BE ADVISED THAT ADDITIONAL SURGERY MAY BE NEEDED IN CASES WHERE PAIN ANDOR FIRMNESS ARE SEVERE THIS SURGERY RANGES FROM REMOVAL OF THE IMPLANT CAPSULE TISSUE TO REMOVAL AND POSSIBLE REPLACEMENT OF THE IMPLANT ITSELF THIS SURGERY MAY RESULT IN LOSS OF BREAST TISSUE CAPSULAR CONTRACTURE MAY HAPPEN AGAIN AFTER THESE ADDITIONAL SURGERIES CAPSULAR CONTRACTURE MAY INCREASE THE RISK OF DEFLATION ADDITIONAL COMPLICATIONS Â¿ AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS IN THE PASS STUDY AT LEAST 1 REOPERATION WAS PERFORMED ON 315 PATIENTS 365 THROUGH 10 YEARS A TOTAL OF 424 REOPERATIONS WERE PERFORMED THE PRIMARY REASON FOR REOPERATION THROUGH 10 YEARS ON AUGMENTATION PATIENTS WAS IMPLANT DEFLATION AT 217 THE PERCENTAGE OF REOPERATIONS DUE TO LUMPMASSCYST INCREASED FROM 85 OF 293 REOPERATIONS THROUGH 5 YEARS TO 139 OF 424 REOPERATIONS THROUGH 10 YEARS THE OCCURRENCE OF LUMPS MASSES AND CYSTS CAN BE EXPECTED TO NATURALLY INCREASE AS PATIENTS AGE AND COULD BE AN EXPLANATION FOR THE INCREASE BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL FOR MORE COMPLETE AND UP-TO-DATE INFORMATION ON FDAÂ¿S ANALYSIS AND REVIEW OF THE ALCL IN PATIENTS WITH BREAST IMPLANTS PLEASE VISIT HTTPWWWFDAGOVMEDICALDEVICESPRODUCTSANDMEDICALPROCEDURESIMPLANTSANDPROSTHETICSBREASTIMPLANTSUCM239995HTM YOU ARE ALSO REQUIRED TO REPORT ANY PRODUCT PROBLEM OR SERIOUS ADVERSE EVENT TO ALLERGAN DEATHS MUST BE REPORTED TO ALLERGAN AND FDA SILICONE DEVICE LABELING ONE OF THE KEY COMPLICATIONS REPORTED IS CALLED Â¿CAPSULAR CONTRACTUREÂ¿ CAPSULAR CONTRACTURE IS A TIGHTENING OF THE SCAR TISSUE ALSO CALLED A CAPSULE THAT NORMALLY FORMS AROUND THE BREAST IMPLANT DURING THE HEALING PROCESS AFTER SURGERY IN SOME WOMEN THE SCAR TISSUE CAPSULE SQUEEZES THE IMPLANT THIS RESULTS IN FIRMNESS OR HARDENING OF THE BREAST AND IT IS A RISK FOR IMPLANT RUPTURE DEGREES OF CAPSULAR CONTRACTURE ARE CLASSIFIED BY THE BAKER GRADING SCALE1 CAPSULAR CONTRACTURE BAKER GRADES III AND IV ARE THE MOST SEVERE BAKER GRADE III OFTEN RESULTS IN THE NEED FOR ADDITIONAL SURGERY REOPERATION BECAUSE OF PAIN AND POSSIBLY ABNORMAL APPEARANCE BAKER GRADE IV USUALLY RESULTS IN THE NEED FOR REOPERATION BECAUSE OF PAIN AND UNACCEPTABLE APPEARANCE DO NOT TREAT CAPSULAR CONTRACTURE BY CLOSED CAPSULOTOMY OR FORCEFUL EXTERNAL COMPRESSION WHICH WILL LIKELY RESULT IN IMPLANT DAMAGE RUPTURE FOLDS ANDOR HEMATOMA ALLERGAN HAS NOT TESTED THE EFFECTS OF RADIATION THERAPY IN PATIENTS WHO HAVE BREAST IMPLANTS THE LITERATURE SUGGESTS THAT RADIATION THERAPY MAY INCREASE THE LIKELIHOOD OF CAPSULAR CONTRACTURE NECROSIS AND IMPLANT EXTRUSION POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY SIMILAR TO A BRUISE A SEROMA OCCURS WHEN THE WATERY PORTION OF THE BLOOD COLLECTS AROUND A SURGICAL INCISION OR AROUND A BREAST IMPLANT YOU SHOULD PERFORM SELF-EXAMINATION OF YOUR BREASTS EVERY MONTH FOR CANCER SCREENING HOWEVER THIS MAY BE MORE DIFFICULT WITH IMPLANTS YOU SHOULD ASK YOUR SURGEON TO HELP YOU DISTINGUISH THE IMPLANT FROM YOUR BREAST TISSUE THE PRESENCE OF LUMPS PERSISTENT PAIN SWELLING HARDENING OR CHANGES IN IMPLANT SHAPE MAY BE SIGNS OF A RUPTURE OF THE IMPLANT THESE SIGNS SHOULD BE REPORTED TO YOUR SURGEON AND POSSIBLY EVALUATED WITH AN MRI AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHY CHEST WALL DEFORMITY ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL FOR MORE COMPLETE AND UP-TO-DATE INFORMATION ON FDAÂ¿S ANALYSIS AND REVIEW OF THE ALCL IN PATIENTS WITH BREAST IMPLANTS PLEASE VISIT HTTPWWWFDAGOVMEDICALDEVICESPRODUCTSANDMEDICALPROCEDURESIMPLANTSANDPROSTHETICSBREASTIMPLANTSUCM239995HTM|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|04/17/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6571801|75326410|N|1||CONCOMITANT MEDICAL PRODUCTS NITROGLYCERIN VALIUM 2 ZOLOFT B4 FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE HISTORY RECORD DHR REPORTS REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES THAT MAY BE ASSOCIATED WITH THE REPORTED DEVICE EVENT ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BREAST IMPLANTS ARE NOT LIFETIME DEVICES BREAST IMPLANTS RUPTURE WHEN THE SHELL DEVELOPS A TEAR OR HOLE RUPTURES CAN OCCUR AT ANY TIME AFTER IMPLANTATION BUT THEY ARE MORE LIKELY TO OCCUR THE LONGER THE IMPLANT IS IMPLANTED THE FOLLOWING THINGS MAY CAUSE IMPLANTS TO RUPTURE DAMAGE BY SURGICAL INSTRUMENTS STRESSING THE IMPLANT DURING IMPLANTATION AND WEAKENING IT FOLDING OR WRINKLING OF THE IMPLANT SHELL EXCESSIVE FORCE TO THE CHEST EG DURING CLOSED CAPSULOTOMY WHICH IS CONTRAINDICATED TRAUMA COMPRESSION DURING MAMMOGRAPHIC IMAGING AND SEVERE CAPSULAR CONTRACTURE BREAST IMPLANTS MAY ALSO SIMPLY WEAR OUT OVER TIME LABORATORY STUDIES HAVE IDENTIFIED SOME OF THE CAUSES OF RUPTURE FOR ALLERGANÂ¿S PRODUCT IT IS NOT CONCLUSIVELY KNOWN WHETHER THESE TESTS HAVE IDENTIFIED ALL CAUSES OF RUPTURE LABORATORY STUDIES TO IDENTIFY ANY ADDITIONAL CAUSES OF RUPTURE ARE ONGOING SILICONE GEL FILLED IMPLANT RUPTURES ARE MOST OFTEN SILENT THIS MEANS THAT MOST OF THE TIME NEITHER YOU NOR YOUR PATIENT WILL KNOW IF THE IMPLANT HAS A TEAR OR HOLE IN THE SHELL MRI EXAMINATION IS CURRENTLY THE BEST METHOD TO SCREEN FOR RUPTURE SOMETIMES THERE ARE SYMPTOMS ASSOCIATED WITH GEL IMPLANT RUPTURE THESE SYMPTOMS INCLUDE HARD KNOTS OR LUMPS SURROUNDING THE IMPLANT OR IN THE ARMPIT CHANGE OR LOSS OF SIZE OR SHAPE OF THE BREAST OR IMPLANT PAIN TINGLING SWELLING NUMBNESS BURNING AND HARDENING OF THE BREAST WHEN MRI SIGNS OF RUPTURE ARE FOUND SUCH AS SUBCAPSULAR LINES CHARACTERISTIC FOLDED WAVY LINES TEARDROP SIGN KEYHOLE SIGN NOOSE SIGN OR IF THERE ARE SIGNS OR SYMPTOMS OF RUPTURE YOU SHOULD REMOVE THE IMPLANT AND ANY GEL YOU DETERMINE YOUR PATIENT HAS WITH OR WITHOUT REPLACEMENT OF THE IMPLANT IT ALSO MAY BE NECESSARY TO REMOVE THE TISSUE CAPSULE THERE ARE ALSO CONSEQUENCES OF RUPTURE IF RUPTURE OCCURS SILICONE GEL MAY EITHER REMAIN WITHIN THE SCAR TISSUE CAPSULE SURROUNDING THE IMPLANT INTRACAPSULAR RUPTURE MOVE OUTSIDE THE CAPSULE EXTRACAPSULAR RUPTURE OR MOVE OUTSIDE THE BREAST GEL MIGRATION THERE IS ALSO A POSSIBILITY THAT RUPTURE MAY PROGRESS FROM INTRACAPSULAR TO EXTRACAPSULAR AND BEYOND|STYLE 110 SILICONE GEL FILLED BREAST IMPLANT|110-420|05/17/2017||||N|R||0HP|FTR|1.0|04/15/2004|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||49463|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6670624|78496499|N|1||FURTHER INFORMATION FROM THE REPORTER REGARDING THE EVENT PRODUCT ANDOR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE LABELING ADDRESSES THE REPORTED EVENT AS FOLLOWS BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|06/27/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6460158|71723777|D|1||REPORTED EVENT OF A PATIENT THAT WAS DIAGNOSED WITH Â¿ALCLÂ¿ AND Â¿SUBCUTANEOUS TUMORÂ¿ WAS FOUND IN Â¿A CASE OF SUSPECTED LATE-STAGE RECURRENCE OF ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA AT BREAST IMPLANT INSERTION SITE PUBLISHED IN THE JOURNAL OF JAPANESE PATHOLOGY ASSOCIATION VOL 102 NUMBER 1 PG 137 APR 2013 TREATMENT OF Â¿ANTIBIOTICSÂ¿ WAS PROVIDED AND THE DEVICE WAS LATER EXPLANTED THE MANUFACTURER OF THE DEVICE IS UNKNOWN THIS MEDWATCH REPRESENTS THE RIGHT SIDE SEE MFR 9617229-2017-00128 FOR THE LEFT SIDE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|04/05/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6460158|71723776|N|1||ARTICLE CITATION Â¿A CASE OF SUSPECTED LATE-STAGE RECURRENCE OF ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA AT BREAST IMPLANT INSERTION SITEÂ¿ BY Y FUKUSHIMA M ISHII T INOUE T SAKURAI PUBLISHED IN THE JOURNAL OF JAPANESE PATHOLOGY ASSOCIATION VOL 102 NUMBER 1 PG 137 APR 2013 THE EVENTS OF LYMPHOMA AND LUMPNODULE ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING THE EVENT PRODUCT ANDOR PATIENT DETAILS WAS REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|04/05/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6734621|80749897|N|1||THE DEVICE REMAINS IMPLANTED THE EVENT OF BREAST CANCER IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT A REVIEW OF THE DEVICE HISTORY RECORD HAS BEEN INITIATED IF ANY NEW CHANGED OR CORRECTED INFORMATION IS NOTED A SUPPLEMENTAL MEDWATCH WILL BE SUBMITTED FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY CANCER PUBLISHED STUDIES INDICATE THAT BREAST CANCER IS NO MORE COMMON IN WOMEN WITH IMPLANTS THAN THOSE WITHOUT IMPLANTS A LARGE LONG-TERM FOLLOW-UP FOUND NO SIGNIFICANT INCREASES IN THE RISK RATES FOR A WIDE VARIETY OF CANCERS INCLUDING STOMACH CANCER LEUKEMIA AND LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL FOR MORE COMPLETE AND UP-TO-DATE INFORMATION ON FDAÂ¿S ANALYSIS AND REVIEW OF THE ALCL IN PATIENTS WITH BREAST IMPLANTS PLEASE VISIT HTTPWWWFDAGOVMEDICALDEVICESPRODUCTSANDMEDICALPROCEDURESIMPLANTSANDPROSTHETICSBREASTIMPLANTSUCM239995HTM|STYLE 68 SALINE FILLED BREAST IMPLANT|68-240|07/21/2017||||N|R||0HP|FWM|1.0|04/05/2010|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||1257756|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6323429|67161071|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/10/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6638620|77500427|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|06/13/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6730694|80619208|D|1||THIS COMPLAINT IS FROM A LITERATURE SOURCE IT WAS REPORTED THAT 23 CASES OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA WERE DIAGNOSED IN 15 REGIONAL CENTERS THROUGHOUT THE B6 BETWEEN 2012 AND 2016 AMONG THEM ONE PATIENT HAD STAGE I DISEASE AND PRESENTED WITH A RECURRENT LARGE VOLUME EFFUSION PATIENT WAS IMPLANTED WITH MENTOR BECKER IMPLANT IN 2005 INAMED ST410 IN 2006 AND INAMED IN 2007 THE INDICATIONS FOR IMPLANT INSERTION WAS BILATERAL MX AND CONTRALATERAL RADIOTHERAPY PATIENT PRESENTED MISSHAPEN BREAST AND SWELLING IN 2016 PATIENT HAD BILATERAL CAPSULECTOMY AND BILATERAL IMPLANT REMOVAL TITLE Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA THE B6 EXPERIENCE RECOMMENDATIONS ON ITS MANAGEMENT AND IMPLICATIONS FOR INFORMED CONSENTÂ¿|nan|UNKNOWN GEL IMPLANT|07/20/2017||||N|R||0HP|FTR|1.0||BREAST IMPLANT||UNK|3041 SKYWAY CIRCLE||NORTH IRVING|US|MENTOR WORLDWIDE LLC|750383540|TX|75038|3540||UNKNOWN GEL IMPLANT|True
6315868|67108883|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/09/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6752720|81359775|N|1||FOLLOW-UP IS COMPLETE AS REPORTING COMPETENT AUTHORITY WILL NOT PROVIDE ANY FURTHER INFORMATION TO SAFEGUARD THE PRIVACY OF THE INVOLVED PATIENTSÂ¿ THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE LABELING ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410MF|07/28/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6567310|75169069|N|1||ARTICLE CITATION Â¿CD30+ T CELLS IN LATE SEROMA MAY NOT BE DIAGNOSTIC OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ BY MARSHALL E KADIN MD JOHN MORGAN PHD HAIYING XU BS AND CAROLINE A GLICKSMAN MD PUBLISHED IN AESTHETIC SURGERY JOURNAL 11APR2017 PP 1-5 THE EVENT OF SEROMA IS A PHYSIOLOGICAL COMPLAINT AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT A REQUEST FOR FURTHER INFORMATION WAS MADE TO THE REPORTING PHYSICIAN NO ADDITIONAL INFORMATION WILL BE PROVIDED AS FURTHER FOLLOW UP IS NOT POSSIBLE AS THE DOCTOR IS NOT AVAILABLE FOR ADDITIONAL QUESTIONING DEVICE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|05/15/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6567310|75169070|D|1||REPORTED EVENT OF A PATIENT WITH A LEFT SIDE Â¿NATRELLE STYLE 410 HIGHLY COHESIVE TEXTURED SILICONE GEL IMPLANTÂ¿ EXPERIENCED A Â¿LARGE SEROMA AND DISCOMFORTÂ¿ WAS FOUND IN THE ARTICLE Â¿CD30+ T CELLS IN LATE SEROMA MAY NOT BE DIAGNOSTIC OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA PUBLISHED IN AESTHETIC SURGERY JOURNAL 11APR2017 PP 1-5 THE DEVICE WAS EXPLANTED AND REPLACED WITH AN ALLERGAN Â¿NATRELLE INSPIRA SMOOTH ROUND SILICONE GEL IMPLANTÂ¿|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|05/15/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6460781|71746777|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK SALINE IMPLANT|UNK SALINE IMPLANT|04/05/2017|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6677037|78706810|N|1||FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME THE REPORTED EVENT IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT REPORTED EVENT IS ADDRESSED IN THE LABELING ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|06/29/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6341238|67800491|N|1||IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP IS BEING PERFORMED FOR DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/17/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6498277|72952111|N|1||THE EVENTS OF LYMPHOMA AND EDEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|04/17/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6572184|75359098|D|1||RIGHT OPEN CAPSULECTOMY AND IMPLANT REMOVAL WITH DIAGNOSIS OF ANAPLASTIC LARGE CELL LYMPHOMA B6 2012 THAT REQUIRED RADIATION THERAPY B6 2012 IMPLANT EXCHANGE 2007 TO TEXTURED SILICONE STYLE 120 600CC VOLUME DR B6 B6 2010 RIGHT BREAST PERIPROSTHETIC FLUID AND CAPSULAR CONTRACTURE TREATED WITH LEVAQUIN DR B6 IMPLANT EXCHANGE B6 2010 WITH BILATERAL STRATTICE FOR CAPSULAR CONTRACTURE - NO PATHOLOGY SENT - PLASCMEEN TOF MENTOR SMOOTH ROUND MODERATE PLUS STYLE 1000 700CC DR B6 PROGRESSIVE CAPSULAR CONTRACTURE RIGHT 1210 WITH OPEN CAPSULOTOMY USING SAME IMPLANT DR B6 WITH RESOLUTION OF SYMPTOMS MOTOR VEHICLE COLLISION B6 WITH HEMATOMA RIGHT BREAST THAT WAS UNTREATED AND PROGRESSIVE CAPSULAR CONTRACTURE RETURNED B6 2011 UNDERWENT RIGHT CAPSULOTOMYPARTIAL CAPSULECTOMY WITH SAME IMPLANT DIAGNOSIS OR REASON FOR USE BREAST AUGMENTATION|BREAST IMPLANT SILICONE STYLE 120 600CC||05/15/2017||||N|I||0HP|FTR|1.0||BREAST IMPLANT|||||||ALLERGAN|||||||True
6572184|75359098|D|1||RIGHT OPEN CAPSULECTOMY AND IMPLANT REMOVAL WITH DIAGNOSIS OF ANAPLASTIC LARGE CELL LYMPHOMA B6 2012 THAT REQUIRED RADIATION THERAPY B6 2012 IMPLANT EXCHANGE 2007 TO TEXTURED SILICONE STYLE 120 600CC VOLUME DR B6 B6 2010 RIGHT BREAST PERIPROSTHETIC FLUID AND CAPSULAR CONTRACTURE TREATED WITH LEVAQUIN DR B6 IMPLANT EXCHANGE B6 2010 WITH BILATERAL STRATTICE FOR CAPSULAR CONTRACTURE - NO PATHOLOGY SENT - PLASCMEEN TOF MENTOR SMOOTH ROUND MODERATE PLUS STYLE 1000 700CC DR B6 PROGRESSIVE CAPSULAR CONTRACTURE RIGHT 1210 WITH OPEN CAPSULOTOMY USING SAME IMPLANT DR B6 WITH RESOLUTION OF SYMPTOMS MOTOR VEHICLE COLLISION B6 WITH HEMATOMA RIGHT BREAST THAT WAS UNTREATED AND PROGRESSIVE CAPSULAR CONTRACTURE RETURNED B6 2011 UNDERWENT RIGHT CAPSULOTOMYPARTIAL CAPSULECTOMY WITH SAME IMPLANT DIAGNOSIS OR REASON FOR USE BREAST AUGMENTATION|MENTOR SMOOTH ROUND PLUS STYLE, 1000 700CC||05/15/2017||||N|I||0HP|FTR|2.0||BREAST IMPLANT|||||||ALLERGAN|||||||True
6725178|80442607|D|1||THIS IS EVENT WAS REPORTED VIA  MW5023558 A PATIENT REPORTED THAT SHE UNDERWENT COSMETIC BREAST SURGERY USING MENTOR SALINE IMPLANTS FOR PRIMARY AUGMENTATION IN 1986 IN 2008 SHE WAS DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA THE PATIENT WAS TREATED WITH CHEMOTHERAPY AND RADIATION THERAPY HER RIGHT IMPLANT WAS STILL RED AND SWOLLEN AFTER TREATMENT SO SHE HAD IMPLANTS EXPLANTED NO CONTACT INFORMATION WAS PROVIDED IN MW REPORT THEREFORE NO FURTHER INFORMATION HAS BEEN MADE AVAILABLE|nan|UNKNOWN SALINE IMPLANT|07/19/2017||||N|R||0HP|FWM|1.0||BREAST IMPLANT||UNK|3041 SKYWAY CIRCLE||NORTH IRVING|US|MENTOR WORLDWIDE LLC|750383540|TX|75038|3540||UNKNOWN SALINE IMPLANT|True
6395062|69619795|N|1||THE EVENTS OF LYMPHOMA SEROMA AND LUMPNODULE ARE A PHYSIOLOGICAL COMPLAINT AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING THE EVENT PRODUCT ANDOR PATIENT DETAILS WAS REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK SALINE IMPLANT|UNK SALINE IMPLANT|03/10/2017|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6309206|66741539|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLAINT AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING THE EVENT PRODUCT ANDOR PATIENT DETAILS WAS REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/07/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6595799|76126750|N|1||FOLLOW-UP IS BEING PERFORMED FOR FURTHER INFORMATION REGARDING THIS REPORT IF NEW INFORMATION IS RECEIVED IT WILL BE REPORTED IN A SUPPLEMENTAL REPORT THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN THE LABELING ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/26/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6595799|76126750|N|1||FOLLOW-UP IS BEING PERFORMED FOR FURTHER INFORMATION REGARDING THIS REPORT IF NEW INFORMATION IS RECEIVED IT WILL BE REPORTED IN A SUPPLEMENTAL REPORT THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN THE LABELING ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410LX|05/26/2017|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6617685|76841698|N|1||ALLERGAN IS UNABLE TO CONFIRM WITH THE HEALTHCARE PROFESSIONAL THEREFORE ADDITIONAL EVENT PRODUCT OR PATIENT DETAILS ARE NOT ATTAINABLE THE REPORTED EVENTS OF LYMPHOMA SEROMA AND EDEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN THE LABELING THE PATIENT SHOULD BE TOLD THAT THE PRESENCE OF LUMPS PERSISTENT PAIN SWELLING HARDENING OR CHANGE IN THE IMPLANT SHAPE MAY BE SIGNS OF SYMPTOMATIC RUPTURE OF THE IMPLANT IF THE PATIENT HAS ANY OF THESE SIGNS SHE SHOULD BE TOLD TO REPORT THEM AND POSSIBLY HAVE AN MRI EVALUATION TO SCREEN FOR RUPTURE POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY SIMILAR TO A BRUISE A SEROMA OCCURS WHEN THE WATERY PORTION OF THE BLOOD COLLECTS AROUND A SURGICAL INCISION OR AROUND A BREAST IMPLANT AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHY CHEST WALL DEFORMITY ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 110 SILICONE GEL FILLED BREAST IMPLANT|27-110241|06/07/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6309203|66741187|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLAINT AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING THE EVENT PRODUCT ANDOR PATIENT DETAILS WAS REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/07/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6663360|78278939|N|1||FOLLOW-UP IS BEING PERFORMED FOR FURTHER INFORMATION REGARDING THIS EVENT NEW INFORMATION RECEIVED WILL BE REPORTED IN A SUPPLEMENTAL REPORT THE REPORTED EVENT IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT REPORTED EVENTS ARE ADDRESSED IN THE LABELING ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|TSF385|06/23/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|KILBRIDE INDUSTRIAL ESTATE||ARKLOW, COUNTY WICKLOW||ALLERGAN (ARKLOW)|||||||True
6574813|75416230|N|1||ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMABÂ¿ BY BY L JOHNSON J ODONOGHUE H STARK N COLLIS A LENNARD M BUTTERWORTH N MCLEAN M YOUSSEF G GUI I LYBURN J BRISTOL J HURREN S SMITH R JACKLIN D CUNNINGHAM AND F MACNEILL PUBLISHED IN CANCER RESEARCH FEB2017 ELECTRONICALLY PUBLISHED APR2017 THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN THE LABELING THE OCCURRENCE OF LUMPS MASSES AND CYSTS CAN BE EXPECTED TO NATURALLY INCREASE AS PATIENTS AGE AND COULD BE AN EXPLANATION FOR THE INCREASE ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL REPORTS IN THE MEDICAL LITERATURE INDICATE THAT PATIENTS WITH BREAST IMPLANTS ARE NOT AT A GREATER RISK THAN THOSE WITHOUT BREAST IMPLANTS FOR DEVELOPING BREAST CANCER REPORTS HAVE SUGGESTED THAT BREAST IMPLANTS MAY INTERFERE WITH OR DELAY BREAST CANCER DETECTION BY MAMMOGRAPHY ANDOR BIOPSY HOWEVER OTHER REPORTS IN THE PUBLISHED MEDICAL LITERATURE INDICATE THAT BREAST IMPLANTS NEITHER SIGNIFICANTLY DELAY BREAST CANCER DETECTION NOR ADVERSELY AFFECT CANCER SURVIVAL OF WOMEN WITH BREAST IMPLANTS A LARGE FOLLOW-UP STUDY REPORTED NO EVIDENCE OF AN ASSOCIATION BETWEEN BREAST IMPLANTS AND CANCER AND EVEN SHOWED A DECREASED INCIDENCE OF BREAST CANCER COMPARED TO THE GENERAL POPULATION ONE STUDY HAS REPORTED AN INCREASED INCIDENCE OF BRAIN CANCER IN WOMEN WITH BREAST IMPLANTS AS COMPARED TO THE GENERAL POPULATION THE INCIDENCE OF BRAIN CANCER HOWEVER WAS NOT SIGNIFICANTLY INCREASED IN WOMEN WITH BREAST IMPLANTS WHEN COMPARED TO WOMEN WHO HAD OTHER PLASTIC SURGERIES A PUBLISHED REVIEW OF 4 LARGE STUDIES IN WOMEN WITH COSMETIC IMPLANTS AND AN ADDITIONAL LONG-TERM FOLLOW-UP STUDY CONCLUDED THAT THE EVIDENCE DOES NOT SUPPORT AN ASSOCIATION BETWEEN BRAIN CANCER AND BREAST IMPLANTS AN EPIDEMIOLOGICAL REVIEW ALSO LENT SUPPORT TO THE LACK OF CAUSATION BETWEEN IMPLANTS AND ANY TYPE OF CANCER STUDIES HAVE REPORTED AN INCREASED INCIDENCE OF RESPIRATORYLUNG CANCER IN WOMEN WITH BREAST IMPLANTS OTHER STUDIES OF WOMEN IN SWEDEN AND DENMARK HAVE FOUND THAT WOMEN WHO GET BREAST IMPLANTS ARE MORE LIKELY TO BE CURRENT SMOKERS THAN WOMEN WHO GET BREAST REDUCTION SURGERY OR OTHER TYPES OF COSMETIC SURGERY SEVERAL LARGE STUDIES HAVE FOUND NO ASSOCIATION BETWEEN BREAST IMPLANTS AND RESPIRATORYLUNG CANCER TWO STUDIES REPORTED AN INCREASED INCIDENCE OF CERVICALVULVAR CANCER IN WOMEN WITH BREAST IMPLANTS ANOTHER LONG-TERM FOLLOW-UP STUDY SHOWED EQUIVALENT INCIDENCES OF CERVICAL CANCER IN WOMEN WITH BREAST IMPLANTS COMPARED TO THE GENERAL POPULATION OTHER RECENT LARGE STUDIES CONCLUDED THAT THE EVIDENCE DOES NOT SUPPORT AN ASSOCIATION BETWEEN REPRODUCTIVE SYSTEM CANCERS AND BREAST IMPLANTS THERE HAVE BEEN SEVERAL STUDIES PUBLISHED THAT EXAMINED THE RISK OF OTHER TYPES OF CANCERS EG THYROID CANCERS URINARY SYSTEM CANCERS SARCOMA ENDOCRINE CANCER CONNECTIVE TISSUE CANCER CANCER OF THE EYE AND UNSPECIFIED CANCERS IN WOMEN WITH BREAST IMPLANTS ALL OF THOSE STUDIES FOUND NO INCREASED RISK IN WOMEN WITH BREAST IMPLANTS|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6574813|75416231|D|1||REVIEWED ABSTRACT Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMAB ABSTRACT REPORTS Â¿PATIENTS PRESENTED WITH STAGE IIA DISEASE AND ONE OF THE PATIENTS HAD BBA AND PRESENTED WITH A MASS ADJACENT TO THE IMPLANT AND PROGRESSED RAPIDLY THROUGH NEOADJUVANT CHOP TO DEVELOP LIFE THREATENING CHEST WALLTHORACIC CAVITY INVOLVEMENT PATIENT ACHIEVED COMPLETE PATHOLOGICAL RESPONSE WITH SIX CYCLES OF BRENTUXIMAB FOLLOWED BY BILATERAL TOTAL CAPSULECTOMY AND IMPLANT REMOVAL THIS IS THE FIRST REPORTED CASE OF NEO-ADJUVANT ANTIBODY THERAPY IN BIA-ALCLÂ¿ EVENT OF ALCL WILL BE CAPTURED AS LYMPHOMA AS THE NECESSARY HISTOLOGICAL MARKERS ARE NOT CONFIRMED MANUFACTURER OF DEVICE IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6574824|75417105|D|1||REVIEWED ABSTRACT Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMAB ABSTRACT REPORTS Â¿PATIENTS PRESENTED WITH STAGE IIA DISEASE ONE HAD PREVIOUS RRM AND IMPLANT RECONSTRUCTION AND PRESENTED WITH A MASS TREATMENT WAS CHOP+ ECHELON2 TRIAL RADIOTHERAPY AND IMPLANT REMOVALREMAINS WELL AT TWO YEARSÂ¿ EVENT OF ALCL WILL BE CAPTURED AS LYMPHOMA AS THE NECESSARY HISTOLOGICAL MARKERS ARE NOT CONFIRMED MANUFACTURER OF DEVICE IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6574824|75417104|N|1||ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMABÂ¿ BY BY L JOHNSON J ODONOGHUE H STARK N COLLIS A LENNARD M BUTTERWORTH N MCLEAN M YOUSSEF G GUI I LYBURN J BRISTOL J HURREN S SMITH R JACKLIN D CUNNINGHAM AND F MACNEILL PUBLISHED IN CANCER RESEARCH FEB2017 ELECTRONICALLY PUBLISHED APR2017 THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN THE LABELING THE OCCURRENCE OF LUMPS MASSES AND CYSTS CAN BE EXPECTED TO NATURALLY INCREASE AS PATIENTS AGE AND COULD BE AN EXPLANATION FOR THE INCREASE ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6597657|76167628|D|1||DEVELOPED ALCL ANAPLASTIC LARGE CELL LYMPHOMA AFTER BREAST IMPLANTS WITH TEXTURED SILICONE DEVICES PREVIOUS RIGHT BREAST IMPLANT ALSO NATRELLE 120-300 SERIAL NUMBER B4 IMPLANTED ON B6 2008 THIS IMPLANT WAS REMOVED AND SEROMA FLUID EXAMINED THEN BUT FOUND TO BE NORMAL|NATRELLE||05/26/2017||||*|I||I|FTR|2.0||SILICONE-FILLED TEXTURED BREAST|||||GOLETA|US|ALLERGAN|93117|CA|93117||||True
6597657|76167628|D|1||DEVELOPED ALCL ANAPLASTIC LARGE CELL LYMPHOMA AFTER BREAST IMPLANTS WITH TEXTURED SILICONE DEVICES PREVIOUS RIGHT BREAST IMPLANT ALSO NATRELLE 120-300 SERIAL NUMBER B4 IMPLANTED ON B6 2008 THIS IMPLANT WAS REMOVED AND SEROMA FLUID EXAMINED THEN BUT FOUND TO BE NORMAL|NATRELLE|120-300|05/26/2017||||Y|I||0HP|FTR|1.0||SILICONE-FILLED TEXTURED BREAST|||||GOLETA|US|ALLERGAN|93117|CA|93117||120-300||True
6315886|67108821|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/09/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6323469|67162000|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/10/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6584653|75765031|N|1||B4 THE EVENTS OF LYMPHOMA LUMPNODULE SKIN RASHDERMATITIS AND CAPSULAR CONTRACTURE BAKER GRADE III ARE A PHYSIOLOGICAL COMPLAINT AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING THE EVENT PRODUCT ANDOR PATIENT DETAILS WAS REQUESTED DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL FOR MORE COMPLETE AND UP-TO-DATE INFORMATION ON FDAÂ¿S ANALYSIS AND REVIEW OF THE ALCL IN PATIENTS WITH BREAST IMPLANTS PLEASE VISIT HTTPWWWFDAGOVMEDICALDEVICESPRODUCTSANDMEDICALPROCEDURESIMPLANTSANDPROSTHETICSBREASTIMPLANTSUCM239995HTM LITERATURE REPORTS HAVE ALSO BEEN MADE ASSOCIATING SILICONE BREAST IMPLANTS WITH VARIOUS RHEUMATOLOGICAL SIGNS AND SYMPTOMS SUCH AS SKIN RASHES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE CAPSULAR CONTRACTURE PATIENTS SHOULD BE ADVISED THAT CAPSULAR CONTRACTURE MAY BE MORE COMMON FOLLOWING INFECTION HEMATOMA AND SEROMA AND THE CHANCE OF IT HAPPENING MAY INCREASE OVER TIME CAPSULAR CONTRACTURE OCCURS MORE COMMONLY IN REVISION PATIENTS THAN IN PRIMARY AUGMENTATION OR RECONSTRUCTION PATIENTS CAPSULAR CONTRACTURE IS ALSO A RISK FACTOR FOR IMPLANT RUPTURE AND IT IS ONE OF THE MOST COMMON REASONS FOR REOPERATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|05/23/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6613947|76724095|N|1||B4 THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN THE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY SIMILAR TO A BRUISE A SEROMA OCCURS WHEN THE WATERY PORTION OF THE BLOOD COLLECTS AROUND A SURGICAL INCISION OR AROUND A BREAST IMPLANT AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHY CHEST WALL DEFORMITY ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-MX140-520|06/06/2017|||DA|N|R||0HP|FTR|1.0|10/31/2014|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1777073|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6551502|74631918|N|1||B4 FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME THE EVENTS OF LYMPHOMA LATE SEROMA LYMPHADENOPATHY AND BREAST LUMPS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS EVENTS ARE ADDRESSED IN THE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY ADDITIONAL COMPLICATIONS Â¿ AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS THE OCCURRENCE OF LUMPS MASSES AND CYSTS CAN BE EXPECTED TO NATURALLY INCREASE AS PATIENTS AGE AND COULD BE AN EXPLANATION FOR THE INCREASE BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/08/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6551502|74631919|D|1||PHYSICIAN REPORTED A COMPLETE RIGHT CAPSULECTOMY AND BIOPSY OF THREE MACROSCOPICALLY AFFECTED LYMPH NODES WERE PERFORMED PATIENT COMPLAINED OF CHRONIC SEROMA AND UNDERWENT REMOVAL OF IMPLANT AS A RESULT OF WHICH THE SEROMA RESOLVED PATIENT THEN NOTICED A NODULE IN THE RIGHT BREAST CONFIRMED AS ANAPLASTIC LARGE CELL LYMPHOMA FOLLOWING CORE NEEDLE BIOPSY CASE OF ALCL WILL BE REPORTED AS LYMPHOMA AS NECESSARY PATHOLOGICAL MARKERS HAVE NOT BEEN CONFIRMED|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/08/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6323298|67155236|N|1||B4 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS DEVICE CURRENTLY REMAINS IMPLANTED AND WILL BE REQUESTED AFTER PLANNED EXPLANT THE EVENTS OF LYMPHOMA PLEURAL EFFUSION LATE SEROMA COLLAPSED IPSILATERAL LUNG LYMPHADENOPATHY BREAST LUMPS AND DYSPNEA AND ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING DEVICE DETAILS IS BEING REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY|INSPIRA SMOOTH SILICONE GEL FILLED BREAST IMPLANT|SSF370|02/10/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|KILBRIDE INDUSTRIAL ESTATE||ARKLOW, COUNTY WICKLOW||ALLERGAN (ARKLOW)|||||||True
6752840|81359304|N|1||FOLLOW-UP IS COMPLETE AS REPORTING COMPETENT AUTHORITY WILL NOT PROVIDE ANY FURTHER INFORMATION TO SAFEGUARD THE PRIVACY OF THE INVOLVED PATIENTSÂ¿ THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE LABELING ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410MX|07/28/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6574800|75414969|N|1||ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMABÂ¿ BY BY L JOHNSON J ODONOGHUE H STARK N COLLIS A LENNARD M BUTTERWORTH N MCLEAN M YOUSSEF G GUI I LYBURN J BRISTOL J HURREN S SMITH R JACKLIN D CUNNINGHAM AND F MACNEILL PUBLISHED IN CANCER RESEARCH FEB2017 ELECTRONICALLY PUBLISHED APR2017 THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN THE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY SIMILAR TO A BRUISE A SEROMA OCCURS WHEN THE WATERY PORTION OF THE BLOOD COLLECTS AROUND A SURGICAL INCISION OR AROUND A BREAST IMPLANT AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHY CHEST WALL DEFORMITY ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6574800|75414970|D|1||REVIEWED ABSTRACT Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMAB ABSTRACT REPORTS Â¿STAGE I CASES THAT PRESENTED WITH RECURRENT SEROMA WERE TREATED SUCCESSFULLY WITH IMPLANT REMOVAL AND TOTAL CAPSULECTOMY FOUR PATIENTS HAD BILATERAL BREAST AUGMENTATION BBAÂ¿ THIS MEDWATCH REPORT REPRESENTS THESE FOUR STAGE I CASES OF PATIENTS WITH BILATERAL BREAST AUGMENTATION REGARDING TREATMENT ABSTRACT REPORTS SOME CASES Â¿HAD SURGERY TO REMOVE BOTH IMPLANTS AND IPSILATERAL TOTAL CAPSULECTOMY AND OTHERS CONTRALATERAL CAPSULECTOMY AND THE PATHOLOGY WAS BENIGN OR UNILATERAL CAPSULECTOMY AND BILATERAL EXCHANGE OF IMPLANTSÂ¿ WITH THE CURRENT INFORMATION PROVIDED IT IS IMPOSSIBLE TO KNOW WHICH SPECIFIC TREATMENT WAS USED IN THESE CASES EVENT OF ALCL WILL BE CAPTURED AS LYMPHOMA AS THE NECESSARY HISTOLOGICAL MARKERS ARE NOT CONFIRMED MANUFACTURER OF DEVICE IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6434492|70859690|N|1||B4 THE EVENTS OF LYMPHOMA ALCL SEROMA LUMPNODULE AND EDEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE HISTORY RECORD DHR REPORTS BASED ON THE RISK ANALYSIS PERFORMED THE AE TERM CODE LYMPHOMA-ALCL WAS SELECTED FOR ANALYSIS AS IT REPRESENTS THE HIGHEST RISK FALLING ON THE MONITOR RISK REGION WITH AN APPLICABLE INVESTIGATION LEVEL OF 3 REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM SAP WAS VERIFIED AND THERE WAS NO SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER 2493185 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL HEMATOMASEROMA AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|FF-410535|03/24/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2493185|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6751820|81359250|N|1||FOLLOW-UP IS COMPLETE AS REPORTING COMPETENT AUTHORITY WILL NOT PROVIDE ANY FURTHER INFORMATION TO SAFEGUARD THE PRIVACY OF THE INVOLVED PATIENTSÂ¿ THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE LABELING ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|07/28/2017||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6641177|77604162|N|1||FOLLOW-UP IS BEING PERFORMED FOR FURTHER INFORMATION REGARDING THIS EVENT NEW INFORMATION RECEIVED WILL BE REPORTED IN A SUPPLEMENTAL REPORT THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REVIEW OF DHR FOR WORK ORDER 2436682 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES THAT MAY BE ASSOCIATED WITH THE REPORTED DEVICE EVENT ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM SAP WAS VERIFIED AND THERE WAS NOT SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS THE QMS LISTING REPORT INDICATES THAT THERE WERE NO NCMRS OR DEVIATIONS RELATED FOR UNITS MANUFACTURED ON WORK ORDER 2436682 ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER 2436682 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS REPORTED EVENTS ARE ADDRESSED IN THE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY SIMILAR TO A BRUISE A SEROMA OCCURS WHEN THE WATERY PORTION OF THE BLOOD COLLECTS AROUND A SURGICAL INCISION OR AROUND A BREAST IMPLANT AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHY CHEST WALL DEFORMITY ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-MF130-375|06/14/2017|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2436682|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6638628|77497013|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|06/13/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6544056|74409595|N|1||B4 FOLLOW-UP IS CURRENTLY BEING PERFORMED FOR FURTHER DETAILS REGARDING THIS CASE IF ANY NEW INFORMATION IS RECEIVED IT WILL BE SENT IN A SUPPLEMENTAL MEDWATCH THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REVIEW OF DHR DEVICE HISTORY RECORD FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS DHR FOR WORK ORDER B4 INDICATES THAT THERE WAS A REPROCESS FOR TWO UNITS ON THE PRIMARY PACKAGING OPERATION HOWEVER THIS WAS COMPLETED ON A DIFFERENT SERIAL NUMBER UNIT AND THIS HAS NO RELATION NEITHER CAN CAUSE THE REPORTED EVENT THE DHR ASSEMBLY REPORT FROM ORACLE WAS VERIFIED AND THERE WAS NOT ANY SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS REPORTED EVENTS ARE ADDRESSED IN THE LABELING ALLERGAN HAS NOT TESTED THE EFFECTS OF RADIATION THERAPY IN PATIENTS WHO HAVE BREAST IMPLANTS THE LITERATURE SUGGESTS THAT RADIATION THERAPY MAY INCREASE THE LIKELIHOOD OF CAPSULAR CONTRACTURE NECROSIS AND IMPLANT EXTRUSION POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY SIMILAR TO A BRUISE A SEROMA OCCURS WHEN THE WATERY PORTION OF THE BLOOD COLLECTS AROUND A SURGICAL INCISION OR AROUND A BREAST IMPLANT YOU SHOULD PERFORM SELF-EXAMINATION OF YOUR BREASTS EVERY MONTH FOR CANCER SCREENING HOWEVER THIS MAY BE MORE DIFFICULT WITH IMPLANTS YOU SHOULD ASK YOUR SURGEON TO HELP YOU DISTINGUISH THE IMPLANT FROM YOUR BREAST TISSUE THE PRESENCE OF LUMPS PERSISTENT PAIN SWELLING HARDENING OR CHANGES IN IMPLANT SHAPE MAY BE SIGNS OF A RUPTURE OF THE IMPLANT THESE SIGNS SHOULD BE REPORTED TO YOUR SURGEON AND POSSIBLY EVALUATED WITH AN MRI AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHY CHEST WALL DEFORMITY ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|TRM310|05/04/2017||||N|R||0HP|FTR|1.0|09/14/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1327562|KILBRIDE INDUSTRIAL ESTATE||ARKLOW, COUNTY WICKLOW||ALLERGAN (ARKLOW)|||||||True
6574799|75414182|N|1||ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMABÂ¿ BY BY L JOHNSON J ODONOGHUE H STARK N COLLIS A LENNARD M BUTTERWORTH N MCLEAN M YOUSSEF G GUI I LYBURN J BRISTOL J HURREN S SMITH R JACKLIN D CUNNINGHAM AND F MACNEILL PUBLISHED IN CANCER RESEARCH FEB2017 ELECTRONICALLY PUBLISHED APR2017 THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN THE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY SIMILAR TO A BRUISE A SEROMA OCCURS WHEN THE WATERY PORTION OF THE BLOOD COLLECTS AROUND A SURGICAL INCISION OR AROUND A BREAST IMPLANT AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHY CHEST WALL DEFORMITY ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6574799|75414183|D|1||REVIEWED ABSTRACT Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMAB ABSTRACT REPORTS STAGE I CASE OF ALCL AND TWO HAD BILATERAL RISK-REDUCING MASTECTOMIES RRM WITH IMPLANT RECONSTRUCTION THIS MEDWATCH REPORT REPRESENTS TWO STAGE I CASES OF PATIENTS WHO HAD BILATERAL RISK-REDUCING MASTECTOMIES WITH IMPLANT RECONSTRUCTION REGARDING TREATMENT ABSTRACT REPORTS SOME CASES Â¿HAD SURGERY TO REMOVE BOTH IMPLANTS AND IPSILATERAL TOTAL CAPSULECTOMY AND OTHERS CONTRALATERAL CAPSULECTOMY AND THE PATHOLOGY WAS BENIGN OR UNILATERAL CAPSULECTOMY AND BILATERAL EXCHANGE OF IMPLANTSÂ¿ WITH THE CURRENT INFORMATION PROVIDED IT IS IMPOSSIBLE TO KNOW WHICH SPECIFIC TREATMENT WAS USED IN THESE CASES EVENT OF ALCL WILL BE CAPTURED AS LYMPHOMA AS THE NECESSARY HISTOLOGICAL MARKERS ARE NOT CONFIRMED MANUFACTURER OF DEVICE IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6574818|75418664|D|1||REVIEWED ABSTRACT Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMAB ABSTRACT REPORTS STAGE I ALCL CASE OF PATIENT WITH UNILATERAL MASTECTOMY AND IMPLANT RECONSTRUCTION FOR BREAST CANCER REGARDING TREATMENT ABSTRACT STATES STAGE I CASES THAT PRESENTED WITH RECURRENT SEROMA WERE TREATED SUCCESSFULLY WITH IMPLANT REMOVAL AND TOTAL CAPSULECTOMY EVENT OF ALCL WILL BE CAPTURED AS LYMPHOMA AS THE NECESSARY HISTOLOGICAL MARKERS ARE NOT CONFIRMED MANUFACTURER OF DEVICE IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6574818|75418663|N|1||ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMABÂ¿ BY BY L JOHNSON J ODONOGHUE H STARK N COLLIS A LENNARD M BUTTERWORTH N MCLEAN M YOUSSEF G GUI I LYBURN J BRISTOL J HURREN S SMITH R JACKLIN D CUNNINGHAM AND F MACNEILL PUBLISHED IN CANCER RESEARCH FEB2017 ELECTRONICALLY PUBLISHED APR2017 THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN THE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY SIMILAR TO A BRUISE A SEROMA OCCURS WHEN THE WATERY PORTION OF THE BLOOD COLLECTS AROUND A SURGICAL INCISION OR AROUND A BREAST IMPLANT AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHY CHEST WALL DEFORMITY ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6635007|77400539|N|1||ARTICLE CITATION A SHOCKING DIAGNOSIS BREAST IMPLANTS GAVE ME CANCER B6 B6 MAY 14 2017 THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT AND PRODUCT DETAILS CANNOT BE OBTAINED AS PATIENT AND EXPLANTING PHYSICIAN CONTACT INFORMATION WAS NOT PROVIDED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|06/12/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6545873|74473872|D|1||HEALTHCARE PROFESSIONAL REPORTED LEFT SIDE ANAPLASTIC LARGE CELL LYMPHOMA PATIENTÂ¿S INITIAL DIAGNOSIS PROVIDED AS Â¿FIBROCYSTIC BREAST DISEASEÂ¿ BUT AMENDED TO LYMPHOMA ALCL PATIENT ADDITIONALLY EXPERIENCED LEFT SIDE SWELLING AND A SEROMA A CAPSULECTOMY WAS PERFORMED AND THE DEVICE WAS REMOVED APPROXIMATELY 200 RNL OF CHALKY WHITE FLUID WAS FOUND UPON ENTERING THE CAPSULE PHYSICIAN ADDITIONALLY REPORTED THERE WAS A LARGE THICK RIND AROUND THE CAPSULE|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|FF-410740|05/04/2017||||N|R||0HP|FTR|1.0|08/24/2008|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||236550|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6545873|74473871|N|1||B4 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE HISTORY RECORD DHR PROVIDES REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES THAT MAY BE ASSOCIATED WITH THE REPORTED DEVICE EVENT ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY |STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|FF-410740|05/04/2017||||N|R||0HP|FTR|1.0|08/24/2008|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||236550|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6315895|67104048|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/09/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6574798|75415102|N|1||ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMABÂ¿ BY BY L JOHNSON J ODONOGHUE H STARK N COLLIS A LENNARD M BUTTERWORTH N MCLEAN M YOUSSEF G GUI I LYBURN J BRISTOL J HURREN S SMITH R JACKLIN D CUNNINGHAM AND F MACNEILL PUBLISHED IN CANCER RESEARCH FEB2017 ELECTRONICALLY PUBLISHED APR2017 THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN THE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY SIMILAR TO A BRUISE A SEROMA OCCURS WHEN THE WATERY PORTION OF THE BLOOD COLLECTS AROUND A SURGICAL INCISION OR AROUND A BREAST IMPLANT AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHY CHEST WALL DEFORMITY ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6574798|75415103|D|1||REVIEWED ABSTRACT Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMAB ABSTRACT REPORTS STAGE I ALCL CASE OF PATIENT WITH UNILATERAL MASTECTOMY AND IMPLANT RECONSTRUCTION FOR BREAST CANCER REGARDING TREATMENT ABSTRACT STATES STAGE I CASES THAT PRESENTED WITH RECURRENT SEROMA WERE TREATED SUCCESSFULLY WITH IMPLANT REMOVAL AND TOTAL CAPSULECTOMY EVENT OF ALCL WILL BE CAPTURED AS LYMPHOMA AS THE NECESSARY HISTOLOGICAL MARKERS ARE NOT CONFIRMED MANUFACTURER OF DEVICE IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6574819|75418485|N|1||ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMABÂ¿ BY BY L JOHNSON J ODONOGHUE H STARK N COLLIS A LENNARD M BUTTERWORTH N MCLEAN M YOUSSEF G GUI I LYBURN J BRISTOL J HURREN S SMITH R JACKLIN D CUNNINGHAM AND F MACNEILL PUBLISHED IN CANCER RESEARCH FEB2017 ELECTRONICALLY PUBLISHED APR2017 THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN THE LABELING THE OCCURRENCE OF LUMPS MASSES AND CYSTS CAN BE EXPECTED TO NATURALLY INCREASE AS PATIENTS AGE AND COULD BE AN EXPLANATION FOR THE INCREASE ALCL IS NOT BREAST CANCER IT IS A RARE TYPE OF NON-HODGKINÂ¿S LYMPHOMA A CANCER INVOLVING THE CELLS OF THE IMMUNE SYSTEM BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6574819|75418486|D|1||REVIEWED ABSTRACT Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCLÂ¿THE UK EXPERIENCE AND FIRST REPORTED CASE OF NEOADJUVANT BRENTUXIMAB ABSTRACT REPORTS Â¿PATIENTS PRESENTED WITH STAGE IIA DISEASE AND ONE PATIENT WITH PREVIOUS BBA FOLLOWING A ROUTINE IMPLANT EXCHANGE DEVELOPED A BIA-ALCL MASS AT THE DRAIN SITE PATIENT WAS TREATED WITH LOCAL EXCISION ADJUVANT CHOP AND RADIOTHERAPY PATIENT IS WELL AT FOUR YEARSÂ¿ EVENT OF ALCL WILL BE CAPTURED AS LYMPHOMA AS THE NECESSARY HISTOLOGICAL MARKERS ARE NOT CONFIRMED MANUFACTURER OF DEVICE IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/18/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6428377|70695168|D|1||THE DAY AFTER A ROUTINE MAMMOGRAM THERE WAS SWELLING IN RIGHT BREAST SURGEON SUSPECTED RUPTURED CAPSULE SURGERY ON B6 2014 IMPLANT WAS REMOVED FLUID WAS SUSPICIOUS AND TESTING INDICATED LYMPHOMA ANOTHER SURGERY ON B6 2014 TO SECURE MORE TISSUE FOR TESTING - LEFT IMPLANT WAS ALSO REMOVED AT THAT TIME REPORT CONFIRMED ANAPLASTIC LARGE CELL LYMPHOMA IN THE RIGHT BREAST HISTORY 1990 - LUMPECTOMY AFTER DIAGNOSIS OF LOBULAR CANCER IN SITU IN RIGHT BREAST 1991 - BILATERAL MASTECTOMIES AND RECONSTRUCTION WITH SILICONE IMPLANTS B6 2004 - RUPTURED CAPSULE IN LEFT BREAST - IMPLANT REMOVED AND REPLACED CELLULITIS DEVELOPED IN LEFT BREAST RIGHT IMPLANT REMOVED AND REPLACED IN B6 2005 AFTER CELLULITIS WAS TREATED THERE WAS A HOT SPOT ON THE LEFT SIDE THAT APPEARED TO BE A STRAY LYMPH NODE IT STAYED THE SAME FOR ABOUT 2 YEARS THEN APPEARED SMALLER AND FINALLY DISAPPEARED ONCOLOGIST ATTEMPTED A BIOPSY OF THE SPOT BUT IT WAS UNSUCCESSFUL BECAUSE OF THE LOCATION - THEY WERE UNABLE TO GET ENOUGH TISSUE FOR A DIAGNOSIS NO CHEMO OR RADIATION MY CASE MAY HAVE BEEN SUBMITTED BY FDA BY MY SURGEON DR B6 B6 ONCOLOGIST IS DR B6 B6|SILICONE BREAST IMPLANT||03/22/2017||||N|I||I|FTR|3.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE|||||||UNK|||||||True
6428377|70695168|D|1||THE DAY AFTER A ROUTINE MAMMOGRAM THERE WAS SWELLING IN RIGHT BREAST SURGEON SUSPECTED RUPTURED CAPSULE SURGERY ON B6 2014 IMPLANT WAS REMOVED FLUID WAS SUSPICIOUS AND TESTING INDICATED LYMPHOMA ANOTHER SURGERY ON B6 2014 TO SECURE MORE TISSUE FOR TESTING - LEFT IMPLANT WAS ALSO REMOVED AT THAT TIME REPORT CONFIRMED ANAPLASTIC LARGE CELL LYMPHOMA IN THE RIGHT BREAST HISTORY 1990 - LUMPECTOMY AFTER DIAGNOSIS OF LOBULAR CANCER IN SITU IN RIGHT BREAST 1991 - BILATERAL MASTECTOMIES AND RECONSTRUCTION WITH SILICONE IMPLANTS B6 2004 - RUPTURED CAPSULE IN LEFT BREAST - IMPLANT REMOVED AND REPLACED CELLULITIS DEVELOPED IN LEFT BREAST RIGHT IMPLANT REMOVED AND REPLACED IN B6 2005 AFTER CELLULITIS WAS TREATED THERE WAS A HOT SPOT ON THE LEFT SIDE THAT APPEARED TO BE A STRAY LYMPH NODE IT STAYED THE SAME FOR ABOUT 2 YEARS THEN APPEARED SMALLER AND FINALLY DISAPPEARED ONCOLOGIST ATTEMPTED A BIOPSY OF THE SPOT BUT IT WAS UNSUCCESSFUL BECAUSE OF THE LOCATION - THEY WERE UNABLE TO GET ENOUGH TISSUE FOR A DIAGNOSIS NO CHEMO OR RADIATION MY CASE MAY HAVE BEEN SUBMITTED BY FDA BY MY SURGEON DR B6 B6 ONCOLOGIST IS DR B6 B6|SILICONE BREAST IMPLANT||03/22/2017||||N|I||I|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE|||||||UNK|||||||True
6428377|70695168|D|1||THE DAY AFTER A ROUTINE MAMMOGRAM THERE WAS SWELLING IN RIGHT BREAST SURGEON SUSPECTED RUPTURED CAPSULE SURGERY ON B6 2014 IMPLANT WAS REMOVED FLUID WAS SUSPICIOUS AND TESTING INDICATED LYMPHOMA ANOTHER SURGERY ON B6 2014 TO SECURE MORE TISSUE FOR TESTING - LEFT IMPLANT WAS ALSO REMOVED AT THAT TIME REPORT CONFIRMED ANAPLASTIC LARGE CELL LYMPHOMA IN THE RIGHT BREAST HISTORY 1990 - LUMPECTOMY AFTER DIAGNOSIS OF LOBULAR CANCER IN SITU IN RIGHT BREAST 1991 - BILATERAL MASTECTOMIES AND RECONSTRUCTION WITH SILICONE IMPLANTS B6 2004 - RUPTURED CAPSULE IN LEFT BREAST - IMPLANT REMOVED AND REPLACED CELLULITIS DEVELOPED IN LEFT BREAST RIGHT IMPLANT REMOVED AND REPLACED IN B6 2005 AFTER CELLULITIS WAS TREATED THERE WAS A HOT SPOT ON THE LEFT SIDE THAT APPEARED TO BE A STRAY LYMPH NODE IT STAYED THE SAME FOR ABOUT 2 YEARS THEN APPEARED SMALLER AND FINALLY DISAPPEARED ONCOLOGIST ATTEMPTED A BIOPSY OF THE SPOT BUT IT WAS UNSUCCESSFUL BECAUSE OF THE LOCATION - THEY WERE UNABLE TO GET ENOUGH TISSUE FOR A DIAGNOSIS NO CHEMO OR RADIATION MY CASE MAY HAVE BEEN SUBMITTED BY FDA BY MY SURGEON DR B6 B6 ONCOLOGIST IS DR B6 B6|SILICONE BREAST IMPLANT||03/22/2017||||N|I||I|FTR|2.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE|||||||UNK|||||||True
6428377|70695168|D|1||THE DAY AFTER A ROUTINE MAMMOGRAM THERE WAS SWELLING IN RIGHT BREAST SURGEON SUSPECTED RUPTURED CAPSULE SURGERY ON B6 2014 IMPLANT WAS REMOVED FLUID WAS SUSPICIOUS AND TESTING INDICATED LYMPHOMA ANOTHER SURGERY ON B6 2014 TO SECURE MORE TISSUE FOR TESTING - LEFT IMPLANT WAS ALSO REMOVED AT THAT TIME REPORT CONFIRMED ANAPLASTIC LARGE CELL LYMPHOMA IN THE RIGHT BREAST HISTORY 1990 - LUMPECTOMY AFTER DIAGNOSIS OF LOBULAR CANCER IN SITU IN RIGHT BREAST 1991 - BILATERAL MASTECTOMIES AND RECONSTRUCTION WITH SILICONE IMPLANTS B6 2004 - RUPTURED CAPSULE IN LEFT BREAST - IMPLANT REMOVED AND REPLACED CELLULITIS DEVELOPED IN LEFT BREAST RIGHT IMPLANT REMOVED AND REPLACED IN B6 2005 AFTER CELLULITIS WAS TREATED THERE WAS A HOT SPOT ON THE LEFT SIDE THAT APPEARED TO BE A STRAY LYMPH NODE IT STAYED THE SAME FOR ABOUT 2 YEARS THEN APPEARED SMALLER AND FINALLY DISAPPEARED ONCOLOGIST ATTEMPTED A BIOPSY OF THE SPOT BUT IT WAS UNSUCCESSFUL BECAUSE OF THE LOCATION - THEY WERE UNABLE TO GET ENOUGH TISSUE FOR A DIAGNOSIS NO CHEMO OR RADIATION MY CASE MAY HAVE BEEN SUBMITTED BY FDA BY MY SURGEON DR B6 B6 ONCOLOGIST IS DR B6 B6|SILICONE BREAST IMPLANT||03/22/2017||||N|I||I|FTR|4.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE|||||||UNK|||||||True
6498283|72956470|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|04/17/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6352879|68133173|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|02/23/2017||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6497172|72917373|D|1||I DEVELOPED ANAPLASTIC LARGE CELL LYMPHOMA FROM BREAST IMPLANTS|SALINE BREAST IMPLANTS 350CC||04/14/2017||||N|I||I|FWM|2.0||SALINE BREAST IMPLANTS||1309976|||||ALLERGAN/MCGHAN|||||68HP||True
6497172|72917373|D|1||I DEVELOPED ANAPLASTIC LARGE CELL LYMPHOMA FROM BREAST IMPLANTS|SALINE BREAST IMPLANTS 350CC||04/14/2017||||N|I||I|FWM|1.0||SALINE BREAST IMPLANTS||1309976|||||ALLERGAN/MCGHAN|||||68HP||True
2390055|19870278|D|1||RECEIVED MENTOR BREAST IMPLANTS IN 1986 IN B6 2008 WAS DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA AND WAS GIVEN CHEMOTHERAPY AND RADIATION MY ONCOLOGIST WAS B6 AFTER BEING TREATED MY RIGHT IMPLANT CONTINUED TO BE RED AND SWOLLEN SO WE PROCEDED TO DO AN EXPLANTATION MY PLASTIC SURGEON WAS B6 HE DID BOTH THE IMPLANTING AND EXPLANTING RECENTLY IVE READ ABOUT THE LINK BETWEEN THE TYPE OF CANCER I HAD AND BREAST IMPLANTS EXACTLY THE TYPE I HAD I FELT IT WAS IMPORTANT THAT I REPORT MY CASE DIAGNOSIS OR REASON FOR USE COSMETIC|MENTOR SALINE BREAST IMPLANTS|UNK|12/21/2011||||N|||0HP|FWM|1.0||SALINE BREAST IMPLANTS|||||||MENTOR|||||UNK||True
1888850|1687082|D|1||HEALTHCARE PROFESSIONAL REPORTS A CASE OF SEROMA AND ANAPLASTIC LARGE CELL LYMPHOMA ALCL FU FINDINGS PT HAS TEXTURED SALINE BREAST IMPLANT MFR UNK ALLERGAN TAKES THE CONSERVATIVE APPROACH TO REPORTING FU FINDINGS PT HAD WELL CARE APPOINTMENT TWO MONTHS AFTER MULTIPLE BIOPSIES TWO DAYS LATER DEVELOPED BREAST SWELLING PT THEN HAD A GENERAL SURGERY CONSULTATION AND EVAL WITH THREE PERCUTANEOUS DRAINAGE PROCEDURES AND BIOPSIES DIAGNOSIS OF ALCL MADE PRIMARY VS SECONDARY BREAST ALCL UNCLEAR BUT STAGE IV AT DIAGNOSIS MULTI-AGENT CHEMOTHERAPY PROVIDED REFRACTORY TO CHEMOTHERAPY MEDIASTINAL LYMPH NODES IDENTIFIED BY CT SCAN FU FINDINGS PT HAD SUPRA CLAVICULAR AND AXILLARY NODES IN ADDITION TO PRESENTING WITH SWOLLEN BREAST LIVER CHEST WALL MEDIASTINAL LYMPHADENOPATHY RIGHT PLEURAL EFFUSION LUNG NODULES ABDOMINAL WALL RETROPERITONEAL LYMPH NODES FINDINGS INVESTIGATION CONTINUES|UNKNOWN SALINE IMPLANT|UNK SALINE IMPLANT|10/19/2010|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2210599|16724199|D|1||RECEIVED AN ABSTRACT ENTITLED PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST OCCURRING IN PTS WITH SILICONE BREAST IMPLANTS WILL BE PUBLISHED IN THE FINAL ARTICLE ENTITLED LEUKEMIA AND LYMPHOMA AUG 20115281481-1487 WITHIN THE ARTICLE THIS PT IS IDENTIFIED AS PT 7 THIS IS A COSMETIC PT AUGMENTATION SHE WAS DIAGNOSED BY EXCISIONAL BIOPSY OF A NODULE FROM THE LEFT BREAST ADJACENT TO THE IMPLANT SHE WAS IMMEDIATELY TREATED WITH SIX CYCLES OF CHOP AFTER WHICH SHE ACHIEVED WENT INTO REMISSION SHE THEN HAD HER IMPLANTS REMOVED FOLLOWED BY RADIATION TO THE LEFT BREAST PET SCAN AT 6 MONTHS AFTER COMPLETION OF RADIATION SHOWED RELAPSE IN THE RIGHT BREAST AXILLA AND ABDOMEN SHE WAS THEN GIVEN ESHAP ETOPOSIDE METHYLPREDNISOLONE HIGH-DOSE ARA-C AND CISPLATIN SALVAGE FOLLOWED BY STEM CELL COLLECTION FOLLOWING AN AUTOLOGUS TRANSPLANT THE PT HAS BEEN IN REMISSION FOR 6 YEARS THIS MW IS FOR THE LEFT SIDE REFER TO MFR REPORT 2024601-2011-00674 FOR THE RIGHT SIDE|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|08/10/2011|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2112878|2143713|D|1||ALCL CASE REPORT B6 FEMALE B6 ALCL DIAGNOSIS DATE OF DIAGNOSIS - B6 2011 ANATOMIC SITE OF ALCL LEFT BREAST IMPLANT CAPSULE PRIMARY SITE CONFIRMED BY PATHOLOGY INITIAL CLINICAL PRESENTATION B6 2010 THIS IS B6 FEMALE WITH A HISTORY OF DUCTAL CARCINOMA IN SITU OF THE LEFT BREAST DIAGNOSED IN 1998 SHE SUBSEQUENTLY UNDERWENT A LEFT MASTECTOMY WHERE THE SPECIMEN WEIGHT WAS 596 GRAMS SHE UNDERWENT IMMEDIATE RECONSTRUCTION WITH PLACEMENT OF SUBMUSCULAR TISSUE EXPANDER BY PLASTIC SURGEON 1 THE TISSUE EXPANDER WAS PLACED COMPLETELY SUBPECTORAL AND ALSO IN A SUBSERRATUS POCKET THE EXPANDER WAS REMOVED IN 1999 AND REPLACED WITH A MCGHAN 440 ML DUAL-CHAMBER SILICONE AND SALINE-FILLED IMPLANT SHE RECEIVED NO POSTOPERATIVE CHEMOTHERAPY OR RADIATION THERAPY WITHIN A YEAR SHE DEVELOPED SIGNIFICANT HARDENING AND DISTORTION OF THE LEFT RECONSTRUCTED BREAST WITH GRADUAL ELEVATION OF THE IMPLANT TIGHTENING OF THE TISSUE AROUND THE IMPLANT AND DISCOMFORT IN THE LEFT CHEST WALL SHE WAS SEEN IN EVALUATION IN 2006 BY PLASTIC SURGEON 2 WHO RE-OPERATED ON HER LEFT BREAST AND REMOVED THE EXISTING IMPLANT PERFORMED PERIPROSTHETIC CAPSULOTOMIES WHICH WERE NOT SPECIFIED IN THE OPERATIVE NOTE SUBMITTED CAPSULAR TISSUE FOR HISTOLOGIC EXAMINATION INTERPRETED AS NEGATIVE AND REPLACED A SMALLER SALINE IMPLANT THIS WAS AN ALLERGAN-STYLE 68MP SALINE IMPLANT SIZE 390-420 ML THIS RECONSTRUCTION WAS SOFT FOR SEVERAL MONTHS BUT WITHIN 1 YEAR SHE HAD RECURRENCE OF THE CAPSULAR CONTRACTURE WITH TIGHTENING OF THE TISSUE AROUND THE IMPLANT GRADUAL ELEVATION OF THE IMPLANT LOCATION AND DISCOMFORT IN THE LEFT CHEST WALL SHE WAS SEEN IN EVALUATION IN 2009 BY PLASTIC SURGEON 4 WHO RECOMMENDED THAT SHE CONSIDER REVISION OF HER RECONSTRUCTION WITH THE ADDITION OF AN CELLULAR DERMAL MATRIX TO REDUCE THE POTENTIAL FOR RECURRENCE OF HER CAPSULAR CONTRACTURE AROUND THE DEVICE PLASTIC SURGEON 4 ALSO RECOMMENDED AUTOLOGOUS ABDOMINAL FLAP RECONSTRUCTION PROCEDURES THE PT WAS INTERESTED IN CONSIDERING A DIEP FLAP AND PLASTIC SURGEON 4 REFERRED HER TO ME B6 SURGEON 5 FOR EVALUATION AND CONSIDERATION OF A FREE FLAP BREAST RECONSTRUCTION PROCEDURE THE PTS PAST MEDICAL HISTORY WAS ADDITIONALLY SIGNIFICANT FOR A HISTORY OF HYPOTHYROIDISM AND BLADDER PROLAPSE HER MEDICATIONS INCLUDED SYNTHROID 88 MCG DAILY VITAMIN D AND ADVIL SHE IS A NONSMOKER AND DRINKS ALCOHOL RARELY INITIAL PHYSICAL EXAMINATION B6 2010 SHOWED THE PT WAS 155 CM TALL 703 KG THE LEFT BREAST WAS ABSENT THROUGH A TRANSVERSE STEWART-TYPE MASTECTOMY INCISION THERE WAS AN IMPLANT PRESENT IN THE SUBPECTORAL POSITION ON THE LEFT SIDE THERE WAS A BAKER GRADE IV CAPSULE CONTRACTURE AROUND THIS DEVICE WHICH WAS RIGIDLY AFFIXED TO HER CHEST WALL AND SOMEWHAT TENDER TO MANIPULATION THE WOUNDS WERE WELL HEALED WITH NO EVIDENCE OF SCAR HYPERTROPHY THE RIGHT BREAST WAS MORE PTOTIC WITH A DEGREE OF PSEUDOPTOSIS LATERAL BOTTOMING OUT AND A WISE-PATTERN SCAR FROM PREVIOUS MASTOPEXY - RESULTING IN SUBSTANTIAL SHAPE AND VOLUME ASYMMETRY ON THE LEFT SIDE THE STERNAL NOTCH TO INFRAMAMMARY FOLD DISTANCE WAS 20 CM ON THE RIGHT SIDE THE STERNAL NOTCH TO INFRAMAMMARY FOLD DISTANCE WAS 23 CM THE MID-CLAVICULAR POINT TO NIPPLE DISTANCE ON THE RIGHT WAS 21 CM EXAMINATION OF THE ABDOMEN SHOWED A GENEROUS AMOUNT OF TISSUE IN THE LOWER 13 OF THE ABDOMEN FOR ABDOMINAL FLAP CONSIDERATION INITIAL IMPRESSION B6 2010 THIS WAS A B6 FEMALE WITH RECURRENT CAPSULAR CONTRACTURE FOLLOWING 2 PREVIOUS IMPLANT-BASED RECONSTRUCTION SURGERIES ON THE LEFT SIDE THE LEFT BREAST RECONSTRUCTION SHOWED ELEVATION OF THE INFRAMAMMARY FOLD AND A SEVERE CAPSULAR CONTRACTURE AROUND THE EXISTING IMPLANT I RECOMMENDED REMOVAL OF THE EXISTING LEFT BREAST IMPLANT RECONSTRUCTION OF THE ORIGINS OF THE LEFT PECTORALIS MAJOR MUSCLE AND RECONSTRUCTION OF THE LEFT BREAST WITH A FREE ABDOMINAL FLAP OPERATIVE FINDINGS ON B6 2011 THE LEFT BREAST IMPLANT CAPSULE WAS OPENED AND CONTAINED A CLOUDY YELLOW FLUID UNDER ENORMOUS PRESSURE THE FLUID SQUIRTED OUT OF THE CAPSULAR INCISION AND TRAVELED AT LEAST 56 INCHES THERE WAS A COLLECTION OF GELATINOUS MATERIAL WITHIN THE CAPSULE AS WELL AS AN INTACT SALINE BREAST IMPLANT THE CAPSULE WAS THICKENED AND COVERED WITH PLAQUE-LIKE LESIONS INTERNALLY A TOTAL CAPSULECTOMY WAS PERFORMED THE PECTORALIS MAJOR MUSCLE WAS REATTACHED TO ITS 5TH RIB ORIGINS THE PERIPROSTHETIC FLUID WAS CAPTURED AND ALL MATERIAL WAS SENT FOR PATHOLOGIC AND CYTOLOGIC EVALUATION INCLUDING FROZEN SECTION WHICH WAS CONSISTENT WITH A DIAGNOSIS OF ALCL THE REMAINING RECONSTRUCTION WAS ABANDONED PENDING FINAL PATHOLOGY EVALUATION SPECIMEN DETAILED PATHOLOGY FINDINGS LEFT BREAST PERI-PROSTHETIC MATERIAL LARGE ATYPICAL CELLS PRESENT MOST CONSISTENT WITH INVOLVEMENT BY ANAPLASTIC LARGE CELL LYMPHOMA IMPLANT LEFT BREAST IMPLANT CAPSULE INVOLVEMENT BY ANAPLASTIC LARGE CELL LYMPHOMA B6|MODERATE PROFILE SMOOTH ROUND SALINE BREAST IMPLANT||05/27/2011||||Y|||0HP|FWM|1.0||68MP 390CC||1316501|||||MCGHAN MEDICAL - AKA ALLERGAN MEDICAL|||||68MP 390CC||True
2097844|18413658|D|1||COMPANY SALES REPRESENTATIVE REPORTED ANAPLASTIC LARGE CELL LYMPHOMA ALCL IN RIGHT BREAST CONFIRMED BY HEALTH PROFESSIONAL CYTOLOGY CONFIRMED DIAGNOSIS CD30 POSITIVE ALK NEGATIVE PATIENT HAS A HISTORY OF LEFT SIDE BREAST CANCER THE PATIENT PRESENTED WITH SEROMA ONLY NO SYSTEMIC SYMPTOMS|STYLE 153 SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 153|05/04/2011|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2162357|2127483|D|1||A REPORT OF NULL-TYPE ANAPLASTIC LARGE CELL LYMPHOMA ARISING IN A SILICONE BREAST IMPLANT CAPSULE WRITTEN IN PLASTIC AND RECONSTRUCTIVE SURGERY JUNE 2011 VOL 127 NUMBER 6 WAS REVIEWED AND ADDITIONAL INFO WAS REQUESTED BY THE AUTHOR THE AUTHOR SUBMITTED MINIMAL DEVICE INFO HE WAS ABLE TO INFORM PRODUCT SUPPORT THAT THE PT WAS IMPLANTED 19 YEARS AGO WITH A SMOOTH SILICONE DEVICE AND REPLACED WITH A TEXTURED DEVICE IN 2006 BUT IS UNSURE OF THE STYLE IN 2007 THE PT HAD A CAPSULECTOMY THE DEVICE REMAINS IMPLANTED AS IT WAS FOUND TO BE INTACT FINALLY IN 2009 SHE WAS REPLACED WITH A MCGHAN 110-220 TEXTURED SILICONE IMPLANT BOTH IMPLANTS WERE REMOVED ACCORDING TO THE ARTICLE THERE WAS SERIOUS HEMATIC FLUID AROUND THE RIGHT PROSTHESIS CAPSULECTOMY WAS PERFORMED THE PATHOLOGIC FINDINGS WERE CONSISTENT WITH A DIAGNOSIS OF NULL-TYPE ANAPLASTIC LYMPHOMA KINASE NEGATIVE NON-HODGKINS ANAPLASTIC LARGE CELL LYMPHOMA|STYLE 110 SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 110|07/07/2011|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2210614|15512186|D|1||RECEIVED AN ABSTRACT ENTITLED PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST OCCURRING IN PTS WITH SILICONE BREAST IMPLANTS WILL BE PUBLISHED IN THE FINAL ARTICLE ENTITLED LEUKEMIA AND LYMPHOMA AUG 20115281481-1487 WITHIN THE ARTICLE THIS PT IS IDENTIFIED AS PT 6 SHE IS A COSMETIC AUGMENTATION PT WHO WAS FOUND TO HAVE A NODULE IN THE INFRAMAMMARY FOLD OF THE LEFT BREAST WHICH GREW OVER SEVERAL MONTHS BUT WAS NEGATIVE BY MAMMOGRAM SHE HAD HER LEFT IMPLANT REMOVED AND THE TISSUE IN THE FIBROUS CAPSULE WAS DIAGNOSED AS ALCL THE PT WAS TREATED WITH 6 CYCLES OF CHOP BUT EXPERIENCED TUMOR REGROWTH WITHIN 2 WEEKS OF COMPLETION ICE SALVAGE WAS GIVEN WITH RADIATION BUT WAS INEFFECTIVE FINALLY SHE RECEIVED AN AUTOLOGUS TRANSPLANT USING CBV CYCLOPHOSPHAMIDE CARMUSTINE AND ETOPOSIDE CONDITIONING REGIMEN AND HAD BEEN IN REMISSION FOR 75 YEARS AT LAST FU THIS MW IS FOR THE LEFT SIDE REFER TO MFR REPORT 2024601-2011-00674 FOR THE RIGHT SIDE|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|08/10/2011|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2218186|15143339|D|1||A B6 FEMALE HISTORY OF SALINE BREAST AUGMENTATION 2001 WITH COMPLAINTS OF ITCHING AND PAIN FOR 1 YEAR INVOLVING THE LEFT BREAST PT HAD MAMMOGRAM AFTER NOTICING FIRMNESS OF LEFT BREAST FOR ONE MONTH MAMMOGRAMSONOGRAM REVEALED CIRCUMFERENTIAL FLUID COLLECTION SURROUNDING ENTIRE LEFT BREAST EXTENDING TO AXILLARY REGION ULTRASOUND GUIDED FLUID ASPIRATION PERFORMED ON B6 2011 REVEALED ATYPICAL LYMPHOID PROLIFERATION CONSISTENT WITH CD30 POSITIVE ALK NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA SURGERY PERFORMED B6 2011 TO REMOVE IMPLANTS HAD CONFIRMATION OF PATHOLOGY|MCGHAN MEDICAL||08/16/2011||||N|||0|FWM|1.0||BREAST IMPLANT SALINE||57787B|71 SOUTH LOS CARNEROS||GOLETA|US|ALLERGAN|93111|CA|93111||||True
2210613|2193837|D|1||ABSTRACT RECEIVED ENTITLED PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST OCCURRING IN PTS WITH SILICONE BREAST IMPLANTS WAS REPORTED AND WILL BE PUBLISHED IN THE FINAL ARTICLE ENTITLED LEUKEMIA AND LYMPHOMA AUG 20115281481-1487 WITHIN THE ARTICLE THIS PT IS IDENTIFIED AS PT 1 IT INDICATES THAT SHE IS A COSMETIC AUGMENTATION WHO ORIGINALLY PRESENTED WITH SWELLING OF THE LEFT BREAST AFTER DRAINAGE OF THE FLUID THE FLUID SHOWED LARGE AMOUNTS OF ATYPICAL LYMPHOCYTES THE FLUID ACCUMULATION DID NOT RECUR FOR 2 YEARS AT WHICH TIME SHE EXPERIENCED RAPID SWELLING OF THE LEFT BREAST THE WORK-UP YIELDED A DIAGNOSIS OF ALCL ALK- THE PT PRESENTED TO CITY OF HOPE FOR A SECOND OPINION CHOP WAS RECOMMENDED BUT TREATMENT WAS CARRIED OUT ELSEWHERE AND OUTCOME IS UNK|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|08/10/2011|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2210610|16745564|D|1||RECEIVED AN ABSTRACT ENTITLED PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST OCCURRING IN PTS WITH SILICONE BREAST IMPLANTS WAS REPORTED AND WILL BE PUBLISHED IN THE FINAL ARTICLE ENTITLED LEUKEMIA AND LYMPHOMA AUG 20115281481-1487 WITHIN THE ARTICLE THIS PT IS IDENTIFIED AS PT 7 THIS IS A COSMETIC PT AUGMENTATION SHE WAS DIAGNOSED BY EXCISIONAL BIOPSY OF A NODULE FROM THE LEFT BREAST ADJACENT TO THE IMPLANT SHE WAS IMMEDIATELY TREATED WITH SIX CYCLES OF CHOP AFTER WHICH SHE ACHIEVED WENT INTO REMISSION SHE THEN HAD HER IMPLANTS REMOVED FOLLOWED BY RADIATION TO THE LEFT BREAST PET SCAN AT 6 MONTHS AFTER COMPLETION OF RADIATION SHOWED RELAPSE IN THE RIGHT BREAST AXILLA AND ABDOMEN SHE WAS THEN GIVEN ESHAP ETOPSIDE METHYLPREDNISOLONE HIGH-DOSE ARA-C AND CISPLATIN SALVAGE FOLLOWED BY STEM CELL COLLECTION FOLLOWING AN AUTOLOGUS TRANSPLANT THE PT HAS BEEN IN REMISSION FOR 6 YEARS THIS MW IS FOR THE RIGHT SIDE REFER TO MEDWATCH MFR REPORT 2024601-2011-00663 FOR THE LEFT SIDE|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|08/10/2011|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2027271|1955552|D|1||A B6 FEMALE DIAGNOSED WITH BREAST-IMPLANT RELATED ANAPLASTIC LARGE CELL LYMPHOMA PT HAD BILATERAL MASTECTOMIES WITH SALINE IMPLANT RECONSTRUCTION IN 1992 DEVELOPED LEFT SIDED IDIOPATHIC LARGE VOLUME SEROMA IN 2009 IMPLANTS REMOVED AND PARTIAL CAPSULECTOMY PERFORMED BY A DIFFERENT PLASTIC SURGEON NO REPLACEMENT OF IMPLANTS AT THAT TIME PATHOLOGY REPORTS NEGATIVE AT THAT TIME RECURRENT SEROMA FOLLOWING EXPLANTATION REQUIRING REPEAT CAPSULECTOMY AND DRAIN PLACEMENT B6 2010 AGAIN NEGATIVE PATHOLOGY REPORT PT PRESENTED FOR DELAYED TWO-STAGE RECONSTRUCTION IN MY PRACTICE PERFORMED ON B6 2011 LEFT BREAST SEROMA SMALL AND CAPSULE IDENTIFIED COMPLETELY REMOVED PATHOLOGY REPORTS CONFIRMED ALCL OF THE LEFT BREAST CAPSULE ALK-1 NEGATIVE SALINE BREAST IMPLANT UNKNOWN MANUFACTURER NOT SURE IF IT WAS TEXTURED OR SMOOTH PT DOES NOT HAVE RECORDS AND SURGEON WHO REMOVED THE IMPLANTS DOES NOT RECALL OTHER THAN THEY WERE SALINE PATHOLOGY REPORT DOES NOT INDICATE TEXTURED VS SMOOTH|UNK||03/17/2011||||N|||0|FWM|1.0||SALINE BREAST IMPLANT||UNK|||||UNK|||||||True
2222963|2168811|D|1||PT WITH BREAST IMPLANTS HAS DEVELOPED ANAPLASTIC LARGE CELL LYMPHOMA 17 YEARS AFTER UNDERGOING BREAST AUGMENTATION ON B6 1994 IMPLANTS WERE ROUND TEXTURED SALINE IMPLANTS MANUFACTURED BY MCGHAN PT WAS ASYMPTOMATIC UNTIL APPROXIMATELY B6 2011 WHEN SHE DEVELOPED BODY-WIDE PRURITIS NOTED AN INCREASE IN THE SIZE OF HER RIGHT BREAST AND THE DEVELOPMENT OF A RIGHT PARASTERNAL MASS|MCGHAN|27-168301|08/20/2011||||Y|||0HP|FWM|1.0||TEXTURED SALINE BREAST IMPLANT||BP8422|||||MCGHAN MEDICAL CORP.|||||||True
2150825|2102553|D|1||HEALTH PROFESSIONAL REPORTS ANAPLASTIC LARGE CELL LYMPHOMA SEROMA AND GRANULOMATOUS MASS ALL LOCATED IN PATIENTS RIGHT BREAST PATIENT HAS A HISTORY OF PREEXISTING BILATERAL BREAST CANCER AND PRIMARY BREAST RECONSTRUCTION MCGHAN SALINE STYLE 163-360 DEVICES IMPLANTED BILATERALLY IN 1999 THE PATIENT PRESENTED WITH SYMPTOMS OF ACUTE LOCALIZED SWELLING OF RIGHT BREAST RECONSTRUCTION OF THE CAPSULE WAS PERFORMED IN B6 2011 SEROMA DRAINED FLUID SENT FOR CYTOLOGY AND BIOPSY TAKEN OF TISSUE MASS ON B6 2011 FINDINGS CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA DENSE FIBROSIS CONTAINING ATYPICAL CELLS CD30 POSITIVE ALK NEGATIVE THE PATIENT HAD SUBSEQUENT EXPLANT SURGERY AND CAPSULECTOMY ON B6 2011 OTHER TREATMENTS INCLUDING CHEMOTHERAPY OR RADIATION ARE UNKNOWN AT THIS TIME THE PATIENT IS DOING WELL EXPLANTED DEVICE HAS NOT BEEN RETURNED TO ALLERGAN|STYLE 163 SALINE FILLED BREAST IMPLANT|163-360|06/02/2011|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2348477|18501906|D|1||HEALTHCARE PROFESSIONAL REPORTS VIA VOLUNTARY MW B4 A CASE OF ALCL INFECTION PAIN AND BREAST ENLARGEMENT THE HEALTH PROFESSIONAL REPORTS WHITE FEMALE PRESENTED TO MY OFFICE IN 2010 WITH AN INFECTED RIGHT BREAST IMPLANT SHE HAD PREVIOUS SILICONE BREAST IMPLANTS 17 YRS PRIOR TO A LITTLE OVER A YR OF SYMPTOMS INCLUDING PAIN ENLARGEMENT AND MORE RECENTLY REDNESS THERE WAS A FAILED COURSE OF ANTIBIOTIC THERAPY AT THE TIME OF HER PRESENTATION SHE ALSO HAD EPIDERMOLYSIS OF HER HANDS FEET AND PERIAREOLAR REGION EXAM WAS CONSISTENT WITH AN INFECTED BREAST IMPLANT THEREFORE THE IMPLANT WAS REMOVED IN THE OFFICE UNDER LOCAL ANESTHESIAS HER EPIDERMOLYSIS EVENTUALLY CLEARED AND THE INFECTION IMPROVED HOWEVER SHE DEVELOPED AN INFLAMMATORY ABSCESS IN THE INFRAMAMMARY PORTION OF THE RIGHT BREAST THAT REQUIRED OPERATIVE EXCISION AND DEBRIDEMENT UNDER ANESTHESIA THE TISSUE THAT WAS REMOVED AND SENT TO THE LABORATORY CAME BACK ANAPLASTIC LARGE CELL LYMPHOMA THE PT HAD A CONSULT FOR TREATMENT AND RECEIVED CHEMOTHERAPY SHE REQUESTED REMOVAL OF THE LEFT BREAST IMPLANT AS WELL WHICH WAS UNEVENTFUL BUT FOUND TO BE RUPTURED UPON REMOVAL THE PRODUCT WAS RETAINED AND IS AVAILABLE FOR EXAMINATION THE PT CONTINUED TO BE UNDER MY CARE AT THIS TIME|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|09/30/2011|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2348477|62765167|D|1||HEALTHCARE PROFESSIONAL REPORTED A CASE OF ANAPLASTIC LARGE CELL LYMPHOMA WHICH WILL BE CAPTURED AS LYMPHOMA AS THERE IS NO PATHOLOGY REPORT AVAILABLE TO CONFIRM THE DIAGNOSIS OF ALCL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|09/30/2011|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2210616|2207031|D|1||RECEIVED AN ABSTRACT ENTITLED PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST OCCURRING IN PTS WITH SILICONE BREAST IMPLANTS WAS REPORTED AND WILL BE PUBLISHED IN THE FINAL ARTICLE ENTITLED LEUKEMIA AND LYMPHOMA AUG 20115281481-1487 WITHIN THE ARTICLE THIS PT IS IDENTIFIED AS PT 5 IT DOES NOT INDICATE IF SHE IS AN AUGMENTATION OR RECONSTRUCTION PT THERE IS MINIMAL INFO PROVIDED IN THE ARTICLE REGARDING THIS PT THE ONLY INFO THAT IS NOTED IS THAT THERE WAS A PATHOLOGY CONSULTATION ON TISSUE FROM THE FIBROUS CAPSULE OF THE RIGHT BREAST IMPLANT|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|08/10/2011|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
1985458|1846143|D|1||ALK NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA AFTER BREAST IMPLANTS FOR RECONSTRUCTION FROM BREAST CANCER DATES OF USE B6 2007 DIAGNOSIS OR REASON FOR USE REPLACING SALINE IMPLANTS 1 RUPTURE MENTOR SILICONE BREAST IMPLANTS PUT IN ON B6 2007 RIGHT BREAST REMOVED ON B6 2008 REPLACED SAME DAY WITH MENTOR SILICONE IMPLANT REMOVED BOTH ON B6 2008 VIA RADICAL MASTECTOMY FOUR WRONG DIAGNOSES OF BREAST CANCER MADE 9 WEEKS AFTER MASTECTOMY ALCL DIAGNOSIS MADE TREATED WITH VERY HIGH DOSING CHEMO SEVERAL KINDS STEM CELL TRANSPLANT ADDL CHEMO AND RADIATION EVENT ABATED AFTER USE NO EVENT REAPPEARED AFTER REINTRODUCTION YES|MENTOR||02/07/2011||||N|||0HP|FTR|1.0||SILICONE BREAST IMPLANTS|||||||MENTOR|||||||True
2210612|2207030|D|1||RECEIVED THE ABSTRACT ENTITLED PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST OCCURRING IN PTS WITH SILICONE BREAST IMPLANTS WAS REPORTED AND WILL BE PUBLISHED IN THE FINAL ARTICLE ENTITLED LEUKEMIA AND LYMPHOMA AUG 20115281481-1487 WITHIN THE ARTICLE THIS PT IS IDENTIFIED AS PT 2 IT IS UNK IF SHE IS AN AUGMENTATION PT OR A RECONSTRUCTION PT SHE WAS DIAGNOSED WITH TISSUE FROM THE FIBROUS CAPSULE OF THE LEFT BREAST IMPLANT THE INFO PROVIDED FOR THIS PT IS MINIMAL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|08/10/2011|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2210600|2186240|D|1||RECEIVED AN ABSTRACT ENTITLED PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST OCCURRING IN PTS WITH SILICONE BREAST IMPLANTS WAS REPORTED AND WILL BE PUBLISHED IN THE FINAL ARTICLE ENTITLED LEUKEMIA AND LYMPHOMA AUG 20115281481-1487 WITHIN THE ARTICLE THIS PT IS IDENTIFIED AS PT 4 SHE IS A COSMETIC AUGMENTATION PT WHO HAD RECEIVED INTRAPARENCHYMAL SILICONE INJECTIONS 30 YEARS PRIOR TO DIAGNOSIS WHICH WERE REPLACED 3 YEARS LATER AT THE TIME OF DIAGNOSIS SHE HAD ONLY THE RIGHT IMPLANT REMOVED ALONG WITH FLUID AND LYMPHOMATOUS TISSUE FROM THE CAPSULE THIS PT WAS TREATED WITH 6 CYCLES OF CHOP AND RADIATION BUT RECURRED AGAIN WITH RECURRENCE IN 2 MONTHS AFTER UNSUCCESSFUL ATTEMPTS TO COLLECT FOR STEM CELLS PT PURSUED ALTERNATIVE TREATMENTS|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|08/10/2011|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2140645|2119287|D|1||ALK NEGATIVE ALCL - ANAPLASTIC LARGE CELL LYMPHOMA POSSIBLY RELATED TO BREAST IMPLANTS HX OF HL - TREATED WITH MANTLE FIELD RADIATION THERAPY AND BREAST CANCER TREATED WITH SURGERY CHEMO AND TAMOXIFEN|BREAST IMPLANTS||06/22/2011||||N|||0|FWM|1.0||BREAST IMPLANTS|||||||nan|||||||True
2338306|2365004|D|1||A REPORT OF LYMPHOMA OF THE BREAST CAPSULE IN SILICONE IMPLANT-RECONSTRUCTED PT PUBLISHED IN THE AMERICAN SURGEON SEPT 2010 VOL 76 PG 1030-31 WAS REVIEWED AND ADDL INFO HAS BEEN REQUESTED BY THE AUTHOR THE AUTHOR HAS NOT RESPONDED TO THIS DATE WITHIN THE ARTICLE THE AUTHOR NOTES A B6 WOMAN WITH A TISSUE DIAGNOSIS OF ADENOCARCINOMA OF THE LEFT BREAST UNDERWENT A LEFT MODIFIED RADICAL MASTECTOMY WITH PROPHYLACTIC RIGHT BREAST SIMPLE MASTECTOMY IN 1999 THIS WAS IMMEDIATELY FOLLOWED BY PRIMARY RECONSTRUCTION WITH SILICONE IMPLANTS THE LYMPH NODE BASIN WAS FREE OF DISEASE AND THE PT RECEIVED NO CHEMOTHERAPY OR RADIATION THERAPY SIX YEARS LATER SHE PRESENTED TO HER PRIMARY CARE WITH A LUMP IN HER RECONSTRUCTED RIGHT BREAST ON EXAMINATION SHE HAD A 3CM NON-TENDER MOBILE CYSTIC MASS IN THE RIGHT BREAST AT THE 9 OCLOCK POSITION COMPRESSION OF THE IMPLANT CAUSED ENLARGEMENT OF THE LESION SHE DID NOT REPORT NIPPLE DISCHARGE OR RETRACTION THE SKIN AND AREOLA COMPLEX WERE NORMAL AND THERE WERE NO PALPABLE LYMPH NODES HER PRIMARY CARE PHYSICIAN PERFORMED A NEEDLE ASPIRATION OF THE MASS WHICH WAS ORANGE IN COLOR WITH CYTOLOGIC FEATURES OF ADENOCARCINOMA SHE UNDERWENT BILATERAL IMPLANT REMOVAL EXCISION OF THE CYSTIC MASS AND BIOPSIES OF BOTH CAPSULES THE LEFT BREAST IMPLANT WAS INTACT AND THE CAPSULE WAS NORMAL IN APPEARANCE THE RIGHT BREAST IMPLANT WAS INTACT AS WELL HOWEVER THE ANTERIOR AND POSTERIOR WALLS OF THE CAPSULE WERE COATED WITH A NECROTIC HETEROGENEOUS MATERIAL INITIAL BIOPSIES OF THE RIGHT BREAST CAPSULE SHOWED POORLY DIFFERENTIATED ADENENOCARCINOMA IT WAS IMMUNOPOSITIVE FOR CD30 EMA AND T-CELL MARKERS CD45RO CD43 FINAL PATHOLOGY OF THE MASS AFTER REVIEW BY A SECOND PATHOLOGIST AT A UNIVERSITY HOSPITAL WAS ANAPLASTIC LARGE CELL LYMPHOMA ALK- T CELL PHENOTYPE THE POST OP RECOVER WAS UNEVENTFUL THE PT HAD A COURSE OF CHOP PROTOCOL OUR PTS LYMPHOMA WAS DISCOVERED AS A CYSTIC LESION INVOLVING THE RIGHT BREAST CAPSULE THE PRELIMINARY CYTOLOGIC FEATURE OF THE LESION WAS POORLY DIFFERENTIATED ADENENOCARCINOMA SIMILAR TO THE PRIOR DIAGNOSIS OF THE LEFT BREASTONLY AFTER IMMUNOHISTOCHEMISTRY OF THE SPECIMEN WAS SHE CORRECTLY DIAGNOSED WITH ALCL T-CELL LYMPHOMA AND TREATED WITH CHOP CHEMOTHERAPY PROTOCOL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|11/09/2011|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2030915|1919205|D|1||ON B6 2010 DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA ALCL ALK-NEGATIVE POSSIBLY RELATED OR CAUSED BY BREAST IMPLANTS RECEIVED IN B6 2002 FOR AUGMENTATION EXPERIENCED COMPLICATIONS WITH LEFT IMPLANT DIAGNOSED AS CAPSULAR CONTRACTION IMPLANT REPLACED ON B6 2008 STILL EXPERIENCING CAPSULAR CONTRACTION AFTER REPLACEMENT B6 2010 - B6 2011 RECEIVED 12 DOSES OF CHEMOTHERAPY RECEIVED 20 DOSES OF RADIATION THERAPY PREPARING FOR STEM CELL TRANSPLANT SCHEDULED FOR B6 2011 B6 2010 NEEDLE BIOPSY - DIAGNOSIS LYMPHOMA B6 2010 SURGICAL BIOPSY - DIAGNOSIS ALCL B6 2010 SURGICAL BIOPSY - DIAGNOSIS ALCL|NATRELLE||03/17/2011||||N|||0HP|FWM|1.0||SALINE - FILLED BREAST IMPLANT||RIGHT: 579142|||IRVINE|US|ALLERGAN, INC.||CA|||STYLE # 468||True
2030915|1919205|D|1||ON B6 2010 DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA ALCL ALK-NEGATIVE POSSIBLY RELATED OR CAUSED BY BREAST IMPLANTS RECEIVED IN B6 2002 FOR AUGMENTATION EXPERIENCED COMPLICATIONS WITH LEFT IMPLANT DIAGNOSED AS CAPSULAR CONTRACTION IMPLANT REPLACED ON B6 2008 STILL EXPERIENCING CAPSULAR CONTRACTION AFTER REPLACEMENT B6 2010 - B6 2011 RECEIVED 12 DOSES OF CHEMOTHERAPY RECEIVED 20 DOSES OF RADIATION THERAPY PREPARING FOR STEM CELL TRANSPLANT SCHEDULED FOR B6 2011 B6 2010 NEEDLE BIOPSY - DIAGNOSIS LYMPHOMA B6 2010 SURGICAL BIOPSY - DIAGNOSIS ALCL B6 2010 SURGICAL BIOPSY - DIAGNOSIS ALCL|NATRELLE||03/17/2011||||N|||0HP|FWM|2.0||SALINE - FILLED BREAST IMPLANT|||||IRVINE|US|ALLERGAN, INC.||CA|||STYLE # 468||True
1976502|1898383|D|1||PATIENT WAS DIAGNOSED WITH ALCL - ANAPLASTIC LARGE CELL LYMPHOMA - AROUND HER RIGHT SALINE BREAST IMPLANT THE IMPLANTS WERE ORIGINALLY PLACED IN 1998 THE IMPLANTS HAVE BEEN REMOVED AND SHE HAS BEEN TREATED FOR HER LYMPHOMA|SALINE BREAST IMPLANT||01/26/2011||||N|||0LP|FWM|1.0||SALINE BREAST IMPLANT|||||||ALLERGAN|||||||True
2025987|1914162|D|1||HEALTH PROFESSIONAL INITIALLY REPORTS PATIENT HAD HISTORY OF PREEXISTING BREAST CANCER WITH RECONSTRUCTION SURGERY BILATERAL TISSUE EXPANDERS AND MCGHAN SALINE TEXTURED IMPLANTS PLACED THE PATIENT PRESENTED WITH SWELLING OF LEFT BREAST SIX YEARS POST RECONSTRUCTION SALINE DEVICES EXPLANTED PER PATIENTS REQUEST AND EXCHANGED WITH ALLERGAN SILICONE SMOOTH DEVICES FLUID SENT FOR PATHOLOGYCYTOLOGY OPERATIVE NOTE DESCRIBE FLUID AS MODERATE BROWN LIQUID OLD BLOOD SENT TO CYTOLOGY AND THE RESULTS SHOWED CD30+ ALK- LEFT SEROMA CYTOLOGY DIAGNOSED AS ANAPLASTIC LARGE CELL LYMPHOMA NO CHEMOTHERAPY OR RADIATION THERAPY DONE THE DEVICE HAS BEEN EXPLANTED BUT THE DEVICE HAS NOT BEEN RETURNED TO ALLERGAN FOR ANALYSIS PATIENT IS DOING WELL IS SCHEDULED FOR A FOLLOW-UP ULTRA-SOUND AND CT SCAN AND IS BEING FOLLOWED BY AN ONCOLOGIST|STYLE 20 SILICONE GEL FILLED BREAST IMPLANT|20-500|03/16/2011|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
1976511|1898917|D|1||ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSIS ASSOCIATED WITH A SILICONE BREAST IMPLANT DIAGNOSIS OR REASON FOR USE BREAST RECONSTRUCTION|nan||01/26/2011||||N|||0HP|FTR|1.0||BREAST IMPLANT|||||||nan|||||||True
2210597|2206520|D|1||RECEIVED ABSTRACT ENTITLED PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST OCCURRING IN PTS WITH SILICONE BREAST IMPLANTS WILL BE PUBLISHED IN THE FINAL ARTICLE ENTITLED LEUKEMIA AND LYMPHOMA AUG 20115281481-1487 WITHIN THE ARTICLE THIS PT IS IDENTIFIED AS PT 3 WHO WAS A COSMETIC AUGMENTATION PT WHO DID NOT INITIALLY HAVE HER IMPLANTS REMOVED SHE WAS IMMEDIATELY TREATED WITH SIX CYCLES OF CHOP BUT DID NOT RESPOND TO TREATMENT IT WAS THEN THAT HER IMPLANTS WERE REMOVED AND SHE WAS TREATED WITH RADIATION HER MASS WAS INCREASING IN SIZE WHILE RECEIVING RADIATION SHE FINALLY WENT INTO REMISSION FOLLOWING 3 CYCLES OF ICE AND SALVAGE THERAPY THE PT WAS SOON LOST TO FU|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|08/10/2011|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2162376|2140768|D|1||PATIENT REPORTED THIS CASE OF ANAPLASTIC LARGE CELL LYMPHOMA TO THE FDA WHO CONFIRMED THE CASE WITH HER PHYSICIAN PATIENT HAS HISTORY OF BILATERAL BREAST AUGMENTATION AND SUBSEQUENT BILATERAL SEROMAS TWO YEARS POST AUGMENTATION BIOPSY OF SEROMA FLUID POSITIVE FOR ANAPLASTIC LARGE CELL LYMPHOMA T-CELL TYPE ALK NEGATIVE OF LEFT BREAST ONLY BILATERAL CAPSULECTOMIES AND EXPLANTS PERFORMED NO CHEMOTHERAPY OR RADIATION THERAPY PATIENT DOING WELL UNDER OBSERVATION AT THIS TIME|STYLE 168 SALINE FILLED BREAST IMPLANT|168-420|07/07/2011|||DA|N|R||0HP|FWM|1.0|10/23/2008|nan||1046378|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
2121010|2056222|D|1||RECEIVED VOLUNTARY B4 FROM THE FDA STATING PATIENT WAS DIAGNOSED WITH ALCL  ANAPLASTIC LARGE CELL LYMPHOMA - AROUND HER RIGHT SALINE BREAST IMPLANT A CALL WAS PLACED TO THE SURGEONS OFFICE TO GATHER ADDL INFO ABOUT THE DEVICE PT DEMOGRAPHICS AND PATHOLOGY THE DEVICE WAS PLACED IN 1998 THE DEVICES HAVE BEEN REMOVED AND SHE HAS BEEN TREATED FOR HER LYMPHOMA AT THE TIME OF THIS SUBMISSION THERE HAS BEEN NO ADDL INFO RECEIVED FROM THE OFFICE|UNK SALINE IMPLANT|UNK SALINE IMPLANT|05/26/2011|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2369793|17557106|D|1||PT DEVELOPED SEROMA AND CAPSULAR CONTRACTURE OF LEFT BREAST AFTER SILICONE BREAST AUGMENTATION B6 2007 COMPLETE LEFT BREAST CAPSULECTOMY AND IMPLANT EXCHANGE WAS PERFORMED ON B6 2011 PATHOLOGY SUBSEQUENTLY REPORTED AS IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA|ALLERGAN NATRELLE|15-575|12/08/2011||||N|||0HP|FTR|1.0||BREAST IMPLANT|||||IRVINE|US|ALLERGAN||CA|||15||True
2210596|2193346|D|1||RECEIVED ABSTRACT ENTITLED PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST OCCURRING IN PATIENTS WITH SILICONE BREAST IMPLANTS WILL BE PUBLISHED IN THE FINAL ARTICLE ENTITLED LEUKEMIA AND LYMPHOMA AUG 20115281481-1487 WITHIN THE ARTICLE THIS PT IS IDENTIFIED AS PT 8 WHO WAS A COSMETIC AUGMENTATION CASE THIS PT PRESENTED WITH FLUID ACCUMULATION IN THE LEFT BREAST AFTER SECOND DRAINAGE OF A LARGE VOLUME OF FLUID WHILE WAITING FOR THE CYTOLOGY REPORT SHE HAD HER TEXTURED IMPLANTS REMOVED AND REPLACED WITH SMOOTH SALINE IMPLANTS A DIAGNOSIS ALCL ALK-WAS MADE AND CONFIRMED BY B4 T-CELL REARRANGEMENT STUDIES TREATMENT WITH CHOP WAS RECOMMENDED BUT SHE TREATED ELSEWHERE AND THE OUTCOME IS UNK|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|08/10/2011|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2341597|18977395|D|1||NEW DIAGNOSIS OF ANAPLASTIC LARGE CELL LYMPHOMA RIGHT BREAST IN PT WITH BREAST IMPLANT AUGMENTATION IMPLANT PLACED B6 2011 MCGHAN STYLE 168 ROUND TEXTURED MAMMARY SALINE IMPLANT 27 -168211 LOT NUMBER NH6968 ONE YEAR HISTORY OF HARDENING AND LIFTING RIGHT BREAST ABNORMAL MAMMOGRAM AND ULTRASOUND PROMPTED BREAST MRI 66 X55 CM MASS SEEN ON MRI ULTRASOUND GUIDED BREAST BIOPSY ON B6 2011 REVEALED ANAPLASTIC LARGE CELL LYMPHOMA ALK- NEGATIVE PT TO RECEIVE CHOP CHEMOTHERAPY|MCGHAN STYLE 168|27-168211|11/10/2011||||N|||0|FWM|1.0||ROUND TEXTURED MAMMARY IMPLANT||NH6968|||||MCGHAN|||||168||True
2119775|2053625|D|1||B6 IS A B6 WHITE FEMALE WHO PRESENTED TO MY OFFICE B6 2010 WITH AN INFECTED RIGHT BREAST SHE HAD PREVIOUS SILICONE BREAST IMPLANTS 17 YEARS PRIOR TO A LITTLE OVER A YEAR OF SYMPTOMS INCLUDING PAIN ENLARGEMENT AND MORE RECENTLY REDNESS THERE WAS A FAILED COURSE OF ANTIBIOTIC THERAPY AT THE TIME OF HER PRESENTATION SHE ALSO HAD EPIDERMOLYSIS OF HER HANDS FEET AND PERIAREOLAR REGION EXAM WAS CONSISTENT WITH AN INFECTED BREAST IMPLANT THEREFORE THE IMPLANT WAS REMOVED IN THE OFFICE UNDER LOCAL ANESTHESIA HER EPIDERMOLYSIS EVENTUALLY CLEARED AND THE INFECTION IMPROVED HOWEVER SHE DEVELOPED AN INFLAMMATORY ABSCESS IN THE INFRAMAMMARY PORTION OF THE RIGHT BREAST THAT REQUIRED OPERATIVE EXCISION AND DEBRIDEMENT UNDER ANESTHESIA THE TISSUE THAT WAS REMOVED AND SENT TO THE LABORATORY CAME BACK ANAPLASTIC LARGE CELL LYMPHOMA THIS BREAST EVENTUALLY WENT ON TO HEAL SHE WAS SEEN IN CONSULTATION AT B6 AND RECEIVED CHEMOTHERAPY BECAUSE OF THE POSSIBLE ASSOCIATION OF THE CANCER WITH THE IMPLANT ALONG WITH HER ASYMMETRY ISSUES SHE REQUESTED REMOVAL OF THE LEFT IMPLANT WHICH WAS DONE UNEVENTFULLY OF NOTE IS THAT THE IMPLANT ON THE LEFT SIDE WAS RUPTURED BUT IDENTIFICATION WAS ABLE TO BE MADE INDICATING A MCGHAN 360CC SILICONE GEL TEXTURED IMPLANT THE PRODUCT WAS RETAINED AND IS AVAILABLE FOR EXAMINATION THE PT CONTINUES TO BE UNDER MY CARE AT THIS TIME|MCGHAN TEXTURED SILICONE GEL BREAST IMPLANT, 360CC|UNK|06/03/2011||||Y|||000|FTR|1.0||BREAST IMPLANT||UNK|||||MCGHAN CORPORATION|||||UNK||True
2551207|2685956|D|1||DEVELOPED ANAPLASTIC LARGE CELL LYMPHOMA ALK INVOLVING BREAST IMPLANT|UNK|UNK|04/23/2012||||Y|||0|FWM|2.0||SALINE BREAST IMPLANTS||UNK|UNK||UNK||UNK|||||UNK||True
2551207|2685956|D|1||DEVELOPED ANAPLASTIC LARGE CELL LYMPHOMA ALK INVOLVING BREAST IMPLANT|UNK|UNK|04/23/2012||||Y|||0|FWM|1.0||SALINE BREAST IMPLANTS||UNK|UNK||UNK||UNK|||||UNK||True
2617537|2730865|D|1||PT DEVELOPED ANAPLASTIC LARGE CELL LYMPHOMA RELATED TO A BREAST IMPLANT - MCGHAN 650 CC DATES OF USE OVER 30 YEARS REASON FOR USE BREAST AUGMENTATION|MCGHAN 650CC||06/11/2012||||Y|||0|FWM|1.0||BREAST IMPLANT||MCGHAN 650|||||MCGHAN||||||UNK|True
2517651|20917029|D|1||CASE OF ALCL ASSOCIATED WITH RUPTURED SILICONE BREAST IMPLANT PT PRESENTED WITH GROSS INFECTION IN R BREAST 30 YRS FOLLOWING BILATERAL MASTECTOMY RECONSTRUCTIONS WITH SILICONE BREAST PROSTHESES RUPTURED SILICONE IMPLANTS REMOVED SUCCESSFULLY ON BOTH SIDES GROSS INFECTION NOTED ON R EXCESS SKIN TRIMMED PATHOLOGY ON SKIN SHOWED ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH BREAST IMPLANT PT IS DEMENTED DAUGHTER STATES SURGERY SOMETIME IN EARLY 1980S FURTHER DETAILS UNK PT MADE FULL RECOVERY FROM SURGERY NO PLANS FOR CHEMOTHERAPY BUT PTS FAMILY REPORTS WEIGHT LOSS OVER LAST YEAR AND QUESTION OF LESIONS SEEN IN SPLEENLIVER INCIDENTALLY ON CT SCAN IN LAST 2 YRS - I NEVER COULD LOCATE THE REPORT I HAVE PREOP PHOTOS AVAILABLE UNFORTUNATELY THE IMPLANT WAS DISCARDED AS FAR AS I KNOW IMPLANT WAS DISINTEGRATED|UNKNOWN|UNK|04/01/2012||||N|||0|FTR|1.0||SILICONE BREAST IMPLANT||UNK|UNK||UNK||UNK|||||UNK||True
2873438|3241646|D|1||PT IS A B6 FEMALE WHO PRESENTED WITH A UNILATERAL LATE SEROMA IN HER RIGHT BREAST 16 YRS AFTER UNDERGOING A COSMETIC BREAST AUGMENTATION WITH SALINE IMPLANTS SHE HAD NO RECENT HISTORY OF TRAUMA INFECTION OR OTHER EVENT TO EXPLAIN HER FINDINGS SHE WAS INITIALLY EVALUATED BY A BREAST SURGEON WHO ORDERED A BREAST MRI SUSPECTING AN IMPLANT LEAK MRI SHOWED THE IMPLANT WAS INTACT THERE WAS NO MASS VISUALIZED THERE WAS A LARGE AMOUNT OF FLUID SURROUNDING THE BREAST IMPLANT SHE WAS REFERRED TO ME PLASTIC SURGERY FOR FURTHER EVAL PT WAS SENT FOR ULTRASOUND GUIDED ASPIRATION OF THE FLUID SURROUNDING THE BREAST IMPLANT CULTURE RESULTS OF THE FLUID SHOWED NO BACTERIA PATHOLOGY RESULTS CONFIRMED ANAPLASTIC LARGE CELL LYMPHOMA SHE WAS EVALUATED BY A HEMATOLOGISTONCOLOGIST WHO PERFORMED A STAGING WORKUP SHE THEN UNDERWENT SURGICAL REMOVAL OF BOTH IMPLANTS AND THEIR SURROUNDING CAPSULES ON B6 2012 B4 RIGHT BREAST FLUID ATYPICAL LYMPHOCYTIC INFILTRATE CONSISTENT WITH SEROMA ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA THE PAP STAIN SMEAR AND THE HE STAINED CELL BLOCK SHOWS AN ATYPICAL LYMPHOCYTIC INFILTRATE COMPOSED OF PREDOMINANTLY LARGE NEOPLASTIC CELL INFILTRATES WITH ANAPLASTIC FEATURES THE NEOPLASTIC LYMPHOCYTES EXPRESS CD30 CD45 CD5 CD3 SUBSET EMA SUBSET BCL-2 BUT NOT ALK1 ER PR AE13 CD34 CD20 PAX5 CD68 OR CD10 THE MIB STAIN IS POSITIVE IN LESS THAN 10 OF NEOPLASTIC LYMPHOCYTES THE OVERALL FINDINGS ARE CONSISTENT WITH SEROMA ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA THAT FREQUENTLY OCCURS ADJACENT TO BREAST IMPLANTS MOST OF THE CASES REPORTED HAVE BEEN ASSOCIATED WITH AN INDOLENT CLINICAL COURSE TCR GENE REARRANGEMENT IS PENDING TO FURTHER EVALUATE THE CLONALITY OF THESE NEOPLASTIC LYMPHOCYTES EVENT ABATED AFTER USE STOPPED OR DOSE REDUCED YES|UNKNOWN - NOT LABELED||12/07/2012||||N|||0HP|FWM|1.0||TEXTURED ROUND SALINE BREAST IMPLANT 475 CC|||||||nan|||||||True
2459139|19868903|D|1||RIGHT TOTAL MASTECTOMY POSITIVE FOR ANAPLASTIC LARGE CELL LYMPHOMA OF BREAST IMPLANT CAPSULE|UNKNOWN|UNK|02/17/2012||||N|||0|FWM|1.0||BREAST IMPLANT||UNK|UNK||UNK||UNK|||||||True
2718829|3055395|D|1||PT IS A B6 FEMALE WHO UNDERWENT LEFT MASTECTOMY IN 1996 FOR DUCTAL CARCINOMA IN SITU WITH TISSUE EXPANDER AND SALINE IMPLANT RECONSTRUCTION SHE PRESENTED IN B6 2010 WITH A PERI-IMPLANT HEMATOMA THOUGHT POSSIBLY POST-TRAUMATIC SHE UNDERWENT EVACUATION OF THE HEMATOMA AND CHANGE TO A SILICONE GEL IMPLANT ALL PATHOLOGY SPECIMENS WERE NEGATIVE FOR TUMOR SHE AGAIN PRESENTED IN B6 2012 WITH A SPONTANEOUS HEMATOMA AND AT SURGERY MULTIPLE BIOPSIES REVEALED ANAPLASTIC LARGE CELL LYMPHOMA ALCL LIMITED TO THE PERIPROSTHETIC CAPSULE AND HEMATOMA FLUID AFTER AN EXTENSIVE HEMATOLOGIC AND METASTATIC WORKUP WHICH WAS NEGATIVE SHE UNDERWENT REMOVAL OF THE IMPLANT AND TOTAL PERIPROSTHETIC CAPSULECTOMY CAPSULAR PATHOLOGY SHOWED ALCL|MENTOR SMOOTH ROUND HIGH PROFILE GEL, 450CC|350-4505BC|08/23/2012||||Y|||0HP|FTR|1.0||SILICONE GEL BREAST IMPLANT||6004844|||SANTA BARBARA|US|MENTOR CORP.||CA|||350-4505BC||True
2578247|2650283|D|1||ADDITIONAL INFORMATION PROVIDED RECEIVED FROM A LITERATURE ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA AND BREAST IMPLANTS FIVE B6 CASES PUBLISHED IN THE PLASTIC AND RECONSTRUCTIVE SURGERY B6 2012 B4 WITHIN THE ARTICLE THE AUTHOR DESCRIBES SEROMA WITHIN THE ARTICLE THE AUTHOR DESCRIBES A B6 WHO UNDERWENT A RIGHT MASTECTOMY AXILLARY DISSECTION AND IMMEDIATE BEAST RECONSTRUCTION WITH A LATISSIMUS DORSI FLAP AND TISSUE EXPANDER IN B6 1996 SHE DID NOT REQUIRE ADJUVANT THERAPY THE EXPANDER WAS REPLACED WITH A 390CC ROUND SMOOTH IMPLANT IN B6 1996 REVISION WAS PERFORMED ON THE RIGHT BREAST CAPSULE IN B6 1997 IN B6 1999 THE SALINE DEVICE WAS REPLACED WITH A TEXTURED SALINE IMPLANT B4 IN B6 2007 THE PATIENT DEVELOPED A SEROMA THE SEROMA WAS ASPIRATED AND REVEALED ALCL THE DEVICE WAS LEFT IN PLACE DURING CHEMOTHERAPY AS THE SEROMA RECURRED SHE THUS UNDERWENT TOTAL CAPSULECTOMY AND IMPLANT REMOVAL IN B6 2007 HER TREATMENT WAS COMPLETED WITH FURTHER CHEMOTHERAPY AND RADIATION SHE IS NOW DISEASE FREE THIS EVENT WAS ORIGINALLY REPORTED VIA EASR B6 2011|STYLE 468 SALINE FILLED BREAST IMPLANT|UNK STYLE 468|05/09/2012|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2786161|19225058|D|1||HEALTHCARE PROFESSIONAL NOTES LYMPHOMA RECD MW B4 THAT NOTES ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSED APPROXIMATELY 11 YEARS FOLLOWING POST BILATERAL MASTECTOMY RECONSTRUCTION WITH TEXTURED EXPANDERS AND MCGHAN TEXTURED SALINE BREAST IMPLANTS THERE IS NO DEVICE INFO NOR SURGEON INFO IS PROVIDED THERE IS NO HISTOLOGICALCYTOLOGY INFO PROVIDED THERE IS MINIMAL INFO PROVIDED INVESTIGATION IS CLOSED AND CAN BE REOPENED IFWHEN NEW INFO IS PROVIDED AND FORWARDED ALONG|UNK SALINE IMPLANT|UNK SALINE IMPLANT|09/24/2012|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2564353|2651879|D|1||ANAPLASTIC LARGE CELL LYMPHOMA AND BREAST IMPLANTS FIVE B6 CASES PUBLISHED IN THE PLASTIC AND RECONSTRUCTIVE SURGERY B6 2012 B4 WITHIN THE ARTICLE THE AUTHOR DESCRIBES A B6 WOMAN WHO PRESENTED IN 2011 WITH A RIGHT BREAST LUMP HER HISTORY NOTES A WIDE LOCAL EXCISION OF THE RIGHT BREAST FOR DUCTAL CARCINOMA IN SITU FOLLOWED BY RADIOTHERAPY IN 1995 IN 1998 SHE HAD A MASTECTOMY FOR RECURRENT DISEASE AND RECONSTRUCTION WITH A PEDICLED LATISSIMUS DORSI FLAP IN 2006 SHE HAD A REVISION WITH A RIGHT BREAST AUGMENTATION SUBPECTORALIS AND LATISSIMUS DORSI FLAP AND LEFT BREAST AUGMENTATION FOR SYMMETRY SUBFASCIAL WITH A TEXTURED MCGHAN IMPLANTS SHE UNDERWENT AN OPEN BIOPSY IN WHICH TWO MASSES WERE FOUND ONE MEDIAL AND ONE LATERAL THE MEDIAL MASS WAS FOUND TO HAVE THE IMPLANT WHICH HAD RUPTURED IMMEDIATELY UNDER IT THE IMPLANT WAS REMOVED A TOTAL CAPSULECTOMY WAS PERFORMED AND THE IMPLANT REPLACED THE ASSUMPTION THE MASS WAS A SILICOMA HISTOPATHOLOGIC ANALYSIS REVEALED BOTH MASSES TO BE ALK- ALCL CD30+ AND THE REMAINDER OF THE CAPSULE WAS NEGATIVE THE REMAINDER OF HER WOUND FAILED TO HEAL AND THE RIGHT BREAST IMPLANT WAS REMOVED CT SCAN AND PET SCAN WERE NORMAL AS WAS THE BONE MARROW SHE BEGAN CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE DOXORUBICIN VINCRISTINE AND PREDNISONE AND IS AWAITING RADIATION SHE CURRENTLY HAS NO RECURRENCE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|05/01/2012|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2702764|17972089|D|1||RECEIVED A MEDWATCH B4 FORM ON B6 2012 WITH A REPORT FROM THE HEALTHCARE PROFESSIONAL REPORTING PT REMOVED HER IMPLANTS AFTER THE DEVELOPMENT OF LEFT PERO-IMPLANT SEROMA CAPSULAR CONTRACTURE BAKER GRADE UNKNOWN AND LYMPHOMA AND A RIGHT SIDE IMPLANT REMOVAL NO COMPLAINT AGAINST THE DEVICE LEFT BREAST CAPSULE WAS RESECTED AND POSITIVE FOR ALK NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA THE HEALTHCARE PROFESSIONAL PROVIDES TEST RESULTS AND REPORTED PET WAS NEGATIVE AND BONE MARROW BIOPSY WAS NEGATIVE FOR MALIGNANCY PT IS CURRENTLY UNDERGOING CHEMOTHERAPY TO ERADICATE RESIDUAL DISEASE WHICH WILL BE FOLLOWED BY EXTERNAL RADIATION THERAPY TO INVOLVED FIELD OF LEFT BREAST MULTIPLE ATTEMPTS HAVE BEEN MADE TO GATHER DEVICE AND ADDITIONAL INFORMATION HOWEVER TO DATE THERE HAS BEEN NO ADDITIONAL INFORMATION PROVIDED|UNK SALINE IMPLANT|UNK SALINE IMPLANT|08/13/2012|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2578281|2650718|D|1||ADDITIONAL INFORMATION RECEIVED FROM A LITERATURE ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA AND BREAST IMPLANTS FIVE AUSTRALIAN CASES PUBLISHED IN THE PLASTIC AND RECONSTRUCTIVE SURGERY APRIL 2012 PG 610E-617E WITHIN THE ARTICLE THE AUTHOR DESCRIBES A B6 AUGMENTATION PATIENT WHO HAD SURGERY 25 YEARS PRIOR SHE PRESENTED TO HER PRIMARY CARE PHYSICIAN FOR GENERAL MALAISE AND LETHARGY THE DETAILS WERE UNAVAILABLE TO THE AUTHOR HE NOTES HE HAD PERFORMED A HOST OF INVESTIGATIONS THE MAMMOGRAM AND ULTRASOUND SUGGEST RUPTURE WITH PERIPROSTHETIC FLUID COLLECTION AND A THICK CAPSULE SURGERY WAS SCHEDULED TO REMOVE AND REPLACE HER RUPTURED IMPLANTS AT THE TIME OF SURGERY HER IMPLANTS WERE FOUND TO BE INTACT THE CAPSULE HAD GRANULOMATOUS GROWTHS WITHIN IT AND A MODERATE AMOUNT OF SEROMA THAT WAS DRAINED NEW IMPLANTS WERE INSERTED AND CAPSULECTOMIES WERE PERFORMED THE OLD IMPLANTS WERE FOUND TO BE ROUND TEXTURED SILICONE GEL FILLED OF UNKNOWN MAKE HISTOLOGICAL ANALYSIS OF THE RIGHT BREAST CAPSULE WAS CONSISTENT WITH LOCALIZED SYSTEMIC ALCL ALK- HER SYMPTOMS OF LETHARGY AND MALAISE RESOLVED SHE WENT ON TO HAVE CHEMOTHERAPY BUT DECLINED RADIATION WHEN LAST SEEN SHE WAS DISEASE FREE THIS EVENT WAS ORIGINALLY SENT VIA B4 24JAN2011|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/09/2012|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2648318|15024103|D|1||LATE SEROMA LEFT BREAST AFTER BILATERAL BREAST IMPLANTS SUBMUSCULAR ALLERGAN TEXTURED IMPLANTS DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA|ALLERGAN TEXTURED SALINE IMPLANTS||07/06/2012||||Y|||0|FWM|1.0||SALINE BREAST IMPLANTS|||||||ALLERGAN|||||||True
2622560|2762059|D|1||PT DEVELOPED ALK NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST IN ASSOCIATION WITH BREAST IMPLANT ORIGINAL IMPLANTS WERE REPORTEDLY SALINE PLACED IN 1987 AT B6 HOSP THESE IMPLANTS WERE REMOVED AND NEW SALINE IMPLANTS WERE PLACED IN 1995 IN B6 REPORTED AS MCGHAN TEXTURED SALINE IMPLANT 380ML VOLUME ON B6 2012 AFTER THE DEVELOPMENT OF LEFT PERI-IMPLANT SEROMA BILATERAL IMPLANTS WERE REMOVED AND THE LEFT BREAST CAPSULE WAS RESECTED AND POSITIVE FOR ALK NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA PET WAS NEGATIVE AND BONE MARROW BIOPSY WAS NEGATIVE FOR MALIGNANCY PT IS CURRENTLY ON CHEMOTHERAPY TO ERADICATE RESIDUAL DISEASE WHICH WILL BE FOLLOWED BY XRT TO INVOLVED FIELD OF LEFT BREAST PT ALSO HAD A PREVIOUS BREAST IMPLANT REMOVED IN 1995 AS ABOVE I DONT KNOW ANYTHING ADDL ABOUT THIS IMPLANT|MCGHAN||06/10/2012||||N|||0|FWM|1.0||TEXTURED SALINE BREAST IMPLANT||UNK|||||MCGHAN|||||||True
2888498|60381987|D|1||THROUGH MY RESEARCH REVIEW AS RN PRODUCT SUPPORT SPECIALIST THE FOLLOWING ARTICLE CAME TO MY ATTENTION SILICONE IMPLANT AND PRIMARY BREAST ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA FACT OR FICTION INT J CLN EXP PATHOL 2010 31 117-127|UNK SALINE IMPLANT|UNK SALINE IMPLANT|12/20/2012|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
2888498|60340181|D|1||REPORTED EVENTS WITHIN JOURNAL ARTICLE SILICONE IMPLANT AND PRIMARY BREAST ALK1-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA FACT OR FICTION INT J CLN EXP PATHOL 201031117-127 JOURNAL ARTICLE STATES ABOUT FIVE AND A HALF YEARS FOLLOWING THE SURGERY PATIENT WAS FOUND TO HAVE LEFT BREAST SWELLING WITH A PAINLESS MASS MAGNETIC RESONANCE IMAGING MRI OF THE CHEST SHOWED FLUID COLLECTION AROUND PATIENTS IMPLANT FINE NEEDLE ASPIRATION OF THE FLUID AROUND THE BREAST IMPLANT SHOWED LARGE ATYPICAL MONO NUCLEAR CELLS WITH IRREGULAR NUCLEAR CONTOURS AND PROMINENT NUCLEOLI IN A BACKGROUND OF SMALL LYMPHOCYTES SUSPICIOUS FOR RECURRENCE OF THE PATIENTÂ¿S INFILTRATING DUCTAL CARCINOMA THE IMPLANT WAS THEN SURGICALLY REMOVED AND SUBMITTED FOR PATHOLOGICAL EXAMINATIONÂ¿ ARTICLE FURTHER STATES Â¿THE MORPHOLOGIC IMMUNOHISTOCHEMICAL AND MOLECULAR FINDINGS SUPPORT A DIAGNOSIS OF ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ PATIENT WAS TREATED WITH Â¿6 CYCLES OF CHOPÂ¿ AND NO EVIDENCE OF DISEASE 10 MONTHS AFTER TREATMENTÂ¿|UNK SALINE IMPLANT|UNK SALINE IMPLANT|12/20/2012|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
2645572|2874280|D|1||HEALTH PROFESSIONAL REPORTED RIGHT SIDE ANAPLASTIC LARGE CELL LYMPHOMA SEROMA CAPSULAR CONTRACTURE BAKER GRADE UNK THE PTÂ¿S NOTES INDICATE THAT AUGMENTATION SURGERY WAS PERFORMED IN 1990 WITH A SMOOTH SILICONE IMPLANT IN 1999 THE PT UNDERWENT REVISION SURGERY AND HAD A TEXTURED SILICONE IMPLANT PLACED THAT WAS 365CC CYTOLOGY REPORT SUBMITTED AND NOTES THE PT HAD RIGHT BREAST SEROMA 300 CC OF YELLOW FLUID DRAINED AND SENT FOR CYTOLOGY THE CYTOLOGY WAS POSITIVE FOR CD30 TIA1 AND CD3 THERE WAS FOCAL CD56 ALK AND CD20 WERE NEGATIVE|STYLE 110 SILICONE GEL FILLED BREAST IMPLANT|110-330|06/29/2012||05/31/2012|DA|R|Y||0HP|FTR|1.0|03/15/2003|nan||40897|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
2822645|3025069|D|1||PT UNDERWENT BILATERAL SILICONE BREAST IMPLANTS IN 1989 STARTING IN B6 2011 SHE DEVELOPED DISCOMFORT IN LEFT CHEST WALL A LARGE FLUID COLLECTION SURROUNDING THE LEFT IMPLANT WAS FOUND IN B6 2012 FLUID DRAINAGE SHOWED ALK NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA CELLS WITHOUT A MASS SHE UNDERWENT REMOVAL OF BILATERAL BREAST IMPLANTS ON B6 2012 EVENT ABATED AFTER USE STOPPED OR DOSE REDUCED YES|MCGHAN 300 CC|UNKNOWN|11/01/2012||||Y|||0LP|FWM|1.0||BREAST IMPLANT||UNKNOWN|||||UNKNOWN|||||UNKNOWN||True
2766557|2912622|D|1||BREAST IMPLANT - RELATED ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSED WHEN BREAST IMPLANTS CELL REMOVED - B6 2012 THE PT HAD IMPLANTS PLACED 20 YEARS AGO|BREAST IMPLANTS MCGHAN||09/24/2012|||||||0|FWM|2.0||BREAST IMPLANTS|||||||MCGHAN|||||||True
2766557|2912622|D|1||BREAST IMPLANT - RELATED ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSED WHEN BREAST IMPLANTS CELL REMOVED - B6 2012 THE PT HAD IMPLANTS PLACED 20 YEARS AGO|BREAST IMPLANTS MCGHAN||09/24/2012|||||||0|FWM|1.0||BREAST IMPLANTS|||||||MCGHAN|||||||True
2844637|3044749|D|1||REPORTED AS ANAPLASTIC LARGE CELL LYMPHOMA CONTRACTURE AND ASSOCIATED ASYMMETRY FROM RESEARCH ARTICLE 2008 AMERICAN JOURNAL OF SURGICAL PATHOLOGY WONG ET AL ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH A BREAST IMPLANT CAPSULE A CASE REPORT AND REVIEW OF THE LITERATURE FOLLOW-UP FINDINGS DOCTOR STATES IS ALLERGAN DEVICE BUT IS UNABLE TO EXONERATE DEVICE AS INSUFFICIENT STUDY EVIDENCE B4|UNK SALINE IMPLANT|UNK SALINE IMPLANT|11/16/2012|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2708456|2756351|D|1||ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSED APPROXIMATELY 11 YEARS FOLLOWING POST BILATERAL MASTECTOMY RECONSTRUCTION WITH TEXTURED SALINE TISSUE EXPANDERS AND MCGHAN TEXTURED SALINE BREAST IMPLANTS|MCGHAN||08/16/2012||||N|||0|FWM|1.0||TEXTURED SALINE BREAST IMPLANT||UNK|||SANTA BARBARA|US|MCGHAN MEDICAL||CA|||||True
2834717|16866252|D|1||ANAPLASTIC LARGE CELL LYMPHOMA AFTER IMPLANTS|STYLE 153 360ML ALLERGAN DOUBLE||10/05/2012||||N|||0|FTR|2.0||BREAST IMPLANT|||||||ALLERGAN|||||||True
2834717|16866252|D|1||ANAPLASTIC LARGE CELL LYMPHOMA AFTER IMPLANTS|STYLE 133 LV 400ML ALLERGAN TISS||10/05/2012||||N|||0|FTR|1.0||BREAST IMPLANT|||||||ALLERGAN|||||||True
2883100|21051084|D|1||PATIENT HAD PRIOR BILATERAL BREAST IMPLANTS MCGHAN 390ML IMPLANTS CURRENTLY KNOWN AS ALLERGAN INAMED SHE WAS EXPERIENCING BILATERAL CAPSULAR CONTRACTURE AND ENLARGING RIGHT BREAST  SURGEON SUSPECTED SEVERE RIGHT BREAST IMPLANT RUPTURE WITH RADIOLOGIC STUDIES  SHE ELECTED TO REMOVE BOTH IMPLANTS WHICH WAS DONE TODAY  NO REPLACEMENT IMPLANTS WERE DONE  THE PATHOLOGY REPORT AND SURGICAL FINDINGS INCLUDED LEFT BREAST IMPLANT WITH NO SUSPICIOUS FINDINGS RIGHT BREAST FOUND RESOLVING HEMATOMA WHICH WAS EXTRUDED THE IMPLANT APPEARED INTACT  THE PATHOLOGY OF THE RIGHT BREAST IMPLANT CAPSULE REVEALED ANAPLASTIC LARGE CELL LYMPHOMA THE PATIENT IS CURRENTLY RECEIVING TREATMENT FOR LYMPHOMA  THE PATHOLOGIST WAS AWARE THAT THE FDA WAS REQUESTING REPORTS OF IMPLANTS ASSOCIATED WITH THIS TYPE OF LYMPHOMA|INAMED|*|10/31/2012||||N|||*|FWM|1.0||BREAST IMPLANT||*|71 SOUTH LOS CARNEROS ROAD||GOLETA|US|ALLERGAN|93117|CA|93117||*|*|True
3030985|21262828|D|1||LEFT SIDE REPORTED AS ANAPLASTIC LARGE CELL LYMPHOMA CONTRACTURE AND ASSOCIATED ASYMMETRY FROM RESEARCH ARTICLE PUBLISHED 2008 AMERICAN JOURNAL OF SURGICAL PATHOLOGY WONG ET AL ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH A BREAST IMPLANT CAPSULE A CASE REPORT AND REVIEW OF THE LITERATURE FU FINDINGS DOCTOR STATES IS ALLERGAN DEVICE BUT IS UNABLE TO EXONERATE DEVICE AS INSUFFICIENT STUDY EVIDENCE|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|11/29/2012|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
3487103|16685068|D|1||HEALTHCARE PROFESSIONAL REPORTS A CASE OF LYMPHOMA AND OTHER B-SYMPTOMS VIA MW B4 THE MW NOTES THAT THE REPORTER CALLED ON BEHALF OF A PT WHO WAS DIAGNOSED WITH ALCL THE PT PRESENTED WITH ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSED IN 2013 HISTORY OF HODGKINS LYMPHOMA DIAGNOSED IN 2011 THESE TWO EVENTS CAME ABOUT AFTER THE PT UNDERWENT BREAST AUGMENTATION IN 1994 IN 2010 PT PRESENTED WITH AN ABNORMAL MAMMOGRAM PERFORMED IN 2010 BREAST PAIN SKIN COLOR CHANGE SKIN TEXTURE CHANGE AND INFLOWING DIFFUSION FORM THE RIGHT BREAST UP TO RIGHT NECK AND SHOULDER THE PT WAS RUNNING A FEVER THROUGHOUT THE ENTIRE PROCESS AFTER AN MRI AND SUBSEQUENT TEST THE PT WAS DIAGNOSED WITH HODGKINS LYMPHOMA AND UNDERWENT MANTLE RADIATION IN 2012 THE PT UNDERWENT SURGERY ESSENTIALLY FOR A BREAST MASS BUT THE PT ALSO DESIRED A MASTECTOMY FOR REMOVAL OF RIGHT AND LEFT IMPLANTS AND CAPSULES THE PATHOLOGY OF THE OPERATION SOON REPORTED THAT THE PT ALSO HAS ALCL THE MASS HAD COME FROM THE LYMPHOMA|UNK SALINE IMPLANT|UNK SALINE IMPLANT|11/07/2013|||DA|N|R||0HP|FWM|1.0||nan||NI|||BOLETA|US|ALLERGAN||CA|||||True
3165371|62390606|D|1||HEALTH PROFESSIONAL REPORTED  A SUBPECTORAL SALINE IMPLANT IS IDENTIFIED ON THE RIGHT CAPSULAR INFOLDING - CAPSULAR CONTRACTURES ARE IDENTIFIED A SMALL-MODERATE VOLUME OF FLUID IS SEEN AROUND THE IMPLANT ADDITIONALLY PATIENT REPORTS TO HEALTH PROFESSIONAL ITCHING OF THE RIGHT BREAST PATIENT HAD A MASTECTOMY TEN YEARS AGO POST OP PATIENT HAD A MILD INFECTION WHICH RESOLVED WITH ANTIBIOTICS PATIENT WAS RECENTLY DIAGNOSED WITH SUPRACLAVICULAR AND AXILLARY LYMPHADENOPATHY RECENT PET THAT SHOWED ENLARGED RIGHT EPITROCHLEAR LYMPH NODE THE BIOPSY SHOWED HODGKIN LYMPHOMA NODULAR SCLEROSIS BONE MARROW BIOPSY WAS NEGATIVE FOR LYMPHOMA PATIENT WAS TREATED WITH ABVD SUBSEQUENT SPECIMENS REVIEW HERE FROM PERI-PROSTHETIC FLUID OF THE RIGHT CHEST WAS REPORTED AS ATYPICAL LYMPHOID CELLS MOST CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA IN PERIPROSTHETIC FLUID AND SUBSEQUENT EXCISIONAL BIOPSY OF THE RIGHT BREAST CAPSULE IMMUNOHISTOCHEMICAL STAINS SHOW THAT THE ATYPICAL LYMPHOID CELLS ARE POSITIVE FOR CD15 AND CD30 THESE FINDINGS RAISE THE POSSIBILITY OF HODGKINS LYMPHOMA PATHOLOGICAL MARKERS DID NOT CONFIRM ALCL EVENT WILL BE CAPTURED AS LYMPHOMA DEVICE WAS REMOVED AND PATIENT HAD A PARTIAL CAPSULECTOMY|UNK SALINE IMPLANT|UNK SALINE IMPLANT|06/07/2013|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
3165371|62391233|D|1||HEALTH PROFESSIONAL REPORTED  Â¿A SUBPECTORAL SALINE IMPLANT IS IDENTIFIED ON THE RIGHT CAPSULAR INFOLDING Â¿ CAPSULAR CONTRACTURES ARE IDENTIFIED A SMALL-MODERATE VOLUME OF FLUID IS SEEN AROUND THE IMPLANTÂ¿ ADDITIONALLY PATIENT REPORTS TO HEALTH PROFESSIONAL Â¿ITCHING OF THE RIGHT BREASTÂ¿PATIENT HAD A MASTECTOMY TEN YEARS AGOÂ¿POST OP PATIENT HAD A MILD INFECTION WHICH RESOLVED WITH ANTIBIOTICSÂ¿ PATIENT WAS RECENTLY DIAGNOSED WITH SUPRACLAVICULAR AND AXILLARY LYMPHADENOPATHY Â¿RECENT PET THAT SHOWED Â¿ENLARGED RIGHT EPITROCHLEAR LYMPH NODEÂ¿ THE BIOPSY SHOWED Â¿HODGKIN LYMPHOMA NODULAR SCLEROSIS BONE MARROW BIOPSY WAS NEGATIVE FOR LYMPHOMA PATIENT WAS TREATED WITH ABVD SUBSEQUENT SPECIMENS REVIEW HERE FROM PERI-PROSTHETIC FLUID OF THE RIGHT CHEST WAS REPORTED AS ATYPICAL LYMPHOID CELLS MOST CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA IN PERIPROSTHETIC FLUID AND SUBSEQUENT EXCISIONAL BIOPSY OF THE RIGHT BREAST CAPSULE IMMUNOHISTOCHEMICAL STAINS SHOW THAT THE ATYPICAL LYMPHOID CELLS ARE POSITIVE FOR CD15 AND CD30 THESE FINDINGS RAISE THE POSSIBILITY OF HODGKINÂ¿S LYMPHOMAÂ¿ PATHOLOGICAL MARKERS DID NOT CONFIRM ALCL EVENT WILL BE CAPTURED AS LYMPHOMA DEVICE WAS REMOVED AND PATIENT HAD A PARTIAL CAPSULECTOMY|UNK SALINE IMPLANT|UNK SALINE IMPLANT|06/07/2013|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
3487123|4026308|D|1||HEALTHCARE PROFESSIONAL REPORTS A CASE OF LYMPHOMA AND OTHER B-SYMPTOMS VIA MW B4 THE MW NOTES THAT THE REPORTER CALLED ON BEHALF OF PT WHO WAS DIAGNOSED WITH ALCL THE PT PRESENTED WITH ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSED IN 2013 HISTORY OF HODGKINS LYMPHOMA DIAGNOSED IN 2011 THESE TWO EVENTS CAME ABOUT AFTER THE PT UNDERWENT BREAST AUGMENTATION IN 1994 IN 2010 PT PRESENTED WITH AN ABNORMAL MAMMOGRAM PERFORMED IN 2010 BREAST PAIN SKIN COLOR CHANGE SKIN TEXTURE CHANGE AND INFLOWING DIFFUSION FROM THE RIGHT BREAST UP TO RIGHT CHECK AND SHOULDER THE PT WAS RUNNING A FEVER THROUGHOUT THE ENTIRE PROCESS AFTER AN MRI AND SUBSEQUENT TESTS THE PT WAS DIAGNOSED WITH HODGKINS LYMPHOMA AND UNDERWENT MANTLE RADIATION IN 2012 THE PT UNDERWENT SURGERY ESSENTIALLY FOR A BREAST MASS BUT THE PT ALSO DESIRED A MASTECTOMY FOR REMOVAL OF RIGHT AND LEFT IMPLANTS AND CAPSULES THE PATHOLOGY OF THE OPERATION SOON REPORTED THAT THE PT ALSO HAS ALCL THE MASS HAD COME FROM THE LYMPHOMA|UNK SALINE IMPLANT|UNK SALINE IMPLANT|11/07/2013|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
3405834|62723956|D|1||ADDITIONAL INFORMATION REPORTED FROM JOURNAL ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED BREAST IMPLANT A CASE REPORT AND REVIEW OF THE LITERATURE DETORRES ET AL  REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY 18 2013 DEVELOPED DURING THE FOLLOW UP AN AXILLARY LYMPH NODE THE EXCISIONAL BIOPSY OF THAT NODE SHOWED AN ALK NEGATIVE ALCL THE PET-TAC SHOWS A FOCAL INCREASED OF FDG UPTAKE AT LEFT AXILLAR REGION AND AT THE BREAST PROSTHETIC FLUID AREA WITH NO OTHER PATHOLOGICAL FINDINGS THE PATIENT RECEIVED 4 CYCLES OF CHOP CYCLOPHOSPHAMIDE DOXORUBICIN AND VINCRISTINE CHEMOTHERAPY THE PROSTHESES WAS REMOVED AND THEN THE PATIENT RECEIVED POSTOPERATIVE ADJUVANT RADIOTHERAPY ON THE CHEST WALL AND REGIONAL LYMPH NODES TO A TOTAL DOSE OF 36 GY NO PATHOLOGY OR FOLLOW-UP CONFIRMING CD30+ THEREFORE EVENT WILL REMAIN REPORTABLE AS LYMPHOMA|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|10/04/2013|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
3405834|62724174|D|1||RECEIVED AN ARTICLE FROM PRODUCT WATCH ENTITLED ALCL ASSOCIATED BREAST IMPLANT A CASE REPORT AND REVIEW OF THE LITERATURE WRITTEN BY DETORRES ET AL WITHIN THE ARTICLE IT IS NOTED THE PATIENT HAD SEROMA AND LYMPHOMA THE MANUFACTURER OF THIS DEVICE IS UNKNOWN ADDITIONAL INFORMATION REPORTED FROM JOURNAL ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED BREAST IMPLANT A CASE REPORT AND REVIEW OF THE LITERATURE DETORRES ET AL REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY 18 2013 DEVELOPED DURING THE FOLLOW UP AN AXILLARY LYMPH NODE THE EXCISIONAL BIOPSY OF THAT NODE SHOWED AN ALK NEGATIVE ALCL THE PET-TAC SHOWS A FOCAL INCREASED OF FDG UPTAKE AT LEFT AXILLAR REGION AND AT THE BREAST PROSTHETIC FLUID AREA WITH NO OTHER PATHOLOGICAL FINDINGS THE PATIENT RECEIVED 4 CYCLES OF CHOP CYCLOPHOSPHAMIDE DOXORUBICIN AND VINCRISTINE CHEMOTHERAPY THE PROSTHESES WAS REMOVED AND THEN THE PATIENT RECEIVED POSTOPERATIVE ADJUVANT RADIOTHERAPY ON THE CHEST WALL AND REGIONAL LYMPH NODES TO A TOTAL DOSE OF 36 GY NO PATHOLOGY OR FOLLOW-UP CONFIRMING CD30+ THEREFORE EVENT WILL REMAIN REPORTABLE AS LYMPHOMA|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|10/04/2013|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
3031007|3327052|D|1||REPORTED AS ANAPLASTIC LARGE CELL LYMPHOMA CONTRACTURE AND ASSOCIATED ASYMMETRY FROM RESEARCH ARTICLE PUBLISHED 2008 AMERICAN JOURNAL OF SURGICAL PATHOLOGY WONG ET AL ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH A BREAST IMPLANT CAPSULE A CASE REPORT AND REVIEW OF THE LITERATURE THIS EVENT WAS SUBMITTED INITIALLY VIA B6 Q4 B6 2008 B6 2010 B6 2011|STYLE 168 SALINE FILLED BREAST IMPLANT|UNK STYLE 168|11/29/2012|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
3023802|10610793|N|1||B4 DEVICE LABELLING ADDRESSES SEROMA AND ALCL ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFO REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MFRS BREAST IMPLANTS YOU SHOULD CONSIDER POSSIBILITY OF ALCL WHEN YOU HAVE A PT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMENT FOR PERI-IMPLANT ALCL FOR MORE COMPLETE AND UP-TO-DATE INFO ON FDAS ANALYSIS AND REVIEW OF THE ALCL IN PTS WITH BREAST IMPLANTS PLEASE VISIT HTTPWWWFDAGOVMEDICALDEVICESPRODUCTSANDMEDICALPROCEDURESIMPLANTSAND PROSTHETICSBREASTIMPLANTSUCM239995HTM|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|MM-410360|03/26/2013|||DA|N|R||0HP|FTR|1.0|10/03/2012|nan||1507531|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
3340784|3809032|D|1||ANAPLASTIC LARGE CELL LYMPHOMA|SALINE MAMMARY PROSTHESIS|350-16XX|01/09/2013||||N|R||0HP|FWM|1.0||BREAST IMPLANT|||||IRVING|US|MENTOR||TX|||||True
3134127|10793581|N|1||B4 THE B4 LABELING ADDRESSES ANAPLASTIC LARGE CELL LYMPHOMA ALCL ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MFRS BREAST IMPLANT YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM R OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL FOR MORE COMPLETE AND UP-TO-DATE INFORMATION ON FDAS ANALYSIS AND REVIEW OF THE ALCL PTS WITH BREAST IMPLANTS PLEASE VISIT HTTPWWWFDAGOVMEDICALDEVICESPRODUCTSANDMEDICALPROCEDURESIMPLANTSANDPROSETHETICSBREASTIMPLANTSUCM239995HTM THE 410 LABELING ADDRESSES CAPSULAR CONTRACTURE CAPSULAR CONTRACTURE - PTS SHOULD BE ADVISED THAT CAPSULAR CONTRACTURE MAY BE MORE COMMON FOLLOWING INFECTION HEMATOMA SEROMA AND THE CHANCE OF IT HAPPENING MAY INCREASE OVER TIME CAPSULAR CONTRACTURE OCCURS MORE COMMONLY IN REVISION PTS THAN IN PRIMARY AUGMENTATION OR RECONSTRUCTION PTS CAPSULAR CONTRACTURE IS ALSO A RISK FACTOR FOR IMPLANT RUPTURE AND IT IS ONE OF THE MOST COMMON REASONS FOR REOPERATION THE B4 LABELING ADDRESSES SEROMA ADDITIONAL COMPLICATIONS - AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME PAIN HEMATOMASEROMA CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|05/24/2013|||DA|N|R||0HP|FTR|1.0||nan||NI|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
3134127|61102729|D|1||ADDITIONAL INFORMATION NOTED IN ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST ARISING AROUND MAMMARY IMPLANT CAPSULE- AN B6 REPORT WRITTEN IN AESTHETIC PLASTIC SURGERY 2013 ARTICLE NOTES REGARDING THE RIGHT SIDE A REVIEW OF PREVIOUS SPECIMENS WAS PERFORMED MOST OF THE PREVIOUS TISSUE SAMPLES SHOWED AN INFLAMMATORY PROCESS HOWEVER A VERY SMALL AREA OF LARGE CELL LYMPHOMA WAS FOUND ADDITIONAL NOTE OF RIGHT SIDE INTRACAPSULAR ROUND LESION ABOUT 04 CM IN DIAMETER WAS PRESENT IN THE CHEST WALL CLOSE TO THE PARASTERNAL LINE AND IS FURTHER SPECIFIED AS A PARASTERNAL NODULE|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|05/24/2013|||DA|N|R||0HP|FTR|1.0||nan||NI|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
3134127|3458905|D|1||ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST ARISING AROUND MAMMARY IMPLANT CAPSULE A B6 REPORT WRITTEN IN B4 REPORTS ALCL SEROMA AND CAPSULAR CONTRACTURE|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|05/24/2013|||DA|N|R||0HP|FTR|1.0||nan||NI|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
3134124|61099626|D|1||ADDITIONAL INFORMATION NOTED IN ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST ARISING AROUND MAMMARY IMPLANT CAPSULE AN ITALIAN REPORT WRITTEN IN AESTHETIC PLASTIC SURGERY 2013 ARTICLE NOTES IN REGARDS TO THE RIGHT SIDE NECROSIS AND CHRONIC INFLAMMATION SIGNS ARE PRESENT AND SKIN ABOVE THE IMPLANT BECAME RED AND PAINFUL AND THE PATIENT HAD FEBRILE EPISODES TREATMENT NOTED FOR THE EVENT OF SEROMA AS A BROAD-SPECTRUM ANTIBIOTIC|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|05/24/2013|||DA|N|R||0HP|FTR|1.0||nan||NI|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
3134124|18173802|N|1||B4 THE 410 DEVICE LABELING ADDRESSES ANAPLASTIC LARGE CELL LYMPHOMA ALCL ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MFRS BREAST IMPLANT YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM ER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL FOR MORE COMPLETE AND UP-TO-DATE INFORMATION ON FDAS ANALYSIS AND REVIEW OF THE ALCL PTS WITH BREAST IMPLANTS PLEASE VISIT HTTPWWWFDAGOVMEDICAL DEVICESPRODUCTSAND MEDICALPROCEDURESIMPLANTSANDPROSETHETICSBREASTIMPLANTSUCM239995HTM THE 410 LABELING ADDRESSES SEROMA AND PAIN ADDITIONAL COMPLICATIONS - AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME PAIN HEMATOMASEROMA CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|05/24/2013|||DA|N|R||0HP|FTR|1.0||nan||NI|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
3134124|17839593|D|1||ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST ARISING AROUND MAMMARY IMPLANT CAPSULE AN B6 REPORT WRITTEN IN AESTHETIC PLASTIC SURGERY 2013 REPORTS ALCL SEROMA PAIN|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|05/24/2013|||DA|N|R||0HP|FTR|1.0||nan||NI|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
3030984|3326574|D|1||THROUGH MY RESEARCH REVIEW AS RN PRODUCT SUPPORT SPECIALIST THE FOLLOWING ARTICLE CAME TO MY ATTENTION ANAPLASTIC LARGE CELL LYMPHOMA INVOLVING THE BREAST ARCH PATHOLOGY LAB MEDICAL JOURNAL- VOL 133 SEP 2009 WITHIN THE ARTICLE THE AUTHOR NOTES SEROMA AND LYMPHOMA ADDL INFO FROM ARTICLE ENTITLE BREAST IMPLANT CAPSULE-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIC-ALCL DIAGNOSTIC PATHOLOGY JOURNAL THERE ARE NO NEW EVENTS TO REPORT|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|11/29/2012|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
3487125|4004895|D|1||HEALTHCARE PROFESSIONAL REPORTS VIA B4 A CASE OF LATE SEROMA AND LYMPHOMA THIS REPORT COMES FROM AN UNIDENTIFIED HEALTHCARE PROFESSIONAL THE B4 NOTES TO WHOM IT MAY CONCERN PURSUANT TO THE PARTNERSHIP BETWEEN THE FDA AND CONCERNING BREAST IMPLANT-ASSOCIATED ALCL WE ARE REPORTING A CASE OF ALCL ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH A BREAST IMPLANT PT FIRST PRESENTED AFTER HAVING HAD BREAST AUGMENTATION SEVERAL YEARS PRIOR SHE HAD NOTICED SWELLING OF THE LEFT BREAST WHICH EVENTUALLY BECAME PAINFUL AND CAUSED HER TO SEEK TREATMENT WORKUP EVENTUALLY REVEALED SEROMA AROUND THE BREAST IMPLANT THE FLUID CAME BACK AS CD 30 POSITIVE ALK NEGATIVE CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA HER IMPLANTS WERE REMOVED BILATERALLY AND IT IS FELT THAT THIS IS ADEQUATE TREATMENT FOR THE PROBLEM SHE CONTINUES TO UNDERGO SURVEILLANCE BY US IN ADDITION TO THE HEMATOLOGYONCOLOGY TEAM OF NOTE SHE WAS FOUND TO HAVE NONRUPTURED 410 CC TEXTURED SILICONE IMPLANT MAY BE CUI NOT AVAILABLE IN THE UNITED STATES THE PTS CARE WAS COORDINATED BETWEEN THE PLASTIC SURGERY AND THE HEMATOLOGYONCOLOGY TEAMS BREAST IMPLANTS REMOVED NOT REPLACED PT WILL UNDERGO SURVEILLANCE WITH MRI AND ULTRASOUND|UNK CUI GEL|UNK CUI GEL|11/07/2013|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
3011109|3312625|D|1||RECEIVED MW B4 WITHOUT A SOURCE OF WHERE THE INFORMATION IS FROM WITHIN THE MW IT NOTES ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSED FROM LEFT BREAST THIS PT HAD STYLE 468 TEXTURED SALINE BREAST IMPLANT FROM MCGHAN EXPLANT DATE IS NOTED AS B6 2012 THERE IS NO OTHER INFORMATION TO COMPLETE AN INVESTIGATION ON THIS EVENT HOWEVER IF INFORMATION BECOMES AVAILABLE THE FILE WILL BE REVIEWED AND SUBMITTED|STYLE 468 SALINE FILLED BREAST IMPLANT|UNK STYLE 468|03/13/2013|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
3390404|3798157|D|1||BILATERAL SUBGLANDULAR TEXTURED SILICONE GEL BREAST IMPLANTS IMPLANTED 15 YEARS AGO WITH RECENT DEVELOPMENT OF 700 CC OF OPAQUE PERI-IMPLANT SEROMA AND CAPSULAR THICKENING INF LEFT BREAST STATUS POST BILATERAL IMPLANT EXPLANTATION AND BILATERAL CAPSULECTOMY WITH DIAGNOSIS OF LEFT BREAST IMPLANT- ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA ALCL ON LEFT BREAST CAPSULECTOMY PATHOLOGICAL SPECIMEN AND L BREAST SEROMA FLUID POSITIVE FOR ALCL CELLS FOLLOWING REPEAT BILATERAL CAPSULECTOMY DIAGNOSIS BILATERAL BREAST AUGMENTATIONCOSMESIS|TEXTURED SILICONE GEL IMPLANT 220CC||10/02/2013||||N|||000|FTR|1.0||BREAST IMPLANTS|||||||MCGHAN/ALLERGAN|||||||True
3095897|22114235|D|1||PT HAD BREAST CANCER 6 YEARS AGO SHE UNDERWENT A UNILATERAL MASTECTOMY WITH AN EXPANDER THEN RADIATION THE EXPANDER WAS LATER REMOVED AND A PERMANENT SILICONE IMPLANT PLACED MENTOR 450CC HIGH PROFILE SILICONE TEXTURED GEL SHE HAS A CONTRALATERAL MASTOPEXY FOR SYMMETRY I SAW HER RECENTLY FOR ASYMMETRIC BREASTS I OPERATED ON HER A COUPLE OF WEEKS AGO ON B6 2013 AND SHE HAD A LARGE SEROMA AND SOME FIBRINOUS GELATINOUS TISSUE UNDER THE IMPLANT I SENT THAT FOR CYTOLOGY PATHOLOGY AND CULTURE AND IT CAME BACK AS ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH BREAST IMPLANTS IN THE CYTOLOGY AND IN THE GELATINOUS TISSUE NO BACTERIA IDENTIFIED AS FAR AS I KNOW THERE ARE ONLY 34 CONFIRMED CASES IN THE FDA IN THE USA WITH THIS I AM LETTING THE FDA AND MENTOR KNOW ABOUT THE SITUATION UNFORTUNATELY I WAS NOT SMART ENOUGH TO SAVE THE IMPLANT A FEW WEEKS AGO AT SURGERY I PLAN ON TAKING HER BACK TO THE OPERATING ROOM FOR NEW IMPLANT REMOVAL AND CAPSULECTOMY SHE WILL BE SEEING AN ONCOLOGIST AS WELL|MENTOR SILTEX BREAST IMPLANT|354-4450|04/30/2013||||N|||0HP|FTR|1.0||SILTEX BREAT IMPLANT, 450CC HIGH PROFILE TEXTURED GEL||5769207|||||MENTOR|||||354-4450||True
3428755|21496558|D|1||ALCL CASE REPORT PT B6 PRESENTED WITH LATE SEROMA AND CAPSULAR CONTRACTURE PAIN IN RIGHT BREAST B6 2013 PT DELAYED SURGICAL INTERVENTION AS SEROMA WAS TEMPORARILY BETTER PHYSICIAN INSISTED ON INTERVENTION DEVICE REMOVED B6 2013 DIAGNOSIS B6 2013 RIGHT BREAST SEROMA FLUID - MALIGNANT CELLS PRESENT FLUID ONLY CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA NO LARGE CELLS NOTED OUTSIDE OF THE FIBROUS CAPSULE NO CAPSULAR INVASION OR EXTRACAPSULAR EXTENSION NOTED|SILICONE GEL - FILLED TEXTURED BREAST IMPLANT|20621-525U|10/18/2013|||DA|N|R||0HP|FTR|1.0|04/01/2008|nan|||11220 GRADER ST|STE 100|DALLAS|US|SILIMED, INC.|75238|TX|75238||20621||True
3170177|21675522|D|1||REPORTER CALLED ON BEHALF OF A PT WHO WAS DIAGNOSED WITH ALCL THE PT PRESENTED WITH ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSED ON B6 2013 HISTORY OF HODGKINS LYMPHOMA DIAGNOSED B6 2011 THESE TWO EVENTS CAME ABOUT AFTER THE PT UNDERWENT BREAST AUGMENTATION IN 1994 THIS REPORT IS FILED IN RESPONSE TO THE FOLLOWING REPORT WWWFDAGOVMEDICALDEVICESPRODUCTSANDMEDICALPROCEDURESIMPLANTSANDPROSTHETICSBREASTIMPLANTUCM239995HTM IN 2010 PT PRESENTED WITH AN ABNORMAL MAMMOGRAM DONE ON B6 2010 BREAST PAIN SKIN COLOR CHANGE SKIN TEXTURE CHANGE AND INFLOWING DIFFUSION FROM THE RIGHT BREAST UP TO RIGHT NECK AND SHOULDER THE PT WAS RUNNING A FEVER THROUGHOUT THE ENTIRE PROCESS AFTER AN MRI AND SUBSEQUENT TESTS THE PT WAS DIAGNOSED WITH HODGKINS LYMPHOMA AND UNDERWENT MANTLE RADIATION ON B6 2012 THE PT UNDERWENT SURGERY ESSENTIALLY FOR A BREAST MASS BUT THE PT ALSO DESIRED A MASTECTOMY FOR REMOVAL OF RIGHT AND LEFT IMPLANTS AND CAPSULES THE PATHOLOGY OF THE OPERATION SOON REPORTED THAT THE PT ALSO HAS ALCL THE MASS HAD COME FROM THE LYMPHOMA|MCGHAN 420 CC BREAST IMPLANTS (RIGHT & LEFT)||06/13/2013|||||||0|FWM|1.0||SALINE BREAST IMPLANT|||||||MCGHAN MED CORP|||||||True
3269181|3756340|D|1||SUDDEN ONSET OF SWELLING LATE SEROMA OF LEFT BREAST IMPLANT RECONSTRUCTION SHE PREVIOUSLY HAD 2-STAGE BREAST RECONSTRUCTION WITH PLACEMENT OF BILATERAL TISSUE EXPANDERS ON B6 2005 MCGHAN REF 67-133LV13 EXPANDERS WITH LEFT SN B4 LOT 623514 AND RIGHT SN B4 AND LOT 1030255 IMPLANTS WERE PLACED ON B6 2005 INAMED REF 27-FF125-375 WITH LEFT SN B4 AND LOT 335112 AND RIGHT SN B4 AND LOT 380839 PRESENTATION OF LATE SEROMA WAS ALMOST 8 YRS AFTER IMPLANT PLACEMENT SEROMA FLUID WAS ASPIRATED UNDER ULTRASOUND GUIDANCE AND WAS POSITIVE FOR MALIGNANT CELL ANAPLASTIC LARGE CELL LYMPHOMA ALCL INPATIENT SURGERY FOR REMOVAL OF BILATERAL BREAST IMPLANTS WITH TOTAL CAPSULECTOMIES WAS PERFORMED AND PATHOLOGY REVEALED ANAPLASTIC LARGE CELL LYMPHOMA INVOLVING BUT NOT EXTENDING BEYOND THE LEFT CAPSULE THE CONTRALATERAL RIGHT SIDE HAD SEROMA FLUID AROUND IT AND AT THE TIME OF SURGERY THIS FLUID WAS SENT FOR CYTOLOGY AND ALSO FOUND TO BE POSITIVE FOR ANAPLASTIC LARGE CELL LYMPHOMA NO EVIDENCE OF DISTANT DISEASE TISSUE EXPANDERS WERE USED FOR 1ST STAGE BREAST RECONSTRUCTION PRIOR TO PLACEMENT OF THE IMPLANT EXPANDERS WERE PLACED ON B6 2005 AND REMOVED ON B6 2005 WHEN THE FINAL IMPLANTS WERE PLACED EXPANDERS WERE MCGHAN 133LV INAMED EXPANDERS WITH REFERENCECATALOG 76-133LV13 SERIAL NUMBERS AND LOT NUMBERS AS DESCRIBED IN INITIAL NARRATIVE OF EVENT REASON FOR USE 1 - POSTMASTECTOMY BREAST RECONSTRUCTION 2 - POSTMASTECTOMY BREAST RECONSTRUCTION EVENT ABATED AFTER USE STOPPED OR DOSE REDUCED 1 - YES 2 - YES|410FF BREAST IMPLANT LEFT|27-FF125-375|08/01/2013||||Y|||0LP|FWM|1.0||BREAST IMPLANT, HIGHLY-TEXTURED FORM-STABLE||335112|||||INAMED CORPORATION, NOW ALLERGAN|||||||True
3269181|3756340|D|1||SUDDEN ONSET OF SWELLING LATE SEROMA OF LEFT BREAST IMPLANT RECONSTRUCTION SHE PREVIOUSLY HAD 2-STAGE BREAST RECONSTRUCTION WITH PLACEMENT OF BILATERAL TISSUE EXPANDERS ON B6 2005 MCGHAN REF 67-133LV13 EXPANDERS WITH LEFT SN B4 LOT 623514 AND RIGHT SN B4 AND LOT 1030255 IMPLANTS WERE PLACED ON B6 2005 INAMED REF 27-FF125-375 WITH LEFT SN B4 AND LOT 335112 AND RIGHT SN B4 AND LOT 380839 PRESENTATION OF LATE SEROMA WAS ALMOST 8 YRS AFTER IMPLANT PLACEMENT SEROMA FLUID WAS ASPIRATED UNDER ULTRASOUND GUIDANCE AND WAS POSITIVE FOR MALIGNANT CELL ANAPLASTIC LARGE CELL LYMPHOMA ALCL INPATIENT SURGERY FOR REMOVAL OF BILATERAL BREAST IMPLANTS WITH TOTAL CAPSULECTOMIES WAS PERFORMED AND PATHOLOGY REVEALED ANAPLASTIC LARGE CELL LYMPHOMA INVOLVING BUT NOT EXTENDING BEYOND THE LEFT CAPSULE THE CONTRALATERAL RIGHT SIDE HAD SEROMA FLUID AROUND IT AND AT THE TIME OF SURGERY THIS FLUID WAS SENT FOR CYTOLOGY AND ALSO FOUND TO BE POSITIVE FOR ANAPLASTIC LARGE CELL LYMPHOMA NO EVIDENCE OF DISTANT DISEASE TISSUE EXPANDERS WERE USED FOR 1ST STAGE BREAST RECONSTRUCTION PRIOR TO PLACEMENT OF THE IMPLANT EXPANDERS WERE PLACED ON B6 2005 AND REMOVED ON B6 2005 WHEN THE FINAL IMPLANTS WERE PLACED EXPANDERS WERE MCGHAN 133LV INAMED EXPANDERS WITH REFERENCECATALOG 76-133LV13 SERIAL NUMBERS AND LOT NUMBERS AS DESCRIBED IN INITIAL NARRATIVE OF EVENT REASON FOR USE 1 - POSTMASTECTOMY BREAST RECONSTRUCTION 2 - POSTMASTECTOMY BREAST RECONSTRUCTION EVENT ABATED AFTER USE STOPPED OR DOSE REDUCED 1 - YES 2 - YES|410FF BREAST IMPLANT RIGHT|27-FF125-375|08/01/2013||||Y|||0LP|FWM|2.0||BREAST IMPLANT, HIGHLY-TEXTURED FORM-STABLE||380839|||||INAMED CORPORATION, NOW ALLERGAN|||||||True
3269181|3756340|D|1||SUDDEN ONSET OF SWELLING LATE SEROMA OF LEFT BREAST IMPLANT RECONSTRUCTION SHE PREVIOUSLY HAD 2-STAGE BREAST RECONSTRUCTION WITH PLACEMENT OF BILATERAL TISSUE EXPANDERS ON B6 2005 MCGHAN REF 67-133LV13 EXPANDERS WITH LEFT SN B4 LOT 623514 AND RIGHT SN B4 AND LOT 1030255 IMPLANTS WERE PLACED ON B6 2005 INAMED REF 27-FF125-375 WITH LEFT SN B4 AND LOT 335112 AND RIGHT SN B4 AND LOT 380839 PRESENTATION OF LATE SEROMA WAS ALMOST 8 YRS AFTER IMPLANT PLACEMENT SEROMA FLUID WAS ASPIRATED UNDER ULTRASOUND GUIDANCE AND WAS POSITIVE FOR MALIGNANT CELL ANAPLASTIC LARGE CELL LYMPHOMA ALCL INPATIENT SURGERY FOR REMOVAL OF BILATERAL BREAST IMPLANTS WITH TOTAL CAPSULECTOMIES WAS PERFORMED AND PATHOLOGY REVEALED ANAPLASTIC LARGE CELL LYMPHOMA INVOLVING BUT NOT EXTENDING BEYOND THE LEFT CAPSULE THE CONTRALATERAL RIGHT SIDE HAD SEROMA FLUID AROUND IT AND AT THE TIME OF SURGERY THIS FLUID WAS SENT FOR CYTOLOGY AND ALSO FOUND TO BE POSITIVE FOR ANAPLASTIC LARGE CELL LYMPHOMA NO EVIDENCE OF DISTANT DISEASE TISSUE EXPANDERS WERE USED FOR 1ST STAGE BREAST RECONSTRUCTION PRIOR TO PLACEMENT OF THE IMPLANT EXPANDERS WERE PLACED ON B6 2005 AND REMOVED ON B6 2005 WHEN THE FINAL IMPLANTS WERE PLACED EXPANDERS WERE MCGHAN 133LV INAMED EXPANDERS WITH REFERENCECATALOG 76-133LV13 SERIAL NUMBERS AND LOT NUMBERS AS DESCRIBED IN INITIAL NARRATIVE OF EVENT REASON FOR USE 1 - POSTMASTECTOMY BREAST RECONSTRUCTION 2 - POSTMASTECTOMY BREAST RECONSTRUCTION EVENT ABATED AFTER USE STOPPED OR DOSE REDUCED 1 - YES 2 - YES|MCGHAN BREAST IMPLANT RIGHT|67-133LV13|08/01/2013||||Y|||0LP|FWM|4.0||BREAST IMPLANT||1030255|||||MCGHAN MEDICAL CORP|||||||True
3269181|3756340|D|1||SUDDEN ONSET OF SWELLING LATE SEROMA OF LEFT BREAST IMPLANT RECONSTRUCTION SHE PREVIOUSLY HAD 2-STAGE BREAST RECONSTRUCTION WITH PLACEMENT OF BILATERAL TISSUE EXPANDERS ON B6 2005 MCGHAN REF 67-133LV13 EXPANDERS WITH LEFT SN B4 LOT 623514 AND RIGHT SN B4 AND LOT 1030255 IMPLANTS WERE PLACED ON B6 2005 INAMED REF 27-FF125-375 WITH LEFT SN B4 AND LOT 335112 AND RIGHT SN B4 AND LOT 380839 PRESENTATION OF LATE SEROMA WAS ALMOST 8 YRS AFTER IMPLANT PLACEMENT SEROMA FLUID WAS ASPIRATED UNDER ULTRASOUND GUIDANCE AND WAS POSITIVE FOR MALIGNANT CELL ANAPLASTIC LARGE CELL LYMPHOMA ALCL INPATIENT SURGERY FOR REMOVAL OF BILATERAL BREAST IMPLANTS WITH TOTAL CAPSULECTOMIES WAS PERFORMED AND PATHOLOGY REVEALED ANAPLASTIC LARGE CELL LYMPHOMA INVOLVING BUT NOT EXTENDING BEYOND THE LEFT CAPSULE THE CONTRALATERAL RIGHT SIDE HAD SEROMA FLUID AROUND IT AND AT THE TIME OF SURGERY THIS FLUID WAS SENT FOR CYTOLOGY AND ALSO FOUND TO BE POSITIVE FOR ANAPLASTIC LARGE CELL LYMPHOMA NO EVIDENCE OF DISTANT DISEASE TISSUE EXPANDERS WERE USED FOR 1ST STAGE BREAST RECONSTRUCTION PRIOR TO PLACEMENT OF THE IMPLANT EXPANDERS WERE PLACED ON B6 2005 AND REMOVED ON B6 2005 WHEN THE FINAL IMPLANTS WERE PLACED EXPANDERS WERE MCGHAN 133LV INAMED EXPANDERS WITH REFERENCECATALOG 76-133LV13 SERIAL NUMBERS AND LOT NUMBERS AS DESCRIBED IN INITIAL NARRATIVE OF EVENT REASON FOR USE 1 - POSTMASTECTOMY BREAST RECONSTRUCTION 2 - POSTMASTECTOMY BREAST RECONSTRUCTION EVENT ABATED AFTER USE STOPPED OR DOSE REDUCED 1 - YES 2 - YES|MCGHAN BREAST IMPLANT LEFT|67-133LV13|08/01/2013||||Y|||0LP|FWM|3.0||BREAST IMPLANT||623514|||||MCGHAN MEDICAL CORP|||||||True
3199749|10822419|N|1||MEDWATCH SUBMITTED 05202013 ALLERGAN LABELING ADDRESSES THE EVENT OF BREAST LUMPS AS FOLLOWS BREAST SELF-EXAMINATIONS FOLLOWING BREAST AUGMENTATION YOU SHOULD CONTINUE TO PERFORM BREAST SELF-EXAMINATION MONTHLY THIS MAY BE MORE DIFFICULT WITH A BREAST IMPLANT IN PLACE TO CONTINUE TO PERFORM A MONTHLY BREAST SELF EXAMINATION EFFICIENTLY YOU SHOULD ASK YOUR SURGEON TO HELP YOU IDENTIFY THE DIFFERENCE BETWEEN THE IMPLANT AND YOUR BREAST TISSUE BEING ABLE TO IDENTIFY THE IMPLANT FROM BREAST TISSUE WILL DECREASE THE NECESSITY OF EXCESSIVE SQUEEZING OF THE IMPLANT DURING EXAMINATION ANY NEW LUMPS SHOULD BE EVALUATED WITH A BIOPSY AS APPROPRIATE IF A BIOPSY IS PERFORMED BE SURE TO INFORM THE MEDICAL PROFESSIONAL PERFORMING THE BIOPSY THAT YOU HAVE BREAST IMPLANTS SO THAT CARE WILL BE TAKEN TO AVOID INJURING THE IMPLANT THE 410 DEVICE LABELING ADDRESSES ANAPLASTIC LARGE CELL LYMPHOMA ALCL BASED ON INFO REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL FOR MORE COMPLETE AND UP-TO-DATE INFO ON FDAS ANALYSIS AND REVIEW OF THE ALCL IN PTS WITH BREAST IMPLANTS PLEASE VISIT HTTPWWWFDAGOVMEDICALDEVICESPRODUCTSANDMEDICALPROCEDURESIMPLANTSANDPROSTHETICSBREASTIMPLANTSUCM239995HTM|STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-378|05/20/2013|||DA|N|R||0HP|FTR|1.0|04/24/2011|nan||1267625|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
2933318|3225696|D|1||ALLERGANS LEGAL DEPARTMENT RECEIVED A LETTER REPORTING A PT HAD BILATERAL BREAST AUGMENTATION WITH MCGHAN SALINE IMPLANTS AND WAS DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA THERE IS LIMITED INFO AVAILABLE FOR THIS CASE AFTER THE INITIAL INVESTIGATION AND THERE IS AN UNLIKELY CHANCE THAT THIS INFO WILL BE OBTAINED HOWEVER IF THERE IS ADDL INFO SUCH AS DEVICE INFO IMPLANTINGEXPLANTING PHYSICIAN OR ANY LABS RELATED TO BUT NOT LIMITED TO ANY COMBINED RESULTS OF IMMUNE-CHEMICAL HISTOLOGICAL AND CYTOLOGICAL ANALYSIS OF SPECIMENS ARE SCIENTIFICALLY ACCEPTABLE CRITERIA WITH WHICH TO DIAGNOSE ALCL THE FILE WILL BE REVIEWED AND UPDATED|CUI TEXTURED SALINE FILLED BREAST IMPLANT|UNK STYLE RTV|01/25/2013|||DA|N|R||0HP|FWM|1.0||nan||NI|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
2933317|17460937|D|1||ALLERGANS LEGAL DEPARTMENT RECEIVED A LETTER REPORTING A PATIENT UNDERWENT BREAST AUGMENTATION SURGERY WITH ALLERGAN SALINE FILLED BREAST IMPLANTS AND WAS DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA THERE IS LIMITED INFORMATION AVAILABLE FOR THIS CASE AFTER THE INITIAL INVESTIGATION AND THERE IS AN UNLIKELY CHANCE THAT THIS INFORMATION WILL BE OBTAINED HOWEVER IF THERE IS ADDITIONAL INFORMATION SUCH AS DEVICE INFORMATION IMPLANTINGEXPLANTING PHYSICIAN OR ANY LABS RELATED TO BUT NOT LIMITED TO ANY COMBINED RESULTS OF IMMUNE-CHEMICAL HISTOLOGICAL AND CYTOLOGICAL ANALYSIS OF SPECIMENS ARE SCIENTIFICALLY ACCEPTABLE CRITERIA WITH WHICH TO DIAGNOSE ALCL THE FILE WILL BE REVIEWED AND UPDATED|STYLE 168 SALINE FILLED BREAST IMPLANT|UNK STYLE 168|01/23/2013|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2903656|3063201|D|1||ALCL CASE REPORT DIAGNOSIS ALK NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA CD30+ SP LEFT AXILLARY LN BIOPSY 52110 THE PT IS A B6 FEMALE WITH STAGE IV ALK NEGATIVE ANAPLASTIC LARGE-CELL LYMPHOMA THIS WAS DIAGNOSED ON B6 2010 SHE IS CURRENTLY UNDERGOING CHEMOTHERAPY AND IS FOLLOWED HERE IN ONCOLOGY SHE HAD BILATERAL BREAST AUGMENTATION WITH SILICONE IMPLANTS OVER 30 YEARS AGO SHE HAD A RUPTURE ON THE RIGHT SIDE AND HAD THE IMPLANTS REMOVED AND REPLACED IN 2005 BY A LOCAL PLASTIC SURGEON SHE STATES THEY ARE SUBPECTORAL THROUGH AN INFRAMAMMARY FOLD INCISION SHE BELIEVES THE RIGHT IMPLANT WAS 325 CC AND THE LEFT WAS 350 CC DURING ONE OF HER RECENT CT SCANS PERFORMED FOR LYMPHOMA STAGING THERE APPEARED TO BE EVIDENCE OF RUPTURE OF HER RIGHT BREAST IMPLANT I REMOVED BOTH IMPLANTS ON B6 2012 THEY WERE NOT REPLACED DUE TO THE POSSIBLE LINK BETWEEN BREAST IMPLANTS AND ALCL|INAMED||12/28/2012|||||||0HP|FTR|2.0||SILICONE BREAST IMPLANT||NONE|||IRVINE|US|ALLERGAN||CA|||STYLE 110|REF# 110-390|True
2903656|3063201|D|1||ALCL CASE REPORT DIAGNOSIS ALK NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA CD30+ SP LEFT AXILLARY LN BIOPSY 52110 THE PT IS A B6 FEMALE WITH STAGE IV ALK NEGATIVE ANAPLASTIC LARGE-CELL LYMPHOMA THIS WAS DIAGNOSED ON B6 2010 SHE IS CURRENTLY UNDERGOING CHEMOTHERAPY AND IS FOLLOWED HERE IN ONCOLOGY SHE HAD BILATERAL BREAST AUGMENTATION WITH SILICONE IMPLANTS OVER 30 YEARS AGO SHE HAD A RUPTURE ON THE RIGHT SIDE AND HAD THE IMPLANTS REMOVED AND REPLACED IN 2005 BY A LOCAL PLASTIC SURGEON SHE STATES THEY ARE SUBPECTORAL THROUGH AN INFRAMAMMARY FOLD INCISION SHE BELIEVES THE RIGHT IMPLANT WAS 325 CC AND THE LEFT WAS 350 CC DURING ONE OF HER RECENT CT SCANS PERFORMED FOR LYMPHOMA STAGING THERE APPEARED TO BE EVIDENCE OF RUPTURE OF HER RIGHT BREAST IMPLANT I REMOVED BOTH IMPLANTS ON B6 2012 THEY WERE NOT REPLACED DUE TO THE POSSIBLE LINK BETWEEN BREAST IMPLANTS AND ALCL|INAMED||12/28/2012||10/01/2012||R|||0HP|FTR|1.0||SILICONE BREAST IMPLANT||NONE|||IRVINE|US|ALLERGAN||CA|||STYLE 110|REF# 110-420|True
2930345|17450111|D|1||ALLERGANS LEGAL DEPARTMENT RECEIVED A LETTER REPORTING A PATIENT WHO HAD BILATERAL BREAST AUGMENTATION WITH MCGHAN SILICONE GEL FILLED BREAST IMPLANTS AND DIAGNOSED WITH CB-30 POSITIVE ALK NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA THERE IS LIMITED INFORMATION AVAILABLE FOR THIS CASE AFTER THE INITIAL INVESTIGATION AND HERE IS AN UNLIKELY CHANCE THAT HIS INFORMATION WILL BE OBTAINED HOWEVER IF THERE IS ADDITIONAL INFORMATION SUCH AS DEVICE INFORMATION IMPLANTINGEXPLANTING PHYSICIAN OR ANY LABS RELATED TO BUT NOT LIMITED TO ANY COMBINED RESULTS OF IMMUNE-CHEMICAL HISTOLOGICAL AND CYTOLOGICAL ANALYSIS OF SPECIMENS ARE SCIENTIFICALLY ACCEPTABLE CRITERIA WITH WHICH TO DIAGNOSE ALCL THE FILE WILL BE REVIEWED AND UPDATED|UNK SALINE IMPLANT|UNK SALINE IMPLANT|01/22/2013|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA||||NI|True
3070387|3264818|D|1||TO WHOM IT MAY CONCERN PURSUANT TO THE PARTNERSHIP BETWEEN THE FDA AND B4 CONCERNING BREAST IMPLANT-ASSOCIATED ALCL WE ARE REPORTING A CASE OF ALCL ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH A BREAST IMPLANT PT IS B6 FEMALE WHO FIRST PRESENTED LAST B6 AFTER HAVING HAD BREAST AUGMENTATION IN B6 SEVERAL YEARS PRIOR SHE HAD NOTICED SWELLING OF THE LEFT BREAST WHICH EVENTUALLY BECAME PAINFUL AND CAUSED HER TO SEEK TREATMENT WORKUP EVENTUALLY REVEALED SEROMA AROUND THE BREAST IMPLANT THE FLUID CAME BACK AS CD 30 POSITIVE ALK NEGATIVE CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA HER IMPLANTS WERE REMOVED BILATERALLY AND IT IS FELT THAT THIS IS ADEQUATE TREATMENT FOR THE PROBLEM SHE CONTINUES TO UNDERGO SURVEILLANCE BY US IN ADDITION TO THE HEMATOLOGYONCOLOGY TEAM OF NOTE SHE WAS FOUND TO HAVE NONRUPTURED 410 CC TEXTURED SILICONE IMPLANTS MADE BY CUI NOT AVAILABLE IN THE UNITED STATES THE PTS CARE WAS COORDINATED BETWEEN THE PLASTIC SURGERY AND THE HEMATOLOGYONCOLOGY TEAMS AT B6 BREAST IMPLANTS REMOVED NOT REPLACED PT WILL UNDERGO SURVEILLANCE WITH MRI AND ULTRASOUND|TEXTURED SILICONE BREAST IMPLANT||04/16/2013|||DA|N|||0HP|FTR|1.0||TESTURED SILICONE BREAST IMPLANT, 410 CC||UNK|||||CUI|||||||True
3530889|61048210|D|1||ALLERGAN LEGAL REPORTED DIFFUSE EXTRAVASATED FLUID IS NOTED AROUND THE RIGHT BREAST IMPLANT CONSISTENT WITH A LEAK AND CYTOLOGY NOTES OF THE FLUID PERCUTANEOUS ASPIRATE OF RIGHT BREAST FLUID COLLECTION POSITIVE FOR MALIGNANT CELLS ANAPLASTIC LARGE CELL LYMPHOMA  THE FLUID SEEN AROUND THE IMPLANT HAS BEEN DEEMED A SEROMA ADDITIONAL EVENT REPORTED OF DIAGNOSIS OF CELIAC DISEASE TREATMENT SPECIFIED AS MEDICATION FOR SYMPTOMS OF CELIAC DISEASE THIS MEDWATCH IS FOR THE RIGHT SIDE SEE MFR REPORT  2024601-2013-00971 FOR THE LEFT SIDE|STYLE 468 SALINE FILLED BREAST IMPLANT|468-495|12/17/2013|||DA|N|R||0HP|FWM|1.0||nan||NI|71 SOUTH LOS CARNEROS ROAD||GOLETA|US|ALLERGAN|93117|CA|93117||||True
3519392|3961243|D|1||RECEIVED A REPORT OF ALCL VIA B4 THERE IS LIMITED INFORMATION NOTED ON THE FORM IT STATES ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSED FROM THE LEFT BREAST THIS PATIENT HAD STYLE 468 TEXTURED SALINE BREAST IMPLANT FROM B6 NO CONTACT INFORMATION WAS PROVIDED THEREFORE NO INVESTIGATION IS ABLE TO BE PERFORMED AT THIS TIME|STYLE 468 SALINE FILLED BREAST IMPLANT|UNK STYLE 468|12/03/2013|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2933302|3232091|D|1||ALLERGANS LEGAL DEPARTMENT RECEIVED A LETTER REPORTING A PATIENT UNDERWENT BREAST AUGMENTATION SURGERY WITH IMPLANTATION OF A GEL FILLED IMPLANT AND WAS DIAGNOSED WITH SEROMA ASSOCIATED PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA ADJACENT TO THE IMPLANT THERE IS LIMITED INFORMATION AVAILABLE FOR THIS CASE AFTER THE INITIAL INVESTIGATION AND THERE IS AN UNLIKELY CHANCE THAT THIS INFORMATION WILL BE OBTAINED HOWEVER IF THERE IS ADDITIONAL INFORMATION SUCH AS DEVICE INFORMATION IMPLANTINGEXPLANTING PHYSICIAN OR ANY LABS RELATED TO BUT NOT LIMITED TO ANY COMBINED RESULTS OF IMMUNE-CHEMICAL HISTOLOGICAL AND CYTOLOGICAL ANALYSIS OF SPECIMENS ARE SCIENTIFICALLY ACCEPTABLE CRITERIA WITH WHICH TO DIAGNOSE ALCL THE FILE WILL BE REVIEWED AND UPDATED|STYLE 153 SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 153|01/23/2013|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
3474087|17927884|D|1||TEXTURED SILICONE BREAST IMPLANT WITH DEVELOPMENT OF ALK-1 NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA IN THE BREAST ADDITIONAL INFO DATES USE 17 YEARS DIAGNOSIS OF REASON FOR USE RECONSTRUCTIVE COSMETIC BREAST IMPLANT AFTER PRIOR MASTECTOMIES|BREAST IMPLANT, TEXTURED SILICONE||11/13/2013||||Y|||0HP|FTR|1.0||BREAST IMPLANT|||||||UNKNOWN|||||||True
3031001|3257910|D|1||REPORTED AS ANAPLASTIC LARGE CELL LYMPHOMA FROM RESEARCH ARTICLE PUBLISHED 2008 AMERICAN JOURNAL OF SURGICAL PATHOLOGY ENTITLED ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH A BREAST IMPLANT CAPSULE A CASE REPORT AND REVIEW OF THE LITERATURE FOLLOW-UP FINDINGS DOCTOR STATES IN ALLERGAN DEVICE BUT IS UNABLE TO EXONERATE DEVICE AS INSUFFICIENT STUDY EVIDENCE|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|11/29/2012|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA, NE|US|ALLERGAN||CA|||||True
2960519|3138896|D|1||PT HAD BILATERAL SILICONE IMPLANTS PLACED IN B6 IN THE 1970S FOR AUGMENTATION SHE HAD ISSUES WITH SILICONE LEAK IN THE 1990S WITH REMOVAL OF BILATERAL IMPLANTS SHE HAD REMOVAL OF FIBROTIC AND FIRM TISSUE AND CAPSULE ON THE LEFT IN 2008 SHE PRESENTED WITH A NEW PALPABLE MASS IN THE LEFT BREAST PARENCHYMA B6 2013 WE PERFORMED A CORE BIOPSY OF THE PALPABLE MASS WHICH WAS HYPOECHOIC AND CONCERNING ON BEDSIDE ULTRASOUND BIOPSY RESULTS SHOW ANAPLASTIC LARGE CELL LYMPHOMA|UNKNOWN||02/07/2013||||N|||0|FTR|1.0||SILICONE BREAST IMPLANT|||UNK||UNK||UNK|||||||True
3738245|4226865|D|1||EXPLANTING PHYSICIAN REPORTS MASSIVE SEROMA AT THE TIME OF SURGERY A VERY LARGE SEROMA WITH THICKENED CAPSULE WAS FOUND IMPLANT WAS INTACT HISTOLOGY FROM THE IMPLANT CAPSULE SHOWED AN ANAPLASTIC LARGE CELL LYMPHOMA ORIGINAL IMPLANT WAS FOLLOWING MASTECTOMY NO CYTOLOGY OR PATHOLOGY CONFIRMATION HAS BEEN RECD AND THERE IS LIMITED INFORMATION AT THIS TIME IF FURTHER INFORMATION BECOMES AVAILABLE IT WILL BE REPORTED|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-FF155-740|03/31/2014|||DA|N|R||0HP|FTR|1.0|02/15/2004|nan||47173|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
3738245|11860603|N|1||DEVICE LABELING ADDRESSES ANAPLASTIC LARGE CELL LYMPHOMA ALCL BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMAWHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-FF155-740|03/31/2014|||DA|N|R||0HP|FTR|1.0|02/15/2004|nan||47173|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
3642248|4203744|D|1||LITERATURE REVIEW OF CHEMOTHERAPY-RESISTANT BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA MURALIDHARAN PARTHASARATHY ET AL BMJ CASE REP 2013 THE ARTICLE REPORTS A PT PRESENTING WITH SYMPTOMS OF DISCOMFORT AND HARDENING OF THE LEFT BREAST EXAM REVEALED A VAGUE MASS MEASURING ABOUT 5 CM IN THE UPPER OUTER QUADRANT OF THE LEFT BREAST TOGETHER WITH PALPABLE AXILLARY LYMPH NODES THREE YEARS PRIOR THE PT HAD BEEN TREATED FOR A SEROMA WHICH HAD BEEN DRAINED NO SEROMA WAS NOTED AT THIS TIME BILATERAL CAPSULAR CONTRACTURE WAS NOTED THE LEFT MORE THAN RIGHT DIAGNOSTICS CONFIRMED ALCL OF THE LEFT BREAST AFTER CHEMOTHERAPY TREATMENT CYCLOPHOSPHAMIDE DOXORUBICIN VINCRISTINE AND PREDNISONE THE PT WAS REASSESSED AND THE LEFT BREAST MASS WAS UNCHANGED SECOND LINE CHEMOTHERAPY WAS GIVEN CISPLATIN AND GEMCITABINE A REPEAT CORE BIOPSY CONFIRMED PERSISTENT ALK NEGATIVE ALCL THE PT HAD A LEFT MASTECTOMY WITH REMOVAL OF THE LEFT BREAST IMPLANT THIS WAS FOLLOWED BY RADIATION THERAPY THE PT HAS SINCE RECOVERED WITH NO SIGNS OF RECURRENCE ALTHOUGH THE MFR OF THE DEVICE IS UNK IT IS ALLERGANS APPROACH TO COMPLIANCE TO RESOLVE ALL DOUBT IN FAVOR OF REPORTING|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|01/31/2014|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
3642248|55007799|D|1||LITERATURE REVIEW OF CHEMOTHERAPY-RESISTANT BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA MURALIDHARAN PARTHASARATHY ET AL BMJ CASE REP 2013 THE ARTICLE REPORTS A PATIENT PRESENTING WITH SYMPTOMS OF DISCOMFORT AND HARDENING OF THE LEFT BREAST EXAM REVEALED A VAGUE MASS MEASURING ABOUT 5 CM IN THE UPPER OUTER QUADRANT OF THE LEFT BREAST TOGETHER WITH PALPABLE AXILLARY LYMPH NODES THREE YEARS PRIOR THE PATIENT HAD BEEN TREATED FOR A SEROMA WHICH HAD BEEN DRAINED NO SEROMA WAS NOTED AT THIS TIME BILATERAL CAPSULAR CONTRACTURE WAS NOTED THE LEFT MORE THAN RIGHT DIAGNOSTICS CONFIRMED ALCL OF THE LEFT BREAST AFTER CHEMOTHERAPY TREATMENT CYCLOPHOSPHAMIDE DOXORUBICIN VINCRISTINE AND PREDNISONE THE PATIENT WAS REASSESSED AND THE LEFT BREAST MASS WAS UNCHANGED SECOND LINE CHEMOTHERAPY WAS GIVEN CISPLATIN AND GEMCITABINE A REPEAT CORE BIOPSY CONFIRMED PERSISTENT ALK NEGATIVE ALCL THE PATIENT HAD A LEFT MASTECTOMY WITH REMOVAL OF THE LEFT BREAST IMPLANT THIS WAS FOLLOWED BY RADIATION THERAPY THE PATIENT HAS SINCE RECOVERED WITH NO SIGNS OF RECURRENCE ALTHOUGH THE MANUFACTURER OF THE DEVICE IS UNKNOWN IT IS ALLERGANS APPROACH TO COMPLIANCE TO RESOLVE ALL DOUBT IN FAVOR OF REPORTING|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|01/31/2014|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
3896044|4422726|D|1||PT REPORTED A RIGHT SIDE LUMP AND ANAPLASTIC LARGE CELL LYMPHOMA THE MEDICAL SAFETY TEAM WAS DETERMINED THAT COMBINED RESULTS OF IMMUNE-CHEMICAL HISTOLOGICAL CRITERIA WITH WHICH TO DIAGNOSE ALCL THERE IS LIMITED INFO AVAILABLE FOR THIS CASE AFTER THE INITIAL INVESTIGATION AND THERE IS AN UNLIKELY CHANCE THAT THIS INFO WILL BE OBTAINED HOWEVER IF THERE IS ADDL INFO SUCH AS DEVICE INFO IMPLANTINGEXPLANTING PHYSICIAN OR ANY LABS RELATED TO BUT NOT LIMITED TO ANY COMBINED RESULTS OF IMMUNE-CHEMICAL HISTOLOGICAL AND CYTOLOGICAL ANALYSIS OF SPECIMENS ARE SCIENTIFICALLY ACCEPTABLE CRITERIA WITH WHICH TO DIAGNOSED ALCL THE FILE WILL BE REVIEWED AND UPDATED|STYLE 168 SALINE FILLED BREAST IMPLANT|168-210|06/12/2014|||DA|N|R||0HP|FWM|1.0|07/27/2012|nan||1643163|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
3946570|54659173|D|1||HEALTHCARE PROFESSIONAL REPORTS INCIDENCE OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL THAT APPEARS TO BE ASSOCIATED WITH THE USE OF TEXTURED BREAST IMPLANTS I HAVE ENCOUNTERED 3 CASES WITHIN THE PAST 3 YEARS OVER 130 CASES HAVE BEEN REPORTED WORLDWIDE AND TWO OF THESE WERE IN PATIENTS WHO HAD MCGHAN IMPLANTS IE THE SAME TEXTURING PROCESS THAT ALLERGAN CURRENTLY USE THE MEDICAL SAFETY TEAM HAS DETERMINED THAT COMBINED RESULTS OF IMMUNE-CHEMICAL HISTOLOGICAL AND CYTOLOGICAL ANALYSIS OF SPECIMENS ARE SCIENTIFICALLY ACCEPTABLE CRITERIA WITH WHICH TO DIAGNOSE ALCL MULTIPLE ATTEMPTS HAVE BEEN MADE TO OBTAIN FURTHER INFORMATION INCLUDING CYTOLOGYPATHOLOGY REPORTS DEVICE INFORMATION ETC IFWHEN ADDITIONAL INFORMATION DOES BECOME AVAILABLE IT WILL BE FORWARDED|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|07/14/2014|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
3946570|4604105|D|1||HEALTHCARE PROFESSIONAL REPORTS INCIDENCE OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL THAT APPEARS TO BE ASSOCIATED WITH THE USE OF TEXTURED BREAST IMPLANTS I HAVE ENCOUNTERED 3 CASES WITHIN THE PAST 3 YEARS OVER 130 CASES HAVE BEEN REPORTED WORLDWIDE AND TWO OF THESE WERE IN PTS WHO HAD MCGHAN IMPLANTS IE THE SAME TEXTURING PROCESS THAT ALLERGAN CURRENTLY USE THE MEDICAL SAFETY TEAM HAS DETERMINED THAT COMBINED RESULTS OF IMMUNE-CHEMICAL HISTOLOGICAL AND CYTOLOGICAL ANALYSIS OF SPECIMENS ARE SCIENTIFICALLY ACCEPTABLE CRITERIA WITH WHICH TO DIAGNOSE ALCL MULTIPLE ATTEMPTS HAVE BEEN MADE TO OBTAIN FURTHER INFO INCLUDING CYTOLOGYPATHOLOGY REPORTS DEVICE INFO ETC IFWHEN ADDL INFO DOES BECOME AVAILABLE IT WILL BE FORWARDED|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|07/14/2014|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
3827677|4447620|D|1||HEALTHCARE PROFESSIONAL REPORTS A CASE OF LYMPHOMA AND SEROMA WITHIN AN ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH BREAST IMPLANTS DIAGNOSTIC CYTOPATHOLOGY VOL 00 NO 00 CHAI ET AL THIS REPORTED CASE IS OF A 52 YO PT WITH A HISTORY OF RECONSTRUCTION FOLLOWING BILATERAL MASTECTOMY FOR BREAST CANCER THE SIDE OF THE CANCER IS NOT NOTED IN THIS ARTICLE THE DEVICE INFO IS NOTED AS SILICONE NO OTHER INFO IS PROVIDED IT ALSO NOTES PERIPROSTHETIC SWELLING THE PT UNDERWENT CAPSULECTOMY AND CHOP HER CURRENT STATUS IS NOTED AS NO EVIDENCE OF DISEASE THERE IS NO OTHER MEDICAL HISTORY NOTED THE TIME TO PRESENTATION IS 35 YEARS CYTOLOGY REPRESENTS POSITIVE TO CD45 CD4 CD43 CD30 AND EMA AND IS NEGATIVE FOR ALK THERE IS NO MFR INFO IF FURTHER INFO BECOMES AVAILABLE IT WILL BE SUBMITTED|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|05/08/2014|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
3827707|22261095|D|1||HEALTHCARE PROFESSIONAL REPORTS A CASE OF LYMPHOMA AND SEROMA WITHIN AN ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH BREAST IMPLANTS DIAGNOSTIC CYTOPATHOLOGY VOL 00 NO 00 CHAI ET AL THE AUTHOR NOTES A 48 YEAR OLD PT WITH A HISTORY OF RECONSTRUCTION FOLLOWING MASTECTOMY FOR BREAST CANCER THE SIDE OF THE CANCER IS NOT NOTED IN THIS ARTICLE THE DEVICE INFO IS NOTED AS SILICONE NO OTHER INFO IS PROVIDED IT ALSO NOTES PERIPROSTHETIC SWELLINGFLUID THE PT UNDERWENT CAPSULECTOMY HER CURRENT STATUS IS NOTED AS NO EVIDENCE OF DISEASE THERE IS NO OTHER MEDICAL HISTORY NOTED THE TIME TO PRESENTATION WAS 4 YEARS THERE IS NO MFR INFO|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|05/08/2014|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
3895999|16446469|D|1||L BREAST IMPLANTED LARGE CELL LYMPHOMA SP L BREAST IMPLANT PLACEMENT IN 2003 IN 1998- AT B6 DIAGNOSED WITH L BREAST CA AND L LUMPECTOMY WITH RADIATION DONE IN 2002-L LATISSIMUS DORSI MYOCUTANEOUS FLAP RECONSTRUCTION WITH TISSUE EXPANDER MENTOR REFB4 LOT 248391 AND R SUBQ MASTECTOMY WITH IMMEDIATE RECONSTRUCTION WITH SALINE IMPLANT MENTOR REFB4 SILTEX CONTOUR PROFILE MAMM PROSTH LOT 251827 SN B4 ADDED 450ML TO IMPLANT PATH REPORT ON B6 2002 WAS NEGATIVE FOR CARCINOMA IN EITHER BREAST ON B62013 SECOND STAGE RECONSTRUCTION L BREAST EXPANDER REMOVED MCGHAN 163 SALINE IMPLANT PLACED REF B4 SN B4 LOT 582791 380CC PRESENTED TO DR B6 B6 2014 WITH PAIN AND SWELLING IN L BREAST-GRADE IV CAPSULE CONTRACTURE NOTED SHE DID NOT WISH TO SCHEDULE SURGERY AT THAT TIME SECOND CONSULTATION ON B6 2014 NEW LUMP IN L BREAST ULTRASOUND MRI AND L BREAST BIOPSY DONE ON B6 2014 REMOVED INTACT IMPLANT L BREAST MCGHAN STYLE 163 SALINE TEXTURED IMPLANT L TOTAL CAPSULECTOMY L BREAST PATH REPORT SHOWS ALCL ANAPLASTIC LARGE CELL LYMPHOMA|MCGHAN|27-163361|06/20/2014|||||||0HP|FWM|1.0||SALINE IMPLANT||582791|||SANTA BARBARA||INAMED|93111||93111||STYLE 163||True
3883642|4565748|D|1||ADDITIONAL INFO RECEIVED FROM A LITERATURE ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA AND BREAST IMPLANTS FIVE AUSTRALIAN CASES PUBLISHED IN THE PLASTIC AND RECONSTRUCTIVE SURGERY ON B6 2012 PG 610E-617E WITHIN THE ARTICLE THE AUTHOR DESCRIBES A B6 WHO UNDERWENT BILATERAL AUGMENTATION WITH 110-360 INAMED TEXTURED ROUND DEVICES VIA INFRAMAMMARY INTO A SUB GLANDULAR POCKET IN B6 2008 THE PT PRESENTED WITH SPONTANEOUS LEFT BREAST SWELLING ALTHOUGH SHE WAS WITH ON FEVER AND MILD DISCOMFORT THE LEFT BREAST WAS DIFFUSELY SWOLLEN THE PT HAD A NORMAL MAMMO IN 2008 AND IN 2009 ULTRASOUND REVEALED A SEROMA A CT SCAN SHOWED AN INFOLDING OF THE IMPLANT BETWEEN 7 AND 9 OCLOCK WITH AN APPARENT MASS WITH SLIGHTLY INCREASED DENSITY IN B6 2009 SURGERY WAS PLANNED TO REMOVE THE PRESUMED RUPTURED IMPLANT AT THE TIME OF SURGERY A STRAW COLORED SEROMA OF 200CC WAS FOUND THE IMPLANT WAS INTACT WITHIN THE CAPSULE THERE WERE TWO AREAS OF GRANULOMATOUS TISSUE AND THICK MASS INFEROMEDIALLY THE CAPSULE AND MASS WERE SENT TO MICROBIOLOGY CULTURE AND HISTOPATHOLOGY THE LYMPHOID CELLS WERE HIGHLY ATYPICAL SHOWING ENLARGED AND IRREGULARLY CONFIGURED NUCLEI IMMUNOHISTOCHEMICAL ANALYSIS SHOWED CD30 + ALK- B-CELL MARKER NEGATIVE AND T-CELL MARKER PARTIAL AND PATCHILY-POSITIVE CD3 CD43 CD45RO AND CD5 TISSUE THE FINDINGS WERE CONSISTENT WITH LOCALIZED FORM OF SYSTEMIC ALCL LARGE T-CELL LYMPHOMA THE BREAST HEALED BUT A RECURRENT MASS APPEARED WEEKS LATER STAGING CT OF CHEST ABD PELVIS AND PET SCAN SHOWED NO EVIDENCE OF DISEASE OUTSIDE THE BREAST SHE UNDERWENT CHEMO WITH CYCLOPHOSPHAMIDE DOXORUBICIN VINCRISTINE AND PREDNISONE IN B6 2009 THE MASS FAILED TO RESPOND AND PROGRESSED TO A WOUND THE LYMPHOMA METASTASIZED TO THE THORACOLUMBAR REGION AND THE RIGHT LUNG AS SEEN IN THE B6 2009 PET SCAN SHE WAS TREATED WITH RADIATION AND A SECOND ROUND OF CHEMO USING GEMCITABINE IFOSFAMIDE AND VINORELBINE SHE RESPONDED WELL AND UNDERWENT A BONE MARROW TRANSPLANT IN 122009 TWO YEARS AFTER DIAGNOSIS SHE REMAINS IN REMISSION THIS EVENT WAS ORIGINALLY SUBMITTED VIA B4 ON B4 2011|STYLE 110 SILICONE GEL FILLED BREAST IMPLANT|27-110361|06/18/2014|||DA|N|R||0HP|FTR|1.0|09/30/2010|nan||1148082|||ARKLOW, COUNTY, WICKLOW|EI|ALLERGAN|||||||True
3827676|4503337|D|1||HEALTHCARE PROFESSIONAL REPORTS A CASE OF LYMPHOMA AND SEROMA WITHIN AN ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH BREAST IMPLANTS DIAGNOSTIC CYTOPATHOLOGY VOL 00 NO 00 CHAI ET AL THIS REPORTED 49 YEAR OLD PT PRESENTED WITH SWELLING AND PERI-PROSTHETIC FLUID THE PT HAD RECONSTRUCTION FOLLOWING A MASTECTOMY FOR BREAST CANCER THE SIDE OF THE CANCER IS NOT NOTED IN THIS ARTICLE THE DEVICE INFORMATION IS NOTED AS SALINE NO OTHER INFORMATION INCLUDING MANUFACTURER IS PROVIDED THERE IS NO OTHER MEDICAL HISTORY NOTED THE TIME TO PRESENTATION IS 8 YEARS|UNK SALINE IMPLANT|UNK SALINE IMPLANT|05/08/2014|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||GOLETA, NE|US|UNKNOWN MANUFACTURER||CA|||||True
3827676|54779306|D|1||HEALTHCARE PROFESSIONAL REPORTS A CASE OF LYMPHOMA AND SEROMA WITHIN AN ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH BREAST IMPLANTS DIAGNOSTIC CYTOPATHOLOGY VOL 00 NO 00 CHAI ET AL THIS REPORTED B6 PATIENT PRESENTED WITH SWELLING AND PERI-PROSTHETIC FLUID THE PATIENT HAD RECONSTRUCTION FOLLOWING A MASTECTOMY FOR BREAST CANCER THE SIDE OF THE CANCER IS NOT NOTED IN THIS ARTICLE THE DEVICE INFORMATION IS NOTED AS SALINE NO OTHER INFORMATION INCLUDING MANUFACTURER IS PROVIDED THERE IS NO OTHER MEDICAL HISTORY NOTED THE TIME TO PRESENTATION IS 8 YEARS|UNK SALINE IMPLANT|UNK SALINE IMPLANT|05/08/2014|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||GOLETA, NE|US|UNKNOWN MANUFACTURER||CA|||||True
3611913|4170417|D|1||REPORTED EVENTS OF CUTANEOUS ALCL CASE 2 BREAST PRESENTATION MASS EFFECT FLUID AROUND IMPLANT AS STATED IN JOURNAL ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA INVOLVING THE BREAST ARCH PATHOLOGY LAB MEDICAL JOURNAL- VOLUME 133 SEPTEMBER 2009 ALTHOUGH THE MANUFACTURER OF THE DEVICE IS UNKNOWN IT IS ALLERGANS APPROACH TO COMPLIANCE TO RESOLVE ALL DOUBT IN FAVOR OR REPORTING|UNK SALINE IMPLANT|UNK SALINE IMPLANT|01/30/2014|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA, NE||ALLERGAN||CA|||||True
3693307|11615224|N|1||THIS EVENT WAS INITIALLY SUBMITTED VIA EASR ON B6 2010 WITH THE ADVERSE EVENT TERM CODE OF CANCER NON BREAST AN UPDATE TO OUR SAFETY DATABASE FOR THIS REPORTED EVENT NOTES THAT THE TERM CODE HAS BEEN CHANGED FROM CANCER NONBREAST TO LYMPHOMA - ALCL DUE TO INCREASED SPECIFICITY DEVICE LABELING ADDRESSES THE FOLLOWING ADVERSE EVENTS AS PER FOUR STUDY TRIALS OF SALINE IMPLANTS IRRITATION THE FOLLOWING IS A LIST OF POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH BREAST IMPLANT SURGERY THE RISKS INCLUDE ADDITIONAL SURGERY IRRITATIONINFLAMMATION PER THE CORE STUDY OF SILICONE IMPLANT IRRITATION WAS REPORTED AT A RATE OF 0 DEVICE LABELING REVIEWED THERE WERE NO EVENTS FOR LYMPHOMA OR ANAPLASTIC LARGE CELL LYMPHOMA LISTED IN THE CORE STUDY FOR SILICONE OR THE STUDY TRIALS IN THE LABELING FOR SALINE BREAST IMPLANTS|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|03/14/2014|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
3693307|4293361|D|1||THIS CASE REPORT OF A B6 OLD PT WAS RECEIVED FROM THE RESEARCH ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH A BREAST IMPLANT CAPSULE A CASE REPORT AND REVIEW OF THE LITERATURE AMERICAN JOURNAL OF SURGICAL PATHOLOGY PUBLISHED IN 2008 THE CASE STUDY WAS PUBLISHED PREVIOUSLY BY ANOTHER PHYSICIAN ET AL SEPTEMBER 2006 VIRCHOWS ARCH ANAPLASTIC LARGE-CELL NON-HODGKINS LYMPHOMA OF THE BREAST PERIPROSTHETIC LOCALIZATION 32 YEARS AFTER TREATMENT FOR PRIMARY BREAST CANCER - A CASE REPORT THE PT HAD BEEN DIAGNOSED WITH BREAST CANCER AND TREATED WITH BREAST-ABLATIVE SURGERY THE PT HAD RECONSTRUCTION SURGERY HAD POLYURETHANE-COATED SILICONE IMPLANTS FOR SIXTEEN YEARS MFR UNK THE PT PRESENTED WITH A LEFT SIDE SKIN ULCER ON THE LEFT BREAST BOTH ANAPLASTIC LARGE CELL NON-HODGKINS LYMPHOMA AND CUTANEOUS ANAPLASTIC LARGE CELL TYPE WERE STATED WITHIN THE ARTICLE AS POSSIBLE DIAGNOSES SUMMARY ABSTRACT STATES THE IMMUNOPROFILE OF THE TUMOR SHOWED NEGATIVITY FOR CYTOKERATINS AND LED TO THE DIAGNOSIS OF A CD30 - POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA THE PT REFUSED ANY FURTHER DIAGNOSTIC OR TREATMENT|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|03/14/2014|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
3946569|4537478|D|1||HEALTHCARE PROFESSIONAL REPORTS INCIDENCE OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL THAT APPEARS TO BE ASSOCIATED WITH THE USE OF TEXTURED BREAST IMPLANTS I HAVE ENCOUNTERED 3 CASES WITHIN THE PAST 3 YEARS OVER 130 CASES HAVE BEEN REPORTED WORLDWIDE AND TWO OF THESE WERE IN PTS WHO HAD MCGHAN IMPLANTS IE THE SAME TEXTURING PROCESS THAT ALLERGAN CURRENTLY USE THE MEDICAL SAFETY TEAM HAS DETERMINED THAT COMBINED RESULTS OF IMMUNE-CHEMICAL HISTOLOGICAL AND CYTOLOGICAL ANALYSIS OF SPECIMENS ARE SCIENTIFICALLY ACCEPTABLE CRITERIA WHICH TO DIAGNOSE ALCL MULTIPLE ATTEMPTS HAVE BEEN MADE TO OBTAIN FURTHER INFO INCLUDING CYTOLOGYPATHOLOGY REPORTS DEVICE INFO ETC IFWHEN ADDL INFO DOES BECOME AVAILABLE IT WILL BE FORWARDED|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|07/14/2014|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
4037715|4723086|D|1||LEFT BREAST IMPLANT ASSOCIATED SEROMA LEFT BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BILATERAL BREAST IMPLANTS PLACED FOR RECONSTRUCTION IN 2002|UNK||08/21/2014|||||||0HP|FTR|1.0||SILICONE BREAST IMPLANT|||||||nan|||||||True
3874163|4506744|D|1||ANAPLASTIC LARGE CELL LYMPHOMA ALCL BREAST IMPLANT RELATED DISCOVERED UPON REMOVING BREAST IMPLANT CAPSULE AND SEROMA FLUID FROM RIGHT BREAST IN PT WHO HAD TEXTURED SALINE-FILLED ALLERGAN IMPLANTS PLACED FOR COSMETIC BREAST ENLARGEMENT IN B6 2009 PT NOTICED BREAST ASYMMETRY IN SUMMER OF 2013 WHICH PROGRESSED TO RIGHT BREAST NOTICEABLY LARGER THAN LEFT SIDE WITH ULTRASOUND STUDY DONE ON B6 2014 SHOWING WHAT APPEARED TO BE FLUID AROUND THE RIGHT IMPLANT - POSSIBLE DEFLATION THIS IMPLANT WAS INTACT UPON REMOVAL BUT HAD A LARGE SURROUNDING SEROMA BECAUSE OF SUSPICION FOR ALCL A RIGHT BREAST IMPLANT TOTAL CAPSULECTOMY AND IMPLANT REMOVAL WAS DONE CAPSULE AND SEROMA FLUID SPECIMENS SENT FOR HISTOLOGYPATHOLOGY EVALUATION|NATRELLE SALINE IMPLANT|168-330|06/11/2014|||||||0HP|FWM|1.0||SALINE IMPLANT|||||||ALLERGAN|||||168 NATRELLE SALINE- FILLED||True
3946563|19797996|D|1||HEALTHCARE PROFESSIONAL REPORTS INCIDENCE OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL THAT APPEARS TO BE ASSOCIATED WITH THE USE OF TEXTURED BREAST IMPLANTS I HAVE ENCOUNTERED 3 CASES WITHIN THE PAST 3 YEARS OVER 130 CASES HAVE BEEN REPORTED WORLDWIDE AND TWO OF THESE WERE IN PATIENTS WHO HAD MCGHAN IMPLANTS IE THE SAME TEXTURING PROCESS THAT ALLERGAN CURRENTLY USE THE MEDICAL SAFETY TEAM HAS DETERMINED THAT COMBINED RESULTS OF IMMUNE-CHEMICAL HISTOLOGICAL AND CYTOLOGICAL ANALYSIS OF SPECIMENS ARE SCIENTIFICALLY ACCEPTABLE CRITERIA WITH WHICH TO DIAGNOSE ALCL MULTIPLE ATTEMPTS HAVE BEEN MADE TO OBTAIN FURTHER INFO INCLUDING CYTOLOGYPATHOLOGY REPORTS DEVICE INFO ETC IFWHEN ADDITIONAL INFO DOES BECOME AVAILABLE IT WILL BE FORWARDED|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|07/14/2014|||DA|N|R||0HP|FWM|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
3642249|17838426|D|1||EVENT OF ANAPLASTIC LARGE CELL LYMPHOMA REPORTED IN JOURNAL ARTICLE PRIMARY AND SECONDARY T-CELL LYMPHOMAS OF THE BREAST GABRIELA ET AL APPL IMMUNOHISTOCHEM MOL MORPHOL VOLUME 17 NUMBER 4 JULY 2009 ALTHOUGH THE MFR OF THE DEVICE IS UNK IT IS ALLERGANS APPROACH TO COMPLIANCE TO RESOLVE ALL DOUBT IN FAVOR OF REPORTING|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|02/05/2014|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
3827678|54778045|D|1||HEALTHCARE PROFESSIONAL REPORTS A CASE OF LYMPHOMA AND SEROMA WITHIN AN ARTICLE  ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH BREAST IMPLANTS DIAGNOSTIC CYTOPATHOLOGY VOL 00 NO 00 CHAI ET AL THE AUTHOR NOTES A 49 YEAR OLD PATIENT WITH A HISTORY OF AUGMENTATION SURGERY DATE UNKNOWN THE DEVICE INFORMATION IS NOTED AS SILICONE NO OTHER INFORMATION IS PROVIDED IT ALSO NOTES PERIPROSTHETIC SWELLING WITH PERI-IMPLANT FLUID TREATMENT WAS CAPSULECTOMY AND CHOP FOLLOW UP AT SEVEN MONTHS SHOWS NO EVIDENCE OF DISEASE NO MANUFACTURER INFORMATION IS PROVIDED|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|05/08/2014|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
3827678|4503338|D|1||HEALTHCARE PROFESSIONAL REPORTS A CASE OF LYMPHOMA AND SEROMA WITHIN AN ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH BREAST IMPLANTS DIAGNOSTIC CYTOPATHOLOGY VOL 00 NO 00 CHAI ET AL THE AUTHOR NOTES A 49 YR OLD PT WITH A HISTORY OF AUGMENTATION SURGERY DATE UNK THE DEVICE INFO IS NOTED AS SILICONE NO OTHER INFO IS PROVIDED IT ALSO NOTES PERIPROSTHETIC SWELLING WITH A PERI-IMPLANT FLUID TREATMENT WAS CAPSULECTOMY AND CHOP FU AT SEVEN MONTHS SHOWS NO EVIDENCE OF DISEASE NO MFR INFO IS PROVIDED|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|05/08/2014|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
4250989|19765661|D|1||PT HAS HAD RECURRENT RIGHT PERICAPSULAR FLUID BEGINNING IN B6 2014 WITH CONSTANT DULL PAIN AND SWELLING IT WAS DRAINED TWICE PRIOR TO THE DATE OF ULTRASOUND AND ASPIRATION WHICH IS B6 2014 SPECIMEN A HAD APPROXIMATELY 17 ML OF YELLOW TO STRAW COLORED WATERY FLUID WITH TISSUE FREE-FLOATING THROUGHOUT SPECIMEN B HAD APPROXIMATELY 10CC OF YELLOW STRAW-COLORED FLUID WITH TISSUE FREE-FLOATING THROUGHOUT DIAGNOSIS SPECIMEN A CYTOLOGY RIGHT BREAST -CD30-POSITIVE MALIGNANT NEOPLASM THE CYTOSPIN AND SECTION OF THE CELL BLOCK SHOW SHEETS OF LARGE MALIGNANT CELLS WITH LARGE VESICULAR NUCLEI CONTAINING PUNCTATE TO PROMINENT NUCLEOLI AND MODERATE AMOUNTS OF EOSINOPHILIC CYTOPLASM HALLMARK CELLS ARE IDENTIFIED A BATTERY OF IMMUNOPEROXIDASE STRAINS IS OBTAINED IN ORDER TO FURTHER CHARACTERIZE THESE CELLS WITH THE FOLLOWING RESULTS POSITIVE CD30 THE FINDINGS ARE THOS OF CD30-POSITIVE MALIGNANT NEOPLASM GIVEN THE CLINICAL SETTING OF THE RECURRENT SEROMAS IN A PT WITH IMPLANTS THESE FINDINGS ARE CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA PT UNDERWENT REMOVAL OF IMPLANT WITH IMMEDIATE REPLACEMENT ON B6 2008 COURSE WAS UNEVENTFUL UNTIL B6 2014|STYLE 410|410FX|11/04/2014|||||||0HP|FTR|1.0||BREAST IMPLANT||13423996|||GOLETA|US|ALLERGAN|93117|CA|93117||FX-410615||True
3693305|4292884|D|1||RESEARCH ARTICLE PUBLISHED IN 2008 AMERICAN JOURNAL OF SURGICAL PATHOLOGY ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH A BREAST IMPLANT CAPSULE A CASE REPORT AND REVIEW OF THE LITERATURE REPORTED A B6 PT WITH A HISTORY OF RIGHT SIDE BREAST CANCER AND RECONSTRUCTION WITH ALLERGAN SALINE TEXTURED BREAST IMPLANT IN B6 2005 THE PT PRESENTED WITH A SEROMA SUBSEQUENTLY SHE WAS DIAGNOSED WITH ALCL T CELL TYPE THIS CASE STUDY WAS REPORTED ORIGINALLY BY ANOTHER DOCTOR ET AL IN ANNALS OF PLASTIC SURGERY B6 2007|STYLE 363 SALINE FILLED BREAST IMPLANT|27-363651|03/14/2014|||DA|N|R||0HP|FWM|1.0||nan||532328|||GOLETA|US|ALLERGAN||CA|||||True
3693305|11615223|N|1||THIS EVENT WAS INITIALLY REPORTED VIA EASR ON B6 2010 WITH THE ADVERSE EVENT TERM CODE OF CANCER NON BREAST AN UPDATE TO OUR SAFETY DATA BASE FOR THIS REPORTED EVENT NOTES THAT THE TERM CODE HAS BEEN CHANGED FROM CANCER NONBREAST TO LYMPHOMA - ALCL DUE TO INCREASED SPECIFICITY DEVICE LABELING REVIEWED THERE WERE NO EVENTS FOR LYMPHOMA OR ANAPLASTIC LARGE CELL LYMPHOMA OR THE STUDY TRIALS IN THE LABELING FOR SALINE IMPLANTS|STYLE 363 SALINE FILLED BREAST IMPLANT|27-363651|03/14/2014|||DA|N|R||0HP|FWM|1.0||nan||532328|||GOLETA|US|ALLERGAN||CA|||||True
3611928|4157112|D|1||REPORTED EVENTS OF ALK- ALCL CASE 3 BREAST PRESENTATION PAIN AND SWELLING SCAR NO FLUID AS STATED IN JOURNAL ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA INVOLVING THE BREAST ARCH PATHOLOGY LAB MEDICAL JOURNAL-VOL 133 SEP 2009 ALTHOUGH THE MFR OF THE DEVICE IS UNK IT IS ALLERGANS APPROACH TO COMPLIANCE TO RESOLVE ALL DOUBT IN FAVOR OR REPORTING|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|01/30/2014|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
4300460|17278557|D|1||DURING AN ULTRASOUND EXAM AND FINE NEEDLE ASPIRATION OF A PERIPROSTHETIC EFFUSION THE DIAGNOSIS OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA WAS DONE|ST 510MX 445||12/01/2014|||||||0|FTR|1.0||BREAST IMPLANTS|||||||ALLERGAN|||||||True
5186386|29786531|D|1||HEALTH PROFESSIONAL REPORTED APPEARANCE OF PERI PROSTHETIC RECIDIVIST LIQUID WHICH AT THE HISTOLOGICAL EXAMINATION RESULTED TO BE COMPATIBLE WITH ANAPLASTIC LARGE CELL LYMPHOMA DEVICE WAS EXPLANTED AND A TOTAL CAPSULECTOMY WAS PERFORMED SIDE WAS UNSPECIFIED EVENT WILL BE CAPTURED AS LYMPHOMA UNTIL PATHOLOGICAL MARKERS ARE RECEIVED TO CONFIRM ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MX150-620|10/29/2015||||N|R||0HP|FTR|1.0|09/14/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1325729|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5186386|29786530|N|1||DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MX150-620|10/29/2015||||N|R||0HP|FTR|1.0|09/14/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1325729|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5108565|26936205|D|1||HEALTH PROFESSIONAL REPORTED SPONTANEOUS RECURRENT SEROMA IN THE RIGHT BREAST POSITIVE CYTOLOGY ANAPLASTIC LYMPHOMA DEVICE WAS REMOVED AND THE CAPSULE WAS ANALYZED WITH RESULT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL SIDE OF DIAGNOSED CAPSULE WAS NOT SPECIFIED ALCL WILL BE CAPTURED AS LYMPHOMA AS PATHOLOGICAL MARKERS HAVE NOT BEEN RECEIVED SEE MFR  9617229-2015-00372 FOR THE LEFT SIDE|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-FX140-560|09/28/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1509947|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5108565|26936204|N|1|| DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-FX140-560|09/28/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1509947|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5067426|25380333|D|1||HEALTH PROFESSIONAL REPORTED PATIENT PRESENTED WITH SWELLING + FIRMNESS OF RIGHT BREAST NO FEVER OR PAIN NO HISTORY OF BLUNT TRAUMA TO BREAST ULTRASOUND ORDERED + ANTIBIOTIC STARTED ULTRASOUND REPORT STATES ON THE RIGHT THERE IS A FAIRLY LARGE QUANTITY OF FLUID NOTED SURROUNDING THE IMPLANT THIS IS MOST MARKED IN THE AXILLARY TAIL ALTHOUGH THIS COULD BE RELATED TO AN INFECTIOUS PROCESS THE FLUID DOES NOT CONTAIN DEBRIS OR SEPTATIONS AND HENCE A SEROMA IS QUESTIONED AT THE 12 OCLOCK POSITION 5 CM FROM THE NIPPLE ON THE RIGHT AND THERE IS A 7MM CYST A SECOND CYST AT THE 1 OCLOCK POSITION 3 CM FROM THE NIPPLE A 5 MM SIZE IS NOTED ON THAT SIDE FLUID ASPIRATION REPORT STATES THESE CELLS ARE IMMUNOPOSITIVE FOR CD30 AND IMMUNONEGATIVE FOR CD20 CD3 CD43 AND ALK DIAGNOSIS STATES NON-HODGKINS LYMPHOMA CD30 + ANAPLASTIC LARGE CELL LYMPHOMA DEVICE REMAINS IMPLANTED|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MM120-280|09/10/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4791712|22282406|N|1||B4 DEVICE LABELING ADDRESSES THE POSSIBILITY OF ADVERSE EVENTS AS POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY DISCUSS WITH THE PT THE WARNINGS PRECAUTIONS IMPORTANT FACTORS TO CONSIDER POSSIBLE ADVERSE EVENTS AND ALLERGANS CORE CLINICAL STUDY RESULTS BASED ON INFO REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT|STYLE 110 SILICONE GEL FILLED BREAST IMPLANT|110-270|05/21/2015||07/22/2015|DA|R|Y||0HP|FTR|1.0|01/24/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2084366|900 PARKWAY GLOBAL PARK|ZONA FRANCA|LA AURORA DE HEREDIA|CS|ALLERGAN (COSTA RICA)|||||||True
5048951|24795080|N|1||DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY PUBLISHED STUDIES INDICATE THAT BREAST CANCER IS NO MORE COMMON IN WOMEN WITH IMPLANTS THAN THOSE WITHOUT IMPLANTS A LARGE LONG-TERM FOLLOW-UP FOUND NO SIGNIFICANT INCREASES IN THE RISK RATES FOR A WIDE VARIETY OF CANCERS INCLUDING STOMACH CANCER LEUKEMIA AND LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 468 SALINE FILLED BREAST IMPLANT|468-270|09/02/2015||||N|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||540807|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5048951|24795081|D|1||HEALTH PROFESSIONAL REPORTED VIA VOLUNTARY MEDWATCH 5042321 PATIENT NOTED INCREASED SIZE OF THE LEFT BREAST AND A FIRM MASS MEDIALLY ALSO IN THE LEFT BREAST ULTRASONIC-GUIDED NEEDLE BIOPSY OF BOTH THE BREAST MASS WHICH PROVIDED TO BE RETRO-PECTORAL AND LEFT AXILLARY LYMPH NODES DONE SHOWED ANAPLASTIC LARGE CELL LYMPHOMA ALK NEG IN THE BREAST AND THE NODES PETCT SHOWED THE BREAST MASS TO BE HIGHLY HYPERMETABOLIC ENLARGED HYPERMETABOLIC LEFT AXILLARY NODES THE PATIENT RECEIVED CHEMOTHERAPY CYCLOPHOSPHAMIDE DOXORUBICIN VINCRISTINE PREDNISONE ETOPOSIDE WITH GOOD RESPONSE BREAST IMPLANT REMOVAL HAS BEEN RECOMMENDED PER FOLLOW-UP HEALTH PROFESSIONAL ADDITIONALLY REPORTED THAT THE PATIENT HAS LEFT SIDE CAPSULAR CONTRACTURE AND HAD NOTED A BULGING ON THE LEFT SIDE BAKER GRADE WAS NOT PROVIDED HEALTH PROFESSIONAL CONFIRMED THAT THE LEFT SIDE DEVICE REMAINS IMPLANTED AND THAT THE PATIENT HAS DECLINED TO HAVE IT REMOVED THIS EVENT WILL BE CAPTURED AS LYMPHOMA AS CONFIRMATION OF ALCL HAS NOT BEEN RECEIVED|STYLE 468 SALINE FILLED BREAST IMPLANT|468-270|09/02/2015||||N|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||540807|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5286885|33230445|D|1||PHYSICIAN REPORTED RIGHT SIDE DEVICE REMOVAL WITH REPLACEMENT AND A DIAGNOSIS OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL AS PATHOLOGICAL MARKERS HAVE NOT BEEN PROVIDED THIS CASE WILL BE CAPTURED AS LYMPHOMA UNTIL CONFIRMATION HAS BEEN RECEIVED|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|27-120301|12/10/2015|||DA|N|R||0HP|FTR|1.0|10/21/2010|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1157331|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5286885|33230384|N|1||DEVICE LABELING ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS  YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|27-120301|12/10/2015|||DA|N|R||0HP|FTR|1.0|10/21/2010|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1157331|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5270622|32776696|N|1||MEDWATCH SUBMITTED ON 12072015 DEVICE LABELING ADDRESSES PUBLISHED STUDIES INDICATE THAT BREAST CANCER IS NO MORE COMMON IN WOMEN WITH IMPLANTS THAN THOSE WITHOUT IMPLANTS A LARGE LONG-TERM FOLLOW-UP FOUND NO SIGNIFICANT INCREASES IN THE RISK RATES FOR A WIDE VARIETY OF CANCERS INCLUDING STOMACH CANCER LEUKEMIA AND LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 468 SALINE FILLED BREAST IMPLANT|468-300|12/07/2015|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||565193|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5088633|26204676|N|1||MEDWATCH SUBMITTED ON 09182015 DEVICE LABELING PUBLISHED STUDIES INDICATE THAT BREAST CANCER IS NO MORE COMMON IN WOMEN WITH IMPLANTS THAN THOSE WITHOUT IMPLANTS A LARGE LONG-TERM FOLLOW-UP FOUND NO SIGNIFICANT INCREASES IN THE RISK RATES FOR A WIDE VARIETY OF CANCERS INCLUDING STOMACH CANCER LEUKEMIA AND LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|09/18/2015|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|UNKNOWN MANUFACTURER|||||||True
5088633|54646607|D|1||PHYSICIAN REPORTED A CASE OF BREAST IMPLANT ALCL ANAPLASTIC LARGE CELL LYMPHOMA AND A PATHOLOGY CONFIRMED EFFUSION SIDE IS UNKNOWN TREATMENT HAS NOT YET OCCURRED DEVICE REMAINS IMPLANTED MANUFACTURER OF DEVICE IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|09/18/2015|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|UNKNOWN MANUFACTURER|||||||True
5088633|26204677|D|1||PHYSICIAN REPORTED A CASE OF BREAST IMPLANT ALCL ANAPLASTIC LARGE CELL LYMPHOMA AND A PATHOLOGY CONFIRMED EFFUSION SIDE IS UNKNOWN TREATMENT HAS NOT YET OCCURRED DEVICE REMAINS IMPLANTED MANUFACTURER OF DEVICE IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|09/18/2015|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|UNKNOWN MANUFACTURER|||||||True
5331748|34569574|N|1||MEDWATCH SUBMITTED ON 12292015 B4 DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-FF130-425|12/29/2015|||DA|N|R||0HP|FTR|1.0|04/19/2015|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1832218|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4680690|13211132|N|1||B4 DEVICE LABELING UNDERGOING ANY TYPE OF SURGICAL PROCEDURE INVOLVES RISKS SUCH AS THE EFFECTS OF ANESTHESIA INFECTION SWELLING REDNESS BLEEDING PAIN AND EVEN DEATH SOME OF THESE RISKS ARE SERIOUS AND ALL OF THESE RISKS NEED TO BE BALANCED AGAINST THE BENEFITS OF THE SURGERY WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ANAPLASTIC LARGE CELL LYMPHOMA OR ALCL IN THE SCAR TISSUE AND FLUID ADJACENT TO THE IMPLANT ALCL IS NOT BREAST CANCER - IT IS A RARE TYPE OF NON-HODGKINS LYMPHOMA CANCER OF THE IMMUNE SYSTEM ALCL HAS BEEN REPORTED GLOBALLY IN PTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS MOST PTS WERE DIAGNOSED WHEN THEY SOUGH MEDICAL TREATMENT FOR IMPLANT-RELATED SYMPTOMS SUCH AS PAIN LUMPS SWELLING OR ASYMMETRY THAT DEVELOPED AFTER THEIR INITIAL SURGICAL SITES WERE FULLY HEALED IN THE CASES REPORTED ALCL WAS TYPICALLY DIAGNOSED YEARS AFTER THE IMPLANT SURGERY ONE RECONSTRUCTION PT IN THE PIVOTAL STUDY WAS REPORTED WITH ALCL THROUGH 10 YEARS|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-LF140-440|04/09/2015|||DA|N|R||0HP|FTR|1.0|03/20/2012|nan||1408999|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
4742777|16612615|N|1||UNIQUE IDENTIFIER UDI  NOT APPLICABLE THE EVENT OF ANAPLASTIC LARGE CELL LYMPHOMA WAS INITIALLY REPORTED ON B6 2011 WITH THE ADVERSE EVENT TERM CODE OF CANCER AN UPDATE TO OUR SAFETY DATABASE FOR THIS REPORTED EVENT NOTES THAT THE TERM CODE HAS BEEN CHANGED FROM CANCER TO LYMPHOMA-ALCL DUE TO INCREASED SPECIFICITY PATIENT IDENTIFIER B6 RELATES TO PATIENTS RECORD PREVIOUSLY EXISTING IN EASY TRACK DATABASE CURRENT DATABASE PATIENT IDENTIFIER IS B6 DEVICE LABELING PATIENTS SHOULD BE ADVISED THAT IMPLANTS ARE NOT CONSIDERED LIFETIME DEVICES AND THEY WILL POTENTIALLY UNDERGO IMPLANT REMOVAL WITH OR WITHOUT REPLACEMENT OVER THE COURSE OF THEIR LIFE PATIENTS SHOULD ALSO BE ADVISED THAT THE CHANGES TO THEIR BREAST FOLLOWING EXPLANTATION ARE IRREVERSIBLE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|04/30/2015|||DA|N|R||0HP|FTR|1.0||nan||NI|LA AURORA DE HEREDIA||NE|CS|ALLERGAN|||||||True
5285719|38372148|D|1||COMPANY REPRESENTATIVE REPORTED PHYSICIAN STATED POSSIBLE ALCLNO OTHER SPECIFICS WERE GIVEN TO ME FOLLOW-UP WITH HEALTH PROFESSIONAL CONFIRMS THAT THE MANUFACTURER IS ALLERGAN AND THAT THE PATIENT PRESENTED WITH RIGHT BREAST VERY SWOLLEN AND RED FINE NEEDLE ASPIRATION REPORTS APPARENT TINY CALCIFICATIONSÂ¿ AND Â¿APPROXIMATELY ONE LITER OF YELLOW SLIGHTLY TURBID FLUID WAS OBTAINEDÂ¿ IMPRESSION STATES Â¿THERE ARE AREAS OF SOFT TISSUE NODULARITY ALONG THE MARGINS OF THE FLUID COLLECTION WHICH ARE SUSPICIOUS FOR LYMPHOMA CYTOLOGY SHOWS MALIGNANCY CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ PATHOLOGY REPORT NOTES CD30 POSITIVE AND ALK-1 NEGATIVE CAPSULECTOMY AND EXPLANTATION OCCURRED ADDITIONALLY HEALTH PROFESSIONAL REPORTED INCREASED TENDERNESS AND SMALL AREAS OF SKIN BREAKDOWN AND ON THE ANTERIOR CAPSULE THERE WAS WHITE NECROTIC APPEARING TISSUE THAT IN SEVERAL SPOTS EXTENDED ALL THE WAY UP TO THE DEEP DERMIS PAIN HAS BEEN DEEMED SECONDARY TO THE EVENT OF NECROSIS|STYLE 468 SALINE FILLED BREAST IMPLANT|468-350|12/10/2015||01/08/2016|DA|R|Y||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5285719|33288642|N|1||MEDWATCH SUBMITTED ON 12102015 DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 468 SALINE FILLED BREAST IMPLANT|468-350|12/10/2015||01/08/2016|DA|R|Y||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5285719|35139726|D|1||COMPANY REPRESENTATIVE REPORTED PHYSICIAN STATED POSSIBLE ALCL NO OTHER SPECIFICS WERE GIVEN TO ME FOLLOW-UP WITH HEALTH PROFESSIONAL CONFIRMS THAT THE MANUFACTURER IS ALLERGAN AND THAT THE PATIENT PRESENTED WITH RIGHT BREAST VERY SWOLLEN AND RED FINE NEEDLE ASPIRATION REPORTS APPARENT TINY CALCIFICATIONS AND APPROXIMATELY ONE LITER OF YELLOW SLIGHTLY TURBID FLUID WAS OBTAINED IMPRESSION STATES THERE ARE AREAS OF SOFT TISSUE NODULARITY ALONG THE MARGINS OF THE FLUID COLLECTION WHICH ARE SUSPICIOUS FOR LYMPHOMA CYTOLOGY SHOWS MALIGNANCY CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA PATHOLOGY REPORT NOTES B4 POSITIVE AND ALK-1 NEGATIVE CAPSULECTOMY AND EXPLANTATION OCCURRED|STYLE 468 SALINE FILLED BREAST IMPLANT|468-350|12/10/2015||01/08/2016|DA|R|Y||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5285719|39855319|D|1||COMPANY REPRESENTATIVE REPORTED PHYSICIAN STATED POSSIBLE ALCLNO OTHER SPECIFICS WERE GIVEN TO ME FOLLOW-UP WITH HEALTH PROFESSIONAL CONFIRMS THAT THE MANUFACTURER IS ALLERGAN AND THAT THE PATIENT PRESENTED WITH RIGHT BREAST VERY SWOLLEN AND RED FINE NEEDLE ASPIRATION REPORTS APPARENT TINY CALCIFICATIONSÂ¿ AND Â¿APPROXIMATELY ONE LITER OF YELLOW SLIGHTLY TURBID FLUID WAS OBTAINEDÂ¿ IMPRESSION STATES Â¿THERE ARE AREAS OF SOFT TISSUE NODULARITY ALONG THE MARGINS OF THE FLUID COLLECTION WHICH ARE SUSPICIOUS FOR LYMPHOMA CYTOLOGY SHOWS MALIGNANCY CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ PATHOLOGY REPORT NOTES CD30 POSITIVE AND ALK-1 NEGATIVE CAPSULECTOMY AND EXPLANTATION OCCURRED ADDITIONALLY HEALTH PROFESSIONAL REPORTED INCREASED TENDERNESS AND SMALL AREAS OF SKIN BREAKDOWN AND ON THE ANTERIOR CAPSULE THERE WAS WHITE NECROTIC APPEARING TISSUE THAT IN SEVERAL SPOTS EXTENDED ALL THE WAY UP TO THE DEEP DERMIS PAIN HAS BEEN DEEMED SECONDARY TO THE EVENT OF NECROSIS|STYLE 468 SALINE FILLED BREAST IMPLANT|468-350|12/10/2015||01/08/2016|DA|R|Y||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5054360|24980549|N|1||DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT PLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY CASE-CONTROL STUDIES TO EVALUATE THE ASSOCIATION BETWEEN NATRELLEÂ® 410 BREAST IMPLANTS AND 5 RARE DISEASE OUTCOMES RARE CONNECTIVE TISSUE DISEASES NEUROLOGICAL DISEASES BRAIN CANCER CERVICALVULVAR CANCER AND LYMPHOMA ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|MF-410580|09/03/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2429863|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4385729|12634624|N|1||DEVICE LABELING ADDRESSES THE REPORTED EVENT OF ALCL AS FOLLOWS BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MFRS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REP PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AND INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL DEVICE LABELING ADDRESSES THE REPORTED EVENT OF SEROMA AS FOLLOWS POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSISTWITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS DEVICE LABELING ADDRESSES THE REPORTED EVENT OF JUMPMASSCYST AS FOLLOWS IN THE B6 STUDY AT LEAST 1 REOPERATION WAS PERFORMED ON 315 PATIENTS 365 THROUGH 10 YEARS A TOTAL OF 424 REOPERATIONS WERE PERFORMED THE PRIMARY REASON FOR REOPERATION THROUGH 10 YEARS ON AUGMENTATION PATIENTS WAS IMPLANT DEFLATION AT 217 THE PERCENTAGE OF REOPERATIONS DUE TO LUMPMASSCYST INCREASED FROM 85 OF 293 REOPERATIONS THROUGH 5 YEARS TO 139 OF 424 REOPERATIONS THROUGH 10 YEARS THE OCCURRENCE OF LUMPS MASSES AND CYSTS CAN BE EXPECTED TO NATURALLY INCREASE AS PTS AGE AND COULD BE AN EXPLANATION FOR THE INCREASE|UNK SALINE IMPLANT|UNK SALINE IMPLANT|12/24/2014|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||LA AURORA DE HEREDIA|CS|UNKNOWN MANUFACTURER|||||||True
4385750|20562037|N|1||DEVICE LABELING ADDRESSES THE REPORTED EVENT OF ALCL AS FOLLOWS BASED ON INFO REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MFRS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REP PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL DEVICE LABELING ADDRESSES THE REPORTED EVENT OF SEROMA AS FOLLOWS POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS|UNK SALINE IMPLANT|UNK SALINE IMPLANT|12/24/2014|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||LA AURORA DE HEREDIA|CS|UNKNOWN MANUFACTURER|||||||True
5108543|32666145|D|1||HEALTH PROFESSIONAL REPORTED SEVERAL SPONTANEOUS SEROMA IN THE LEFT BREAST WITH NEGATIVE CYTOLOGY THEY WERE SPONTANEOUSLY RESOLVED DEVICE WAS REMOVED AND THE CAPSULE WAS ANALYZED WITH RESULT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL SIDE OF DIAGNOSED CAPSULE WAS NOT SPECIFIED ALCL WILL BE CAPTURED AS LYMPHOMA AS PATHOLOGICAL MARKERS HAVE NOT BEEN RECEIVED SEE MFR  9617229-2015-00373 FOR THE RIGHT SIDE|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-FX140-560|09/28/2015||10/07/2015|DA|R|Y||0HP|FTR|1.0|09/25/2012|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1490828|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5108543|26936807|N|1||DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-FX140-560|09/28/2015||10/07/2015|DA|R|Y||0HP|FTR|1.0|09/25/2012|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1490828|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5108543|32280916|D|1||HEALTH PROFESSIONAL REPORTED SEVERAL SPONTANEOUS SEROMA IN THE LEFT BREAST WITH NEGATIVE CYTOLOGY THEY WERE SPONTANEOUSLY RESOLVED DEVICE WAS REMOVED AND THE CAPSULE WAS ANALYZED WITH RESULT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL SIDE OF DIAGNOSED CAPSULE WAS NOT SPECIFIED ALCL WILL BE CAPTURED AS LYMPHOMA AS PATHOLOGICAL MARKERS HAVE NOT BEEN RECEIVED SEE MFR  9617229-2015-00373 FOR THE RIGHT SIDE|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-FX140-560|09/28/2015||10/07/2015|DA|R|Y||0HP|FTR|1.0|09/25/2012|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1490828|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5108543|49682505|D|1||HEALTH PROFESSIONAL REPORTED SEVERAL SPONTANEOUS SEROMA IN THE LEFT BREAST WITH NEGATIVE CYTOLOGY THEY WERE SPONTANEOUSLY RESOLVED DEVICE WAS REMOVED AND THE CAPSULE WAS ANALYZED WITH RESULT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL SIDE OF DIAGNOSED CAPSULE WAS NOT SPECIFIED ALCL WILL BE CAPTURED AS LYMPHOMA AS PATHOLOGICAL MARKERS HAVE NOT BEEN RECEIVED SEE MFR  9617229-2015-00373 FOR THE RIGHT SIDE|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-FX140-560|09/28/2015||10/07/2015|DA|R|Y||0HP|FTR|1.0|09/25/2012|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1490828|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5108543|26936808|D|1||HEALTH PROFESSIONAL REPORTED SEVERAL SPONTANEOUS SEROMA IN THE LEFT BREAST WITH NEGATIVE CYTOLOGY THEY WERE SPONTANEOUSLY RESOLVED DEVICE WAS REMOVED AND THE CAPSULE WAS ANALYZED WITH RESULT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL SIDE OF DIAGNOSED CAPSULE WAS NOT SPECIFIED ALCL WILL BE CAPTURED AS LYMPHOMA AS PATHOLOGICAL MARKERS HAVE NOT BEEN RECEIVED SEE MFR  9617229-2015-00373 FOR THE RIGHT SIDE|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-FX140-560|09/28/2015||10/07/2015|DA|R|Y||0HP|FTR|1.0|09/25/2012|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1490828|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4859987|5847605|D|1||HEALTH PROFESSIONAL REPORTED PT DEVELOPED A LARGE VOLUME LATE SEROMA AROUND THE RIGHT RECONSTRUCTIVE BREAST IMPLANT FLUID WAS ASPIRATED AND SENT TO CYTOLOGY THIS CONFIRMED ANAPLASTIC LARGE CELL LYMPHOMA ALK-1 NEGATIVE SUBSEQUENT PET SCAN - MILD ACTIVITY IN INTERNAL MAMMARY LYMPH NODES AWAITING FINAL HAEMATOLOGY REVIEW DEVICE WAS REMOVED FURTHER FOLLOW-UP REPORTED FINE NEEDLE ASPIRATION OF SEROMA FLUID AROUND RIGHT IMPLANT CONFIRMED THE DIAGNOSIS OF ALK-1 NEGATIVE ALCL THE ALCL WAS CONTAINED WITHIN THE CAPSULE IN THE PERIPROSTHETIC FLUID ONLY PATHOLOGY REPORT CONFIRMED  CD30 LARGE CELL POSITIVE  ALK-1 NEGATIVE AND OVERALL THESE FINDINGS ARE SUGGESTIVE OF ALK-1 NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA STAGE 1AE PET-CT SCAN REPORTS THERE ARE BILATERAL BORDERLINE ENLARGED INTERNAL MAMMARY LYMPH NODES WHICH SHOW MILDLY INCREASED METABOLIC ACTIVITY|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|FM-410500|06/19/2015|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
4385762|5263418|D|1||MEDICAL STAFF REPORTED EXPLANTATION OF THE PERIPROSTHETIC RIGHT SIDE ANAPLASTIC LARGE CELL LYMPHOMA T-CELL FORMED IN THE EXUDATE AND WITHOUT INFILTRATION OF THE TUMOR IN THE CAPSULE ALCL HAS NOT YET BEEN CONFIRMED VIA DIAGNOSTICS THEREFORE THE EVENT OF LYMPHOMA WILL BE REPORTED|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MF120-295|12/31/2014|||DA||R||0HP|FTR|1.0|02/08/2013|nan||1553196|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
5078001|40431380|D|1||HEALTH PROFESSIONAL REPORTED A RIGHT SIDE DEFLATION HEALTH PROFESSIONAL ADDITIONALLY REPORTED ENLARGED RIGHT BREAST SEROMA RIGHT BREAST IMPLANT POCKET PATIENT WAS GIVEN SOME ANTIBIOTICS WITH SOME IMPROVEMENT BUT WITH RECURRENT SUDDENLY ENLARGING RIGHT BREASTÂ¿ AT THE TIME OF SURGERY A CLEAR STRAW COLORED FLUID APPROXIMATELY 450CC WAS REMOVED SOME PROTEINACEOUS EXUDATE WAS FOUND IN AND AROUND THE POCKET AND THE IMPLANTÂ¿ PATHOLOGY REPORT STATES DIAGNOSIS OF Â¿CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA ALK-NEGATIVE ALCL ASSOCIATED WITH BREAST IMPLANT NEOPLASTIC CELLS ARE CD30 CD4 AND CD43 POSITIVEÂ¿ PER ADDITIONAL INFORMATION HEALTH PROFESSIONAL NOTED SWELLING INVOLVING THE RIGHT BREAST WHICH WAS BELIEVED TO BE AN INFECTION TREATED WITH ANTIBIOTICS|STYLE 168 SALINE FILLED BREAST IMPLANT|168-420|09/15/2015||08/21/2015|DA|R|Y||0HP|FWM|1.0|05/01/2005|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||564274|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4385745|18428752|N|1||DEVICE LABELING ADDRESSES THE REPORTED EVENT OF ALCL AS FOLLOWS BASED ON INFO REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MFRS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PTS PRESENTED WITH CAPSULAR CONTRACTURE OF MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL DEVICE LABELING ADDRESSES THE REPORTED EVENT OF SEROMA AS FOLLOWS POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS|UNK SALINE IMPLANT|UNK SALINE IMPLANT|12/24/2014|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||LA AURORA DE DEREDIA|CS|UNKNOWN MANUFACTURER|||||||True
4648716|13098279|N|1||THE EVENT OF ANAPLASTIC LARGE CELL LYMPHOMA WAS INITIALLY REPORTED VIA B4 ON B4 2010 WITH THE ADVERSE EVENT TERM CODE OF CANCER THE EVENT WAS REPORTED AGAIN VIA B4 ON B4 2012 WITH THE ADVERSE EVENT TERM CODE OF LYMPHOMA AN UPDATE TO OUR SAFETY DATABASE FOR THIS REPORTED EVENT NOTES THAT THE TERM CODE HAS BEEN CHANGED TO LYMPHOMA ALCL DUE TO INCREASED SPECIFICITY B6 DEVICE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHY CHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS POSTOPERATIVE HEMATOMA AND SEROMA MAY BE MINIMIZED BY METICULOUS ATTENTION TO HEMOSTASIS DURING SURGERY AND POSSIBLY ALSO BY POSTOPERATIVE USE OF A CLOSED DRAINAGE SYSTEM PERSISTENT EXCESSIVE BLEEDING MUST BE CONTROLLED BEFORE IMPLANTATION ANY POSTOPERATIVE EVACUATION OF HEMATOMA OR SEROMA MUST BE CONDUCTED WITH CARE TO AVOID BREAST IMPLANT CONTAMINATION OR DAMAGE FROM SHARP INSTRUMENTS USE CARE IN SUBSEQUENT PROCEDURES SUCH AS OPEN CAPSULOTOMY BREAST POCKET REVISION HEMATOMASEROMA ASPIRATION AND BIOPSYLUMPECTOMY TO AVOID DAMAGE TO THE IMPLANT THE B4 STUDY WILL CONTINUE TO EVALUATE THE LONG-TERM B4 SAFETY AND EFFECTIVENESS OF THESE PRODUCTS IN ADDITION ALLERGAN HAS INITIATED A SEPARATE B4 POST-APPROVAL STUDY B4 TO ADDRESS SPECIFIC ISSUES WHICH ALLERGANS CORE STUDY WAS NOT DESIGNED TO FULLY ANSWER AS WELL AS TO PROVIDE A REAL-WORLD ASSESSMENT OF SOME ENDPOINTS B4 ALLERGAN WILL UPDATE THEIR LABELING ON A REGULAR BASIS WITH THE RESULTS OF THESE TWO STUDIES B4 THERE WERE NO REPORTS OF OTHER CANCERS SUCH AS BRAIN RESPIRATORY OR CERVICALVULVAR IN PRIMARY RECONSTRUCTION OR REVISION-RECONSTRUCTION PATIENTS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|03/31/2015|||DA|N|R||0HP|FTR|1.0||nan||NI|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4648716|5757553|D|1||JOURNAL TITLED ANAPLASTIC LARGE CELL LYMPHOMA ARISING IN A SILICONE BREAST IMPLANT CAPSULE STATES PATIENT PRESENTED WITH SWELLING AND TENDERNESS AT THE LEFT BREAST IMPLANT SITE AT SURGERY A SUBSTANTIAL AMOUNT OF STRAW COLORED FLUID WAS DRAINED FROM THE PERIPROSTHETIC CAPSULAR SPACE THE PROSTHESIS WAS REMOVED FOLLOWED BY CAPSULECTOMY RESULTS IN TABLE OF ARTICLE SHOW CD300 POSITIVE AND ALK-1 NEGATIVE PT WAS TREATED WITH RADIOTHERAPY AND REVEALED NO SYSTEMIC DISEASE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|03/31/2015|||DA|N|R||0HP|FTR|1.0||nan||NI|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
5105218|26823377|N|1||DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MX120-325|09/25/2015||||N|R||0HP|FTR|1.0|11/04/2013|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1671333|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5285827|33170546|N|1||MEDWATCH SUBMITTED ON 12102015 DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 363 SALINE FILLED BREAST IMPLANT|363LF-560|12/10/2015|||DA|N|R||0HP|FWM|1.0|12/04/2010|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||1375592|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5061707|25188101|N|1||MEDWATCH SUBMITTED ON 09082015 DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT PLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MX125-370|09/08/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1331894|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4702227|13234344|N|1||B4 DEVICE LABELING BASED ON INFORMATION TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL THERE WERE 9 PRIMARY AUGMENTATION PATIENTS 19 WITH A NEW DIAGNOSIS OF BREAST CANCER THROUGH 10 YEARS IN THE ALLERGAN PIVOTAL STUDY IN PRIMARY AUGMENTATION PATIENTS THERE WAS 1 REPORT OF SKIN CANCER AND 1 REPORT OF RENAL CELL CANCER AND 1 PRIMARY AUGMENTATION PATIENT WHO WAS PREGNANT AT THE TIME OF IMPLANTATION GAVE BIRTH TO A CHILD WHO LATER DEVELOPED HISTIOCYTOSIS THERE WAS 1 REVISION-AUGMENTATION PATIENT 08 WITH A NEW DIAGNOSIS OF BREAST CANCER THROUGH 10 YEARS AND 1 PATIENT REPORT OF BLADDER CANCER AND 1 PATIENT REPORT OF MULTIPLE MYELOMA THERE WERE 17 RECONSTRUCTION PATIENTS 76 WITH RECURRENCE OF BREAST CANCER THROUGH 10 YEARS 1 REPORT OF NON-HODGKINS LYMPHOMA AND 1 REPORT OF UTERINE CANCER THERE WERE NO REVISION-RECONSTRUCTION PATIENTS WHO REPORTED A RECURRENCE OF BREAST CANCER THROUGH 10 YEARS AND NO REPORTS OF OTHER CANCERS IN REVISION-RECONSTRUCTION PATIENTS ONE RECONSTRUCTION PATIENT IN THE PIVOTAL STUDY WAS REPORTED WITH ALCL THROUGH 10 YEARS SOMETIMES THERE ARE SYMPTOMS ASSOCIATED WITH GEL IMPLANT RUPTURE THESE SYMPTOMS INCLUDE HARD KNOTS OR LUMPS SURROUNDING THE IMPLANT OR IN THE ARMPIT CHANGE OR LOSS OF SIZE OR SHAPE OF THE BREAST OR IMPLANT PAIN TINGLING SWELLING NUMBNESS BURNING AND HARDENING OF THE BREAST LITERATURE REPORTS HAVE ALSO BEEN MADE ASSOCIATING SILICONE BREAST IMPLANTS WITH VARIOUS RHEUMATOLOGICAL SIGNS AND SYMPTOMS SUCH AS FATIGUE EXHAUSTION JOINT PAIN AND SWELLING MUSCLE PAIN AND CRAMPING TINGLING NUMBNESS WEAKNESS AND SKIN RASHES|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|MF-410335|04/16/2015||02/25/2013|DA|Y|Y||0HP|FTR|1.0|02/02/2011|nan||1223847|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
4702227|5724962|D|1||HEALTH PROFESSIONAL REPORTED ANAPLASTIC LARGE CELL LYMPHOMA AND PATIENT PRESENTED WITH RIGHT BREAST SWELLING EVENT OF ANAPLASTIC LARGE CELL LYMPHOMA WILL BY CAPTURED AS LYMPHOMA UNTIL DIAGNOSTIC TESTING CAN CONFIRM DIAGNOSIS OF ALCL DEVICE HAS BEEN REMOVED|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|MF-410335|04/16/2015||02/25/2013|DA|Y|Y||0HP|FTR|1.0|02/02/2011|nan||1223847|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
4616833|54647640|D|1||REPORTED EVENTS OF 24 UNPUBLISHED CASES OF BI-ALCL FOUND FROM JOURNAL ABSTRACT Â¿1435 BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIALCL A COMPREHENSIVE HISTOPATHOLOGICAL EVALUATION OF 40 CASES WITH A PROPOSAL FOR A PATHOLOGIC STAGING SYSTEMÂ¿ ANNUAL ABSTRACT MEETINGS AS NO DIAGNOSTIC TESTING IS PROVIDED EVENT WILL BE CAPTURED AS LYMPHOMA SIDE IS UNKNOWN MANUFACTURER OF DEVICE IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|03/18/2015|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|LA AURORA DE HEREDIA||NE|CS|UNKNOWN MANUFACTURER|||||||True
4616833|5653848|D|1||REPORTED EVENTS OF 24 UNPUBLISHED CASES OF BI-ALCL FOUND FROM JOURNAL ABSTRACT 1435 BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIALCL A COMPREHENSIVE HISTOPATHOLOGICAL EVALUATION OF 40 CASES WITH A PROPOSAL FOR A PATHOLOGIC STAGING SYSTEM ANNUAL ABSTRACT MEETINGS AS NO DIAGNOSTIC TESTING IS PROVIDED EVENT WILL BE CAPTURED AS LYMPHOMA SIDE IS UNKNOWN MANUFACTURER OF DEVICE IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|03/18/2015|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|LA AURORA DE HEREDIA||NE|CS|UNKNOWN MANUFACTURER|||||||True
4922479|6435381|D|1||HEALTH PROFESSIONAL REPORTED RIGHT SIDE DEVICE REMOVED DUE TO A SEROMA THAT SUDDENLY APPEARED WITH SWELLING OF MAMMARY FOR SEVERAL WEEKS DURING REMOVAL OF RIGHT SIDE IMPLANT A DOUBLE CAPSULE WAS FOUND PATHOLOGICAL TESTING OF THE SEROMA AND CAPSULE REVEALED PATHOLOGICAL MARKERS CD30+ AND ALK- AND FOCAL INFLAMMATORY CHRONIC REARRANGEMENTS THIS CONFIRMS DIAGNOSIS OF RIGHT SIDE ANAPLASTIC LARGE CELL LYMPHOMA ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-LF120-270|07/16/2015|||DA|N|R||0HP|FTR|1.0|08/25/2010|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE, GEL-FILLED||1126779|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
4702228|5721216|D|1||JOURNAL TITLED PRIMARY BREAST LYMPHOMA IN A PT WITH SILICONE BREAST IMPLANTS A CASE REPORT  AND REVIEW OF THE LITERATURE STATES PT PRESENTED TO OUT PLASTIC SURGERY CLINIC WITH RIGHT-SIDED BREAST SWELLING POST AUGMENTATION WITH MCGHAN 550 CC SILICONE GEL IMPLANTS REPORT ADDITIONALLY STATES THE RIGHT BREAST PERIPROSTHETIC FLUID COLLECTION WAS ASPIRATED REVEALING 22CC OF STRAW-COLOURED FLUID AND ADDITIONALLY A PALPABLE MASS WAS APPRECIATED ON EXAM BY THIS TIME AND STEREOTACTIC CORE NEEDLE BIOPSY OF THE MASS WAS PERFORMED REVEALING ANAPLASTIC LARGE CELL LYMPHOMA DEVICE WAS REMOVED AND PATHOLOGY OF THE RIGHT BREAST CAPSULE REVEALED MALIGNANT ANAPLASTIC LARGE CELL LYMPHOMA CELLS PT UNDERWENT CHEMOTHERAPY|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|04/16/2015|||DA|N|R||0HP|FWM|1.0||nan||NI|||LA AURORA DE HEREDIA|CS|ALLERGAN|NE||NE||||True
4702228|13160829|N|1||THE EVENT OF ANAPLASTIC LARGE CELL LYMPHOMA WAS INITIALLY REPORTED VIA B4 ON B4 2010 WITH THE ADVERSE EVENT TERM CODE OF CANCER AN UPDATE TO OUR SAFETY DATABASE FOR THIS REPORTED EVENT NOTES THAT THE TERM CODE HAS BEEN CHANGED FROM CANCER TO LYMPHOMA-ALCL DUE TO INCREASED SPECIFICITY PT IDENTIFIER B6 RELATES TO PTS RECORD PREVIOUSLY EXISTING IN B4 DATABASE CURRENT DATABASE PT IDENTIFIER B6 DEVICE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDED IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES TO NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEN REPORTED IN SOME WOMEN WITH IMPLANTS USE CARE IN SUBSEQUENT PROCEDURES SUCH AS OPEN CAPSULOTOMY BREAST POCKET REVISION HEMATOMASEROMA ASPIRATION AND BIOPSYLUMPECTOMY TO AVOID DAMAGE TO THE IMPLANT PT SHOULD PERFORM BREAST SELF-EXAMINATIONS MONTHLY AND BE SHOWN HOW TO DISTINGUISH THE IMPLANT FROM THEIR BREAST TISSUE THE PT SHOULD NOT MANIPULATE OR SQUEEZE THE EXCESSIVELY THE PT SHOULD BE TOLD THAT THE PRESENCE OF LUMPS PERSISTENT PAIN SWELLING HARDENING OR CHANGE IN THE IMPLANT SHAPE MAY BE SIGNS OF SYMPTOMATIC RUPTURE OF THE IMPLANT IF THE PT HAS ANY OF THESE SIGNS SHE SHOULD BE TOLD TO REPORT THEM AND POSSIBLY HAVE AN MRI EVAL TO SCREEN FOR RUPTURE THE NATRELLE CORE STUDY WILL CONTINUE TO EVALUATE THE LONG-TERM 10 YEARS SAFETY AND EFFECTIVENESS OF THESE PROD IN ADDITION ALLERGAN HAS INITIATED A SEPARATE LARGE 10-YEAR POSTAPPROVAL STUDY BREAST IMPLANT FU STUDIES OR BIFS TO ADDRESS SPECIFIC ISSUES WHICH ALLERGANS CORE STUDY WAS NOT DESIGNED TO FULLY ANSWER AS WELL AS TO PROVIDE A REAL-WORLD ASSESSMENT OF SOME ENDPOINTS THE ENDPOINTS IN THE BIFS LARGE POSTAPPROVAL STUDY INCLUDE LONG-TERM LOCAL COMPLICATIONS CONNECTIVE TISSUE DISEASE CTD CTD SIGNS AND SYMPTOMS NEUROLOGICAL DISEASE NEUROLOGICAL SIGNS AND SYMPTOMS OFFSPRING ISSUES REPRODUCTIVE ISSUES CANCER SUICIDE MAMMOGRAPHY ISSUES AND MRI COMPLIANCE AND RESULTS ALLERGAN WILL UPDATE THEIR LABELING ON A REGULAR BASIS WITH THE RESULTS OF THESE TWO STUDIES THERE WAS 1 PRIMARY AUGMENTATION PT WITH A NEW DIAGNOSIS OF BREAST CANCER THROUGH 7 YEARS IN THE CORE STUDY THERE WAS A 13 BENIGN BREAST DISEASE RATE AND 1 MALIGNANT BREAST DISEASE RATE FOR REVISION-AUGMENTATION PTS THERE WAS 1 PT WITH A NEW DIAGNOSIS OF BREAST CANCER THER WAS A 15 BENIGN BREAST DISEASE RATE AND A 1 MALIGNANT BREAST DISEASE RATE THROUGH 7 YEARS IN PRIMARY AUGMENTATION PTS THERE WAS 1 REPORT OF THYROID CANCER AND 1 REPORT OF BRAIN CANCER THERE WERE NO REPORTS OF OTHER CANCERS SUCH AS RESPIRATORY OR CERVICALVULVAR IN REVISION-AUGMENTATION PTS THERE WERE 8 PRIMARY RECONSTRUCTION PTS 8 WITH NEW REPORTS OF BREAST CANCER THROUGH 7 YEARS IN THE CORE STUDY THERE WAS A 17 BENIGN BREAST DISEASE RATE AND A 10 MALIGNANT BREAST DISEASE RATE THROUGH 7 YEARS FOR REVISION RECONSTRUCTION PTS THERE WERE NO REPORTS OF NEW DIAGNOSES OR REOCCURRENCE OF BREAST CANCER THERE WAS A 7 BENIGN BREAST DISEASE RATE THROUGH 7 YEARS THERE WERE NO REPORTS OF OTHER CANCERS SUCH AS BRAIN RESPIRATORY OR CERVICALVULVAR IN PRIMARY RECONSTRUCTION OR REVISION-RECONSTRUCTION PTS|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|04/16/2015|||DA|N|R||0HP|FWM|1.0||nan||NI|||LA AURORA DE HEREDIA|CS|ALLERGAN|NE||NE||||True
5155756|28464643|N|0||DEVICE LABELING PUBLISHED STUDIES INDICATE THAT BREAST CANCER IS NO MORE COMMON IN WOMEN WITH IMPLANTS THAN THOSE WITHOUT IMPLANTS A LARGE LONG-TERM FOLLOW-UP FOUND NO SIGNIFICANT INCREASES IN THE RISK RATES FOR A WIDE VARIETY OF CANCERS INCLUDING STOMACH CANCER LEUKEMIA AND LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY DEFLATION Â¿ BREAST IMPLANTS ARE NOT LIFETIME DEVICES SALINE BREAST IMPLANTS DEFLATE WHEN THE SHELL DEVELOPS A TEAR OR HOLE DEFLATION CAN OCCUR AT ANY TIME AFTER IMPLANTATION BUT THEY ARE MORE LIKELY TO OCCUR THE LONGER THE IMPLANT IS IMPLANTED THE FOLLOWING THINGS MAY CAUSE IMPLANTS TO DEFLATE DAMAGE BY SURGICAL INSTRUMENTS FOLDING OR WRINKLING OF THE IMPLANT SHELL EXCESSIVE FORCE TO THE CHEST EG DURING CLOSED CAPSULOTOMY WHICH IS CONTRAINDICATED TRAUMA COMPRESSION DURING MAMMOGRAPHIC IMAGING AND SEVERE CAPSULAR CONTRACTURE BREAST IMPLANTS MAY ALSO SIMPLY WEAR OUT OVER TIME LABORATORY STUDIES HAVE IDENTIFIED SOME OF THE CAUSES OF DEFLATION FOR ALLERGANÂ¿S PRODUCT HOWEVER IT IS NOT CONCLUSIVELY KNOWN WHETHER THESE TESTS HAVE IDENTIFIED ALL CAUSES OF DEFLATION|STYLE 168 SALINE FILLED BREAST IMPLANT|168-420|10/16/2015||||N|R||0HP|FWM|1.0|05/01/1996|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||2-163072|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5155756|28464644|D|0||LAW FIRM REPORTED A POSSIBLE LUMP BEHIND PATIENTS LEFT BREAST AND A LEFT IMPLANT RUPTURE ADDITIONAL INFORMATION PROVIDED REVEALS PATIENT PRESENTED WITH A SMALL MASS ON THE LEFT CHEST WALL MEDIAL TO HER RECONSTRUCTION THIS MASS HAS RAPIDLY GROWN IN SIZE AND NOW IS PUSHING IMPLANT LATERALLY IT HAS GOTTEN QUITE UNCOMFORTABLE PATIENT SAW PHYSICIAN WHO OBTAINED A CT DEMONSTRATING A LARGE MASS DEFORMING THE IMPLANT LOCATED SUB-PECTORALLY THE PATIENT WAS ULTIMATELY DIAGNOSED WITH A LEFT SUB-PECTORAL MASS IDENTIFIED AS LYMPHOMA A BIOPSY REVEALED THAT PATIENT HAD ALCL ANAPLASTIC LARGE CELL LYMPHOMA ALK NEGATIVE CD30 RESULTS AND PATHOLOGY TESTS HAVE NOT BEEN PROVIDED THIS UNCONFIRMED REPORT OF ALCL WILL BE CAPTURED AS LYMPHOMA AT THIS TIME TREATMENT INCLUDED MULTIPLE HOSPITALIZATIONS LEFT SIDE DEVICE REMOVAL AND 16 ROUNDS OF CHEMOTHERAPY AND MULTIPLE SURGERIES ADDITIONAL NOTES INCLUDE BASAL CELL CARCINOMA MALIGNANT MELANOMA AND HERPES ZOSTER SIDE NOT SPECIFIED MELANOMA IS NOT RELATED TO THE DEVICE AS IT WAS FIRST DIAGNOSED PRIOR TO IMPLANTATION THIS RECORD IS FOR THE LEFT SIDE|STYLE 168 SALINE FILLED BREAST IMPLANT|168-420|10/16/2015||||N|R||0HP|FWM|1.0|05/01/1996|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||2-163072|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5286834|33227133|N|1||DEVICE LABELING ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/10/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5286834|33227134|D|1||HEALTH PROFESSIONAL REPORTED A PERIPROSTHETIC OEDEMA LEADING TO A PARTIAL CAPSULECTOMY ON THE CAPSULECTOMY LEFT SIDE PATIENT WAS DIAGNOSED WITH ALCL ANAPLASTIC LARGE CELL LYMPHOMA CD30+ ALK-|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/10/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4385769|19013900|N|1||UDI NA DEVICE LABELING ADDRESSES THE REPORTED EVENT OF ALCL AS FOLLOWS BASED ON THE INFO REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REP PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOU PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALLER NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL DEVICE LABELING ADDRESSES THE REPORTED EVENT OF SEROMA AS FOLLOWS POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN THE NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY AFTER A BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS|UNK SALINE IMPLANT|UNK SALINE IMPLANT|12/24/2014|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||LA AURORA DE HEREDIA, NE|CS|UNKNOWN MANUFACTURER|||||||True
4957654|19502324|D|1||HEALTH PROFESSIONAL REPORTED CALCIFICATION IN CAPSULE AND ANAPLASTIC LARGE CELL LYMPHOMA ALCL PATHOLOGY IN THE REMOVED LEFT BREAST CAPSULECTOMY SPECIMEN WITH EXCHANGE OF IMPLANT ALCL HAS NOT BEEN CONFIRMED AS PATHOLOGICAL MARKERS HAVE NOT BEEN RECEIVED THE EVENT WILL BE CAPTURED AS LYMPHOMA AT THIS TIME|STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-290|07/30/2015||08/11/2015|DA|R|Y||0HP|FTR|1.0|06/14/2013|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1627441|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4957654|26958644|D|1||FOLLOW-UP WITH PHYSICIAN REVEALS THE FOLLOWING LEFT SIDE EVENTS CAPSULAR CONTRACTURE BAKER IIIIV NOTED REACTIVE AXILLARY LYMPH NODES EDEMA SUSPECTED AND PAIN PATHOLOGICAL TESTING OF THE LEFT BREAST CAPSULE HAD FEATURES CONSISTENT WITH BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA THE DESCRIPTION OF THE CAPSULE INCLUDED THREE ADJACENT BUT SEPARATE HARD WHITE NODULES MEASURING 50 CM 55 CM AND 60 CM IN MAXIMUM DIAMETER AS TESTING FOR ALK RESULTS WERE NOT PERFORMED ON THE PROVIDED PATHOLOGY TESTS ALCL CANNOT BE CONFIRMED AND WILL CONTINUE TO BE CAPTURED AS LYMPHOMA|STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-290|07/30/2015||08/11/2015|DA|R|Y||0HP|FTR|1.0|06/14/2013|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1627441|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4957654|55248980|N|1||THE EVENT OF LYMPHOMA ALCL IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-290|07/30/2015||08/11/2015|DA|R|Y||0HP|FTR|1.0|06/14/2013|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1627441|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4702205|15310134|D|1||HEALTH PROFESSIONAL REPORTED TO REGULATORY AGENCY VIA VOLUNTARY MW5039346 ALCL CASE REPORT ASSOCIATED WITH BREAST CANCER RECONSTRUCTION PATIENT FOLLOW-UP REVEALS THAT PATIENT HAS A HISTORY OF LEFT BREAST DUCTAL CARCINOMA IN SITU PRIOR TO BREAST IMPLANTS THE PATIENT PRESENTED WITH SWELLING AND PAIN PRIMARY DIAGNOSIS OF ALCL WAS DIAGNOSED AGAINST THE RIGHT SIDE IN THE PERI IMPLANT FLUID AND 1 X 23 CM MASS AT MEDIANINFERIOR EDGE OF IMPLANT THE SEROMA WAS NOTED AS SEVERE PATIENT WAS TREATED WITH CHEMOTHERAPY AND THE RIGHT SIDE DEVICE WAS EXPLANTED PATHOLOGY RESULTS CONFIRM THE DIAGNOSIS SHOULD READ AS BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IMMUNOSTAINS SHOW TUMOR CELLS ARE POSITIVE FOR CD30 CD2 AND CD4 THEY ARE NEGATIVE FOR ER PR HER2 AND CYTOKERATIN S100 CD45 MPO CD3 CD20 AND ALK1|STYLE 363 SALINE FILLED BREAST IMPLANT|363LF-560|04/16/2015|||DA|N|R||0HP|FWM|1.0|12/05/2008|nan||1059645|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4600131|5470590|D|1||PHYSICIAN REPORTED TO REGULATORY AGENCY AS 2 SUICIDE ATTEMPTS FIBROMYALGIA RUPTURE OF THE ROTATOR CUFF LEFT B6 TWO PHLEBITIS A DYSTHYROIDEA IRON DEFICIENCY ANEMIA GASTRITIS WITH ESOPHAGITIS ARTHRITIS REQUIRING IMPLANTATION OF KNEE PROSTHESIS CLINICAL CONSEQUENCE ANAPLASTIC LARGE CELL LYMPHOMA ALCL ALK1 - CD30 LAGC SIDE IS UNKNOWN TREATMENT IS UNKNOWN|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|03/11/2015|||DA|N|R||0HP|FTR|1.0||nan||NI|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
4600131|12978182|N|1||DEVICE LABELING ADDRESSES ALCL ANAPLASTIC LARGE CELL LYMPHOMA ALCL - WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ANAPLASTIC LARGE CELL LYMPHOMA OR ALCL IN THE SCAR TISSUE AND FLUID ADJACENT TO THE IMPLANT ALCL IS NOT BREAST CANCER - IT IS A RARE TYPE OF NON-HODGKINS LYMPHOMA CANCER OF THE IMMUNE SYSTEM ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS MOST PATIENTS WERE DIAGNOSED WHEN THEY SOUGHT MEDICAL TREATMENT FOR IMPLANT RELATED SYMPTOMS SUCH AS PAIN LUMPS SWELLING OR ASYMMETRY THAT DEVELOPED AFTER THEIR INITIAL SURGICAL SITES WERE FULLY HEALED IN THE CASES REPORTED ALCL WAS TYPICALLY DIAGNOSED YEARS AFTER THAT IMPLANT SURGERY DEVICE LABELING ADDRESSES ARTHRITIS AND FIBROMYALGIA CONNECTIVE TISSUE DISEASES INCLUDE DISEASES SUCH AS LUPUS SCLERODERMA RHEUMATOID ARTHRITIS AND FIBROMYALGIA|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|03/11/2015|||DA|N|R||0HP|FTR|1.0||nan||NI|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
5098529|26591653|N|1||DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL THE PATIENT SHOULD BE TOLD THAT THE PRESENCE OF LUMPS PERSISTENT PAIN SWELLING HARDENING OR CHANGE IN THE IMPLANT SHAPE MAY BE SIGNS OF SYMPTOMATIC RUPTURE OF THE IMPLANT IF THE PATIENT HAS ANY OF THESE SIGNS SHE SHOULD BE TOLD TO REPORT THEM AND POSSIBLY HAVE AN MRI EVALUATION TO SCREEN FOR RUPTURE LITERATURE REPORTS HAVE ALSO BEEN MADE ASSOCIATING SILICONE BREAST IMPLANTS WITH VARIOUS RHEUMATOLOGICAL SIGNS AND SYMPTOMS SUCH AS FATIGUE EXHAUSTION JOINT PAIN AND SWELLING MUSCLE PAIN AND CRAMPING TINGLING NUMBNESS WEAKNESS AND SKIN RASHES|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|09/23/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||nan|||||||True
5098529|26591654|D|1||PATIENT REPORTED I WAS DIAGNOSED WITH A RARE FORM OF ANAPLASTIC LARGE CELL LYMPHOMA CANCER MY DOCTOR HAS STATED THIS A DIRECT RESULT OF MY IMPLANTS PATIENT REPORTED I HAVE A LARGE TUMOUR MEASURING 5CM ON MY BREASTS I HAVE STARTED A COURSE OF CHEMOTHERAPY TO REDUCE THIS ASAP THE SWELLING IS UNCOMFORTABLE AND SORE IT MAKES ME BREATHLESS SIDE WAS NOT SPECIFIED THIS FILE IS FOR THE RIGHT SIDE SEE MFR  9617229-2015-00388 FOR THE LEFT SIDE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|09/23/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||nan|||||||True
4922455|14212221|N|1||BASED ON THE INFO REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MFRS BREAST IMPLANTS|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|07/16/2015|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL SALINE||NI|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
5049277|24825793|D|1||AFTER ALMOST NINE YEARS OF HAVING ALLERGAN TEXTURED SILICONE BREAST IMPLANTS I DEVELOPED ANAPLASTIC LARGE CELL LYMPHOMA|INAMED 410 COHESIVE GEL||08/29/2015||||*|*||I|FTR|2.0||BREAST IMPLANT|||||||ALLERGAN|||||||True
5049277|24825793|D|1||AFTER ALMOST NINE YEARS OF HAVING ALLERGAN TEXTURED SILICONE BREAST IMPLANTS I DEVELOPED ANAPLASTIC LARGE CELL LYMPHOMA|INAMED 410 COHESIVE GEL||08/29/2015||||*|*||I|FTR|1.0||BREAST IMPLANT|||||||ALLERGAN|||||||True
5049277|24825793|D|1||AFTER ALMOST NINE YEARS OF HAVING ALLERGAN TEXTURED SILICONE BREAST IMPLANTS I DEVELOPED ANAPLASTIC LARGE CELL LYMPHOMA|INAMED 410 COHESIVE GEL||08/29/2015||||*|*||I|FTR|3.0||BREAST IMPLANT|||||||ALLERGAN|||||||True
5230911|31447415|D|1||VIA MW5055880 A PATIENT REPORTED DEVICE REMOVAL DUE TO DEVELOPING ANAPLASTIC LARGE CELL LYMPHOMA AS NO PATHOLOGICAL MARKERS HAVE BEEN PROVIDED THIS EVENT IS CAPTURED AS LYMPHOMA AT THIS TIME SIDE IS UNKNOWN|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|11/17/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5230911|31447414|N|1||DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 410|11/17/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4553419|19634012|N|1||UNIQUE IDENTIFIER UDI  B4 DEVICE LABELING ADDRESSES ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALAL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|MF-410470|02/25/2015|||DA|N|R||0HP|FTR|1.0|01/15/2011|nan||1210806|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
5222818|31178939|N|1||B4 DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL IN THE PASS STUDY AT LEAST 1 REOPERATION WAS PERFORMED ON 315 PATIENTS 365 THROUGH 10 YEARS A TOTAL OF 424 REOPERATIONS WERE PERFORMED THE PRIMARY REASON FOR REOPERATION THROUGH 10 YEARS ON AUGMENTATION PATIENTS WAS IMPLANT DEFLATION AT 217 THE PERCENTAGE OF REOPERATIONS DUE TO LUMPMASSCYST INCREASED FROM 85 OF 293 REOPERATIONS THROUGH 5 YEARS TO 139 OF 424 REOPERATIONS THROUGH 10 YEARS THE OCCURRENCE OF LUMPS MASSES AND CYSTS CAN BE EXPECTED TO NATURALLY INCREASE AS PATIENTS AGE AND COULD BE AN EXPLANATION FOR THE INCREASE POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY CAPSULAR CONTRACTURE Â¿ PATIENTS SHOULD BE ADVISED THAT CAPSULAR CONTRACTURE MAY BE MORE COMMON FOLLOWING INFECTION HEMATOMA AND SEROMA AND THE CHANCE OF IT HAPPENING MAY INCREASE OVER TIME CAPSULAR CONTRACTURE OCCURS MORE COMMONLY IN REVISION PATIENTS THAN IN PRIMARY AUGMENTATION OR RECONSTRUCTION PATIENTS CAPSULAR CONTRACTURE IS ALSO A RISK FACTOR FOR IMPLANT DEFLATION AND IT IS ONE OF THE MOST COMMON REASONS FOR REOPERATION OF THE 237 PATIENTS IN THE R95 STUDY AT LEAST 1 REOPERATION WAS PERFORMED ON 99 PATIENTS 42 FOR A TOTAL OF 125 REOPERATIONS THROUGH 5 YEARS THE PRIMARY REASON FOR REOPERATION THROUGH 5 YEARS WAS CAPSULAR CONTRACTURE AT 256 OF THE 237 RECONSTRUCTION PATIENTS IN R95 THERE WERE 62 PATIENTS 262 WHO HAD 70 IMPLANTS REMOVED THROUGH 5 YEARS OF THE 70 RECONSTRUCTION IMPLANTS REMOVED THROUGH 5 YEARS 70 WERE REPLACED THE MOST COMMON REASON FOR IMPLANT REMOVAL WAS CAPSULAR CONTRACTURE 314 THROUGH 10 YEARS THERE WERE 104 IMPLANTS REMOVED FROM 85 PATIENTS THE MOST COMMON REASON FOR IMPLANT REMOVAL WAS IMPLANT LEAKAGEDEFLATION 327|STYLE 363 SALINE FILLED BREAST IMPLANT|363LF-410|11/13/2015||||N|R||0HP|FWM|1.0|10/09/2005|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||569053|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5222818|31178940|D|1||PHYSICIAN REPORTED VIA VOLUNTARY MW5055722 THAT THE PATIENT CAME WITH A SKIN LESION ON THE CHEST A BIOPSY ON THE LESION CAME BACK AS ALCL ANAPLASTIC LARGE CELL LYMPHOMA PHYSICIAN ADDITIONALLY NOTED THAT THE RIGHT SIDE DEVICE AND RIGHT SIDE CAPSULE WERE REMOVED AND FLUID WAS SENT FOR CYTOLOGY PHYSICIAN SPECIFIED THAT THE RIGHT BREAST WAS FILLED WITH A THICK RED COLOREDBROWN COLORED FLUID THIS REPORT IS FOR THE RIGHT SIDE FOLLOW-UP REVEALS PATHOLOGY WAS INITIALLY ASSESSED ON AN ABDOMINAL LESION BIOPSY RESULTS ON LESION WERE UPPER ABDOMEN - CD30 POSITIVE LYMPHOMA CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA AND LARGE CELLS ARE ALSO NEGATIVE FOR EBER AND ALK-1 WHEN THE IMPLANTS WERE REMOVED PATHOLOGY INDICATED THAT THE RIGHT BREAST CAPSULE WAS DIAGNOSED WITH ALCL ALK NEGATIVE PATHOLOGY REPORT ADDITIONALLY INDICATES THAT A SINGLE 15 CM NODULE WAS IDENTIFIED AND LOCATED NEAR AN IDENTICAL LESION IN THE RIGHT BREAST CAPSULE THE NODULE TESTED POSITIVE FOR CD30 AND NEGATIVE FOR ALK IT IS ALSO NOTED THAT THE IMPLANT IS RECEIVED WITH MINIMAL AMOUNTS OF ATTACHED BLOOD CLOT AND TISSUE PHYSICIAN ADDITIONALLY REPORTED RIGHT SIDE GRADE IV CAPSULAR CONTRACTURE PHYSICIAN NOTED THAT THE PATIENT REFUSED CHEMOTHERAPY AND RADIOTHERAPY|STYLE 363 SALINE FILLED BREAST IMPLANT|363LF-410|11/13/2015||||N|R||0HP|FWM|1.0|10/09/2005|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||569053|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4902572|55597680|D|1||A REPORT OF NULL-TYPE ANAPLASTIC LARGE CELL LYMPHOMA ARISING IN A SILICONE BREAST IMPLANT CAPSULE WRITTEN IN PLASTIC AND RECONSTRUCTIVE SURGERY JUNE 2011 VOL 127 NUMBER 6 REPORTS PATIENT PRESENTED WITH A PAINFUL RIGHT BREAST AND BAKER GRADE III CAPSULAR CONTRACTUREIMPLANT WAS REMOVED AND THE SUBMUSCULAR POUCH WAS EXPLORED WITH DRAINAGE OF A SEROUS-HEMATIC FLUID SURROUNDING THE RIGHT PROSTHESIS CAPSULECTOMY WAS PERFORMED AND THE REMOVED FIBROUS TISSUE ANALYZED BECAUSE OF ITS ALTERED ASPECT THE PATHOLOGY FINDINGS WERE CONSISTENT WITH A DIAGNOSIS OF NULL-TYPE ANAPLASTIC LYMPHOMA KINASE-NEGATIVE NON-HODGKINS ANAPLASTIC LARGE CELL LYMPHOMA ALCL DEVICE HAS BEEN REMOVED MANUFACTURER OF THE DEVICE IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|07/08/2015|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||LA AURORA DE HEREDIA|CS|UNKNOWN MANUFACTURER|||||||True
4902572|14225628|N|1||UNIQUE IDENTIFIER UDI  NA MEDWATCH SUBMITTED TO THE FDA ON 07082015 DEVICE LABELING POTENTIAL ADVERSE EVENT THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFO REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MFRS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBLY OF ALCL WHEN YOU HAVE A PT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REP PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WITH DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS PTS SHOULD BE ADVISED THAT CAPSULAR CONTRACTURE MAY BE MORE COMMON FOLLOWING INFECTION HEMATOMA AND SEROMA AND THE CHANCE OF IT HAPPENING MAY INCREASE OVER TIME CAPSULAR CONTRACTURE OCCURS MORE COMMONLY IN REVISION PTS THAN IN PRIMARY AUGMENTATION OR RECONSTRUCTION PTS CAPSULAR CONTRACTURE IS ALSO A RISK FACTOR FOR IMPLANT DEFLATION AND IT IS ONE OF THE MOST COMMON REASONS FOR REOPERATION PTS SHOULD ALSO BE ADVISED THAT ADDL SURGERY MAY BE NEEDED IN CASES WHERE PAIN ANDOR FIRMNESS ARE SEVERE THIS SURGERY RANGES FROM REMOVAL OF THE IMPLANT CAPSULE TISSUE TO REMOVAL AND POSSIBLE REPLACEMENT OF THE IMPLANT ITSELF THIS SURGERY MAY RESULT IN LOSS OF BREAST TISSUE CAPSULAR CONTRACTURE MAY HAPPEN AGAIN AFTER THESE ADDL SURGERIES CAPSULAR CONTRACTURE MAY INCREASE THE RISK OF DEFLATION|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|07/08/2015|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||LA AURORA DE HEREDIA|CS|UNKNOWN MANUFACTURER|||||||True
4902572|6067684|D|1||A REPORT OF NULL-TYPE ANAPLASTIC LARGE CELL LYMPHOMA ARISING IN A SILICONE BREAST IMPLANT CAPSULE WRITTEN IN PLASTIC AND RECONSTRUCTIVE SURGERY JUNE 2011 VOL 127 NUMBER 6 REPORTS PT PRESENTED WITH A PAINFUL RIGHT BREAST AND BAKER GRADE III CAPSULAR CONTRACTUREIMPLANT WAS REMOVED AND THE SUBMUSCULAR POUCH WAS EXPLORED WITH DRAINAGE OF A SEROUS-HEMATIC FLUID SURROUNDING THE RIGHT PROSTHESIS CAPSULECTOMY WAS PERFORMED AND THE REMOVED FIBROUS TISSUE ANALYZED BECAUSE OF ITS ALTERED ASPECT THE PATHOLOGY FINDINGS WERE CONSISTENT WITH A DIAGNOSIS OF NULL-TYPE ANAPLASTIC LYMPHOMA KINASE-NEGATIVE NON-HODGKINS ANAPLASTIC LARGE CELL LYMPHOMA ALCL DEVICE HAS BEEN REMOVED MFR OF THE DEVICE IS UNK|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|07/08/2015|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||LA AURORA DE HEREDIA|CS|UNKNOWN MANUFACTURER|||||||True
5138318|27896968|D|1||ALLERGAN REPRESENTATIVE REPORTED A CASE OF ALCL RECEIVED FROM A PHYSICIAN IN WHICH THE PATIENT PRESENTED WITH SEROMA DRAINED SEROMA AND PROCEEDED TO SURGERY DID COMPLETE CAPSULECTOMY AND SEND CAPSULE TO PATHOLOGY PATHOLOGY CONFERRED CD30+ SIDE WAS UNSPECIFIED FOLLOW-UP WITH HEALTH PROFESSIONAL FOUND EXPANDING RIGHT BREAST CATEGORIZED AS SIGNIFICANT SEROMA THERE WAS CAPSULAR CONTRACTURE BUT THE BAKER GRADE WAS DIFFICULT TO DETERMINE DUE TO TENSION CAUSED BY SEROMA DEVICE WAS REMOVED AND INTRAOPERATIVELY NOTED MATERIAL INTRACAPSULE THAT APPEARED OLD HEMATOMA PATIENT HAS NOT YET HAD CHEMOTHERAPY OR RADIOTHERAPY IMMUNOHISTOCHEMISTRY ON THE MALIGNANT APPEARING TUMOR CELLS REVEALS THAT CELLS ARE NEGATIVE FOR CK7 AE1AE3 CD68 CK19 CK20 ER CD20 AND EMA TUMOR CELLS ARE POSITIVE FOR CD3 CD30 AND CD45 IMMUNOHISTOCHEMISTRY SUPPORTS DIAGNOSIS OF ANAPLASTIC LARGE CELL LYMPHOMA T CELL LYMPHOMA ALK- MARKER NOT CONFIRMED THIS EVENT WILL BE CAPTURED AS LYMPHOMA|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MX155-685|10/08/2015||||N|R||0HP|FTR|1.0|11/28/2010|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1172190|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5138318|27896967|N|1||B4 DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MX155-685|10/08/2015||||N|R||0HP|FTR|1.0|11/28/2010|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1172190|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5286954|33227537|D|1||PHYSICIAN REPORTS PATIENT WITH A BREAST IMPLANT AND HAS BEEN DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA ALCL AT THE RIGHT BREAST AS PATHOLOGICAL MARKERS HAVE NOT BEEN PROVIDED THIS CASE WILL BE CAPTURED AS LYMPHOMA UNTIL DIAGNOSTIC CONFIRMATION IS RECEIVED TREATMENT IS UNKNOWN|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|N-TRM240|12/10/2015|||DA|N|R||0HP|FTR|1.0|06/17/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2131883|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5286954|33227536|N|1||DEVICE LABELING ANAPLASTIC LARGE CELL LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|N-TRM240|12/10/2015|||DA|N|R||0HP|FTR|1.0|06/17/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2131883|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5098467|26589689|D|1||PATIENT REPORTED I WAS DIAGNOSED WITH A RARE FORM OF ANAPLASTIC LARGE CELL LYMPHOMA CANCER MY DOCTOR HAS STATED THIS A DIRECT RESULT OF MY IMPLANTS PATIENT REPORTED I HAVE A LARGE TUMOUR MEASURING 5CM ON MY BREASTS I HAVE STARTED A COURSE OF CHEMOTHERAPY TO REDUCE THIS ASAP THE SWELLING IS UNCOMFORTABLE AND SORE IT MAKES ME BREATHLESS SIDE WAS NOT SPECIFIED THIS FILE IS FOR THE LEFT SIDE SEE MFR  9617229-2015-00398 FOR THE RIGHT SIDE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|09/23/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5098467|26589688|N|1||B4 BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL THE PATIENT SHOULD BE TOLD THAT THE PRESENCE OF LUMPS PERSISTENT PAIN SWELLING HARDENING OR CHANGE IN THE IMPLANT SHAPE MAY BE SIGNS OF SYMPTOMATIC RUPTURE OF THE IMPLANT IF THE PATIENT HAS ANY OF THESE SIGNS SHE SHOULD BE TOLD TO REPORT THEM AND POSSIBLY HAVE AN MRI EVALUATION TO SCREEN FOR RUPTURE LITERATURE REPORTS HAVE ALSO BEEN MADE ASSOCIATING SILICONE BREAST IMPLANTS WITH VARIOUS RHEUMATOLOGICAL SIGNS AND SYMPTOMS SUCH AS FATIGUE EXHAUSTION JOINT PAIN AND SWELLING MUSCLE PAIN AND CRAMPING TINGLING NUMBNESS WEAKNESS AND SKIN RASHES|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|09/23/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4974939|26960388|D|1||FOLLOW-UP WITH PATHOLOGIST REVEALS THAT PATIENTS INITIAL PRESENTATION OCCURRED WHEN THE LEFT BREAST BECAME SWOLLEN IT ALSO BECAME RATHER TIGHT AND SORE A THIN LAYER OF FLUID AROUND THE LEFT IMPLANT AND IRRITATION WAS FOUND DURING LEFT SIDE DEVICE REMOVAL THE CAPSULE CAVITY IS ENTERED AT THE LEFT SIDE AND EMPTIED OF WHAT IS ESTIMATED TO BE APPROX 1 LITER SEROUS FLUID THE CAPSULE WAS NOT REMOVED THREE YEARS LATER A SMALL ROUND DENSIFICATION HAS BEEN SHOWN IN THE LEFT MAMMA DIAMETER IS APPROX 8 MM LEFT SIDE CAPSULE WAS REMOVED AND THE CAPSULE RUPTURES AND CLEAR SERUM FLUID FLOWS OUT PATHOLOGY IS TESTED ON TISSUE FROM LEFT BREAST A CYST LESION WAS FOUND ON THE BREAST TISSUE WITHIN THE FIBROUS WALL A RIM OF GRANULATION TISSUE AND PARTLY ORGANIZED SERUMHEMATOMA MATERIAL WAS FOUND PATHOLOGY CONFIRMS THAT THIS IS A MALIGNANT TUMOR WITH CYSTIC NECROSIS A POSITIVE CD30 AND A NEGATIVE REACTION FOR ALK PROTEIN CONFIRMS THE DIAGNOSIS OF ANAPLASTIC LARGE CELL LYMPHOMA PATHOLOGY REPORT ALSO INDICATES THERE ARE NO SIGNS ANYWHERE OF THE TUMOR CELLS INFILTRATING THE SURROUND SOFT TISSUE THROUGH THE FIBROUS CAPSULE PATHOLOGIST NOTED THE PATIENT HAS RECEIVED 3 SERIES OF CHOP CHEMOTHERAPY REGIMEN AND IS CURRENTLY UNDERGOING RADIATION THERAPY|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|08/04/2015|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4974939|14087432|N|1||DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTEDLY GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|08/04/2015|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4399502|19805106|D|1||I WAS ONE OF THE RARE CASES OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL CAUSED BY BREAST IMPLANTS I HAD A CAPSULECTOMY OF BOTH BREASTS AND HAVE SINCE HAD RECONSTRUCTION USING DIFFERENT MAKETYPE OF PROSTHESIS SINCE FIRST DIAGNOSED IN 2009 I HAVE NOT BEEN ABLE TO OBTAIN ANY FURTHER INFORMATION ON WHAT WAS DETERMINED FROM CASES LIKE MINE OR WHAT IF ANY RECOMMENDATIONS WERE GIVEN TO PATIENTS AT THE TIME I DISCOVERED THAT MY FIRST COUSIN ALSO SUFFERED THE CONDITION ALSO CAUSED BY IMPLANTS I WAS ALSO TOLD THAT I WAS CAUGHT EARLY ENOUGH AS TO NOT REQUIRE ANY TREATMENT OTHER THAN REMOVAL ALL OF THIS HAPPENED IN MY BIRTH COUNTRY OF B6 MY PLASTIC SURGEON WAS B6 OF B6 WHO PERFORMED MY ORIGINAL BREAST AUGMENTATION IN 2006 I HAVE RECENTLY STARTED RESEARCHING MY PREVIOUS CONDITION BUT CANNOT FIND ANY DETAILS OR CONTACT INFORMATION IN MY OWN COUNTRY I WAS HOPING THAT THE AMERICAN FDA MAY HAVE SOME CURRENT INFORMATION TO GIVE ME|MOULDED TEARDROP BREAST IMPLANT||01/05/2015|||DA||*||0|FTR|1.0||MOULDED TEARDROP BREAST IMPLANT|||||||MENTOR|||||||True
4399502|19805106|D|1||I WAS ONE OF THE RARE CASES OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL CAUSED BY BREAST IMPLANTS I HAD A CAPSULECTOMY OF BOTH BREASTS AND HAVE SINCE HAD RECONSTRUCTION USING DIFFERENT MAKETYPE OF PROSTHESIS SINCE FIRST DIAGNOSED IN 2009 I HAVE NOT BEEN ABLE TO OBTAIN ANY FURTHER INFORMATION ON WHAT WAS DETERMINED FROM CASES LIKE MINE OR WHAT IF ANY RECOMMENDATIONS WERE GIVEN TO PATIENTS AT THE TIME I DISCOVERED THAT MY FIRST COUSIN ALSO SUFFERED THE CONDITION ALSO CAUSED BY IMPLANTS I WAS ALSO TOLD THAT I WAS CAUGHT EARLY ENOUGH AS TO NOT REQUIRE ANY TREATMENT OTHER THAN REMOVAL ALL OF THIS HAPPENED IN MY BIRTH COUNTRY OF B6 MY PLASTIC SURGEON WAS B6 OF B6 WHO PERFORMED MY ORIGINAL BREAST AUGMENTATION IN 2006 I HAVE RECENTLY STARTED RESEARCHING MY PREVIOUS CONDITION BUT CANNOT FIND ANY DETAILS OR CONTACT INFORMATION IN MY OWN COUNTRY I WAS HOPING THAT THE AMERICAN FDA MAY HAVE SOME CURRENT INFORMATION TO GIVE ME|MOULDED TEARDROP BREAST IMPLANT||01/05/2015|||||*||0|FTR|2.0||MOULDED TEARDROP BREAST IMPLANT|||||||MENTOR|||||||True
4672656|13207851|N|1||B4 THE EVENT OF ANAPLASTIC LARGE CELL LYMPHOMA WAS INITIALLY REPORTED VIA EASR ON B6 2010 WITH THE ADVERSE EVENT TERM CODE OF CANCER AN UPDATE TO OUR SAFETY DATABASE FOR THIS REPORTED EVENT NOTES THAT THE TERM CODE HAS BEEN CHANGED FROM CANCER TO LYMPHOMA-ALCL DUE TO INCREASED SPECIFICITY SEROMA WAS REPORTED AT THAT TIME ALSO DEVICE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHY CHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS BASED ON INFO REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MUFTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL USE CARE IN SUBSEQUENT PROCEDURES SUCH AS OPEN CAPSULOTOMY BREAST POCKET REVISION HEMATOMASEROMA ASPIRATION AND BIOPSYLUMPECTOMY TO AVOID DAMAGE TO THE IMPLANT SHELL OR VALVE ANY POSTOPERATIVE EVACUATION OF HEMATOMA OR SEROMA MUST BE CONDUCTED WITH CARE TO AVOID BREAST IMPLANT CONTAMINATION OR DAMAGE FROM SHARP INSTRUMENTS THE USE OF MICROWAVE DIATHERMY IN PATIENTS WITH BREAST IMPLANTS IS NOT RECOMMENDED AS IT HAS BEEN REPORTED TO CAUSE TISSUE NECROSIS SKIN EROSION AND EXTRUSION OF THE IMPLANT ALLERGAN HAS NOT TESTED THE IN VIVO EFFECTS OF RADIATION THERAPY IN PATIENTS WHO HAVE BREAST IMPLANTS THE LITERATURE SUGGESTS THAT RADIATION THERAPY MAY INCREASE THE LIKELIHOOD OF CAPSULAR CONTRACTURE NECROSIS AND IMPLANT EXTRUSION PATIENTS SHOULD BE INFORMED THAT DISSATISFACTION WITH COSMETIC RESULTS RELATED TO SUCH THINGS AS SCAR DEFORMITY HYPERTROPHIC SCARRING CAPSULAR CONTRACTURE ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION INCORRECT SIZE AND IMPLANT PALPABILITYVISIBILITY MAY OCCUR CAREFUL SURGICAL PLANNING AND TECHNIQUE CAN MINIMIZE BUT NOT PRECLUDE THE RISK OF SUCH RESULTS PRE-EXISTING ASYMMETRY MAY NOT BE ENTIRELY CORRECTABLE REVISION SURGERY MAY BE INDICATED TO MAINTAIN PATIENT SATISFACTION BUT CARRIES ADDITIONAL CONSIDERATIONS AND RISKS RECONSTRUCTION MAIN REASONS FOR REOPERATION THROUGH 5 AND 10 YEARS IMPLANT MALPOSITION YEAR 5 RATE= 32 IMPLANT MALPOSITION YEAR 10 RATE= 38|STYLE 163 SALINE FILLED BREAST IMPLANT|163-530|04/08/2015|||DA|N|R||0HP|FWM|1.0||nan||NI|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4672656|5689022|D|1||HEALTH PROFESSIONAL REPORTED LEFT SIDE DEVICE REMOVED DUE TO PTS REPORT OF SWOLLEN AND TIGHT FEELING HEALTH PROFESSIONAL NOTED A YELLOW CLEAR FLUID WAS DRAINED AND PATHOLOGY SHOWED CYTOLOGIC FEATURES CONSISTENT WITH ATYPICAL CELLS UPON REMOVAL DEVICE WAS NOTED TO BE UPSIDE DOWN AND THE LEFT BREAST CAPSULE HAD MALIGNANT CELLS THAT WERE FOCALLY INFILTRATING THE CAPSULAR SURFACE WITH ASSOCIATED NECROSIS PATHOLOGY RESULTS CONFIRM ANAPLASTIC LARGE CELL LYMPHOMA STRONG POSITIVE FOR CD30+|STYLE 163 SALINE FILLED BREAST IMPLANT|163-530|04/08/2015|||DA|N|R||0HP|FWM|1.0||nan||NI|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4732544|17584118|D|1||B6 UNDERWENT BILATERAL AESTHETIC BREAST AUGMENTATION WITH 285CC TEXTURED ANATOMIC SALINE FILLED BREAST IMPLANTS BY MCGHAN IN A RETRO-PECTORAL POSITION BIA A PERIAREOLAR INCISION ON B6 1999 IN B6 2014 SHE NOTED INCREASED SZE OF THE LEFT BREAST AND A FIRM MASS MEDIALLY  ALSO IN THE LEFT BREAST ULTRASONIC-GUIDED NEEDLE BIOPSY OF BOTH THE BREAST MASS WHICH PROVED TO BE RETRO-PECTORAL AND LEFT AXILLARY LYMPH NODES DONE B6 2014 SHOWED ANAPLASTIC LARGE CELL LYMPHOMA ALK NEG IN THE BREAST AND NODES PETCT SHOWED THE BREAST MASS TO BE HIGHLY HYPERMETABOLIC ENLARGED HYPERMETABOLIC LEFT AND RIGHT AXILLARY NODES THE PATIENT RECEIVED CHEMOTHERAPY CYCLOPHOSPHAMIDE DOXORUBICIN VINCRISTINE PREDNISONE ETOPOSIDE FROM B6 2014 THROUGH B6 2015 WITH GOOD RESPONSE BREAST IMPLANT REMOVAL HAS BEEN RECOMMENDED AND THE PATIENT IS BEING SENT FOR CONSIDERATION OF BONE MARROW TRANSPLANT|MCGHAN BREAST IMPLANT|27-468271|04/22/2015|||||||0|FWM|2.0||MCGHAN BREAST IMPLANT|||||||MCGHAN|||||STYLE 468||True
4732544|17584118|D|1||B6 UNDERWENT BILATERAL AESTHETIC BREAST AUGMENTATION WITH 285CC TEXTURED ANATOMIC SALINE FILLED BREAST IMPLANTS BY MCGHAN IN A RETRO-PECTORAL POSITION BIA A PERIAREOLAR INCISION ON B6 1999 IN B6 2014 SHE NOTED INCREASED SZE OF THE LEFT BREAST AND A FIRM MASS MEDIALLY  ALSO IN THE LEFT BREAST ULTRASONIC-GUIDED NEEDLE BIOPSY OF BOTH THE BREAST MASS WHICH PROVED TO BE RETRO-PECTORAL AND LEFT AXILLARY LYMPH NODES DONE B6 2014 SHOWED ANAPLASTIC LARGE CELL LYMPHOMA ALK NEG IN THE BREAST AND NODES PETCT SHOWED THE BREAST MASS TO BE HIGHLY HYPERMETABOLIC ENLARGED HYPERMETABOLIC LEFT AND RIGHT AXILLARY NODES THE PATIENT RECEIVED CHEMOTHERAPY CYCLOPHOSPHAMIDE DOXORUBICIN VINCRISTINE PREDNISONE ETOPOSIDE FROM B6 2014 THROUGH B6 2015 WITH GOOD RESPONSE BREAST IMPLANT REMOVAL HAS BEEN RECOMMENDED AND THE PATIENT IS BEING SENT FOR CONSIDERATION OF BONE MARROW TRANSPLANT|MCGHAN BREAST IMPLANT|27-468271|04/22/2015|||||||0|FWM|1.0||MCGHAN BREAST IMPLANT|||||||MCGHAN|||||STYLE 468||True
4720409|16988108|D|1||HEALTH PROFESSIONAL REPORTED LATE SEROMA - ASPIRATION WAS POSITIVE FOR ALCL SPECIFIED AS THE RIGHT SIDE CYTOLOGY CONFIRMS THE TUMOUR CELLS EXPRESS THE PAN LYMPHOID MARKER CD45 CD3 AND CD30 THERE ARE VERY FEW B CELLS EXPRESSING CD20 THERE IS NO STAINING WITH ALK1CONCLUSION MALIGNANT BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA BIA-ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-FX130-450|04/21/2015|||DA|N|R||0HP|FTR|1.0|06/14/2015|nan||1850087|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4688919|13145475|N|1||THE EVENT OF ANAPLASTIC LARGE CELL LYMPHOMA WAS INITIALLY REPORTED VIA EASR ON B6 2011 WITH THE ADVERSE EVENT TERM CODE OF CANCER AN UPDATE TO OUR SAFETY DATABASE FOR THIS REPORTED EVENT NOTES THAT THE TERM CODE HAS BEEN CHANGED TO LYMPHOMA - ALCL DUE TO INCREASED SPECIFICITY PATIENT IDENTIFIER B6 RELATES TO PATIENTS RECORD PREVIOUSLY EXISTING IN B6 DATABASE CURRENT DATABASE PATIENT IDENTIFIER IS PR B6 DEVICE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHY CHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS THE NATRELLE CORE STUDY WILL CONTINUE TO EVALUATE THE LONG-TERM 10 YEARS SAFETY AND EFFECTIVENESS OF THESE PRODUCTS IN ADDITION ALLERGAN HAS INITIATED A SEPARATE LARGE 10-YEAR POST-APPROVAL STUDY THE BREAST IMPLANT FOLLOW-UP STUDIES OR BIFS TO ADDRESS SPECIFIC ISSUES WHICH ALLERGANS CORE STUDY WAS NOT DESIGNED TO FULLY ANSWER AS WELL AS TO PROVIDE A REAL-WORLD ASSESSMENT OF SOME ENDPOINTS THE ENDPOINTS IN THE BIFS LARGE POST-APPROVAL STUDY INCLUDE LONG-TERM LOCAL COMPLICATIONS CONNECTIVE TISSUE DISEASE CTD CTD SIGNS AND SYMPTOMS NEUROLOGICAL DISEASE NEUROLOGICAL SIGNS AND SYMPTOMS OFFSPRING ISSUES REPRODUCTIVE ISSUES LACTATION ISSUES CANCER SUICIDE MAMMOGRAPHY ISSUES AND MRI COMPLIANCE AND RESULTS ALLERGAN WILL UPDATE THEIR LABELING ON A REGULAR BASIS WITH THE RESULTS OF THESE TWO STUDIES THERE WAS 1 PRIMARY AUGMENTATION PATIENT WITH A NEW DIAGNOSIS OF BREAST CANCER THROUGH 7 YEARS IN THE CORE STUDY THERE WAS A 13 BENIGN BREAST DISEASE RATE AND A 1 MALIGNANT BREAST DISEASE RATE FOR REVISION-AUGMENTATION PATIENTS THERE WAS 1 PATIENT WITH A NEW DIAGNOSIS OF BREAST CANCER THERE WAS A 15 BENIGN BREAST DISEASE RATE AND A 1 MALIGNANT BREAST DISEASE RATE THROUGH 7 YEARS IN PRIMARY AUGMENTATION PATIENTS THERE WAS 1 REPORT OF THYROID CANCER AND 1 REPORT OF BRAIN CANCER THERE WERE NO REPORTS OF OTHER CANCERS SUCH AS RESPIRATORY OR CERVICALVULVAR IN REVISION-AUGMENTATION PATIENTS THERE WERE 8 PRIMARY RECONSTRUCTION PATIENTS 8 WITH NEW REPORTS OF BREAST CANCER THROUGH 7 YEARS IN THE CORE STUDY THERE WAS A 17 BENIGN BREAST DISEASE RATE AND A 10 MALIGNANT BREAST DISEASE RATE THROUGH 7 YEARS FOR REVISION RECONSTRUCTION PATIENTS THERE WERE NO REPORTS OF NEW DIAGNOSES OR REOCCURRENCE OF BREAST CANCER THERE WAS A 7 BENIGN BREAST DISEASE RATE THROUGH 7 YEARS THERE WERE NO REPORTS OF OTHER CANCERS SUCH AS BRAIN RESPIRATORY OR CERVICALVULVAR IN PRIMARY RECONSTRUCTION OR REVISION-RECONSTRUCTION PATIENTS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|04/13/2015|||DA|N|R||0HP|FTR|1.0||nan||NI|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4730396|17824636|N|1||THE EVENT OF ANAPLASTIC LARGE CELL LYMPHOMA WAS INITIALLY REPORTED VIA EASR ON JULY 28 2010 WITH THE ADVERSE EVENT TERM CODE OF CANCER AN UPDATE TO OUR SAFETY DATABASE FOR THIS REPORTED EVENT NOTES THAT THE TERM CODE HAS BEEN CHANGED FROM CANCER TO LYMPHOMA - ALCL DUE TO INCREASED SPECIFICITY B6|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|04/24/2015|||DA|N|R||0HP|FTR|1.0||nan||NI|LA AURORA DE HEREDIA|||CS|ALLERGAN|||||||True
5092043|26351217|N|1||DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|09/21/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4739847|20018445|D|1||PHYSICIAN REPORTS LEFT SIDE DEVICE REMOVAL AND REPLACEMENT OF PT WITH HISTORY OF BREAST CANCER DUE TO SEROMA AND AS CONFIRMED BY HISTOLOGY ALCL ANAPLASTIC LARGE CELL LYMPHOMA ALCL HAS NOT BEEN CONFIRMED AS TEST RESULTS HAVE NEITHER BEEN PROVIDED OR REPORTED THIS EVENT WILL BE CAPTURED AS LYMPHOMA UNTIL TEST RESULTS ARE RECEIVED|UK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|04/29/2015|||DA|N|R||0HP|FWM|1.0||nan|||||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4541872|16628904|D|1||THE PT IS A B6 FEMALE WITH A HISTORY OF DCIS OF THE LEFT BREAST DIAGNOSED IN 1989 SHE UNDERWENT LUMPECTOMY AND RADIATION THERAPY SHE WAS FOUND TO HAVE RECURRENCE IN 2006 AT THAT TIME SHE UNDERWENT LEFT MASTECTOMY AND SENTINEL LYMPH NODE BIOPSY IN 2006 WITH NO RECONSTRUCTION IN B6 2007 SHE UNDERWENT DELAYED PLACEMENT OF A MENTOR TEXTURED SILTEXT MEDIUM HEIGHT TISSUE EXPANDER REFERENCE 3584-6215 LOT 5725412 SERIAL NUMBER B4 650CC VOLUME INTRAOPERATIVE FILL 180CC SALINE AND LATISSIMUS DORSI FLAP TO THE LEFT SIDE SHE UNDERWENT TISSUE EXPANSION AND SUBSEQUENTLY IN B6 2007 UNDERWENT EXCHANGE OF THE TISSUE EXPANDER FOR A PERMANENT SILICONE TEXTURED MENTOR CPG IMPLANT CONCURRENTLY SHE UNDERWENT RIGHT MASTOPEXY AND AUGMENTATION OF SYMMETRY THE PTS RECORDS FROM DR B6 WERE REVIEWED AND THE PT HAD A MENTOR CPG 323 SILICONE GEL IMPLANT 685 CC ON THE LEFT REF 334-1452G AND MENTOR CPG 323 GEL IMPLANT SIZE 350CC ON THE RIGHT REF 350-3501BC IN B6 2014 SHE NOTICED THAT HER LEFT BREAST WAS SUDDENLY OVER 1-2 WEEKS LARGER THAN THE RIGHT THE FLUID COLLECTION WAS FOUND ON PHYSICAL EXAM SHE UNDERWENT ASPIRATION OF THE FLUID COLLECTION WHICH TOTALED 400 CUBIC CENTIMETERS AND WAS CLEAR YELLOW IN OUTPUT WAS SENT TO PATHOLOGY AND DEMONSTRATED CD30 POSITIVE ALK NEGATIVE ANAPLASTIC LARGE-CELL LYMPHOMA ALCL CONSISTENT WITH BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA ON B6 2014 SHE UNDERWENT BILATERAL BREAST EXPLANTATION WAS WELL AS BILATERAL TOTAL CAPSULECTOMIES WITH EXTENSIVE CAPSULECTOMY ON THE LEFT SIDE MARGINS WERE NEGATIVE PER THE PTS REPORT THERE WAS NO SUSPICIOUS LYMPHADENOPATHY THIS WAS DONE BY B6 WHO ALSO DID THE PTS BREAST RECONSTRUCTION THERE WAS NO MASS ONLY ALCL LOCATED WITHIN THE IMPLANT CAPSULE THE PTS SURGICAL ONCOLOGIST WAS DR B6 THE PT HAS BEEN SEEN BY THE LYMPHOMA SERVICE AND PLASTIC SURGERY AT B4 FOR SURVEILLANCE AND RECONSTRUCTION|CPG MEMORY SHAPE GEL BREAST IMPLANT|334-1452G|02/19/2015|||DA|N|R||0HP|FTR|1.0||BREAST IMPLANT||5719721|||IRVING|US|MENTOR||TX|||||True
6177062|62452555|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 B4 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL SEROMA BREAST LUMPS AND ERYTHEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION ERYTHEMA MAY ALSO OCCUR AS A NORMAL RESPONSE TO EXPANSION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6177062|62452556|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 OLD PATIENT WHO WAS IMPLANTED WITH A LEFT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED MASS SEROMA AND ERYTHEMATOUS SKIN ERUPTION  TREATMENT REPORTED AS IMPLANT REMOVAL AND CYCLOPHOSPHAMIDE ADRIAMYCIN VINCRISTINE AND PREDNISONE 6 CURES CHOP OR CHOP-LIKE FOLLOW-UP FOUND NO EVIDENCE OF DISEASE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6145512|61450146|D|1||PHYSICIAN REPORTED CLOUDY YELLOW FLUID FROM BREAST PROSTHESIS AND DIAGNOSIS OF ANAPLASTIC LARGE CELL LYMPHOMA CYTOLOGICAL MARKERS CD30+ AND ALK- HAVE NOT BEEN CONFIRMED AS SUCH THIS EVENT WILL BE CAPTURED AS LYMPHOMA DEVICE WAS EXPLANTED THIS MEDWATCH IS FOR THE RIGHT SIDE DEVICE SEE MANUFACTURER REPORT  9617229-2016-00173 FOR LEFT SIDE REPORT|STYLE 168 SALINE FILLED BREAST IMPLANT|N-27-168211|12/05/2016||12/16/2016|DA|R|Y||0HP|FWM|1.0|09/03/2015|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||2013309|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5691027|46273890|N|1||MEDWATCH SENT TO FDA ON 06012016 THE EVENTS OF SEROMA AND LYMPHOMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE WILL NOT BE RETURNED AND IS THEREFORE UNAVAILABLE FOR ANALYSIS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|MM-410215|06/01/2016|||DA|N|R||0HP|FTR|1.0|06/02/2013|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1620541|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6177002|62447627|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 PATIENT WHO WAS IMPLANTED WITH A RIGHT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED SEROMA AND Â¿DISRUPTED IMPLANTÂ¿ TREATMENT REPORTED AS IMPLANT REMOVAL AND CYCLOPHOSPHAMIDE ADRIAMYCIN VINCRISTINE AND PREDNISONE 6 CURES CHOP OR CHOP-LIKE FOLLOW-UP FOUND Â¿NO EVIDENCE OF DISEASEÂ¿|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6177002|62447626|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5488699|39950188|N|1||MEDWATCH SUBMITTED ON 03092016 DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 168 SALINE FILLED BREAST IMPLANT|168-330|03/09/2016|||DA|N|R||0HP|FWM|1.0|04/12/2008|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||621428|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5597717|43315362|N|1||MEDWATCH SUBMITTED TO THE FDA ON 04222016 B4  THE DEVICE WILL NOT BE RETURNED THESE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLY CAUSE FOR THIS EVENT DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 168 SALINE FILLED BREAST IMPLANT|168-360|04/22/2016|||DA|N|R||0HP|FWM|1.0|07/12/2001|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||530498|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5597737|43319693|N|1||MEDWATCH SUBMITTED TO THE FDA ON 04222016 B4 THE DEVICE WILL NOT BE RETURNED THESE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLY CAUSE FOR THIS EVENT DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 168 SALINE FILLED BREAST IMPLANT|168-360|04/22/2016|||DA|N|R||0HP|FWM|1.0|01/20/2002|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||533743|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6037732|57779753|N|1||THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/18/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5922918|53782148|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING PATIENT INFORMATION DEVICE INFORMATION SIDE EXPERIENCING POSSIBLE ALCL PATHOLOGY REPORT AND DEVICE RETURN HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK SALINE IMPLANT|UNK SALINE IMPLANT|09/01/2016|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5922918|53782149|D|1||HEALTHCARE PROFESSIONAL REPORTED A PATIENT THAT HAS ANAPLASTIC LARGE CELL LYMPHOMA ALCL EXPLANT SURGERY OCCURRED 3 WEEKS AGO PATHOLOGICAL MARKERS HAS NOT BEEN RECEIVED CONFIRMING ALCL THE EVENT WILL BE CAPTURED AS LYMPHOMA UNTIL MARKERS ARE RECEIVED|UNK SALINE IMPLANT|UNK SALINE IMPLANT|09/01/2016|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5708570|46882993|N|1||MEDWATCH SENT TO FDA ON 06092016 IN RESPONSE TO FDA REPORT NUMBER MW5061580 B4 THESE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE SERIALLOT NUMBER AND PATIENT INFORMATION WERE NOT PROVIDED DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 20 SILICONE GEL FILLED BREAST IMPLANT|20-400|06/09/2016||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5596175|43273718|D|1||HEALTH PROFESSIONAL REPORTED LEFT SIDE CAPSULAR CONTRACTURE BAKER GRADE III-IV DURING THE EXPLANT SURGERY WHEN THE CAPSULE WAS OPENED THE PHYSICIAN LOCATED 5ML BROWN FLOCCULENT MATERIAL IN THE PERIPROSTHETIC SPACE LOOKED LIKE OLD BLOOD NOT LIQUID AT SURGERY FOUND A MASS IN THE CAPSULE NOT PALPABLE FROM THE OUTSIDE PHYSICIAN ALSO STATED WHILE REMOVING THE IMPLANT THEY NOTICED A TUMOR THAT WAS GOING INTO THE PATIENTS RIB CAGE THE MASS WAS DEEMED MALIGNANT AND SENT FOR PATHOLOGY PATHOLOGY REPORTED STATES LEFT BREAST CAPSULE - PATCHY INFILTRATE OF ANAPLASTIC LARGE CELL LYMPHOMA ALK-NEGATIVE WITHIN A BACKGROUND OF FIBROSIS AND INFLAMMATION A SECOND SET OF IMMUNOPEROXIDASE STAINS WERE THEN PERFORMED SHOWING THE TUMOR CELLS TO BE POSITIVE FOR CD30 NEGATIVE FOR EMA ALK-1 AND CD3 CLINICAL HISTORY NOTES PERSONAL HISTORY BREAST CANCER ACQUIRED ABSENCE OF BREAST CONTRACTURE PAIN TREATMENT INCLUDED SURGICAL MANAGEMENT CHEMOTHERAPY AND RADIOTHERAPY|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|120-500|04/21/2016|||DA|N|R||0HP|FTR|1.0|01/14/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1204889|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5596175|43273717|N|1||B4 THE DEVICE WILL NOT BE RETURNED THESE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLY CAUSE FOR THIS EVENT DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NONHODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|120-500|04/21/2016|||DA|N|R||0HP|FTR|1.0|01/14/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1204889|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5596175|47926535|D|1||HEALTH PROFESSIONAL REPORTED LEFT SIDE CAPSULAR CONTRACTURE BAKER GRADE III-IV DURING THE EXPLANT SURGERY WHEN THE CAPSULE WAS OPENED THE PHYSICIAN LOCATED 5ML BROWN FLOCCULENT MATERIAL IN THE PERIPROSTHETIC SPACE LOOKED LIKE OLD BLOOD NOT LIQUID AT SURGERY FOUND A MASS IN THE CAPSULE NOT PALPABLE FROM THE OUTSIDEÂ¿ PHYSICIAN ALSO STATED WHILE REMOVING THE IMPLANT THEY NOTICED A TUMOR THAT WAS GOING INTO THE PATIENTS RIB CAGE THE MASS WAS DEEMED MALIGNANT AND SENT FOR PATHOLOGY PATHOLOGY REPORTED STATES Â¿LEFT BREAST CAPSULE Â¿ PATCHY INFILTRATE OF ANAPLASTIC LARGE CELL LYMPHOMA ALK-NEGATIVE WITHIN A BACKGROUND OF FIBROSIS AND INFLAMMATIONÂ¿A SECOND SET OF IMMUNOPEROXIDASE STAINS WERE THEN PERFORMED SHOWING THE TUMOR CELLS TO BE POSITIVE FOR CD30Â¿NEGATIVE FOR EMA ALK-1 AND CD3Â¿ CLINICAL HISTORY NOTES Â¿PERSONAL HISTORY BREAST CANCER ACQUIRED ABSENCE OF BREAST CONTRACTURE PAINÂ¿ TREATMENT INCLUDED SURGICAL MANAGEMENT CHEMOTHERAPY AND RADIOTHERAPY|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|120-500|04/21/2016|||DA|N|R||0HP|FTR|1.0|01/14/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1204889|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6011867|56822654|D|1||THROUGH ALLERGANÂ¿S LITERATURE REVIEW OF RECENT JOURNAL ARTICLES WE RECEIVED THE FOLLOWING ARTICLE FROM MEDICAL SAFETY Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN AUSTRALIA AND NEW ZEALAND Â¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ THE ARTICLEÂ¿S PURPOSE IS TO CAPTURE ALL REPORTED BIA-ALCL IN AUSTRALIA AND NEW ZEALAND AND TO STUDY THE ASSOCIATION AND RISK OF DIFFERENT IMPLANT SURFACES AND INCIDENCE OF BIA-ALCL A TOTAL OF 46 PATIENTS WERE IDENTIFIED BETWEEN 2007 AND AUGUST 2016 FIVE WOMEN HAD MULTIPLE IMPLANTS WHILE THE REMAINING 41 HAD A SINGLE IMPLANT HISTORY WITH A TOTAL OF 56 IMPLANT PAIRS ARTICLE STATES Â¿ALL PATIENTS WERE EXPOSED TO TEXTURED IMPLANTS AT SOME POINT IN THEIR IMPLANT HISTORYÂ¿ ARTICLE CLARIFIES Â¿THERE WERE A TOTAL OF 46 IMPLANTS THAT WERE PLACED IN AUSTRALIA AND 8 IMPLANTS PLACED IN NEW ZEALAND IN TWO PATIENTS THE IMPLANT WAS PLACED OUTSIDE OF AUSTRALIA AND NEW ZEALAND 1 MEXICO AND 1 THAILANDÂ¿ MANUFACTURER COULD NOT BE SPECIFIED AND ARTICLE STATES Â¿BIOCELL ALLERGANINAMEDMCGHAN ACCOUNTED FOR 571 OF IMPLANTS IN THIS SERIESÂ¿ THE ARTICLE DOES NOT PROVIDE IMPLANTING EXPLANTING PHYSICIAN INFORMATION DEVICE SERIAL OR LOT INFORMATION OR SIDES OF ALCL DIAGNOSIS ARTICLE STATES Â¿ALL PATIENTS UNDERWENT TOTAL CAPSULECTOMY AND REMOVAL OF IMPLANTS BOTH ON DISEASED AND NON-DISEASED SIDE ALL TUMORS WERE CD30 POSITIVE AND ALK NEGATIVEÂ¿|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6011867|56822653|N|1||MEDWATCH SENT TO FDA ON 10072016 ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN AUSTRALIA AND NEW ZEALAND Â¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ A LOCH-WILKINSON KJ BEATH RJW KNIGHT WLF WESSELS M MAGNUSSON T PAPADOPOULOS T CONNELL J LOFTS M LOCKE I HOPPER R COOTER K VICKERY PA JOSHI HM PRINCE  AK DEVA THE EVENT OF LYMPHOMA ALCL IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5670826|45647377|D|1||PHYSICIAN REPORTED THAT APPROXIMATELY FIVE YEARS AFTER IMPLANTATION THE PATIENT CONSULTED A DOCTOR AFTER DISCOVERING THROUGH A SELF-EXAM TEN DAYS EARLIER INFRACLAVICULAR C11 LUMPS IN THE PATIENTS LEFT BREAST AND LEFT AXILLARY ADENOPATHY ULTRASOUND-GUIDED BAG ACCORDING TO BI-RADS ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA ALCL AS CD30 RESULTS HAVE NOT BEEN PROVIDED THIS REPORT OF ALCL IS NOT YET CONFIRMED AND IS CURRENTLY CAPTURED AS LYMPHOMA DEVICE WAS EXPLANTED AND THE PATIENT IS BEING STUDIED FOR CHEMOTHERAPY|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-MM125-320|05/20/2016|||DA|N|R||0HP|FTR|1.0|02/03/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2073435|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6146400|61491852|N|1||B4 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT AND PRODUCT HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL HEMATOMASEROMA AND NECROSIS PUBLISHED STUDIES INDICATE THAT BREAST CANCER IS NO MORE COMMON IN WOMEN WITH IMPLANTS THAN THOSE WITHOUT IMPLANTS A LARGE LONG-TERM FOLLOW-UP FOUND NO SIGNIFICANT INCREASES IN THE RISK RATES FOR A WIDE VARIETY OF CANCERS INCLUDING STOMACH CANCER LEUKEMIA AND LYMPHOMA ARTICLE CITATION Â¿CLASSICAL HODGKIN LYMPHOMA ARISING ADJACENT TO A BREAST IMPLANTÂ¿ CIARA RYAN MB MRCSI FRCPATH1 YASSER GED MB1 FIONA QUINN PHD1 JAN WALKER BSC1 JOHN KENNEDY MB FRCPI1 CHARLES GILLHAM MB MRCP FRCR1 STEFANIA PITTALUGA MD PHD2 RONAN MCDERMOTT MB MRCPI FRCR FFRRCSI1 ELISABETH VANDENBERGHE MB PHD MRCPI MRCPATH1 CLIONA GRANT MB MRCPI1 AND RICHARD FLAVIN MD PHD FRCPATH1 INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY 2016 VOL 245 448Â¿455|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/05/2016|||DA|*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6146400|66166179|D|1||FOLLOW-UP WITH PHYSICIAN REVEALED PATIENT DID NOT HAVE ANAPLASTIC LARGE CELL LYMPHOMA HAD HODGKIN LYMPHOMA AND WE FAILED TO ESTABLISH A DIRECT CAUSATION LINK TO THE IMPLANT EVENT OF LYMPHOMA IS NOT CONSIDERED TO BE DEVICE RELATED EVENTS OF LUMPNODULE PRURITUS CANCER BREAST AND NECROSIS WILL ALL BE CONSIDERED NOT DEVICE RELATED AS THEY ARE SECONDARY TO THE EVENT OF LYMPHOMA EVENT OF LATE SEROMA REMAINS MDR REPORTABLE|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/05/2016|||DA|*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5880065|52274646|N|1||MEDWATCH SENT TO FDA ON 08162016 THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FOLLOW UP HAS BEEN PERFORMED TO DETERMINE THE DEVICE MANUFACTURER SERIAL NUMBER LOT NUMBER IMPLANT DATE PATIENT NAME PATIENT DATE OF BIRTH PATHOLOGICAL TESTING RESULTS EXPLANT DATE AND DEVICE RELATIONSHIP OF THE REPORTED EVENT DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|08/16/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|UNKNOWN MANUFACTURER|||||||True
5936530|54204592|N|1||MEDWATCH SENT TO FDA ON 09082016 THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING SERIAL NUMBER DATE OF IMPLANTEXPLANT IMPLANTING PHYSICIAN PATIENT INFORMATION AND THE RETURN OF PATHOLOGICAL MARKERS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|09/08/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6176674|62457390|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA-ALCL SEROMA AND MASS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176674|62457391|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 PATIENT WHO WAS IMPLANTED WITH A LEFT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED MASS AND SEROMA TREATMENT REPORTED AS IMPLANT REMOVAL AND CYCLOPHOSPHAMIDE ADRIAMYCIN VINCRISTINE AND PREDNISONE 6 CURES CHOP OR CHOP-LIKE FOLLOW-UP FOUND NO EVIDENCE OF DISEASE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6142978|61395222|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL AND DEATH ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/02/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6142978|62721838|D|1||ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ REPORTS A B6 PATIENT WHO WAS IMPLANTED WITH A RIGHT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE CHART ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED A RIGHT SIDE MASS TREATMENT REPORTED AS IMPLANT REMOVAL AND CYCLOPHOSPHAMIDE ADRIAMYCIN VINCRISTINE AND PREDNISONE 6 CURES CHOP OR CHOP-LIKE FOLLOW-UP REVEALED THAT THIS PATIENT DIED FROM LYMPHOMA PROGRESSION THIS REPORT WAS INITIALLY SENT TO REPRESENT TWO PATIENTS DUE TO THE DISCOVERY OF IDENTIFYING INFORMATION THIS SUPPLEMENTAL REPORT WILL NOW REPRESENT THE B6 PATIENT DEVICE AND MFR  9617229-2016-00227 HAS BEEN SENT TO REPRESENT THE OTHER PATIENT PREVIOUSLY REPRESENTED THE INITIAL REPORT OF MFR  9617229-2016-00195|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/02/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6142978|61395223|D|1||LITERATURE ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ REPORTED Â¿19 I-ALCLSÂ¿ CASES ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ ARTICLE REPORTED IN CASES OF Â¿INFILTRATIVE I-ALCLÂ¿ SURVIVAL RATE WAS 525 ARTICLE REPORTS OF THE CASES THAT RESULTED IN DEATH TWO FROM LYMPHOMA PROGRESSION THIS RECORD REPRESENTS THE CASES OF INFILTRATIVE I-ALCL WHICH RESULTED IN DEATH FROM LYMPHOMA PROGRESSION ARTICLE REPORTS THAT HISTOPATHOLOGY REPORTS THAT MALIGNANT CELLS WERE CD30-POSITIVE AND WERE ALK NEGATIVE IN REGARDS TO TREATMENT ABSTRACT REPORTS Â¿IMPLANT REMOVAL WAS PERFORMED IN 17 OUT OF 19 PATIENTS WITH ADDITIONAL TREATMENT BASED ON MOSTLY CHOP OR CHOP-LIKE CHEMOTHERAPY REGIMENS N = 1019 OR IRRADIATION N = 119 CHOP ALONE OR ABVD FOLLOWING RADIATION WITHOUT IMPLANT REMOVAL HAVE BEEN GIVEN IN TWO PATIENTSÂ¿ THERE IS NO WAY OF KNOWING WHICH TREATMENT WAS USED IN THESE TWO CASES MANUFACTURER OF DEVICES IS UNKNOWN|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/02/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6153182|61700301|D|1||JOURNAL ARTICLE Â¿AXILLARY LYMPHADENOPATHY AN OUTSTANDING PRESENTATION FOR BREAST IMPLANT-ASSOCIATED ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ REPORTS Â¿WE REPORT THE CASE OF A PATIENT PRESENTING WITH AN AXILLARY LYMPHADENOPATHY 8 YEARS AFTER BREAST PROSTHESES IMPLANTATION CLINICAL EXAMINATION ULTRASOUND AND MAGNETIC RESONANCE IMAGING DETECTED NO MAMMARY LESIONS THE LYMPH NODE SHOWED INTRASINUSOIDAL INFILTRATION BY LARGE PLEOMORPHIC CELLS EXPRESSING CD30 AND LACKING ALK-IMMUNOREACTIVITY TUMOR STAGING WAS NEGATIVE CELLS WITH IDENTICAL FEATURES WERE FOUND IN THE IPSILATERAL PERIPROSTHETIC CAPSULE THE PATIENT WAS TREATED WITH CHOP AND RADIOTHERAPY AND PATIENT IS ALIVE WITHOUT EVIDENCE OF DISEASE AFTER A 30-MONTH FOLLOW-UPÂ¿ FINE-NEEDLE ASPIRATION CYTOLOGY WAS TAKEN OF THE AXILLARY LYMPH NODE AND CD30+  ALK- WAS CONFIRMED DEVICE REMOVAL AND CAPSULECTOMY WAS PERFORMED MANUFACTURER OF THE DEVICE IS UNKNOWN|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5940718|69962842|N|1||THE EVENTS OF INFLAMMATION LUMPNODULE AND LYMPHOMA ALCL ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS IN SOME CASES PATIENTS PRESENTED WITH MASSES ADJACENT TO THE BREAST IMPLANT IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|09/09/2016|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5940718|54394902|N|1||MEDWATCH SENT TO FDA ON 09092016 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|09/09/2016|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6199283|63133500|D|1||PHYSICIAN REPORTED ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED TO BREAST IMPLANT AS REQUIRED CYTOLOGICAL MARKERS FOR DIAGNOSIS HAVE NOT BEEN RECEIVED THIS EVENT WILL BE CAPTURED BY TERM CODE LYMPHOMA DEVICE WAS EXPLANTED|STYLE 410 SILICONE GEL FILLED BREAST IMPLANT|ST-MM130-360|12/22/2016|||DA|N|R||0HP|FTR|1.0|11/15/2009|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||352966|KILBRIDE INDUSTRIAL ESTATE||ARKLOW, COUNTY WICKLOW||ALLERGAN (ARKLOW)|||||||True
6153188|61710211|N|1||THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL INFECTION BACTERIAL BIOFILM INFECTION DETECTED IN BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE-CELL LYMPHOMAÂ¿ 137 6 1659-1669 BY HONGHUA HU PHD KHALID JOHANI AHMAD ALMATROUDI KAREN VICKERY PHD BVSC BRUCE VAN NATTA MD MARSHALL E KADIN MD GARRY BRODY MD MARK CLEMENS MD CHAN YOON CHEAH MD STEPHEN LADE MD PREETI AVINASH JOSHI MDPHD H MILES PRINCE MDPHD ANAND K DEVA BSCMED MBBS MS PUBLISHED JUNE 2016|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/07/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5659740|45309562|D|1||HEALTH PROFESSIONAL REPORTED RIGHT SIDE SWELLING THAT WOULD COME AND GO AT VARYING TIMES IN ADDITION TO FIRMNESS AND SIGNIFICANT SUPERIOR POLE FULLNESS CAPSULAR CONTRACTURE BAKER GRADE IV WAS CONFIRMED UPON EXPLANT AND CAPSULECTOMY PATHOLOGY NOTED RIGHT BREAST CAPSULE CAPSULECTOMY BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA SEE COMMENT COMMENT NOTES THE LYMPHOMA CELLS APPEAR PRIMARILY CONFINED TO THE INNER SURFACE OF THE RIGHT BREAST CAPSULE SUCH AS DESCRIBED IN EFFUSION-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA ALCLÂ¿ THE GROSS EXAMINATION NOTES Â¿PREVIOUSLY OPENED BREAST CAPSULE WHICH CONTAINS 45 CC OF TURBID TAN-YELLOW FLUIDÂ¿ MICROSCOPIC EXAMINATION NOTES Â¿THE LARGE ATYPICAL CELLS STAIN POSITIVELY FOR CD30Â¿THESE CELLS ARE NEGATIVE FOR ALKÂ¿|STYLE 168 SALINE FILLED BREAST IMPLANT|UNK STYLE 168|05/17/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5659740|45309561|N|1||MEDWATCH SENT TO FDA ON 05172016 B4 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT THE DEVICE WILL NOT BE RETURNED SERIAL NUMBER IS NOT AVAILABLE DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY PUBLISHED STUDIES INDICATE THAT BREAST CANCER IS NO MORE COMMON IN WOMEN WITH IMPLANTS THAN THOSE WITHOUT IMPLANTS A LARGE LONG-TERM FOLLOW-UP FOUND NO SIGNIFICANT INCREASES IN THE RISK RATES FOR A WIDE VARIETY OF CANCERS INCLUDING STOMACH CANCER LEUKEMIA AND LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 168 SALINE FILLED BREAST IMPLANT|UNK STYLE 168|05/17/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5894468|52721867|D|1||COMPANY REPRESENTATIVE REPORTED ON BEHALF OF HEALTH PROFESSIONAL LATE SEROMA THAT TESTED POSITIVE FOR CD30 OPERATIVE REPORT REFERENCES A SURGERY ON B6 2008 IN WHICH THE PATIENT HAD BILATERAL NEOSUBMUSCULAR POCKET WITH REPOSITIONING OF THE EXISTING BREAST IMPLANTS OPERATIVE REPORT ADDITIONALLY NOTES BOTTOMING OUT BREAST IMPLANT BREAST ASYMMETRY CHEST WALL DEFORMITY AND CONSTRICTED BREASTÂ¿ IN ADDITION TO Â¿THE BREAST IMPLANT WAS WIPED OFF WITH ANTIBIOTIC LAP PAD AND THEN REINSERTED INTO THE POCKETÂ¿ IN B6 2015 PATIENT NOTICED THAT THEIR BREAST IMPLANTS WERE ASYMMETRIC AND WAS EVALUATED BY HER PLASTIC SURGEON WHO HAD SUSPECTED CAPSULAR CONTRACTION PHYSICIAN NOTES CLARIFY Â¿ON PHYSICAL EXAMINATION HER LEFT BREAST IS ALMOST TWICE THE SIZE OF THE RIGHT BREAST THERE IS SOME EDEMA OF THE LEFT BREAST SKIN ULTRASOUND LATER CONFIRMED A LEFT SIDE RUPTURE WITH FLUID SURROUNDING THE IMPLANT HER LEFT BREAST LATER BECAME MORE ENGORGED AS SHE DEVELOPED SEROMA WHICH WAS ASPIRATED IN B6 2016 AND FOUND TO BE POSITIVE FOR CD30 ANAPLASTIC LARGE CELL LYMPHOMA PATHOLOGY DATED B6 2016 STATES Â¿LYMPHOID CELLS POSITIVE FOR CD3 AND CD30Â¿THE FINDINGS SUGGEST POSSIBLE BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ EXAM DATED B6 2016 STATES Â¿DIAGNOSIS OF ALCL BREAST WITH PALPABLE LEFT BREAST MASSÂ¿ THE PATIENT HAD SURGERY ON B6 2016 AND HAD A REPLACEMENT AT THAT TIME THE DEVICE IS AVAILABLE FOR RETURN TO ALLERGAN AS OF B6 2016 PATIENT HAS NO EVIDENCE OF ALCL|STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-354|08/22/2016|||DA|N|R||0HP|FTR|1.0|01/13/2012|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1393696|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5894468|52721866|N|1||B4 THE EVENTS OF LYMPHOMA ALCL SEROMA LATE EDEMA AND VISIBILITYPALPABILITY ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE REOPERATION IMPLANT REMOVAL ASYMMETRY IMPLANT MISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY HEMATOMASEROMA AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY|STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-354|08/22/2016|||DA|N|R||0HP|FTR|1.0|01/13/2012|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1393696|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5894468|54359677|D|1||COMPANY REPRESENTATIVE REPORTED ON BEHALF OF HEALTH PROFESSIONAL LATE SEROMA THAT TESTED POSITIVE FOR CD30 OPERATIVE REPORT REFERENCES A SURGERY ON B6 2008 IN WHICH THE PATIENT HAD BILATERAL NEOSUBMUSCULAR POCKET WITH REPOSITIONING OF THE EXISTING BREAST IMPLANTS OPERATIVE REPORT ADDITIONALLY NOTES BOTTOMING OUT BREAST IMPLANT BREAST ASYMMETRY CHEST WALL DEFORMITY AND CONSTRICTED BREASTÂ¿ IN ADDITION TO Â¿THE BREAST IMPLANT WAS WIPED OFF WITH ANTIBIOTIC LAP PAD AND THEN REINSERTED INTO THE POCKETÂ¿ IN B6 2015 PATIENT NOTICED THAT THEIR BREAST IMPLANTS WERE ASYMMETRIC AND WAS EVALUATED BY HER PLASTIC SURGEON WHO HAD SUSPECTED CAPSULAR CONTRACTION PHYSICIAN NOTES CLARIFY Â¿ON PHYSICAL EXAMINATION HER LEFT BREAST IS ALMOST TWICE THE SIZE OF THE RIGHT BREAST THERE IS SOME EDEMA OF THE LEFT BREAST SKIN ULTRASOUND LATER CONFIRMED A LEFT SIDE RUPTURE WITH FLUID SURROUNDING THE IMPLANT HER LEFT BREAST LATER BECAME MORE ENGORGED AS SHE DEVELOPED SEROMA WHICH WAS ASPIRATED IN B6 2016 AND FOUND TO BE POSITIVE FOR CD30 ANAPLASTIC LARGE CELL LYMPHOMA PATHOLOGY DATED B6 2016 STATES Â¿LYMPHOID CELLS POSITIVE FOR CD3 AND CD30Â¿THE FINDINGS SUGGEST POSSIBLE BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ EXAM DATED B6 2016 STATES Â¿DIAGNOSIS OF ALCL BREAST WITH PALPABLE LEFT BREAST MASSÂ¿ THE PATIENT HAD SURGERY ON 06132016 AND HAD A REPLACEMENT AT THAT TIME THE DEVICE IS AVAILABLE FOR RETURN TO ALLERGAN AS OF B6 2016 PATIENT HAS NO EVIDENCE OF ALCL|STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-354|08/22/2016|||DA|N|R||0HP|FTR|1.0|01/13/2012|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1393696|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5935521|54162317|N|1||MEDWATCH SENT TO FDA ON 09082016 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 168 SALINE FILLED BREAST IMPLANT|168-300|09/08/2016|||DA|N|R||0HP|FWM|1.0|05/05/2011|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||1440846|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5904549|58060034|D|1||PHYSICIAN REPORTED THE RIGHT BREAST WAS SWOLLEN FIRM AND SENSITIVE TO DEEP PALPATION PHYSICIAN ALSO STATED AN ANAPLASTIC LARGE CELL LYMPHOMA WAS FOUND IN THE PERI PROSTHETIC FLUID AND FIBRINOID DEPOSITS WITHIN THE PERIPROSTHETIC CAPSULE OF THE RIGHT BREAST PHYSICIAN ALSO STATED THE PT UNDERWENT BILATERAL TOTAL CAPSULECTOMY AND IMPLANT REMOVAL NOW MORE THAN A YEAR AFTER THE PT IS DISEASE FREE CT PET SCANS INCLUDING A RECENT SCAN DO NOT SHOW ANY SIGNS OF THE LYMPHOMA EVENT WILL BE CAPTURED AS LYMPHOMA AS PATHOLOGICAL MARKERS TO CONFIRM ALCL HAVE NOT BEEN RECEIVED|CUI TEXTURED SILICONE GEL FILLED BREAST IMPLANT|MHP-460|08/25/2016||09/29/2016|DA|R|Y||0HP|FTR|1.0|05/15/2009|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||303203|KILBRIDE INDUSTRIAL ESTATE|ZONA FRANCA|ARKLOW, COUNTY WICKLOW||ALLERGAN (ARKLOW)|||||||True
5904549|53036937|D|1||PHYSICIAN REPORTED THE RIGHT BREAST WAS SWOLLEN FIRM AND SENSITIVE TO DEEP PALPATION PHYSICIAN ALSO STATED AN ANAPLASTIC LARGE CELL LYMPHOMA WAS FOUND IN THE PERI PROSTHETIC FLUID AND FIBRINOID DEPOSITS WITHIN THE PERIPROSTHETIC CAPSULE OF THE RIGHT BREAST PHYSICIAN ALSO STATED THE PT UNDERWENT BILATERAL TOTAL CAPSULECTOMY AND IMPLANT REMOVAL NOW MORE THAN A YEAR AFTER THE PT IS DISEASE FREE CT PET SCANS INCLUDING A RECENT SCAN DO NOT SHOW ANY SIGNS OF THE LYMPHOMA EVENT WILL BE CAPTURED AS LYMPHOMA AS PATHOLOGICAL MARKERS TO CONFIRM ALCL HAVE NOT BEEN RECEIVED|CUI TEXTURED SILICONE GEL FILLED BREAST IMPLANT|MHP-460|08/25/2016||09/29/2016|DA|R|Y||0HP|FTR|1.0|05/15/2009|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||303203|KILBRIDE INDUSTRIAL ESTATE|ZONA FRANCA|ARKLOW, COUNTY WICKLOW||ALLERGAN (ARKLOW)|||||||True
5991152|58278327|D|1||GOVERNING BODY REPORTED RIGHT SIDE Â¿CLINICAL SIGNS SIGNS ON MRI AND ON ULTRASOUND ENLARGEMENT OF LYMPH NODES ANAPLASTIC LARGE CELL LYMPHOMA ALK- FURTHER SPECIFIED AS DISCOVERING OF ANAPLASTIC LYMPHOMA ON AXILLARY LYMPHADENOPATHY ALCL DIAGNOSIS RECEIVED IN MAY OF 2016 TREATMENT INCLUDES EXPLANTATION OF BREAST PROSTHESIS AND CAPSULECTOMY WAS PERFORMED ANATOMOPATHOLOGIC RESULT OF MATERIAL WAS KEPT PATIENT WILL RECEIVE A SPECIFIC TREATMENT BY CHEMOTHERAPY AFTER APPROVAL OF COLLEGIAL DECISION DURING A MULTIDISCIPLINARY MEETING|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-MF135-420|09/30/2016||09/29/2016|DA|R|Y||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2334015|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5991152|56059751|N|1||MEDWATCH SENT TO FDA ON 09302016 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE HISTORY REVIEW DHR SUMMARY REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM SAP WAS VERIFIED AND THREE DEVICES WERE SCRAPPED DURING THE ASSEMBLY PROCESS WHICH ARE NOT RELATED TO THE REPORTED EVENT  IN ADDITION DHR FOR SHELL RUNS NUMBER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING SHELL FABRICATION PROCESS ALL SHELLS WERE REVIEWED AS PART OF THE SHELL FABRICATION OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT FABRICATION MET THE REQUIRED SPECIFICATIONS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-MF135-420|09/30/2016||09/29/2016|DA|R|Y||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2334015|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5991152|56059752|D|1||GOVERNING BODY REPORTED RIGHT SIDE CLINICAL SIGNS SIGNS ON MRI AND ON ULTRASOUND ENLARGEMENT OF LYMPH NODES ANAPLASTIC LARGE CELL LYMPHOMA ALK- FURTHER SPECIFIED AS DISCOVERING OF ANAPLASTIC LYMPHOMA ON AXILLARY LYMPHADENOPATHY ALCL DIAGNOSIS RECEIVED IN B6 2016 TREATMENT INCLUDES EXPLANTATION OF BREAST PROSTHESIS AND CAPSULECTOMY WAS PERFORMED ANATOMOPATHOLOGIC RESULT OF MATERIAL WAS KEPT PATIENT WILL RECEIVE A SPECIFIC TREATMENT BY CHEMOTHERAPY AFTER APPROVAL OF COLLEGIAL DECISION DURING A MULTIDISCIPLINARY MEETING|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-MF135-420|09/30/2016||09/29/2016|DA|R|Y||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2334015|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5991152|59996591|D|1||GOVERNING BODY ADDITIONALLY REPORTED RIGHT SIDE CAPSULAR PAIN AT RIGHT SIDE LYMPH NODE TUMOR SYNDROME PRURITUS SINE MATERIAL AXILLARY GANGLIONS AND ANAPLASTIC LARGE CELL LYMPHOMA CD30+ ALK -|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-MF135-420|09/30/2016||09/29/2016|DA|R|Y||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2334015|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6191866|64757804|N|1||THE EVENTS OF ALCL LYMPHOMA CAPSULAR CONTRACTURE AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVALHEMATOMASEROMA AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA PATIENTS SHOULD BE ADVISED THAT CAPSULAR CONTRACTURE MAY BE MORE COMMON FOLLOWINGSEROMA AND THE CHANCE OF IT HAPPENING MAY INCREASE OVER TIME CAPSULAR CONTRACTURE OCCURS MORE COMMONLY IN REVISION PATIENTS THAN IN PRIMARY AUGMENTATION OR RECONSTRUCTION PATIENTS CAPSULAR CONTRACTURE IS ALSO A RISK FACTOR FOR IMPLANT RUPTURE AND IT IS ONE OF THE MOST COMMON REASONS FOR REOPERATION|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-LF145-490|12/20/2016||01/06/2017|DA|R|Y||0HP|FTR|1.0|10/11/2015|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2029824|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6191866|62906212|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-LF145-490|12/20/2016||01/06/2017|DA|R|Y||0HP|FTR|1.0|10/11/2015|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2029824|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6191882|62905244|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-LF145-490|12/20/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5719833|47208525|D|1||PATIENT REPORTED SEROMA RIGHT BREAST PARTIAL CAPSULECTOMY  CAPSULOTOMY WITH EXCHANGE WAS PERFORMED SURGICAL LOG REPORTS THERE WAS 600 CC SEROUS FLUID UNDER PRESENT ON RIGHT SEROLOGY PENDING PATHOLOGY + ALCL PETCT SCAN STATES ONLY FAINT ACTIVITY IS AFFILIATED WITH RIGHT AXILLARY NODES OF RELATIVELY LESS CONCERN AND POTENTIALLY INFLAMMATORYREACTIVE CYTOLOGY REPORT STATES RIGHT BREAST FLUID HIGHLY ATYPICAL LYMPHOCYTES PRESENT CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA ALK NEGATIVE COMMENT THE HIGHLY ATYPICAL LYMPHOCYTES DEMONSTRATES STAINING WITH CD30 NEGATIVE FOR ALK-1 THE IMMUNOHISTOCHEMISTRY PROFILE IS CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA ALK NEGATIVE|STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-469|06/13/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2594775|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5719833|47208524|N|1||MEDWATCH SENT TO FDA ON 06132016 THESE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS IT IS NOT KNOWN IF THE DEVICE WILL BE RETURNED PATIENT DECLINED PERMISSION TO CONTACT THE HEALTH PROFESSIONAL AT THIS TIME DEVICE HISTORY RECORD REPORTS REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM SAP WAS VERIFIED AND THERE WAS NOT ANY SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS IN ADDITION DHR FOR SHELL RUNS NUMBER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING SHELL FABRICATION PROCESS ALL SHELLS WERE REVIEWED AS PART OF THE SHELL FABRICATION OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT FABRICATION MET THE REQUIRED SPECIFICATIONS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-469|06/13/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2594775|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6145514|61451048|D|1||PHYSICIAN REPORTED CLOUDY YELLOW FLUID FROM BREAST PROSTHESIS AND DIAGNOSIS OF ANAPLASTIC LARGE CELL LYMPHOMA CYTOLOGICAL MARKERS CD30+ AND ALK- HAVE NOT BEEN CONFIRMED AS SUCH THIS EVENT WILL BE CAPTURED AS LYMPHOMA DEVICE WAS EXPLANTED THIS MEDWATCH IS FOR THE LEFT SIDE DEVICE SEE MANUFACTURER REPORT B4 FOR RIGHT SIDE REPORT|STYLE 168 SALINE FILLED BREAST IMPLANT|N-27-168211|12/05/2016||12/16/2016|DA|R|Y||0HP|FWM|1.0|09/09/2015|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||2013310|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5531532|44806115|D|1||HEALTH PROFESSIONAL REPORTED LEFT SIDE SWELLING AND SEROMA AND LYMPHOMA CONFIRMED BY CYTOLOGY LYMPHOMA WAS IDENTIFIED AS ANAPLASTIC LARGE CELL LYMPHOMA FOLLOW-UP FINDINGS NOTED PATIENT DID WELL UNTIL RECENTLY WHEN THEY NOTED SWELLING IN THE LEFT BREAST IMAGING STUDY SHOWED A LARGE SEROMA COLLECTION AROUND THE IMPLANT THIS WAS ASPIRATED AND CYTOLOGY SHOWED ANAPLASTIC LARGE CELL LYMPHOMA ALK NEGATIVE WAS NOTED THAT THE MRI DID NOT SHOW ANY SPREAD OF TUMOR BEYOND THE CAPSULE SEROMA WAS DRAINED CYTOLOGY REPORT STATED IMMUNOHISTOCHEMICAL STAINS PERFORMED ON THE CELL BLOCK DEMONSTRATE DIFFUSE STRONG EXPRESSION OF CD30 MAY CELLS EXPRESSING CD3 AND EPITHELIAL MEMBRANE ANTIGEN EMA AND NO CELLS EXPRESSING PAN-CYTOKERATIN OR ALK1 PATHOLOGY REPORT INCLUDES THE MICROSCOPIC DESCRIPTION THAT STATES SECTIONS OF PART A LEFT BREAST CAPSULE SHOW A DIFFUSE INFLAMMATORY INFILTRATE COMPRISED PREDOMINANTLY OF LYMPHOCYTES AND PLASMA CELLS|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|120-550|03/29/2016||04/13/2016|DA|R|Y||0HP|FTR|1.0|02/20/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1235003|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5531532|46702393|D|1||HEALTH PROFESSIONAL REPORTED LEFT SIDE SWELLING AND SEROMA AND LYMPHOMA CONFIRMED BY CYTOLOGY LYMPHOMA WAS IDENTIFIED AS ANAPLASTIC LARGE CELL LYMPHOMA FOLLOW-UP FINDINGS NOTED PATIENT DID WELL UNTIL RECENTLY WHEN THEY NOTED SWELLING IN THE LEFT BREAST IMAGING STUDY SHOWED A LARGE SEROMA COLLECTION AROUND THE IMPLANT THIS WAS ASPIRATED AND CYTOLOGY SHOWED ANAPLASTIC LARGE CELL LYMPHOMA ALK NEGATIVE IT WAS NOTED THAT THE MRI DID NOT SHOW ANY SPREAD OF TUMOR BEYOND THE CAPSULE SEROMA WAS DRAINED CYTOLOGY REPORT STATED IMMUNOHISTOCHEMICAL STAINS PERFORMED ON THE CELL BLOCK DEMONSTRATE DIFFUSE STRONG EXPRESSION OF CD30 MAY CELLS EXPRESSING CD3 AND EPITHELIAL MEMBRANE ANTIGEN EMA AND NO CELLS EXPRESSING PAN-CYTOKERATIN OR ALK1 PATHOLOGY REPORT INCLUDES THE MICROSCOPIC DESCRIPTION THAT STATES SECTIONS OF PART A LEFT BREAST CAPSULE SHOW A DIFFUSE INFLAMMATORY INFILTRATE COMPRISED PREDOMINANTLY OF LYMPHOCYTES AND PLASMA CELLS|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|120-550|03/29/2016||04/13/2016|DA|R|Y||0HP|FTR|1.0|02/20/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1235003|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5531532|41335750|D|1||HEALTH PROFESSIONAL REPORTED LEFT SIDE SWELLING AND SEROMA AND LYMPHOMA CONFIRMED BY CYTOLOGY  LYMPHOMA WAS IDENTIFIED AS ANAPLASTIC LARGE CELL LYMPHOMA FOLLOW-UP FINDINGS NOTED Â¿PATIENT DID WELL UNTIL RECENTLY WHEN THEY NOTED SWELLING IN THE LEFT BREAST IMAGING STUDY SHOWED A LARGE SEROMA COLLECTION AROUND THE IMPLANT THIS WAS ASPIRATED AND CYTOLOGY SHOWED ANAPLASTIC LARGE CELL LYMPHOMA ALK NEGATIVEÂ¿IT WAS NOTED THAT THE MRI DID NOT SHOW ANY SPREAD OF TUMOR BEYOND THE CAPSULEÂ¿ SEROMA WAS DRAINED CYTOLOGY REPORT STATED Â¿IMMUNOHISTOCHEMICAL STAINS PERFORMED ON THE CELL BLOCK DEMONSTRATE DIFFUSE STRONG EXPRESSION OF CD30 MAY CELLS EXPRESSING CD3 AND EPITHELIAL MEMBRANE ANTIGEN EMA AND NO CELLS EXPRESSING PAN-CYTOKERATIN OR ALK1Â¿ PATHOLOGY REPORT INCLUDES THE MICROSCOPIC DESCRIPTION THAT STATES Â¿SECTIONS OF PART A LEFT BREAST CAPSULE SHOW A DIFFUSE INFLAMMATORY INFILTRATE COMPRISED PREDOMINANTLY OF LYMPHOCYTES AND PLASMA CELLS|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|120-550|03/29/2016||04/13/2016|DA|R|Y||0HP|FTR|1.0|02/20/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1235003|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5531532|41335749|N|1||DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|120-550|03/29/2016||04/13/2016|DA|R|Y||0HP|FTR|1.0|02/20/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1235003|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6177211|62456167|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 B4 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL SEROMA LUMP AND ERYTHEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION ERYTHEMA MAY ALSO OCCUR AS A NORMAL RESPONSE TO EXPANSION GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6177211|62456168|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 OLD PATIENT WHO WAS IMPLANTED WITH A LEFT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE CHART ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED A LEFT MASS SEROMA AND Â¿DISRUPTED IMPLANTÂ¿ ARTICLE ADDITIONALLY REPORTS ERYTHEMATOUS SKIN ERUPTION AGAINST THIS CASE TREATMENT REPORTED AS CYCLOPHOSPHAMIDE ADRIAMYCIN VINCRISTINE AND PREDNISONE 6 CURES CHOP OR CHOP-LIKE EXPLANT NOT REPORTED|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5551762|42003099|D|1||PT WITH SILICONE BREAST IMPLANTS PLACED ORIGINALLY APPROX 15 YEARS AGO SP MULTIPLE REVISIONS DIAGNOSED B6 2016 WITH BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA ORIGINAL IMPLANTS WERE NATRELLE 20-400ML IN B6 2015 LEFT BREAST IMPLANT WAS REMOVED AND ALLODERM AND ALLERGAN 2400 IMPLANT WAS INSERTED|NATRELLE 20 - 400ML||04/04/2016||||N|*||I|FTR|1.0||BREAST IMPLANT|||||||nan|||||||True
5708519|46870798|D|1||AUTHORS REPORTED THE CASE OF ONE PATIENT IN THE FOLLOWING JOURNAL ARTICLE BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA A CASE REPORT AND LITERATURE REVIEW AUTHORS REPORTED  A PATIENT PRESENTED WITH PAIN AND FIRMNESS IN PATIENTS RIGHT BREAST FOR SEVERAL WEEKS THE PATIENT HAD UNDERGONE BREAST AUGMENTATION WITH SALINE IMPLANTS 16 YEARS PRIOR TO PRESENTATION ROUTINE LABORATORY WORK REVEALED NO ABNORMALITIES THE PATIENT WAS REFERRED BY THE PATIENTS PRIMARY CARE PHYSICIAN FOR MRI OF THE RIGHT BREAST MRI DEMONSTRATED A LARGE FLUID COLLECTION SURROUNDING THE RIGHT BREAST IMPLANT WITH NO ASSOCIATED SIGNIFICANT ENHANCEMENT THERE WAS NO SUSPICIOUS MASS LESION AND NO AXILLARY ADENOPATHY THE IMPLANT WAS INTACT AN ULTRASOUND WAS PERFORMED AND DEMONSTRATED A SIMPLE FLUID COLLECTION SURROUNDING THE IMPLANT AGAIN NO MASS WAS IDENTIFIED ULTRASOUND-GUIDED FLUID ASPIRATION WAS PERFORMED WHICH YIELDED APPROXIMATELY 20 CUBIC CENTIMETERS OF YELLOW SEROUS FLUID PATHOLOGY DEMONSTRATED A SEROMA-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA OF THE RIGHT BREAST ANAPLASTIC LYMPHOMA KINASE ALK GENE TESTING WAS NEGATIVE THE PATIENT UNDERWENT PETCT WHICH REVEALED NO METASTATIC DISEASE THE PATIENT WAS TAKEN TO SURGERY AND BOTH IMPLANTS WERE REMOVED THE PATIENT DID NOT RECEIVE NEOADJUVANT OR ADJUVANT CHEMOTHERAPY OR RADIATION THERAPY THE PATIENT HAS NOW BEEN DISEASE-FREE WITH NO EVIDENCE OF DISEASE RECURRENCE FOR THREE YEARS CD30 RESULTS NOT PROVIDED THEREFORE THIS REPORTED CASE OF ALCL IS CONSIDERED TO BE A SUSPECTED CASE AND IS CAPTURED AS LYMPHOMA MANUFACTURER OF THE DEVICE IS UNKNOWN|UNK SALINE IMPLANT|UNK SALINE IMPLANT|06/09/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5708519|46870797|N|1||MEDWATCH SENT TO THE FDA ON 06092016 FULL CITATION OF ARTICLE LETTER H ROP B EDISON M N ET AL MARCH 26 2016 BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA A CASE REPORT AND LITERATURE REVIEW  CUREUS 83 E546 DOI 107759CUREUS546 A REQUEST FOR FURTHER INFORMATION REGARDING EVENT DATES PRODUCT INFORMATION PRODUCT RETURN AND PATIENT DETAILS HAVE BEEN MADE ALLERGAN HAS RECEIVED NO RESPONSE FROM THE CORRESPONDING AUTHOR ADDITIONAL ATTEMPTS WILL BE MADE B4 THE EVENTS OF SEROMA FIRMNESS AND ALCL ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT THE REPORTER OF THE EVENT WAS ASKED TO RETURN THE PRODUCT FOR ANALYSIS ALLERGAN HAS NOT RECEIVED THE PRODUCT AT THIS TIME THEREFORE NO ANALYSIS OR TESTING HAS BEEN DONE IF THE DEVICE IN QUESTION WAS MANUFACTURED BY ALLERGAN THE FOLLOWING DEVICE LABELING WOULD APPLY PUBLISHED STUDIES INDICATE THAT BREAST CANCER IS NO MORE COMMON IN WOMEN WITH IMPLANTS THAN THOSE WITHOUT IMPLANTS A LARGE LONG-TERM FOLLOW-UP FOUND NO SIGNIFICANT INCREASES IN THE RISK RATES FOR A WIDE VARIETY OF CANCERS INCLUDING STOMACH CANCER LEUKEMIA AND LYMPHOMA BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK SALINE IMPLANT|UNK SALINE IMPLANT|06/09/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5788476|49361321|N|1||THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT IMPLANT DATE AND DEVICE RETURN STATUS ARE NOT KNOWN AT THIS TIME FOLLOW-UP WILL BE CONDUCTED DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-MX125-370|07/12/2016|||DA|N|R||0HP|FTR|1.0|07/25/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2149083|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5620649|49979256|D|1||EXPLANTING PHYSICIAN REPORTED THAT THE PATIENT WAS TREATED FOR A LATE SEROMA AND ANAPLASTIC LARGE CELL LYMPHOMA ALCL ON THE CONTRALATERAL SIDE FINE NEEDLE ASPIRATION BIOPSY ON THE CONTRALATERAL SIDE REVEALED THE FOLLOWING ADDITIONAL DIAGNOSIS CYTOLOGIC FINDINGS COMPATIBLE WITH LYMPH NODE INVOLVEMENT BY LYMPHOPROLIFERATIVE PROCESS B4-B6 PROBABLY HODGKINS LYMPHOMA AS HODGKINS LYMPHOMA IS A SYSTEMIC DISEASE IT IS NOT A SIDE-SPECIFIC EVENT DIAGNOSTIC TESTING REVEALED NON SIDE-SPECIFIC EVENTS OF GOITER AND LUNG PARENCHYMA WITH MODERATE PARASEPTAL AND CENTRILOBULAR EMPHYSEMA IN THE MIDDLE AND UPPER FIELDS AND LAMINAR ATELECTASIS APPROXIMATELY ONE MONTH AFTER THE LEFT SIDE ALCL DIAGNOSIS THE PATIENTS RIGHT SIDE DEVICE WAS REMOVED PHYSICIAN NOTED AFTER SURGERY IS OBSERVED CLINICAL WORSENING OF THE PATIENT RESPIRATORY FAILURE SECONDARY TO LEFT PLEURAL EFFUSION RESULTING IN ADMISSION IN THE ICU AND THORACIC DRAINAGE THROUGH RECURRENT CHEST TUBE DRAINAGE WAS REQUIRED ON 3 OCCASIONS AFTER THE PATIENTS FIRST STAY IN THE ICU THE PATIENT GOES TO THE FIRST FLOOR AND RECEIVES THE FIRST CYCLE OF CHEMOTHERAPY SHOWING GRADE IV NEUTROPENIA AND DIARRHOEA AFTER THE SECOND CHEMOTHERAPY THE PATIENT SHOWS MARKED CLINICAL DETERIORATION WITH SUSPICIOUS OF TUMOUR LYSIS SYNDROME METABOLIC ACIDOSIS AND RENAL FAILURE THIS RESULTS IN A SECOND ADMISSION IN THE ICU THE PATIENT DIED APPROXIMATELY FIVE WEEKS AFTER IMPLANT REMOVAL THIS MEDWATCH REPRESENTS THE RIGHT SIDE SEE MFR  9617229-2016-00035 FOR THE LEFT SIDE|STYLE 410 SILICONE GEL FILLED BREAST IMPLANT|ST-MM125-320|04/29/2016|||DA|N|R||0HP|FTR|1.0|04/15/2010|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||396184|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5620649|44064473|D|1||EXPLANTING PHYSICIAN REPORTED THAT THE PATIENT WAS TREATED FOR A LATE SEROMA AND ANAPLASTIC LARGE CELL LYMPHOMA ALCL ON THE CONTRALATERAL SIDE FINE NEEDLE ASPIRATION BIOPSY ON THE CONTRALATERAL SIDE REVEALED THE FOLLOWING ADDITIONAL DIAGNOSIS CYTOLOGIC FINDINGS COMPATIBLE WITH LYMPH NODE INVOLVEMENT BY LYMPHOPROLIFERATIVE PROCESS CD30-POSITIVE PROBABLY HODGKINS LYMPHOMA AS HODGKINS LYMPHOMA IS A SYSTEMIC DISEASE IT IS NOT A SIDE-SPECIFIC EVENT DIAGNOSTIC TESTING REVEALED NON SIDE-SPECIFIC EVENTS OF GOITER AND Â¿LUNG PARENCHYMA WITH MODERATE PARASEPTAL AND CENTRILOLOBULAR EMPHYSEMA IN THE MIDDLE AND UPPER FIELDSÂ¿ AND Â¿LAMINAR ATELECTASISÂ¿ APPROXIMATELY ONE MONTH AFTER THE LEFT SIDE ALCL DIAGNOSIS THE PATIENTS RIGHT SIDE DEVICE WAS REMOVED PHYSICIAN NOTED AFTER SURGERY IS OBSERVED CLINICAL WORSENING OF THE PATIENT RESPIRATORY FAILURE SECONDARY TO LEFT PLEURAL EFFUSION RESULTING IN ADMISSION IN THE ICU AND THORACIC DRAINAGE THROUGH RECURRENT CHEST TUBE DRAINAGE WAS REQUIRED ON 3 OCCASIONS AFTER THE PATIENTS FIRST STAY IN THE ICU THE PATIENT GOES TO THE FIRST FLOOR AND RECEIVES THE FIRST CYCLE OF CHEMOTHERAPY SHOWING GRADE IV NEUTROPENIA AND DIARRHOEA AFTER THE SECOND CHEMOTHERAPY THE PATIENT SHOWS MARKED CLINICAL DETERIORATION WITH SUSPICIOUS OF TUMOUR LYSIS SYNDROME METABOLIC ACIDOSIS AND RENAL FAILURE THIS RESULTS IN A SECOND ADMISSION IN THE ICU THE PATIENT DIED APPROXIMATELY FIVE WEEKS AFTER IMPLANT REMOVAL THIS MEDWATCH REPRESENTS THE RIGHT SIDE SEE MFR  9617229-2016-00035 FOR THE LEFT SIDE|STYLE 410 SILICONE GEL FILLED BREAST IMPLANT|ST-MM125-320|04/29/2016|||DA|N|R||0HP|FTR|1.0|04/15/2010|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||396184|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6176804|62446183|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 PATIENT WHO WAS IMPLANTED WITH A LEFT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED SEROMA TREATMENT REPORTED AS IMPLANT REMOVAL FOLLOW-UP FOUND NO EVIDENCE OF DISEASE THIS MEDWATCH IS FOR THE LEFT SIDE MFR 9617229-2016-00241 REPRESENTS THE RIGHT SIDE DEVICE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176804|62446182|N|1||Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6064624|58710791|N|1||THE EVENTS OF LYMPHOMA AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT AND PRODUCT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL HEMATOMASEROMA|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MX140-520|10/28/2016|||DA|*|*||0HP|FTR|1.0|01/29/2014|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1699897|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6135580|61143723|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT AND PRODUCT HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 15 SILICONE GEL FILLED BREAST IMPLANT|15-700|11/30/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6148888|61547076|D|1||REVIEWED JOURNAL ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN A PATIENT WITH LI-FRAUMENI SYNDROMEÂ¿ Â¿WE REPORT A UNIQUE CASE OF BIA-ALCL ARISING IN A PATIENT WITH LIÂ¿FRAUMENI SYNDROME AND GERMLINE MUTATIONS IN TP53 THE CASE IS NOTABLE FOR THE SHORT INTERVAL OF ONLY 3 YEARS BETWEEN THE PLACEMENT OF THE IMPLANTS AND THE DEVELOPMENT OF ALCL AFTER CAPSULECTOMY AND IMPLANT REMOVAL THE PATIENT HAD NO RECURRENCE OF BIA-ALCL WITH CLINICAL FOLLOW-UP OF 7 YEARSÂ¿ ARTICLE FURTHER STATES Â¿THE PATIENT NOTED ASYMMETRIC SWELLING OF THE RIGHT BREAST A FINE NEEDLE ASPIRATION OF A BREAST SEROMA WAS PERFORMED LEADING TO THE DIAGNOSIS OF BIAALCLÂ¿ SAMPLE WAS POSITIVE FOR CD30 AND NEGATIVE FOR ALK ARTICLE ALSO STATES DURING SUBSEQUENT YEARS THE PATIENT WAS DIAGNOSED WITH ADRENOCORTICAL CARCINOMASUBSEQUENTLY DEVELOPED METASTATIC ADRENOCORTICAL CARCINOMA TO LIVER AND LUNG MANUFACTURER OF THE DEVICE IS UNKNOWN THIS MEDWATCH IS FOR THE RIGHT SIDE DEVICE SEE MANUFACTURER REPORT  9617229-2016-00207 FOR LEFT SIDE|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/06/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6148888|61547075|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN A PATIENT WITH LI-FRAUMENI SYNDROMEÂ¿ BY YI-SHAN LEE ARMANDO FILIE DIANE ARTHUR ANTONIO T FOJO AND ELAINE S JAFFE PUBLISHED IN HISTOPATHOLOGY 67 923Â¿935 IN 2015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LATE SEROMA CANCER AND LYMPHOMA-ALCL ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/06/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5820703|50386638|N|1||MEDWATCH SENT TO FDA ON 07252016 B4 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FOLLOW UP IS BEING PERFORMED TO OBTAIN DEVICE MANUFACTURER SERIAL NUMBER LOT NUMBER IMPLANT EXPLANT DATE IMPLANTINGEXPLANTING PHYSICIAN PATIENT NAME PATIENT DATE OF BIRTH DEVICE RETURN STATUS AND DEVICE RELATIONSHIP OF THE REPORTED EVENTS DEVICE HISTORY RECORD UNAVAILABLE AS DEVICE INFORMATION IS UNKNOWN DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|MX-410520|07/25/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5820703|50386639|D|1||FOLLOWING CASE RECEIVED IN AN ARTICLE TITLED SKIN INVOLVEMENT AS THE FIRST MANIFESTATION OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA ARTICLE STATES WE PRESENT A NEW CASE OF BREAST IMPLANT-ASSOCIATED ALCL WITH CUTANEOUS LESIONS MIMICKING CUTANEOUS METASTASES FROM A POORLY DIFFERENTIATED BREAST ADENOCARCINOMA DETAILS INCLUDE SEVERAL CUTANEOUS NODULES OF 2 MONTHSÂ¿ DURATION ON THE RIGHT BREASTÂ¿RADIOGRAPHIC FOLLOW-UP REVEALED A RIGHT SUPRACLAVICULAR MASS AND MULTIPLE ENLARGED LYMPH NODES PATIENT UNDERWENT A CORE NEEDLE BIOPSY OF THE MASS THAT REVEALED EXTENSIVE NECROSIS PATIENT WAS TREATED WITH CHEMOTHERAPY AND RADIATION THERAPY BUT NO IMPROVEMENTS WERE NOTED A SECOND ROUND OF CHEMOTHERAPY WAS PRESCRIBED BUT THE DISEASE PROGRESSED Â¿WITH PROGRESSIVE HARDENING OF THE RIGHT BREAST AND APPEARANCE OF SEVERAL CUTANEOUS LESIONSTHERE WERE ALSO SEVERAL POORLY CIRCUMSCRIBED ERYTHEMATOUS INDURATED PAPULESÂ¿THE PATIENT REPORTED MODERATE PAINÂ¿THE CT SCAN SHOWED A LARGE AMOUNT OF PERI-IMPLANT FLUIDÂ¿ TESTED CELLS Â¿WERE CD15 AND CD30 POSITIVE AND ALK-1 NEGATIVEÂ¿ PATIENT WAS DIAGNOSED WITH ALCL ASSOCIATED WITH A BREAST IMPLANT CAPSULE Â¿PATIENT WAS STARTED ON CHOP THERAPY AND THE BREAST IMPLANT WAS REMOVED PATIENT PRESENTED FEBRILE NEUTROPENIA DURING THE TREATMENT AND FINALLY PATIENT DIED FROM SEPTIC SHOCKÂ¿ AUTOPSY WAS REQUESTED BUT THE FAMILY REFUSED MANUFACTURER OF THE DEVICE IS UNKNOWN THIS MEDWATCH REPRESENTS THE RIGHT SIDE SEE MFR  9617229-2016-00093 FOR THE LEFT SIDE|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|MX-410520|07/25/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5820703|55107988|D|1||FOLLOWING CASE RECEIVED IN AN ARTICLE TITLED SKIN INVOLVEMENT AS THE FIRST MANIFESTATION OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA ARTICLE STATES WE PRESENT A NEW CASE OF BREAST IMPLANT-ASSOCIATED ALCL WITH CUTANEOUS LESIONS MIMICKING CUTANEOUS METASTASES FROM A POORLY DIFFERENTIATED BREAST ADENOCARCINOMA DETAILS INCLUDE SEVERAL CUTANEOUS NODULES OF 2 MONTHSÂ¿ DURATION ON THE RIGHT BREASTÂ¿RADIOGRAPHIC FOLLOW-UP REVEALED A RIGHT SUPRACLAVICULAR MASS AND MULTIPLE ENLARGED LYMPH NODES PATIENT UNDERWENT A CORE NEEDLE BIOPSY OF THE MASS THAT REVEALED EXTENSIVE NECROSIS PATIENT WAS TREATED WITH CHEMOTHERAPY AND RADIATION THERAPY BUT NO IMPROVEMENTS WERE NOTED A SECOND ROUND OF CHEMOTHERAPY WAS PRESCRIBED BUT THE DISEASE PROGRESSED Â¿WITH PROGRESSIVE HARDENING OF THE RIGHT BREAST AND APPEARANCE OF SEVERAL CUTANEOUS LESIONSTHERE WERE ALSO SEVERAL POORLY CIRCUMSCRIBED ERYTHEMATOUS INDURATED PAPULESÂ¿THE PATIENT REPORTED MODERATE PAINÂ¿THE CT SCAN SHOWED A LARGE AMOUNT OF PERI-IMPLANT FLUIDÂ¿  TESTED CELLS Â¿WERE CD15 AND CD30 POSITIVE AND ALK-1 NEGATIVEÂ¿ PATIENT WAS DIAGNOSED WITH ALCL ASSOCIATED WITH A BREAST IMPLANT CAPSULE Â¿PATIENT WAS STARTED ON CHOP THERAPY AND THE BREAST IMPLANT WAS REMOVED PATIENT PRESENTED FEBRILE NEUTROPENIA DURING THE TREATMENT AND FINALLY PATIENT DIED FROM SEPTIC SHOCKÂ¿ AUTOPSY WAS REQUESTED BUT THE FAMILY REFUSED MANUFACTURER OF THE DEVICE IS UNKNOWN THIS MEDWATCH REPRESENTS THE RIGHT SIDE SEE MFR  9617229-2016-00093 FOR THE LEFT SIDE|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|MX-410520|07/25/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6148913|61548012|D|1||REVIEWED JOURNAL ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN A PATIENT WITH LI-FRAUMENI SYNDROMEÂ¿ ARTICLE STATES DURING SUBSEQUENT YEARS THE PATIENT WAS DIAGNOSED WITH ADRENOCORTICAL CARCINOMASUBSEQUENTLY DEVELOPED METASTATIC ADRENOCORTICAL CARCINOMA TO LIVER AND LUNG THIS MEDWATCH IS FOR THE LEFT SIDE DEVICE SEE MANUFACTURER REPORT  9617229-2016-00190 FOR RIGHT SIDE|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/06/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6148913|61548011|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN A PATIENT WITH LI-FRAUMENI SYNDROMEÂ¿ BY YI-SHAN LEE ARMANDO FILIE DIANE ARTHUR ANTONIO T FOJO AND ELAINE S JAFFE PUBLISHED IN HISTOPATHOLOGY 67 923Â¿935 IN 2015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LATE CANCER IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/06/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6176705|62451143|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 PATIENT WHO WAS IMPLANTED WITH A LEFT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED SEROMA AND DISRUPTED IMPLANT TREATMENT REPORTED AS IMPLANT REMOVAL AND RADIOTHERAPY B6 FOLLOW-UP FOUND NO EVIDENCE OF DISEASE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176730|62445769|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176730|62445770|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 YEAR-OLD PATIENT WHO WAS IMPLANTED WITH A RIGHT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED SEROMA TREATMENT REPORTED AS IMPLANT REMOVAL FOLLOW-UP FOUND NO EVIDENCE OF DISEASE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176886|62453117|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 OLD PATIENT WHO WAS IMPLANTED WITH A RIGHT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED MASS SEROMA AND DISRUPTED IMPLANT TREATMENT REPORTED AS IMPLANT REMOVAL AND CYCLOPHOSPHAMIDE ADRIAMYCIN VINCRISTINE AND PREDNISONE 6 CURES CHOP OR CHOP-LIKE FOLLOW-UP FOUND NO EVIDENCE OF DISEASE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176886|62453116|N|1||Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA SEROMA AND MASS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6146425|61492492|N|1||THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL HEMATOMASEROMA ARTICLE CITATION BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA A CASE REPORT AND LITERATURE REVIEW LETTER HALEY ROP BAIYWO EDISON MICHELE N TURNER PATRICIA CUREUS 2016 VOL 8 NO 3 PP E546 ELECTRONIC PUBLICATION DATE 26 MAR 2016 JOURNAL CODE 101596737 B4|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/05/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6146425|61492493|D|1||JOURNAL ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA A CASE REPORT AND LITERATURE REVIEWÂ¿ ABSTRACT STATES Â¿PATIENT PRESENTED WITH SEVERAL WEEKS OF PAIN AND FIRMNESS IN PATIENT RIGHT BREAST MRI AND ULTRASOUND DEMONSTRATED A PERI-IMPLANT FLUID COLLECTION ULTRASOUND-GUIDED ASPIRATION REVEALED ANAPLASTIC LARGE CELL LYMPHOMA THE PATIENT WAS TREATED WITH IMPLANT REMOVAL ALONE AND HAS NOW BEEN IN REMISSION FOR 3 YEARSÂ¿ PATHOLOGICAL MARKERS TO CONFIRM ALCL HAVE NOT YET BEEN RECEIVED THEREFORE THE EVENT WILL BE REPORTED AS LYMPHOMA|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/05/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6176855|62446706|N|1||Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK SALINE IMPLANT|UNK SALINE IMPLANT|12/15/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6176855|62446707|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 PATIENT WHO WAS IMPLANTED WITH A LEFT SIDE TEXTURED SALINE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED SEROMA TREATMENT REPORTED AS IMPLANT REMOVAL FOLLOW-UP FOUND NO EVIDENCE OF DISEASE|UNK SALINE IMPLANT|UNK SALINE IMPLANT|12/15/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6176798|62453768|N|1||Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176798|62453769|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 PATIENT WHO WAS IMPLANTED WITH A RIGHT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED SEROMA TREATMENT REPORTED AS IMPLANT REMOVAL FOLLOW-UP FOUND NO EVIDENCE OF DISEASE THIS MEDWATCH IS FOR THE RIGHT SIDE MFR 9617229-2016-00240 REPRESENTS THE LEFT SIDE DEVICE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6153200|61697778|N|1||THE EVENT OF LYMPHOMA ALCL IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL Â¿COMPLETE SURGICAL EXCISION IS ESSENTIAL FOR THE MANAGEMENT OF PATIENTS WITH BREAST IMPLANTÂ¿ASSOCIATED ANAPLASTIC LARGE-CELL LYMPHOMAÂ¿ MARK W CLEMENS L JEFFREY MEDEIROS CHARLES E BUTLER KELLY K HUNT MICHELLE A FANALE STEVEN HORWITZ DENNIS D WEISENBURGER JUN LIU ELIZABETH A MORGAN RASHMI KANAGAL-SHAMANNA VINITA PARKASH JING NING ALIYAH R SOHANI JUDITH A FERRY NEHA MEHTA-SHAH AHMED DOGAN HUI LIU NORA THORMANN ARIANNA DI NAPOLI STEPHEN LADE JORGE PICCOLINI RUBEN REYES TRAVIS WILLIAMS COLLEEN M MCCARTHY SUMMER E HANSON LORETTA J NASTOUPIL RAKESH GAUR YASUHIRO OKI KEN H YOUNG AND ROBERTO N MIRANDA JOURNAL OF CLINICAL ONCOLOGY VOLUME 34 NUMBER 2 JANUARY 10 2016|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/07/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6011951|56916914|D|1||THROUGH ALLERGANS LITERATURE REVIEW OF RECENT JOURNAL ARTICLES WE RECEIVED THE FOLLOWING ARTICLE FROM MEDICAL SAFETY BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN B6 HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGY TABLE 4 PRESENTATION OF BIA-ALCL N=46 IN THE ARTICLE REPORTS THE FOLLOWING 2 CASES OF SEROMA AND CAPSULAR CONTRACTURE CONTRALATERAL THIS RECORD HAS BEEN CREATED THE CAPTURE THE 2 EVENTS OF CAPSULAR CONTRACTURE CONTRALATERAL EVENT OF SEROMA HAS BEEN CAPTURED IN MDR  9617229-2016-00142 THE ARTICLE DOES NOT PROVIDE IMPLANTING EXPLANTING PHYSICIAN INFORMATION DEVICE SERIAL OR LOT INFORMATION OR SIDES OF ALCL DIAGNOSIS MANUFACTURER COULD NOT BE SPECIFIED AND ARTICLE STATES BIOCELL ALLERGANINAMEDMCGHAN ACCOUNTED FOR 571 OF IMPLANTS IN THIS SERIES ARTICLE STATES ALL PATIENTS UNDERWENT TOTAL CAPSULECTOMY AND REMOVAL OF IMPLANTS BOTH ON DISEASED AND NON-DISEASED SIDE ALL TUMORS WERE CD30 POSITIVE AND ALK NEGATIVE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6011951|56916913|N|1||MEDWATCH SENT TO FDA ON 10072016 ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN B6 Â¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ A LOCH-WILKINSON KJ BEATH RJW KNIGHT WLF WESSELS M MAGNUSSON T PAPADOPOULOS T CONNELL J LOFTS M LOCKE I HOPPER R COOTER K VICKERY PA JOSHI HM PRINCE  AK DEVA THE EVENT OF CAPSULAR CONTRACTURE IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES PATIENTS SHOULD BE ADVISED THAT CAPSULAR CONTRACTURE MAY BE MORE COMMON FOLLOWING INFECTION HEMATOMA AND SEROMA AND THE CHANCE OF IT HAPPENING MAY INCREASE OVER TIME CAPSULAR CONTRACTURE OCCURS MORE COMMONLY IN REVISION PATIENTS THAN IN PRIMARY AUGMENTATION OR RECONSTRUCTION PATIENTS CAPSULAR CONTRACTURE IS ALSO A RISK FACTOR FOR IMPLANT RUPTURE AND IT IS ONE OF THE MOST COMMON REASONS FOR REOPERATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5864951|51736729|N|1||MEDWATCH SENT TO FDA ON 08102016 B4 CONCOMITANT MEDICAL PRODUCTS FOLIC ACID D3 VITAMIN CALCIUM CARBONATE OMEGA 3 PAST MEDICAL HISTORY OF HYDROXYCHLOROQUINE THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL PATIENTS SHOULD BE ADVISED THAT CAPSULAR CONTRACTURE MAY BE MORE COMMON FOLLOWING INFECTION HEMATOMA AND SEROMA AND THE CHANCE OF IT HAPPENING MAY INCREASE OVER TIME POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL CHANGES BREAST SENSATION HEMATOMASEROMA AND LYMPHADENOPATHY|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|N-27-120181|08/10/2016|||DA|N|R||0HP|FTR|1.0|02/20/2017|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2243522|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5864951|51736730|D|1||ENGLISH PRODUCT FIELD NOTE PFN RECEIVED VIA EMAIL REPORTS LEFT SIDE THE PATIENT HAS ALLERGAN PROSTHESIS AND WAS DIAGNOSED WITH ALCL ANAPLASTIC LARGE CELL LYMPHOMA ADENOPATHY AXILLARY ENCAPSULATION WITH INFLAMMATORY PROCESS AND SUPERIOR INTERIOR INTRACAPSULAR LIQUID PATHOLOGIC DIAGNOSTIC OF NON-HODGKIN LYMPHOMA ALK NEGATIVE ANAPLASTIC LYMPHOMA ALK NEGATIVE CD 30+ ASSOCIATED TO BREAST PROSTHESIS CLINICAL STATUS II E  PATIENT HAS A MEDICAL HISTORY OF PRIMARY SJOGREN SYNDROME ON B6 2015 MRI FOUND BIGGER VOLUME OF THE LEFT BREAST AND EDEMA ON SUBCUTANEOUS LAYER PERIPROSTHETIC LIQUID WAS ALSO NOTED PATIENT PRESENTED PAIN NOT RELATED TO THE DEVICE ONE WEEK AFTER THE MRI ON B6 2015 IT WAS NOTED CAPSULAR CONTRACTURE ON B6 2015 A MRI DETECTED A MASS ON THE SUPERIOR AREA OF THE LEFT BREAST BIOPSY OF THE INJURY CAME NEGATIVE ON B6 2016 PATIENT PALPATED LEFT AXILLARY ADENOPATHY ON B6 2016 DURING CONSULTATION IT WAS NOTED NO SIGNALS OF RUPTURE SMALL MASS ON SUPERIOR LEFT PROSTHESIS ON CONSULTATION WITH HEALTHCARE PROFESSIONAL BIOPSY WAS PERFORMED WHICH CONFIRMED LYMPHOMA OF ANAPLASTIC T CELLS ALK - PERIPROSTHETIC LIQUID WAS ALSO NOTED EXPLANT DATE PROVIDED AS B6 2016 IMPLANT WAS NOT REPLACED|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|N-27-120181|08/10/2016|||DA|N|R||0HP|FTR|1.0|02/20/2017|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2243522|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5864951|63818637|D|1||ENGLISH PRODUCT FIELD NOTE PFN RECEIVED VIA EMAIL REPORTS Â¿LEFT SIDE THE PATIENT HAS ALLERGAN PROSTHESIS AND WAS DIAGNOSED WITH ALCL ANAPLASTIC LARGE CELL LYMPHOMA ADENOPATHY AXILLARY ENCAPSULATION WITH INFLAMMATORY PROCESS AND SUPERIOR INTERIOR INTRACAPSULAR LIQUID PATHOLOGIC DIAGNOSTIC OF NON-HODGKIN LYMPHOMA ALK NEGATIVE ANAPLASTIC LYMPHOMA ALK NEGATIVE CD 30+ ASSOCIATED TO BREAST PROSTHESIS CLINICAL STATUS II EÂ¿ PATIENT HAS A MEDICAL HISTORY OF PRIMARY SJOGREN SYNDROME ON B6 2015 MRI FOUND BIGGER VOLUME OF THE LEFT BREAST AND EDEMA ON SUBCUTANEOUS LAYER PERIPROSTHETIC LIQUID WAS ALSO NOTED PATIENT PRESENTED PAIN NOT RELATED TO THE DEVICE ONE WEEK AFTER THE MRI ON B6 2015 IT WAS NOTED CAPSULAR CONTRACTURE ON B6 2015 A MRI DETECTED A MASS ON THE SUPERIOR AREA OF THE LEFT BREAST BIOPSY OF THE INJURY CAME NEGATIVE ON B6 2016 PATIENT PALPATED LEFT AXILLARY ADENOPATHY ON B6 2016 DURING CONSULTATION IT WAS NOTED NO SIGNALS OF RUPTURE SMALL MASS ON SUPERIOR LEFT PROSTHESIS ON CONSULTATION WITH HEALTHCARE PROFESSIONAL BIOPSY WAS PERFORMED WHICH CONFIRMED LYMPHOMA OF ANAPLASTIC T CELLS ALK - PERIPROSTHETIC LIQUID WAS ALSO NOTED EXPLANT DATE PROVIDED AS B6 2016 IMPLANT WAS NOT REPLACED|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|N-27-120181|08/10/2016|||DA|N|R||0HP|FTR|1.0|02/20/2017|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2243522|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5864951|60014363|D|1||B4 PRODUCT FIELD NOTE PFN RECEIVED VIA EMAIL REPORTS LEFT SIDE THE PATIENT HAS ALLERGAN PROSTHESIS AND WAS DIAGNOSED WITH ALCL ANAPLASTIC LARGE CELL LYMPHOMA ADENOPATHY AXILLARY ENCAPSULATION WITH INFLAMMATORY PROCESS AND SUPERIOR INTERIOR INTRACAPSULAR LIQUID PATHOLOGIC DIAGNOSTIC OF NON-HODGKIN LYMPHOMA ALK NEGATIVE ANAPLASTIC LYMPHOMA ALK NEGATIVE CD 30+ ASSOCIATED TO BREAST PROSTHESIS CLINICAL STATUS II E  PATIENT HAS A MEDICAL HISTORY OF PRIMARY SJOGREN SYNDROME ON B6 2015 MRI FOUND BIGGER VOLUME OF THE LEFT BREAST AND EDEMA ON SUBCUTANEOUS LAYER PERIPROSTHESTIC LIQUID WAS ALSO NOTED PATIENT PRESENTED PAIN NOT RELATED TO THE DEVICE ONE WEEK AFTER THE MRI ON B6 2015 IT WAS NOTED CAPSULAR CONTRACTURE ON B6 2015 A MRI DETECTED A MASS ON THE SUPERIOR AREA OF THE LEFT BREAST BIOPSY OF THE INJURY CAME NEGATIVE ON B6 2016 PATIENT PALPATED LEFT AXILLARY ADENOPATHY ON B6 2016 DURING CONSULTATION IT WAS NOTED NO SIGNALS OF RUPTURE SMALL MASS ON SUPERIOR LEFT PROSTHESIS ON CONSULTATION WITH HEALTHCARE PROFESSIONAL BIOPSY WAS PERFORMED WHICH CONFIRMED LYMPHOMA OF ANAPLASTIC T CELLS ALK - PERIPROSTHESTIC LIQUID WAS ALSO NOTED EXPLANT DATE PROVIDED AS B6 2016 IMPLANT WAS NOT REPLACED|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|N-27-120181|08/10/2016|||DA|N|R||0HP|FTR|1.0|02/20/2017|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2243522|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6037704|57781486|N|1||THE EVENTS OF SEROMA AND LYMPHOMA ALCL ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE HISTORY REVIEW DHR SUMMARY REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS DHR FOR WORK ORDER B4 INDICATES THAT THERE WAS A REPROCESS ON THE PRIMARY PACKAGING OPERATION IN WHICH THE REPORTED DEVICE WAS REPROCESSED HOWEVER REVIEW OF THE REPROCESS OF WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES THAT MAY BE ASSOCIATED WITH THE REPORTED DEVICE EVENT THE DHR ASSEMBLY REPORT FROM SAP WAS VERIFIED AND THERE WAS NOT ANY SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS IN ADDITION DHR FOR SHELL RUN NUMBER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING SHELL FABRICATION PROCESS ALL SHELLS WERE REVIEWED AS PART OF THE SHELL FABRICATION OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT FABRICATION MET THE REQUIRED SPECIFICATIONS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL HEMATOMASEROMA|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|N-TSX525|10/18/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2433989|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5343961|35063341|N|1||B4 DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 153 SILICONE GEL FILLED BREAST IMPLANT|153-630|01/05/2016||03/17/2016|DA|R|Y||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||339918|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5488680|46690345|D|1||HEALTH PROFESSIONAL ADDITIONALLY PROVIDED CT CHEST TO PELVIS THAT REPORT Â¿CLINICAL NOTES SHORTNESS OF BREATH RECENT DIAGNOSIS OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ FINDINGS NOTES Â¿LUNGS ARE SATISFACTORY MEDIASTINAL STRUCTURE ARE NORMAL NO LYMPHADENOPATHYÂ¿|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|27-120301|03/09/2016|||DA|N|R||0HP|FTR|1.0|02/15/2009|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||276452|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5488680|39947738|D|1||PATIENT REPORTED DIAGNOSED WITH BREAST IMPLANT ASSOCIATED ALCL PATIENT SOUGHT CONSULT AFTER EXPERIENCING A LOT OF SWELLING THE IMPLANT WAS REMOVED AND PATHOLOGY RESULTS CONFIRMED ALCL FURTHER FOLLOW-UP PROVIDED INDICATED IT WAS THE RIGHT BREAST CYTOPATHOLOGY REPORT STATES FINE NEEDLE ASPIRATION RIGHT BREAST Â¿ 5 ML OF CLOUDY ORANGE FLUID Â¿ BREAST ASPIRATE FROM IMPLANT CAPSULE FOLLOWED BY Â¿POSITIVE ANTIBODIES CD30 STRONGÂ¿ AND Â¿NEGATIVE ANTIBODIES ALK1 CONCLUSIONS REPORTED AS Â¿THIS IMMUNOPHENOTYPE IS TYPICAL OF THAT SEEN IN BREAST-IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ ADDITIONALLY PHYSICIAN NOTES RECEIVED DOCUMENTED A PRIOR 4 X 7 MM SIMPLE CYST AT 1100 OÂ¿CLOCK IN THE RIGHT BREAST HISTOPATHOLOGY REPORT NOTED CAPSULE HAD FOREIGN BODY GRANULOMATOUS AND LYMPHOID REACTION|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|27-120301|03/09/2016|||DA|N|R||0HP|FTR|1.0|02/15/2009|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||276452|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5488680|41343420|D|1||PATIENT REPORTED DIAGNOSED WITH BREAST IMPLANT ASSOCIATED ALCL PATIENT SOUGHT CONSULT AFTER EXPERIENCING A LOT OF SWELLING THE IMPLANT WAS REMOVED AND PATHOLOGY RESULTS CONFIRMED ALCL FURTHER FOLLOW-UP PROVIDED INDICATED IT WAS THE RIGHT BREAST CYTOPATHOLOGY REPORT STATES FINE NEEDLE ASPIRATION RIGHT BREAST - 5 ML OF CLOUDY ORANGE FLUID - BREAST ASPIRATE FROM IMPLANT CAPSULE FOLLOWED BY - POSITIVE ANTIBODIES CD30 STRONG- AND - NEGATIVE ANTIBODIES ALK1 CONCLUSIONS REPORTED AS THIS IMMUNOPHENOTYPE IS TYPICAL OF THAT SEEN IN BREAST-IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA ADDITIONALLY PHYSICIAN NOTES RECEIVED DOCUMENTED A PRIOR 4 X 7 MM SIMPLE CYST AT 1100 OCLOCK IN THE RIGHT BREAST HISTOPATHOLOGY REPORT NOTED CAPSULE HAD FOREIGN BODY GRANULOMATOUS AND LYMPHOID REACTION|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|27-120301|03/09/2016|||DA|N|R||0HP|FTR|1.0|02/15/2009|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||276452|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5844861|51109569|N|1||THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FOLLOW UP HAS BEEN CONDUCTED TO DETERMINE THE FOLLOWING INFORMATION SERIAL NUMBER LOT NUMBER IMPLANT DATE PATIENT NAME PATIENT DATE OF BIRTH PATHOLOGICAL TESTING RESULTS DETERMINATION IF SURGERY WILL BE SCHEDULED AND DEVICE RELATIONSHIP OF THE REPORTED EVENTS DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|08/03/2016|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5607727|43625364|D|1||PHYSICIAN REPORTS PATIENT WITH BIA-ALCL BREAST IMPLANT ASSOCIATED - ANAPLASTIC LARGE CELL LYMPHOMA DEVICE WAS EXPLANTED AS NO PATHOLOGICAL MARKERS HAVE BEEN PROVIDED THIS CASE IS CAPTURED AS LYMPHOMA SIDE IS UNKNOWN|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|MF-410420|04/26/2016||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6158856|62125553|D|1||ALLERGAN PRODUCT SURVEILLANCE RECEIVED LITERATURE ARTICLE Â¿COMPREHENSIVE IMMUNOPHENOTYPIC ANALYSIS OF 64 CASES OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA SHOWS AN ACTIVATED CYTOTOXIC WITH A SILENT T-CELL RECEPTOR PATTERNÂ¿ ON 13NOV2016 ARTICLE REPORTS Â¿64 CASESÂ¿ ARTICLE CONTINUES TO STATE Â¿WE REVIEWED THE WORLD LITERATURE FOR CASES OF BI-ALCL AND ACCRUED CASES IN WHICH IMMUNOPHENOTYPIC DATA DERIVED USING IMMUNOHISTOCHEMICAL OR FLOW CYTOMETRY METHODS WERE USED AND AT LEAST 5 OF THE FOLLOWING 13 MARKERS WERE REPORTED CD3 CD4 CD8 CD30 CD43 CD45 EMATIA-1 GRANZYME-B ALK-1 TCR-Â¿Â¿ AND TCR-GÂ¿ AND EBER IN SITU HYBRIDIZATION WHEN LESS THAN 5 MARKERS WERE REPORTED WE CONTACTED CORRESPONDING AUTHORS FOR AVAILABLE MATERIAL DID ADDITIONAL STUDIES AND INCLUDED THESE DATAÂ¿ Â¿CD30 WAS POSITIVE IN ALL N=64 CASES WHEREAS ALK AND EBER WERE NEGATIVE IN ALL TESTED CASES N=56 AND N=25 RESPECTIVELY CD3 WAS POSITIVE IN 15 OF 62 24 CASES CD4 4361 70 CD8 657 11 CD43 37 46 80 CD45 2949 59 EMA 2542 60 TIA-1 2846 61 GRANZYME-B 28 47 60 TCR Â¿Â¿ 5 24 21 AND TCR GÂ¿ IN 1 OF 23 4 THUS TCR WAS SILENT IN 1824 75 CASESÂ¿ THIS RECORD HAS BEEN CREATED TO CAPTURE THE 8 CASES OF LYMPHOMA IN WHICH THERE WAS NO TESTING FOR ALK|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/09/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6158856|62125552|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED THE AUTHOR HAS RESPONDED AND REFUSED TO PROVIDE ANY FURTHER INFORMATION DEVICE LABELING ADDRESSES PUBLISHED STUDIES INDICATE THAT BREAST CANCER IS NO MORE COMMON IN WOMEN WITH IMPLANTS THAN THOSE WITHOUT IMPLANTS A LARGE LONG-TERM FOLLOW-UP FOUND NO SIGNIFICANT INCREASES IN THE RISK RATES FOR A WIDE VARIETY OF CANCERS INCLUDING STOMACH CANCER LEUKEMIA AND LYMPHOMA Â¿COMPREHENSIVE IMMUNOPHENOTYPIC ANALYSIS OF 64 CASES OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA SHOWS AN ACTIVATED CYTOTOXIC WITH A SILENT T-CELL RECEPTOR PATTERNÂ¿ ANA CLAUDIA FROTA LOPES L JEFFREY MEDEIROS MARK W CLEMENS MING CHAI HUI LIU ARIANNA DI NAPOLI STEPHEN LADE MITUAL AMIN KEN H YOUNG ROBERTO MIRANDA|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/09/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5672723|45694208|D|1||PHYSICIAN REPORTS PATIENT HAS BEEN DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA ALCL AT THE RIGHT BREAST IT CONCERNS A DIAGNOSE OF ALCL CD30+ AND ALK- FOLLOWING THE IDENTIFICATION OF PERIPROSTHETIC SEROMA WITH A BREAST IMPLANT THAT HAD BEEN IMPLANTED 10 YEAR AGO CAPSULECTOMY PERFORMED AND DEVICE EXPLANTED|STYLE 410 SILICONE GEL FILLED BREAST IMPLANT|ST-MM125-320|05/23/2016||||N|R||0HP|FTR|1.0|09/19/2010|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1139476|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5994929|56333880|D|1||THIS COMPLAINT IS FROM A LITERATURE SOURCE IT WAS REPORTED THAT A B6 YEAR-OLD WOMAN WITH MASTECTOMY AND AXILLARY DISSECTION 2004 FOR LYMPH NODE-FREE LOBULAR CARCINOMA OF HER RIGHT BREAST WAS IN COMPLETE REMISSION FOR 11 YEARS SHE UNDERWENT RECONSTRUCTIVE SURGERY WITH BILATERAL ALLERGAN IMPLANTS IN 2005 REPLACED BY MENTOR IMPLANTS IN 2008 A MODERATELY-LARGE LEFT PERI-PROSTHETIC EFFUSION SEEN BY MRI IN 2012 CONTAINED NON-ATYPICAL LYMPHOCYTES AND MACROPHAGES IN A PROTEINACEOUS BACKGROUND AND WAS CYTOLOGICALLY INTERPRETED AS A SEROMA SHE HAD TWO OTHER SEROMAS OF HER RIGHT BREAST 2013 THAT SPONTANEOUSLY REGRESSED WITHOUT EVACUATION ON B6 2015 SHE COMPLAINED OF PAIN AND SWELLING OF HER RIGHT BREAST A LARGE PERI-IMPLANT EFFUSION SUSPICIOUS OF AN INFLAMMATORY PROCESS BY ULTRASOUND WAS COMPLETELY DRAINED BY FNA RECOVERING 85 CC OF CLOUDY YELLOW FLUID BILATERAL IMPLANTS WERE REMOVED SHE IS CURRENTLY UNDERGOING A WAIT-AND-SEE STRATEGY AND IS ALIVE WITHOUT DISEASE 8 MONTHS AFTER HER LYMPHOMA DIAGNOSIS TITLE THE CASE AGAINST BIOFILM AS THE PRIMARY INITIATOR OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA THE PURPOSE OF THIS STUDY WAS TO PRESENT THE FIRST PUBLISHED REPORT OF A BILATERAL ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSED BY CYTOLOGY SUSPECT DEVICE IS MENTOR IMPLANT HOWEVER CATALOG AND LOT NUMBER ARE UNKNOWN CONTACT B6 AGE STUDY AVERAGE B6 DOS UNK SURGEON UNK DEVICE INFO UNK|nan|UNKNOWN|10/03/2016||||N|R||0HP|FTR|1.0||BREAST IMPLANT|||3041 SKYWAY CIRCLE NORTH||IRVING|US|MENTOR WW LLC|75038|TX|75038||UNK||True
6153064|61697996|N|1||ARTICLE CITATION BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA CASE REPORT OF AN UNDIAGNOSED FORM MANAGEMENT AND RECONSTRUCTION ALCL BY S ALHAMAD S GUERID EH EL FAKIR P BIRON C TOURASSE E DELAY PUBLISHED 062016 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/07/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6153064|61697997|D|1||JOURNAL ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA CASE REPORT OF AN UNDIAGNOSED FORM MANAGEMENT AND RECONSTRUCTION ALCLÂ¿ ABSTRACT STATES Â¿THIS ARTICLE REPORTS THE CASE OF A PATIENT WITH A PROGRESSIVE SWELLING OF THE RIGHT BREAST AFTER AESTHETIC BREAST IMPLANTS DIAGNOSTIC WAS DELAYED BECAUSE FIRST SURGEON WAS NOT FAMILIAR WITH THE DISEASE WE PERFORMED AN IMPLANT REMOVAL AND A COMPLETE CAPSULECTOMY PATHOLOGIC REPORT CONFIRMS THE DIAGNOSTIC AFTER ONE YEAR AND NORMAL ULTRASOUND EVALUATION WE RECONSTRUCTED THE BREAST WITH LIPOMODELING AND MASTOPEXYÂ¿ MANUFACTURER OF THE DEVICE IS NOT SPECIFIED|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/07/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6153076|61697270|N|1||THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL INFECTION HEMATOMASEROMA BACTERIAL BIOFILM INFECTION DETECTED IN BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE-CELL LYMPHOMAÂ¿ 137 6 1659-1669 BY HONGHUA HU PHD KHALID JOHANI AHMAD ALMATROUDI KAREN VICKERY PHD BVSC BRUCE VAN NATTA MD MARSHALL E KADIN MD GARRY BRODY MD MARK CLEMENS MD CHAN YOON CHEAH MD STEPHEN LADE MD PREETI AVINASH JOSHI MDPHD H MILES PRINCE MDPHD ANAND K DEVA BSCMED MBBS MS PUBLISHED JUNE 2016|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/07/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5793065|49492129|N|1||MEDWATCH SENT TO FDA ON 07132016 B4 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE DOES NOT GENERALLY ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT SERIAL NUMBER IS NOT AVAILABLE AT THIS TIME IT IS NOT KNOWN IF THE DEVICE WILL BE RETURNED REQUEST FOR INFORMATION HAS BEEN PERFORMED DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL DEVICE HISTORY RECORD REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM ORACLE WAS VERIFIED AND THERE WAS NOT ANY SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS IN ADDITION DHR FOR SHELL RUNS NUMBER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING SHELL FABRICATION PROCESS ALL SHELLS WERE REVIEWED AS PART OF THE SHELL FABRICATION OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT FABRICATION MET THE REQUIRED SPECIFICATIONS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MM110-215|07/13/2016||01/06/2017|DA|R|Y||0HP|FTR|1.0|06/09/2012|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1445246|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6143087|61396767|D|1||ABSTRACT OF LITERATURE ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ REPORTED Â¿19 I-ALCLSÂ¿ CASES ONE OF THE TWO CLINICAL PRESENTATIONS REPORTED WAS Â¿TUMOR MASSÂ¿ 2 PATIENTS EXPERIENCED ALCL AND MASS THIS RECORD REPRESENTS THE 2 CASES OF ALCL WHICH PRESENTED AS TUMOR MASS HISTOPATHOLOGY REPORTS THAT MALIGNANT CELLS WERE CD30-POSITIVE AND WERE ALK NEGATIVE ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IN REGARDS TO TREATMENT ABSTRACT REPORTS Â¿IMPLANT REMOVAL WAS PERFORMED IN 17 OUT OF 19 PATIENTS WITH ADDITIONAL TREATMENT BASED ON MOSTLY CHOP OR CHOP-LIKE CHEMOTHERAPY REGIMENS N = 1019 OR IRRADIATION N = 119 CHOP ALONE OR ABVD FOLLOWING RADIATION WITHOUT IMPLANT REMOVAL HAVE BEEN GIVEN IN TWO PATIENTSÂ¿ THERE IS CURRENTLY NO WAY TO DETERMINE WHICH TREATMENTS WERE USED IN THESE 11 CASES MANUFACTURER OF DEVICES IS UNKNOWN|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/02/2016|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6143087|62805862|D|1||ABSTRACT OF LITERATURE ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ A B6-YEAR-OLD PATIENT WHO WAS IMPLANTED WITH AN UNKNOWN IMPLANT DEVICE MANUFACTURER UNKNOWN PATIENT WAS DIAGNOSED WITH ALCL THE CHART ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED A LEFT SIDE MASS IT IS UNKNOWN IF THE IMPLANT WAS REMOVED TREATMENT WAS REPORTED AS ADRIAMYCINE BLEOMYCINE VINBLASTINE AND DACARBAZINE ABVD AND RADIOTHERAPY 30GY FOLLOW-UP FOUND NO EVIDENCE OF DISEASE THIS REPORT WAS INITIALLY SENT TO REPRESENT TWO PATIENTS DUE TO THE DISCOVERY OF IDENTIFYING INFORMATION THIS SUPPLEMENTAL REPORT WILL NOW REPRESENT THE B6 YEAR-OLD PATIENT DEVICE AND MFR  9617229-2016-00195 HAVE BEEN SENT TO REPRESENT THE OTHER PATIENT PREVIOUSLY REPRESENTED THE INITIAL REPORT OF MFR  9617229-2016-00196|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/02/2016|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6143087|61396766|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL AND LUMPNODULE ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/02/2016|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6177272|62460335|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 PATIENT WHO WAS IMPLANTED WITH A TEXTURED SALINE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED A RIGHT SEROMA AND Â¿DISRUPTED IMPLANTÂ¿ TREATMENT REPORTED AS IMPLANT REMOVAL AND Â¿CYCLOPHOSPHAMIDE ADRIAMYCIN VINCRISTINE AND PREDNISONE 6 CURES CHOP OR CHOP-LIKE FOLLOW-UP FOUND Â¿NO EVIDENCE OF DISEASEÂ¿|UNK SALINE IMPLANT|UNK SALINE IMPLANT|12/15/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6177272|62460334|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|UNK SALINE IMPLANT|UNK SALINE IMPLANT|12/15/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5924670|53824368|D|1||PT IS A VERY PLEASANT B6 YRS OLD FEMALE WITH HISTORY BILATERAL BREAST IMPLANTS 2007 WHO DEVELOPED RIGHT BREAST SWELLING FIRMNESS TENDERNESS SUDDENLY IN B6 2016 EMAIL INVALID B6 2016 SHE HAD PREVIOUS HISTORY OF CONTRACTURE IN THE LEFT BREAST AND THOUGHT SYMPTOMS WERE SIMILAR SOUGHT CARE WITH DR B6 AND UNDERWENT IMPLANT REMOVAL CAPSULECTOMY SURGICAL UNCOMPLICATED PATHOLOGY RESULTED ANAPLASTIC LARGE CELL LYMPHOMA OF THE BREAST|BREAST IMPLANTS, STYLE 115||08/31/2016||||N|*||I|FWM|1.0||BREAST IMPLANT||1382362|||||MCGHAN|||||||True
5697584|46502156|D|1||THE FOLLOWING JOURNAL ARTICLE WAS REVIEWED Â¿BREAST IMPLANTÂ¿ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA REPORT OF 2 CASES AND REVIEW OF THE LITERATUREÂ¿ THE AUTHORS REPORTED THAT A PATIENT Â¿PRESENTED WITH A 6-WEEK HISTORY OF RIGHT BREAST SWELLINGÂ¿ Â¿NINE YEARS EARLIER THE PATIENT HAD UNDERGONE BILATERAL SUBMUSCULAR BREAST AUGMENTATION WITH 510-CC TEXTURED SALINE BIOCELL IMPLANTS ALLERGAN B64 THE PATIENTS MEDICAL HISTORY REVEALED A RECENT DIAGNOSIS OF CELIAC DISEASE CONFIRMED BY DUODENAL BIOPSY CLINICAL EXAMINATION SHOWED SWELLING AND ERYTHEMA OF THE RIGHT BREAST PERCUTANEOUS FLUID ASPIRATION PRODUCED 200 ML OF CLEAR YELLOW FLUID FLOW CYTOMETRIC IMMUNOPHENOTYPING OF THE ASPIRATE DEMONSTRATED A PHENOTYPICALLY ABERRANT POPULATION OF LARGE CELLS THAT EXPRESSED CD2 CD5 CD4 AND CD30 AND FAILED TO EXPRESS CD3 OR CD7 RESULTS OF IMMUNOHISTOCHEMICAL STAINING WITH HEMATOXYLIN AND EOSIN WERE NEGATIVE FOR ANAPLASTIC LYMPHOMA KINASE 1 ALK-L THE DIAGNOSIS WAS ALKÂ¿ ALCL RESULTS OF POSITRON EMISSION TOMOGRAPHY SCAN BONE MARROW ASPIRATE AND BIOPSY WERE DETERMINED TO BE NEGATIVE FOR DISEASE AND THE PATIENTS LEVEL OF LACTATE DEHYDROGENASE WAS NORMAL TREATMENT INCLUDED BILATERAL TOTAL CAPSULECTOMY AND IMPLANT REMOVAL WITHOUT IMPLANT REPLACEMENT APPROXIMATELY SIX MONTHS AFTER PRESENTING SYMPTOMS TO A HEALTH PROFESSIONAL AFTER REMOVAL THE IMPLANTS AND CAPSULES WERE SENT FOR FLOW CYTOMETRY AND CYTOGENETIC ANALYSIS IMMUNOHISTOCHEMICAL STAINING DID NOT SHOW ANY UNIQUE CELL POPULATIONS THERE WAS EVIDENCE OF SILICONE IN THE CAPSULE THROUGHOUT THE 20 MONTHS OF REGULAR FOLLOW-UP SINCE IMPLANT REMOVAL AND CAPSULECTOMY THE PATIENT HAS HAD NO SYSTEMIC EVIDENCE OF THE DISEASEÂ¿ THIS REPORT REPRESENTS THE RIGHT SIDE SEE MFR REPORT  9617229-2016-00066 FOR THE LEFT SIDE|UNK SALINE IMPLANT|UNK SALINE IMPLANT|06/03/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5697584|46502155|N|1||B4 THE CORRESPONDING AUTHOR HAS DECLINED TO PROVIDE ALLERGAN FURTHER INFORMATION REGARDING EVENT PRODUCT PRODUCT RETURN OR PATIENT DETAILS THE EVENTS OF FLUID COLLECTION Â¿RECENT HISTORY OF CELIAC DISEASEÂ¿ ERYTHEMA AND ALCL ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY|UNK SALINE IMPLANT|UNK SALINE IMPLANT|06/03/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6176870|62452744|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 PATIENT WHO WAS IMPLANTED WITH A LEFT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED SEROMA TREATMENT REPORTED AS IMPLANT REMOVAL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176870|62452743|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6011928|56911407|N|1||MEDWATCH SENT TO FDA ON 10072016 ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN AUSTRALIA AND NEW ZEALAND Â¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ A LOCH-WILKINSON KJ BEATH RJW KNIGHT WLF WESSELS M MAGNUSSON T PAPADOPOULOS T CONNELL J LOFTS M LOCKE I HOPPER R COOTER K VICKERY PA JOSHI HM PRINCE  AK DEVA THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6011928|56911408|D|1||THROUGH ALLERGANÂ¿S LITERATURE REVIEW OF RECENT JOURNAL ARTICLES WE RECEIVED THE FOLLOWING ARTICLE FROM MEDICAL SAFETY Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN AUSTRALIA AND NEW ZEALANDÂ¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ TABLE 4 Â¿PRESENTATION OF BIA-ALCL N=46Â¿ IN THE ARTICLE REPORTS THE FOLLOWING 2 CASES OF Â¿SEROMA AND CAPSULAR CONTRACTURE CONTRALATERALÂ¿ THIS RECORD HAS BEEN CREATED THE CAPTURE THE 2 SEROMAS CONTRALATERAL EVENT OF CAPSULAR CONTRACTURE WILL BE CAPTURED IN MDR  9617229-2016-00146 THE ARTICLE DOES NOT PROVIDE IMPLANTING EXPLANTING PHYSICIAN INFORMATION DEVICE SERIAL OR LOT INFORMATION OR SIDES OF ALCL DIAGNOSIS ARTICLE STATES Â¿ALL PATIENTS UNDERWENT TOTAL CAPSULECTOMY AND REMOVAL OF IMPLANTS BOTH ON DISEASED AND NON-DISEASED SIDE ALL TUMORS WERE CD30 POSITIVE AND ALK NEGATIVEÂ¿|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5665954|45480789|D|1||THE 2 BREAST IMPLANTS WERE IMPLANTED ON B6 2008 SINCE THEN ALL WAS FINE THEY HAVE REMAINED INTACT YESTERDAY B6 2016 PT WAS DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA ALCL CAUSED BY THE 2 IMPLANTS SHE IS SCHEDULED TO MEET WITH HER DOCTOR TODAY TO PLAN FOR THE EXPLANTING OF THE DEVICES|MEMORY GEL BREAST IMPLANT||05/18/2016||||*|*||0LP|FTR|2.0||MEMORY GEL BREAST IMPLANT|||3041 SKYWAY CIRCLE NORTH||IRVINE|US|MENTOR|75038|TX|75038||||True
5665954|45480789|D|1||THE 2 BREAST IMPLANTS WERE IMPLANTED ON B6 2008 SINCE THEN ALL WAS FINE THEY HAVE REMAINED INTACT YESTERDAY B6 2016 PT WAS DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA ALCL CAUSED BY THE 2 IMPLANTS SHE IS SCHEDULED TO MEET WITH HER DOCTOR TODAY TO PLAN FOR THE EXPLANTING OF THE DEVICES|MEMORY GEL BREAST IMPLANT||05/18/2016||||*|*||0LP|FTR|1.0||MEMORY GEL BREAST IMPLANT||5746123|3041 SKYWAY CIRCLE NORTH||IRVING|US|MENTOR|75038|TX|75038||||True
6139164|61260978|N|1||ARTICLE CITATION Â¿MARKED EOSINOPHILIA AS INITIAL PRESENTATION OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ BY NICOLA OROFINO FRANCESCA GUIDOTTI DANIELE CATTANEO MARIARITA SCIUMÃ UMBERTO GIANELLI AGOSTINO CORTELEZZI  ALESSANDRA LURLO PUBLISHED IN LEUKEMIA  LYMPHOMA PUBLISHED ELECTRONICALLY ON 17MAR2016 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LATE SEROMA LYMPHOMA-ALCL PRURITUS AND EOSINOPHILIA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/01/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6139164|61260979|D|1||JOURNAL ARTICLE MARKED EOSINOPHILIA AS INITIAL PRESENTATION OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA REPORTS WE HERE DESCRIBE A CASE OF BI-ALCL IN A PATIENT WHO PRESENTED WITH HYPEREOSINOPHILIA AND DIFFUSE PRURITUS PATIENT PRESENTED WITH DISCOMFORT AND MODERATE PAIN IN THE LEFT BREAST AND A DIAGNOSIS OF CHRONIC SEROMA WAS MADE IN LEUKEMIA  LYMPHOMA 5711 2712-2715 DEVICE WAS REMOVED AND REPLACED WITH TEXTURED IMPLANT ALLERGAN PATIENTS SYMPTOMS PERSISTED AND THE REPLACEMENT IMPLANT WAS ALSO REMOVED ARTICLE STATES AS THE CHRONIC SEROMA CONTINUED A TRU-CUT BIOPSY WAS CARRIED OUT THREE YEARS LATER BUT ONLY REVEALED CHRONIC INFLAMMATIONÂ¿ ARTICLE GOES ON TO STATE A HISTOLOGICAL EXAMINATION OF THE PSEUDO-CAPSULE SHOWED THE DIFFUSE INFILTRATION OF LARGE CELLS WITH IRREGULAR ANAPLASTIC OR Â¿EMBRYO-LIKEÂ¿ NUCLEI AND AN ABUNDANT EOSINOPHILIC GRANULAR CYTOPLASM THE MALIGNANT POPULATION TESTED FOR CD30+ AND ALK-1 EXPRESSION AS BONE MARROW BIOPSY PERFORMED FOR STAGING PURPOSES WAS ALSO NEGATIVE A DIAGNOSIS OF BI-ALCL WAS MADE THIS FILE REPRESENTS THE DEVICE REMOVED PREVIOUS TO ALCL|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/01/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6196606|63054804|D|1||JOURNAL ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH BREAST IMPLANT A NEW CASE REPORTS IN B62015 THE PATIENTÂ¿CONSULTS FOR PALPABLE NODULES IN THE RIGHT BREAST FOR 2 MONTHS PATIENT HAS BREAST IMPLANTS SINCE 2011 MAMMOGRAPHY ULTRASOUND AND MAGNETIC RESONANCE NEUROGRAPHY FROM ANOTHER INSTITUTION HAD LED TO A CONCLUSION OF PROBABLE COMPLICATION OF THE RIGHT BREAST IMPLANT ARTICLE GOES ON TO STATE PATIENT IS REEVALUATED IN OUR CENTER WITH NEW MX AND ULTRASOUND WHICH IN ADDITION IDENTIFY IPSILATERAL ADENOPATHIES A CAPSULAR NODULE AND AXILLARY LYMPH NODE WERE RESECTEDÂ¿ THE IMPLANT AND CAPSULE WERE REMOVED ARTICLE ADDITIONALLY STATES Â¿THE CAPSULE UP TO 15 CM THICK HAD HARD YELLOWISH NODULESÂ¿ Â¿THE PATIENT HAD 4 CHOP CYCLES SEVEN MONTHS LATER PATIENT CONDITION IS OPTIMALÂ¿|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/21/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6196606|63054803|N|1||THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS CANNOT BE OBTAINED AT THIS TIME AS CONTACTFOLLOW UP INFORMATION WAS NOT PROVIDED OR FOUND DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS ARTICLE CITATION ANAPLASTIC LARGE CELL LYMPHOMA ASSOCIATED WITH BREAST IMPLANT A NEW CASE ALVARO IBARRA MARCELA JACARD SOLEDAD TORRES PATRICIA FARDELLA MD AMERICAN SOCIETY FOR CLINICAL PATHOLOGY 2016146S1-S26|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/21/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6144474|61423058|N|1||ARTICLE CITATION Â¿WHOLE EXOME SEQUENCING REVEALS ACTIVATING JAK1 AND STAT3 MUTATIONS IN BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA ANAPLASTIC LARGE CELL LYMPHOMA BY PIERS BLOMBERY ELLA R THOMPSON KATE JONES GISELA MIR ARNAU STEPHEN LADE JOHN F MARKHAM JASON LI ANAND DEVA RICKY W JOHNSTONE AMIT KHOT H MILES PRINCE AND DAVID WESTERMAN PUBLISHED IN HAEMATOLOGICA ELECTRONICALLY PUBLISHED SEPTEMBER 2016 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LATE SEROMA AND LYMPHOMA-ALCL ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/05/2016||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6144474|61423059|D|1||REVIEWED JOURNAL ARTICLE Â¿WHOLE EXOME SEQUENCING REVEALS ACTIVATING JAK1 AND STAT3 MUTATIONS IN BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ IN JOURNAL HAEMATOLOGICA SEPTEMBER 2016 101 E387-E390 ARTICLE STATES PATIENT Â¿PRESENTED WITH A THREE MONTH HISTORY OF BREAST SWELLING APPROXIMATELY SEVEN YEARS AFTER INSERTION OF ANATOMIC SALT-LOSS TEXTURED SILICONE- FILLED BREAST IMPLANTS FLUID ASPIRATED FROM THE LEFT BREAST SHOWED LARGE ATYPICAL CELLS WHICH WERE CD2Â¿ CD3Â¿ CD4+ CD5+ CD7Â¿ CD8Â¿ CD30+ AND ALKÂ¿ BY IMMUNOHISTOCHEMISTRY HISTOLOGICAL EXAMINATION SHOWED DISEASE CONFINED TO THE EFFUSION WITH NO EVIDENCE OF INFILTRATION OF THE PSEUDOCAPSULE PATIENT UNDERWENT REMOVAL OF THE IMPLANT WITH NO OTHER LOCAL OR SYSTEMIC THERAPY AND REMAINS CLINICALLY WELL WITH NO EVIDENCE OF RECURRENCE AT SIX MONTHS FOLLOW-UPÂ¿|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/05/2016||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6176830|62457611|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 -YEAR-OLD PATIENT WHO WAS IMPLANTED WITH A RIGHT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED SEROMA TREATMENT REPORTED AS IMPLANT REMOVAL FOLLOW-UP FOUND NO EVIDENCE OF DISEASE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176830|62457610|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5803927|49896516|N|1||THE EVENTS OF CAPSULAR CONTRACTURE NIPPLE SENSATION INCREASEDECREASE SEROMA AND DEFLATION WERE PREVIOUSLY REPORTED VIA ASR ON B6 2016 IN ADDITION TO LAB ANALYSIS RESULTS DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 468 SALINE FILLED BREAST IMPLANT|468-560|07/19/2016||09/25/2015||R|Y||0HP|FWM|1.0|06/26/2006|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||578468|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6153092|61703506|N|1||THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL INFECTION BACTERIAL BIOFILM INFECTION DETECTED IN BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE-CELL LYMPHOMAÂ¿ 137 6 1659-1669 BY HONGHUA HU PHD KHALID JOHANI AHMAD ALMATROUDI KAREN VICKERY PHD BVSC BRUCE VAN NATTA MD MARSHALL E KADIN MD GARRY BRODY MD MARK CLEMENS MD CHAN YOON CHEAH MD STEPHEN LADE MD PREETI AVINASH JOSHI MDPHD H MILES PRINCE MDPHD ANAND K DEVA BSCMED MBBS MS PUBLISHED JUNE 2016|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/07/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6167285|62187250|D|1||ABSTRACT OF LITERATURE ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ REPORTS Â¿19 I-ALCLSÂ¿ CASES ARTICLE ADDITIONALLY STATES Â¿FIVE PATIENTS PRESENTED WITH ERYTHEMATOUS SKIN ERUPTIONÂ¿ THIS RECORD HAS BEEN CREATED TO CAPTURE 5 CASES OF ALCL WITH Â¿ERYTHEMATOUS SKIN ERUPTIONÂ¿ ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IN REGARDS TO TREATMENT ABSTRACT REPORTS Â¿IMPLANT REMOVAL WAS PERFORMED IN 17 OUT OF 19 PATIENTS WITH ADDITIONAL TREATMENT BASED ON MOSTLY CHOP OR CHOP-LIKE CHEMOTHERAPY REGIMENS N = 1019 OR IRRADIATION N = 119 CHOP ALONE OR ABVD FOLLOWING RADIATION WITHOUT IMPLANT REMOVAL HAVE BEEN GIVEN IN TWO PATIENTSÂ¿ THERE IS CURRENTLY NO WAY TO DETERMINE WHICH TREATMENTS WERE USED IN THESE 65 CASES MANUFACTURER OF DEVICES IS UNKNOWN|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/12/2016|||DA|*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6167285|62187249|N|1||Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL AND ERYTHEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST ERYTHEMA MAY ALSO OCCUR AS A NORMAL RESPONSE TO EXPANSION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/12/2016|||DA|*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6167285|62735770|D|1||ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ REPORTS A B6 PATIENT WHO WAS IMPLANTED WITH A LEFT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED A LEFT SEROMA AND Â¿DISRUPTED IMPLANTÂ¿ TREATMENT REPORTED AS IMPLANT REMOVAL FOLLOW-UP REVEALED NO EVIDENCE OF DISEASE THIS REPORT WAS INITIALLY SENT TO REPRESENT FIVE PATIENTS DUE TO THE DISCOVERY OF IDENTIFYING INFORMATION THIS SUPPLEMENTAL REPORT WILL NOW REPRESENT THE B6 PATIENT AND MFR 9617229-2016-00227 9617229-2016-00196 9617229-2016-00244 AND 9617229-2016-00204 HAVE BEEN SENT TO REPRESENT THE OTHER PATIENTS PREVIOUSLY REPRESENTED THE INITIAL REPORT OF MFR 9617229-2016-00206|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/12/2016|||DA|*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6157808|62108428|D|1||LITERATURE ARTICLE Â¿COMPREHENSIVE IMMUNOPHENOTYPIC ANALYSIS OF 64 CASES OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA SHOWS AN ACTIVATED CYTOTOXIC WITH A SILENT T-CELL RECEPTOR PATTERNÂ¿ REPORTS Â¿64 CASESÂ¿ ARTICLE CONTINUES TO STATE Â¿WE REVIEWED THE WORLD LITERATURE FOR CASES OF BI-ALCL AND ACCRUED CASES IN WHICH IMMUNOPHENOTYPIC DATA DERIVED USING IMMUNOHISTOCHEMICAL OR FLOW CYTOMETRY METHODS WERE USED AND AT LEAST 5 OF THE FOLLOWING 13 MARKERS WERE REPORTED CD3 CD4 CD8 CD30 CD43 CD45 EMATIA-1 GRANZYME-B ALK-1 TCR-Â¿Â¿ AND TCR-GÂ¿ AND EBER IN SITU HYBRIDIZATION WHEN LESS THAN 5 MARKERS WERE REPORTED WE CONTACTED CORRESPONDING AUTHORS FOR AVAILABLE MATERIAL DID ADDITIONAL STUDIES AND INCLUDED THESE DATAÂ¿ Â¿CD30 WAS POSITIVE IN ALL N=64 CASES WHEREAS ALK AND EBER WERE NEGATIVE IN ALL TESTED CASES N=56 AND N=25 RESPECTIVELY CD3 WAS POSITIVE IN 15 OF 62 24 CASES CD4 4361 70 CD8 657 11 CD43 37 46 80 CD45 2949 59 EMA 2542 60 TIA-1 2846 61 GRANZYME-B 28 47 60 TCR Â¿Â¿ 5 24 21 AND TCR GÂ¿ IN 1 OF 23 4 THUS TCR WAS SILENT IN 1824 75 CASESÂ¿ CYTOLOGICAL MARKERS ALK- AND CD30+ HAVE BEEN REPORTED THIS RECORD HAS BEEN CREATED TO CAPTURE THE 56 CASES OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/09/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6157808|62108427|N|1||THE EVENT OF LYMPHOMA ALCL IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED THE AUTHOR HAS RESPONDED AND REFUSED TO PROVIDE ANY FURTHER INFORMATION DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL Â¿COMPREHENSIVE IMMUNOPHENOTYPIC ANALYSIS OF 64 CASES OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA SHOWS AN ACTIVATED CYTOTOXIC WITH A SILENT T-CELL RECEPTOR PATTERNÂ¿ ANA CLAUDIA FROTA LOPES L JEFFREY MEDEIROS MARK W CLEMENS MING CHAI HUI LIU ARIANNA DI NAPOLI STEPHEN LADE MITUAL AMIN KEN H YOUNG ROBERTO MIRANDA|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/09/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5612275|43806327|D|1||I WAS DIAGNOSED WITH ALCL AFTER HAVING SILICONE BREAST IMPLANTS PLACED MY LEFT BREAST GREW APPROX 50 LARGER WITH SOME PAIN I HAD FINE NEEDLE ASPIRATION OF A STRAW COLORED FLUID AFTER TWO WEEKS I WAS GIVEN THE DIAGNOSIS OF ALCL ANAPLASTIC LARGE CELL LYMPHOMA I MET WITH A LYMPHOMA SPECIALIST AND BREAST SURGEON IN B6 2016 ON B6 2016 I UNDERWENT A CAPSULECTOMY OF MY LEFT BREAST AND BILATERAL REMOVAL OF THE BREAST IMPLANTS A PET SCAN REVEALED NO SYSTEMIC MIGRATION OF THE LYMPHOMA|SILICONE BREAST IMPLANTS||04/25/2016||||N|*||I|FTR|1.0||SILICONE BREAST IMPLANTS|||||||nan|||||||True
6143032|61396907|D|1||ABSTRACT OF LITERATURE ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ REPORTED Â¿19 I-ALCLSÂ¿ CASES ONE OF THE TWO CLINICAL PRESENTATIONS REPORTED WAS Â¿EFFUSIONÂ¿ ELEVEN PATIENTS EXPERIENCED ALCL AND EFFUSION THIS RECORD REPRESENTS THE 11 CASES OF ALCL WHICH PRESENTED AS EFFUSION HISTOPATHOLOGY REPORTS THAT MALIGNANT CELLS WERE CD30-POSITIVE AND WERE ALK NEGATIVE ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IN REGARDS TO TREATMENT ABSTRACT REPORTS Â¿IMPLANT REMOVAL WAS PERFORMED IN 17 OUT OF 19 PATIENTS WITH ADDITIONAL TREATMENT BASED ON MOSTLY CHOP OR CHOP-LIKE CHEMOTHERAPY REGIMENS N = 1019 OR IRRADIATION N = 119 CHOP ALONE OR ABVD FOLLOWING RADIATION WITHOUT IMPLANT REMOVAL HAVE BEEN GIVEN IN TWO PATIENTSÂ¿ THERE IS CURRENTLY NO WAY TO DETERMINE WHICH TREATMENTS WERE USED IN THESE 11 CASES MANUFACTURER OF DEVICES IS UNKNOWN|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/02/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6143032|62822269|D|1||ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ REPORTS A B6 -YEAR-OLD PATIENT WHO WAS IMPLANTED WITH A LEFT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE CHART ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED A LEFT SIDE SEROMA TREATMENT REPORTED AS IMPLANT REMOVAL AND CYCLOPHOSPHAMIDE ADRIAMYCIN VINCRISTINE AND PREDNISONE 6 CURES CHOP OR CHOP-LIKE FOLLOW-UP FOUND NO EVIDENCE OF DISEASE THIS REPORT WAS INITIALLY SENT TO REPRESENT ELEVEN PATIENTS DUE TO THE DISCOVERY OF IDENTIFYING INFORMATION THIS SUPPLEMENTAL REPORT WILL NOW REPRESENT THE B6 -YEAR-OLD PATIENT DEVICE AND MFR 9617229-2016-00234 9617229-2016-00235 9617229-2016-00206 9617229-2016-00236 9617229-2016-00240 9617229-2016-00241 9617229-2016-00239 9617229-2016-00238 9617229-2016-00242 9617229-2016-00245 AND 9617229-2016-00243 HAVE BEEN SENT TO REPRESENT THE OTHER PATIENTS PREVIOUSLY REPRESENTED THE INITIAL REPORT OF MFR  9617229-2016-00197|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/02/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6143032|61396906|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL AND LATE SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/02/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6011805|56820798|D|1||THROUGH ALLERGANÂ¿S LITERATURE REVIEW OF RECENT JOURNAL ARTICLES WE RECEIVED THE FOLLOWING ARTICLE FROM MEDICAL SAFETY Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN AUSTRALIA AND NEW ZEALAND Â¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ TABLE 5 Â¿TNM STAGING OF PATIENTS IN ANZ COHORTÂ¿ IN THE ARTICLE REPORTS AN ADDITIONAL THREE OCCURRENCES OF DEATH APPROX 2 CASES OF Â¿DEATH  MASS EXTENDING BEYOND CAPSULEÂ¿ THE ARTICLE DOES NOT PROVIDE IMPLANTING EXPLANTING PHYSICIAN INFORMATION DEVICE SERIAL OR LOT INFORMATION OR SIDES OF ALCL DIAGNOSIS MANUFACTURER COULD NOT BE SPECIFIED AND ARTICLE STATES Â¿BIOCELL ALLERGANINAMEDMCGHAN ACCOUNTED FOR 571 OF IMPLANTS IN THIS SERIES ARTICLE STATES Â¿ALL PATIENTS UNDERWENT TOTAL CAPSULECTOMY AND REMOVAL OF IMPLANTS BOTH ON DISEASED AND NON-DISEASED SIDE ALL TUMORS WERE CD30 POSITIVE AND ALK NEGATIVEÂ¿|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6011805|56820797|N|1||ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN AUSTRALIA AND NEW ZEALAND Â¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ A LOCH-WILKINSON KJ BEATH RJW KNIGHT WLF WESSELS M MAGNUSSON T PAPADOPOULOS T CONNELL J LOFTS M LOCKE I HOPPER R COOTER K VICKERY PA JOSHI HM PRINCE  AK DEVA THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5697586|46503421|N|1||MEDWATCH SENT TO THE FDA ON 06032016 LITERATURE CITATION HART ALEXANDRA M LECHOWICZ MARY JO PETERS KENDALL K HOLDEN JEANNINE CARLSON GRANT W Â¿BREAST IMPLANTÂ¿ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA REPORT OF 2 CASES AND REVIEW OF THE LITERATUREÂ¿ AESTHETIC SURGERY JOURNAL 2014 VOL 346 884-894 FIRST PUBLISHED ONLINE 01AUG2014 THE CORRESPONDING AUTHOR HAS DECLINED TO PROVIDE ALLERGAN FURTHER INFORMATION REGARDING EVENT PRODUCT PRODUCT RETURN OR PATIENT DETAILS THE EVENTS OF FLUID COLLECTION AND Â¿RECENT HISTORY OF CELIAC DISEASEÂ¿ ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY|UNK SALINE IMPLANT|UNK SALINE IMPLANT|06/03/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5697586|46503422|D|1||THE FOLLOWING JOURNAL ARTICLE WAS REVIEWED BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA REPORT OF 2 CASES AND REVIEW OF THE LITERATURE THE AUTHORS REPORTED THAT A PATIENTS MEDICAL HISTORY REVEALED A RECENT DIAGNOSIS OF CELIAC DISEASE CONFIRMED BY DUODENAL BIOPSY THE AUTHORS ADDITIONALLY NOTED THAT AN MRI OF THE BREASTS SHOWED POSTERIOR FLUID COLLECTIONS BILATERALLY DEVICE WAS REMOVED AND TOTAL CAPSULECTOMY PERFORMED AUTHORS NOTE EVIDENCE OF SILICONE IN THE CAPSULE SIDE OF CAPSULE NOT SPECIFIED THIS REPORT REPRESENTS THE LEFT SIDE SEE MFR REPORT  9617229-2016-00063 FOR THE RIGHT SIDE|UNK SALINE IMPLANT|UNK SALINE IMPLANT|06/03/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6011770|56819840|N|1||MEDWATCH SENT TO FDA ON 10072016 ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN AUSTRALIA AND NEW ZEALAND Â¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ A LOCH-WILKINSON KJ BEATH RJW KNIGHT WLF WESSELS M MAGNUSSON T PAPADOPOULOS T CONNELL J LOFTS M LOCKE I HOPPER R COOTER K VICKERY PA JOSHI HM PRINCE  AK DEVA THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6011770|56819841|D|1||THROUGH ALLERGANS LITERATURE REVIEW OF RECENT JOURNAL ARTICLES WE RECEIVED THE FOLLOWING ARTICLE FROM MEDICAL SAFETY BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN AUSTRALIA AND NEW ZEALAND - HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGY TABLE 4 PRESENTATION OF BIA-ALCL N=46 IN THE ARTICLE REPORTS THE FOLLOWING 1 CASE OF MASS WITH METASTATIC DISEASE AXILLA TABLE 4 AND DEATH  MASS WITH METASTATIC DISEASE TO ONE LYMPH NODE IN AXILLA TABLE 5 MANUFACTURER COULD NOT BE SPECIFIED AND ARTICLE STATES BIOCELL ALLERGANINAMEDMCGHAN ACCOUNTED FOR 571 OF IMPLANTS IN THIS SERIES THE ARTICLE DOES NOT PROVIDE IMPLANTING EXPLANTING PHYSICIAN INFORMATION DEVICE SERIAL OR LOT INFORMATION OR SIDES OF ALCL DIAGNOSIS ARTICLE STATES ALL PATIENTS UNDERWENT TOTAL CAPSULECTOMY AND REMOVAL OF IMPLANTS BOTH ON DISEASED AND NON-DISEASED SIDE ALL TUMORS WERE CD30 POSITIVE AND ALK NEGATIVE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6153118|61701316|N|1||THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL INFECTION PATIENTS SHOULD BE ADVISED THAT CAPSULAR CONTRACTURE MAY BE MORE COMMON FOLLOWING INFECTION HEMATOMA AND SEROMA AND THE CHANCE OF IT HAPPENING MAY INCREASE OVER TIME CAPSULAR CONTRACTURE OCCURS MORE COMMONLY IN REVISION PATIENTS THAN IN PRIMARY AUGMENTATION OR RECONSTRUCTION PATIENTS CAPSULAR CONTRACTURE IS ALSO A RISK FACTOR FOR IMPLANT DEFLATION AND IT IS ONE OF THE MOST COMMON REASONS FOR REOPERATION PATIENTS SHOULD ALSO BE ADVISED THAT ADDITIONAL SURGERY MAY BE NEEDED IN CASES WHERE PAIN ANDOR FIRMNESS ARE SEVERE THIS SURGERY RANGES FROM REMOVAL OF THE IMPLANT CAPSULE TISSUE TO REMOVAL AND POSSIBLE REPLACEMENT OF THE IMPLANT ITSELF THIS SURGERY MAY RESULT IN LOSS OF BREAST TISSUE CAPSULAR CONTRACTURE MAY HAPPEN AGAIN AFTER THESE ADDITIONAL SURGERIES CAPSULAR CONTRACTURE MAY INCREASE THE RISK OF DEFLATION B4|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/07/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6167248|62147367|D|1||ABSTRACT OF LITERATURE ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ REPORTS Â¿19 I-ALCLSÂ¿ CASES ONE OF THE CLINICAL PRESENTATIONS REPORTED WAS Â¿MASS + SEROMAÂ¿ 6 PATIENTS EXPERIENCED  ALCL WITH Â¿MASS + SEROMAÂ¿ THIS RECORD HAS BEEN CREATED TO CAPTURE 6 CASES OF ALCL WITH Â¿MASS + SEROMAÂ¿ ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿  IN REGARDS TO TREATMENT ABSTRACT REPORTS Â¿IMPLANT REMOVAL WAS PERFORMED IN 17 OUT OF 19 PATIENTS WITH ADDITIONAL TREATMENT BASED ON MOSTLY CHOP OR CHOP-LIKE CHEMOTHERAPY REGIMENS N = 1019 OR IRRADIATION N = 119 CHOP ALONE OR ABVD FOLLOWING RADIATION WITHOUT  IMPLANT REMOVAL HAVE BEEN GIVEN IN TWO PATIENTSÂ¿ THERE IS CURRENTLY NO WAY TO DETERMINE WHICH TREATMENTS WERE USED IN THESE 6 CASES MANUFACTURER OF DEVICES IS UNKNOWN|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/12/2016|||DA|*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6167248|62147366|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL LATE SEROMA AND LUMPNODULE ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/12/2016|||DA|*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6167248|62810641|D|1||ALLERGAN PRODUCT SURVEILLANCE RECEIVED LITERATURE ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMES ARTICLE REPORTS A B6 YEAR-OLD PATIENT WHO WAS IMPLANTED WITH A RIGHT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN TREATMENT REPORTED AS IMPLANT REMOVAL FOLLOW-UP REVEALED NO EVIDENCE OF DISEASE THIS REPORT WAS INITIALLY SENT TO REPRESENT SIX PATIENTS DUE TO THE DISCOVERY OF IDENTIFYING INFORMATION THIS SUPPLEMENTAL REPORT WILL NOW REPRESENT THE B6 YEAR-OLD PATIENT DEVICE AND MFR  9617229-2016-00237 9617229-2016-00227 9617229-2016-00246 9617229-2016-00244 AND 9617229-2016-00204 HAVE BEEN SENT TO REPRESENT THE OTHER PATIENTS PREVIOUSLY REPRESENTED THE INITIAL REPORT OF MFR  9617229-2016-00205|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/12/2016|||DA|*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6011872|56922006|N|1||MEDWATCH SENT TO FDA ON 10072016 ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN B6 Â¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ A LOCH-WILKINSON KJ BEATH RJW KNIGHT WLF WESSELS M MAGNUSSON T PAPADOPOULOS T CONNELL J LOFTS M LOCKE I HOPPER R COOTER K VICKERY PA JOSHI HM PRINCE  AK DEVA THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6011872|56922007|D|1||THROUGH ALLERGANÂ¿S LITERATURE REVIEW OF RECENT JOURNAL ARTICLES WE RECEIVED THE FOLLOWING ARTICLE FROM MEDICAL SAFETY Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN B6 Â¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ TABLE 4 Â¿PRESENTATION OF BIA-ALCL N=46Â¿ IN THE ARTICLE REPORTS THE FOLLOWING 5 CASES OF Â¿MASS ONLYÂ¿ TWO RECORDS THAT CAPTURED THE EVENTS OF LYMPHOMA-ALCL AND MASS ONLY  WERE IDENTIFIED AND WERE PREVIOUSLY REPORTED THIS RECORD HAS BEEN CREATED TO CAPTURE THE REMAINING 3 OF THE 5 CASES NOTED IN THE ARTICLE OF LYMPHOMA-ALCL AND MASS ONLY MANUFACTURER COULD NOT BE SPECIFIED AND ARTICLE STATES Â¿BIOCELL ALLERGANINAMEDMCGHAN ACCOUNTED FOR 571 OF IMPLANTS IN THIS SERIESÂ¿ THE ARTICLE DOES NOT PROVIDE IMPLANTING EXPLANTING PHYSICIAN INFORMATION DEVICE SERIAL OR LOT INFORMATION OR SIDES OF ALCL DIAGNOSIS ARTICLE STATES Â¿ALL PATIENTS UNDERWENT TOTAL CAPSULECTOMY AND REMOVAL OF IMPLANTS BOTH ON DISEASED AND NON-DISEASED SIDE ALL TUMORS WERE CD30 POSITIVE AND ALK NEGATIVEÂ¿|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6011849|56929012|D|1||THROUGH ALLERGANS LITERATURE REVIEW OF RECENT JOURNAL ARTICLES WE RECEIVED THE FOLLOWING ARTICLE FROM MEDICAL SAFETY BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN B6 - HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGY TABLE 4 PRESENTATION OF BIA-ALCL N=46 IN THE ARTICLE REPORTS THE FOLLOWING 35 CASES OF SEROMA ONLY SPECIFIED IN THE ARTICLE AS UNILATERAL LATE SEROMA EIGHTEEN RECORDS THAT CAPTURED THE EVENTS OF LYMPHOMA-ALCL AND SEROMA ONLY  WERE IDENTIFIED AND WERE PREVIOUSLY REPORTED THIS RECORD HAS BEEN CREATED TO CAPTURE THE REMAINING 17 OF THE 35 CASES NOTED IN THE ARTICLE OF LYMPHOMA-ALCL AND SEROMA ONLY MANUFACTURER COULD NOT BE SPECIFIED AND ARTICLE STATES BIOCELL ALLERGANINAMEDMCGHAN ACCOUNTED FOR B4 OF IMPLANTS IN THIS SERIES THE ARTICLE DOES NOT PROVIDE IMPLANTING EXPLANTING PHYSICIAN INFORMATION DEVICE SERIAL OR LOT INFORMATION OR SIDES OF ALCL DIAGNOSIS ARTICLE STATES ALL PATIENTS UNDERWENT TOTAL CAPSULECTOMY AND REMOVAL OF IMPLANTS BOTH ON DISEASED AND NON-DISEASED SIDE ALL TUMORS WERE CD30 POSITIVE AND ALK NEGATIVE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6011849|56929011|N|1||MEDWATCH SENT TO FDA ON 10072016 ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN B6 Â¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ A LOCH-WILKINSON KJ BEATH RJW KNIGHT WLF WESSELS M MAGNUSSON T PAPADOPOULOS T CONNELL J LOFTS M LOCKE I HOPPER R COOTER K VICKERY PA JOSHI HM PRINCE  AK DEVA THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME HEMATOMASEROMA|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5834667|50817904|D|1||ACCORDING TO THE INFORMATION PROVIDED THE PATIENT WAS DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA ALCL THE LEFT PROSTHESIS ASSOCIATED WITH THIS COMPLAINT WILL NOT BE RETURNED TO MENTOR SHOULD ADDITIONAL INFORMATION ANDOR THE DEVICE BECOME AVAILABLE TO PE THIS COMPLAINT WILL BE REEVALUATED AT THAT TIME BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ACCORDING TO THE FDA THE INCIDENCE OF ALCL IN PATIENTS WITH BREAST IMPLANTS IS A VERY SMALL FRACTION OF THE 5-10 MILLION WOMEN WHO HAVE RECEIVED BREAST IMPLANTS WORLDWIDE AN INVESTIGATION OF THE DEVICE HISTORY RECORD REVEALED NO IRREGULARITIES A REVIEW OF THE NC SYSTEM AND COMPLAINT DATABASE REVEALED NO OTHER COMPLAINTS ASSOCIATED WITH LOT 6438477 THE MAIN SYMPTOMS OF ALCL IN WOMEN WITH BREAST IMPLANTS ARE LATE ONSET PERSISTENT SWELLING AND PAIN IN THE VICINITY OF THE IMPLANT AND PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL MENTOR CONCURS WITH FDAS POSITION THAT BECAUSE THE RISK OF ALCL APPEARS VERY SMALL FDA BELIEVES THAT THE TOTALITY OF EVIDENCE CONTINUES TO SUPPORT A REASONABLE ASSURANCE THAT FDA-APPROVED BREAST IMPLANTS ARE SAFE AND EFFECTIVE WHEN USED AS LABELED ANAPLASTIC LARGE CELL LYMPHOMA ALCL IS A KNOWN COMPLICATION ASSOCIATED WITH THESE DEVICES AND IS REFERENCED IN OUR IFU|MEMORY GEL SILTEX ROUND MODERATE PLUS PROFILE MAMMARY PROSTHESIS|3544751|07/29/2016|||DA|N|R||I|FTR|1.0||BREAST IMPLANT||6438477|3041 SKYWAY CIRCLE NORTH||IRVING|US|MENTOR WW LLC|75038|TX|75038||||True
5695364|46431599|D|1||HEALTH PROFESSIONAL REPORTED THAT THE PATIENT SUFFERED SIZE INCREASE OF RECONSTRUCTED RIGHT BREAST APPROXIMATELY THREE YEARS AND FOUR MONTHS AFTER IMPLANTATION THE SIZE INCREASE WAS COMPATIBLE WITH SEROMA CONSERVATIVE TREATMENT WAS INITIATED CONSISTING OF ANTIBIOTIC THERAPY CORTICOSTEROIDS AND THE PATIENT WAS ADVISED TO REST THE RIGHT ARM IT IS PUNCTURED TWICE TO PERFORM HISTOLOGICAL ANALYSIS OF GERMINAL CELL THE RESULTS DETERMINED ATYPICAL CELLS FOR THIS REASON THE DEVICE WAS EXPLANTED AND A COMPLETE CAPSULECTOMY WAS MADE TO THE PATIENT THE PATHOLOGY REPORT ON THE CAPSULE WAS POSITIVE FOR ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA ALCL ASSOCIATED WITH BREAST IMPLANTS AS CD30 RESULTS HAVE NOT BEEN PROVIDED THIS CASE IS CURRENTLY A SUSPECTED-ALCL AND IS CAPTURED AS LYMPHOMA THE PATIENTS CONDITION PROGRESSED FAVOURABLY|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-MX135-445|06/02/2016||||N|R||0HP|FTR|1.0|01/24/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2070807|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5440576|38326420|D|1||ALCL CASE REPORT WE REPORT THE CASE OF A B6 WOMAN SHE HAS PREVIOUS HISTORY OF SMOKING AND MULTIPLE BREAST AUGMENTATION SURGERIES WITH IMPLANTS THE FIRST ONE WAS 20 YEARS AGO THEN 15 YEARS AGO AND THE LAST WAS 3 YEARS AGO B6 2012 SHE DENIED ANY HISTORY OF ALLERGIC REACTION TRANSFUSION OR MEDICAL PROBLEMS SHE WAS TAKING ASPIRIN 81MG AT THE MOMENT OF THE EVENT SHE WAS ADMITTED TO THE HOSPITAL IN B6 2016 BECAUSE A 5 MONTH HISTORY OF PROGRESSIVE SWELLING OF THE RIGHT ARM ALSO SHE HAD AN ERYTHEMATOUS RASH ON HER ARM EXTENDING THROUGH THE CHEST AND RIGHT BREAST THE SKIN WAS INDURATED WITH A FIRM LUMP IN THE RIGHT EXTERNAL QUADRANT OF THE RIGHT BREAST SHE HAD PAIN ON HER ARM BUT SHE DIDNT HAVE FEVER WE ORDERED AN MRI OF THE ARM INVOLVING THE BREAST IT SHOWED A FASCIAL HYPERINTENSITY AND SWELLING OF THE SOFT TISSUE ADDITIONALLY WE PERFORMED ROUTINE LABORATORIES THAT SHOWED HYPERLEUKOCYTOSIS OF 38000 WITH SEVERE EOSINOPHILIA OF 26000 THE HAEMOGLOBIN AND PLATELETS WERE NORMAL THE HS-CRP WAS 292 AND THE PROCALCITONIN WAS NEGATIVE THE LDH WAS 393 AND THE BETA-2 MICROGLOBULIN WAS 2000 THE KIDNEY AND LIVER FUNCTION TEST WERE UNREMARKABLE WE PERFORMED A PET SCAN THAT SHOWED HYPERMETABOLISM OF THE PREVIOUS DESCRIBED SWOLLEN AREA AND ENLARGEMENT AND HYPERMETABOLISM OF PERIHEPATIC LYMPH NODES THEREFORE A BIOPSY OF THE ARM WAS PERFORMED THE PATHOLOGIC SPECIMEN INCLUDED SKIN SOFT TISSUE FASCIA AND MUSCLE THE PATHOLOGY RESULT WAS CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA CD4+ CD30+ EMA+ ALT- SO A SURGICAL REMOVAL OF BOTH BREAST IMPLANTS WAS CARRIED OUT THE PATHOLOGY LAB CONFIRMED THAT AROUND THE IMPLANTS CAPSULE OF THE RIGHT BREAST WAS AN EXTENDED INFILTRATION OF NEOPLASTIC CELLS CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA WITH THE SAME IMMUNOHISTOCHEMISTRY PROFILE INTERESTINGLY THE NEOPLASTIC CELLS WERE SURROUNDED BY AN EOSINOPHIL-RICH INFLAMMATORY INFILTRATE THE LEFT IMPLANT DIDNT HAVE NEOPLASTIC CELLS THE IMPLANTS WERE ALLERGAN MODEL MHP WITH A VOLUME OF 130 CUBIC CENTIMETERS THEY WERE ROUND AND FILLED BY COHESIVE SILICONE CURRENTLY THE PT IS UNDER SYSTEMIC CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE DOXORUBICIN ETOPOSIDE VINCRISTINE AND PREDNISONE|ALLERGAN SILICONE BREAST IMPLANT||02/11/2016||||*|*||0HP|FTR|1.0||ALLERGAN SILICONE BREAST IMPLANT||||||US|ALLERGAN|||||MHP||True
5440576|38326420|D|1||ALCL CASE REPORT WE REPORT THE CASE OF A B6 WOMAN SHE HAS PREVIOUS HISTORY OF SMOKING AND MULTIPLE BREAST AUGMENTATION SURGERIES WITH IMPLANTS THE FIRST ONE WAS 20 YEARS AGO THEN 15 YEARS AGO AND THE LAST WAS 3 YEARS AGO B6 2012 SHE DENIED ANY HISTORY OF ALLERGIC REACTION TRANSFUSION OR MEDICAL PROBLEMS SHE WAS TAKING ASPIRIN 81MG AT THE MOMENT OF THE EVENT SHE WAS ADMITTED TO THE HOSPITAL IN B6 2016 BECAUSE A 5 MONTH HISTORY OF PROGRESSIVE SWELLING OF THE RIGHT ARM ALSO SHE HAD AN ERYTHEMATOUS RASH ON HER ARM EXTENDING THROUGH THE CHEST AND RIGHT BREAST THE SKIN WAS INDURATED WITH A FIRM LUMP IN THE RIGHT EXTERNAL QUADRANT OF THE RIGHT BREAST SHE HAD PAIN ON HER ARM BUT SHE DIDNT HAVE FEVER WE ORDERED AN MRI OF THE ARM INVOLVING THE BREAST IT SHOWED A FASCIAL HYPERINTENSITY AND SWELLING OF THE SOFT TISSUE ADDITIONALLY WE PERFORMED ROUTINE LABORATORIES THAT SHOWED HYPERLEUKOCYTOSIS OF 38000 WITH SEVERE EOSINOPHILIA OF 26000 THE HAEMOGLOBIN AND PLATELETS WERE NORMAL THE HS-CRP WAS 292 AND THE PROCALCITONIN WAS NEGATIVE THE LDH WAS 393 AND THE BETA-2 MICROGLOBULIN WAS 2000 THE KIDNEY AND LIVER FUNCTION TEST WERE UNREMARKABLE WE PERFORMED A PET SCAN THAT SHOWED HYPERMETABOLISM OF THE PREVIOUS DESCRIBED SWOLLEN AREA AND ENLARGEMENT AND HYPERMETABOLISM OF PERIHEPATIC LYMPH NODES THEREFORE A BIOPSY OF THE ARM WAS PERFORMED THE PATHOLOGIC SPECIMEN INCLUDED SKIN SOFT TISSUE FASCIA AND MUSCLE THE PATHOLOGY RESULT WAS CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA CD4+ CD30+ EMA+ ALT- SO A SURGICAL REMOVAL OF BOTH BREAST IMPLANTS WAS CARRIED OUT THE PATHOLOGY LAB CONFIRMED THAT AROUND THE IMPLANTS CAPSULE OF THE RIGHT BREAST WAS AN EXTENDED INFILTRATION OF NEOPLASTIC CELLS CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA WITH THE SAME IMMUNOHISTOCHEMISTRY PROFILE INTERESTINGLY THE NEOPLASTIC CELLS WERE SURROUNDED BY AN EOSINOPHIL-RICH INFLAMMATORY INFILTRATE THE LEFT IMPLANT DIDNT HAVE NEOPLASTIC CELLS THE IMPLANTS WERE ALLERGAN MODEL MHP WITH A VOLUME OF 130 CUBIC CENTIMETERS THEY WERE ROUND AND FILLED BY COHESIVE SILICONE CURRENTLY THE PT IS UNDER SYSTEMIC CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE DOXORUBICIN ETOPOSIDE VINCRISTINE AND PREDNISONE|ALLERGAN SILICONE BREAST IMPLANT||02/11/2016||||*|*||0HP|FTR|2.0||ALLERGAN SILICONE BREAST IMPLANT||||||US|ALLERGAN|||||MHP||True
5759530|48466890|D|1||PATIENT REPORTED LEFT BREAST CAPSULAR CONTRACTURE WITH SEROMA TOTAL CAPSULECTOMY AND LEFT BREAST EXCHANGE WAS PERFORMED SURGICAL LOG REPORTS THERE WAS 200 CC SEROUS FLUID UNDER PRESENT ON LEFT SEROLOGY + ALCL PATHOLOGY + ALCL CYTOLOGY REPORT DATED B6 2016 STATES LEFT BREAST FLUID HIGHLY ATYPICAL LYMPHOCYTES PRESENT CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA ALK NEGATIVE COMMENT THE MORPHOLOGY OF THE HIGHLY ATYPICAL CELLS SEEN IN SPECIMEN B IS SIMILAR TO THAT OF SPECIMEN A THESE CELLS DEMONSTRATE STAINING WITH CD30 THE OVERALL FEATURES ARE CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA ALK NEGATIVE|STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-469|06/29/2016|||DA|N|R||0HP|FTR|1.0|08/30/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2180804|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5759530|48466889|N|1||MEDWATCH SENT TO FDA ON 06292016 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT IT IS NOT KNOWN IF THE DEVICE WILL BE RETURNED PATIENT DECLINED PERMISSION TO CONTACT DOCTOR FOR FURTHER INFORMATION AT THIS TIME DEVICE LABELING ADDRESSES POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-469|06/29/2016|||DA|N|R||0HP|FTR|1.0|08/30/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2180804|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5759530|50477356|D|1||PATIENT REPORTED LEFT BREAST CAPSULAR CONTRACTURE WITH SEROMA TOTAL CAPSULECTOMY AND LEFT BREAST EXCHANGE WAS PERFORMED SURGICAL LOG REPORTS THERE WAS 200 CC SEROUS FLUID UNDER PRESENT ON LEFT SEROLOGY + ALCL PATHOLOGY + ALCL CYTOLOGY REPORT DATED B6 2016 STATES 62213FT BREAST FLUID HIGHLY ATYPICAL LYMPHOCYTES PRESENT CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA ALK NEGATIVE COMMENT THE MORPHOLOGY OF THE HIGHLY ATYPICAL CELLS SEEN IN SPECIMEN B IS SIMILAR TO THAT OF SPECIMEN A THESE CELLS DEMONSTRATE STAINING WITH CD30 THE OVERALL FEATURES ARE CONSISTENT WITH ANAPLASTIC LARGE CELL LYMPHOMA ALK NEGATIVE62282|STYLE 115 SILICONE GEL FILLED BREAST IMPLANT|115-469|06/29/2016|||DA|N|R||0HP|FTR|1.0|08/30/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2180804|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6176648|62440610|D|1||LITERATURE ARTICLE Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ ARTICLE REPORTED IN CASES OF Â¿INFILTRATIVE I-ALCLÂ¿ SURVIVAL RATE WAS 525 A B6 PATIENT WHO WAS IMPLANTED WITH A TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE CHART ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED A LEFT SEROMA AND MASS ARTICLE ADDITIONALLY STATES PATIENT 11 Â¿PRESENTED WITH ERYTHEMATOUS SKIN ERUPTION TREATMENT REPORTED AS IMPLANT REMOVAL AND CYCLOPHOSPHAMIDE ADRIAMYCIN VINCRISTINE AND PREDNISONE 6 CURES CHOP OR CHOP-LIKE FOLLOW-UP REVEALED THAT THIS PATIENT DIED FROM LYMPHOMA PROGRESSION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176648|62440609|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 B4 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF DEATH LYMPHOMA ALCL SEROMA LUMP AND ERYTHEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION ERYTHEMA MAY ALSO OCCUR AS A NORMAL RESPONSE TO EXPANSION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5901883|52941730|N|1||B4 THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING DEVICE INFORMATION HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN BREAST SENSATION SEROMA NECROSIS AND LYMPHADENOPATHY |UNK SALINE IMPLANT|UNK SALINE IMPLANT|08/24/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6106949|60072475|N|1||THE EVENTS OF LYMPHOMA AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS IT IS CURRENTLY UNKNOWN IF THE EXPLANTED DEVICE WILL BE RETURNED AS THE REPORTER HAS CONFIRMED THAT DEVICE WAS SENT TO PATHOLOGY NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE HISTORY RECORD DHR REVIEW REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM B4 WAS VERIFIED AND THERE WAS NOT ANY SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS IN ADDITION DHR FOR SHELL RUN NUMBER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING SHELL FABRICATION PROCESS ALL SHELLS WERE REVIEWED AS PART OF THE SHELL FABRICATION OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT FABRICATION MET THE REQUIRED SPECIFICATIONS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANS AND OTHER MANUFACTURERS BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL IMPLANT PALPABILITYVISIBILITY HEMATOMASEROMA|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-FF125-375|11/16/2016||||*|*||0HP|FTR|1.0|11/08/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1359584|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6141438|61344363|D|1||REPORTED EVENTS OF Â¿ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ AND Â¿LATE SEROMAÂ¿ OCCURRING WITH A MCGHAN STYLE 153 LUMEN DEVICE WAS FOUND WITHIN THE JOURNAL ARTICLE Â¿LONG-TERM OUTCOMES WITH THE MCGHAN STYLE 153 DUAL-LUMEN BREAST IMPLANT IMPLICATIONS FOR FUTURE IMPLANT DESIGNÂ¿ IN JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY 69 02 JUL 2016 PP 1211-1217 ARTICLE STATES Â¿ONE CASE 075 OF ANAPLASTIC LARGE CELL LYMPHOMA WAS DIAGNOSED AFTER THE DEVELOPMENT OF A LATE SEROMA TEN YEARS POST-OPERATIVELYÂ¿ NO FURTHER INFORMATION IS PROVIDED AS PATHOLOGICAL MARKERS CONFIRMING ALCL HAVE NOT BEEN RECEIVED THE EVENT WILL BE CAPTURED AS LYMPHOMA THE AFFECTED SIDE WAS NOT SPECIFIED|STYLE 153 SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 153|12/02/2016||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6141438|61344362|N|1||ARTICLE CITATION LONG-TERM OUTCOMES WITH THE MCGHAN STYLE 153 DUAL-LUMEN BREAST IMPLANT IMPLICATIONS FOR FUTURE IMPLANT DESIGNÂ¿ BY DC HAMMOND AND WP SCHMITT PUBLISHED IN J PLAST RECONSTR AESTHET SURG ELECTRONICALLY PUBLISHED 07022016 FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME THE EVENTS OF LYMPHOMA AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE LABELING POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SILICONE GEL FILLED BREAST IMPLANT SURGERY INCLUDE IMPLANT RUPTURE CAPSULAR CONTRACTURE REOPERATION IMPLANT REMOVAL PAIN CHANGES IN NIPPLE AND BREAST SENSATION INFECTION SCARRING ASYMMETRY WRINKLING IMPLANT DISPLACEMENTMIGRATION IMPLANT PALPABILITYVISIBILITY BREASTFEEDING COMPLICATIONS HEMATOMASEROMA IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL - ATTACHMENT ARTICLE - LONG-TERM OUTCOMESPDF|STYLE 153 SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 153|12/02/2016||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5962723|55115726|N|1||MEDWATCH SENT TO FDA ON 09202016 ALLERGAN HAS INITIATED AN INVESTIGATION INTO THIS LATE REPORT B4 ARTICLE CITATION FIRST CASE REPORT IN MEXICO AND LATIN AMERICA OF ANAPLASTIC LARGE CELL LYMPHOMA IN A PATIENT WITH MAMMARY IMPLANTS TORRES-RIVERO CESAR RAMOS-GALLARDO GUILLERMO NAMBO-LUCIO M DE JESÃS VAQUERO-PÃREZ M MAR CIR PLÃST IBEROLATINOAM-VOL 42 Â¿ NO 2 APRIL Â¿ MAY Â¿ JUNE 2016  P 175-180 THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING SERIAL NUMBER LOT NUMBER IMPLANTEXPLANT DATE IMPLANTINGEXPLANTING PHYSICIAN PATIENT DATE OF BIRTH DEVICE RETURN STATUS AND DEVICE RELATIONSHIP OF THE REPORTED EVENTS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL PAIN OF VARYING INTENSITY AND LENGTH OF TIME MAY OCCUR AND PERSIST FOLLOWING BREAST IMPLANT SURGERY PATIENTS SHOULD BE ADVISED TO CONTACT THEIR SURGEON IF THERE IS SIGNIFICANT PAIN OR IF PAIN PERSISTS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|09/20/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5962723|55115727|D|1||THE FOLLOWING JOURNAL ARTICLE WAS REVIEWED Â¿FIRST CASE REPORT IN MEXICO AND LATIN AMERICA OF ANAPLASTIC LARGE CELL LYMPHOMA IN A PATIENT WITH MAMMARY IMPLANTS THE AUTHORS REPORT TO OUR KNOWLEDGE WE PRESENT THE FIRST CASE REPORTED BY A PLASTIC SURGEON IN MEXICO AND LATIN AMERICA IN A PATIENT WITH HISTORY OF BREAST AUGMENTATION AND UNILATERAL ASYMMETRY DUE TO LATE SEROMA AFTER 2 UNSUCCESSFUL PUNCTURES REMOVAL OF THE BREAST IMPLANT AND CAPSULECTOMY WERE SCHEDULED DIAGNOSIS OF ALCL WAS CONFIRMED IN THE PERIPROSTHETIC FLUID DEVICE DETAILS SPECIFIED AS PLACEMENT OF 290 CC TEXTURED COHESIVE GEL ANATOMICAL IMPLANTS MCGHAN MEDICAL CORPORATION B6 ADDITIONAL EVENT DETAILS INCLUDE A YEAR FROM THE PROCEDURE THE PATIENT PRESENTED DISCOMFORTS AND EDEMA IN THE RIGHT BREAST WHICH CEASED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AT THE DOSE OF 120 MG A DAY FOR 7 DAYS LATER PROGRESS WAS SATISFACTORY UNTIL 2015 THAT IS 5 YEARS AFTER THESE SYMPTOMS AND 6 FOLLOWING THE INTERVENTION WHEN THE PATIENT PRESENTED AGAIN DISCOMFORTS AND EDEMA IN THE RIGHT BREAST IMAGING STUDIES WERE PERFORMED ON PATIENT THROUGH MAGNETIC RESONANCE MR DOCUMENTING THE PRESENCE OF ABUNDANT PERIPROSTHETIC FLUID IN THE AFFECTED BREASTÂ¿ Â¿THE SAMPLE WAS SENT FOR CYTOLOGICAL STUDY WHICH INFORMED CHRONIC MASTITIS WITH GRANOMALOTOUS REACTION AND NEGATIVE CULTURE HOWEVER THE GRADUAL INCREASE OF THE BREAST CONTINUED IN THE FOLLOWING MONTHS WHERE 2 NEW PUNCTURES WERE PERFORMED UNSUCCESSFULLY IN THE SECOND PUNCTURE FLUID WAS SENT AGAIN FOR MALIGNANCY STUDY BEFORE THE SUSPECTED POSSIBLE DUCTAL CARCINOMAÂ¿ Â¿THE PATIENT WAS AGAIN ASSESSED THROUGH ULTRASOUND ASSISTED IMAGING STUDIES AND MR WITHOUT FINDING ANOMALIES IN THE MAMMARY PARENCHYMA REASON WHY IT WAS OPTED FOR WITHDRAWAL OF THE IMPLANT WITH CAPSULECTOMY AND EXAMINATION OF THE BREAST TISSUE THROUGH TRANSOPERATIVE BIOPSYÂ¿ THE PATIENT HAS REJECTED ANY FURTHER TREATMENT AS THEY ARE CURRENTLY ASYMPTOMATIC|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|09/20/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5846890|51223996|D|1||ACCORDING TO THE INFORMATION PROVIDED THE PATIENT EXPERIENCED A RIGHT RUPTURE ALONG WITH ANAPLASTIC LARGE CELL LYMPHOMA ALCL BASED ON THE RESULTS OF THE LABORATORY EVALUATION PE IDENTIFIED THREE RENTS IN THE SHELL OF THE DEVICE THE FIRST RENT MEASURED APPROXIMATELY 3CM IN LENGTH THE TWO ADDITIONAL RENTS BOTH MEASURED APPROXIMATELY  1CM IN THE SHELL OF THE DEVICE AREAS OF SHELL WEAR WERE ALSO OBSERVED IN THE SHELL ALTHOUGH THE ROOT CAUSE OF THE RENTS COULD NOT BE DETERMINED SHELL WEAR SUGGEST IN-VIVO FOLDING OR CREASING OF THE DEVICE NO OTHER ANOMALIES WERE OBSERVED BREAST IMPLANTS ARE NOT LIFETIME DEVICES RUPTURE CAN OCCUR AT ANY TIME AFTER IMPLANTATION RUPTURE IS A KNOWN COMPLICATION ASSOCIATED WITH THESE DEVICES AND IS REFERENCED IN OUR PIDS BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINS LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ACCORDING TO THE FDA THE INCIDENCE OF ALCL IN PATIENTS WITH BREAST IMPLANTS IS A VERY SMALL FRACTION OF THE 5-10 MILLION WOMEN WHO HAVE RECEIVED BREAST IMPLANTS WORLDWIDE AN INVESTIGATION OF THE DEVICE HISTORY RECORD REVEALED NO IRREGULARITIES A REVIEW OF THE NC SYSTEM AND COMPLAINT DATABASE REVEALED NO OTHER COMPLAINTS OF THIS TYPE ASSOCIATED WITH LOT 5746123 THE MAIN SYMPTOMS OF ALCL IN WOMEN WITH BREAST IMPLANTS ARE LATE ONSET PERSISTENT SWELLING AND PAIN IN THE VICINITY OF THE IMPLANT AND PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL MENTOR CONCURS WITH FDAS POSITION THAT BECAUSE THE RISK OF ALCL APPEARS VERY SMALL FDA BELIEVES THAT THE TOTALITY OF EVIDENCE CONTINUES TO SUPPORT A REASONABLE ASSURANCE THAT FDA-APPROVED BREAST IMPLANTS ARE SAFE AND EFFECTIVE WHEN USED AS LABELED ANAPLASTIC LARGE CELL LYMPHOMA ALCL IS A KNOWN COMPLICATION ASSOCIATED WITH THESE DEVICES AND IS REFERENCED IN OUR PIDS|MEMORY GEL SILTEX ROUND MODERATE PLUS PROFILE MAMMARY PROSTHESIS|354-4507|08/04/2016||06/28/2016||R|Y||0HP|FTR|1.0||BREAST IMPLANT||5746123|3041 SKYWAY CIRCLE NORTH||IRVING|US|MENTOR WW LLC|75038|TX|75038||||True
5896122|52746118|N|1||MEDWATCH SENT TO FDA ON 08232016 THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING DEVICE SERIAL NUMBER IMPLANTEXPLANT DATE IMPLANTINGEXPLANTING PHYSICIAN PATIENT NAME PATIENT DATE OF BIRTH DEVICE RETURN STATUS PATHOLOGICAL MARKERS AND DEVICE RELATIONSHIP OF THE REPORTED EVENT HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|08/23/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6051104|58191673|D|1||ANAPLASTIC LARGE CELL LYMPHOMA RELATED TO BREAST IMPLANT ELEVEN YEARS HISTORY OF BREAST RECONSTRUCTION SALINE TEXTURED IMPLANT DEVELOPED SEROMA IN THE LAST YEAR|BREAST IMPLANT||10/21/2016||||N|*||I|FWM|1.0||BREAST IMPLANT|||UNK||UNK||UNK|||||||True
6011835|56821577|D|1||THROUGH ALLERGANÂ¿S LITERATURE REVIEW OF RECENT JOURNAL ARTICLES WE RECEIVED THE FOLLOWING ARTICLE FROM MEDICAL SAFETY Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN AUSTRALIA AND NEW ZEALAND Â¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ TABLE 5 Â¿TNM STAGING OF PATIENTS IN ANZ COHORTÂ¿ IN THE ARTICLE REPORTS AN ADDITIONAL THREE OCCURRENCES OF DEATH ONE CASE OF Â¿DEATH  MASS WITH METASTATIC DISEASE TO MULTIPLE LYMPH NODESÂ¿ MANUFACTURER COULD NOT BE SPECIFIED AND ARTICLE STATES Â¿BIOCELL ALLERGANINAMEDMCGHAN ACCOUNTED FOR 571 OF IMPLANTS IN THIS SERIES THE ARTICLE DOES NOT PROVIDE IMPLANTING EXPLANTING PHYSICIAN INFORMATION DEVICE SERIAL OR LOT INFORMATION OR SIDES OF ALCL DIAGNOSIS ARTICLE STATES Â¿ALL PATIENTS UNDERWENT TOTAL CAPSULECTOMY AND REMOVAL OF IMPLANTS BOTH ON DISEASED AND NON-DISEASED SIDE ALL TUMORS WERE CD30 POSITIVE AND ALK NEGATIVEÂ¿|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6011835|56821576|N|1||MEDWATCH SENT TO FDA ON 10072016 ARTICLE CITATION Â¿BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN AUSTRALIA AND NEW ZEALAND Â¿ HIGHER RISK FOR MACROTEXTURED IMPLANTS SUPPORTS A BACTERIAL ETIOLOGYÂ¿ A LOCH-WILKINSON KJ BEATH RJW KNIGHT WLF WESSELS M MAGNUSSON T PAPADOPOULOS T CONNELL J LOFTS M LOCKE I HOPPER R COOTER K VICKERY PA JOSHI HM PRINCE  AK DEVA THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL -|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|10/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176965|62446268|D|1||ARTICLE Â¿Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿Â¿ REPORTED A PATIENT DIAGNOSED WITH ALCL ARTICLE REPORTED CASES OF BOTH Â¿IN SITU I-ALCLÂ¿ AND Â¿INFILTRATIVE I-ALCLÂ¿ IT IS UNKNOWN WHICH TYPE OF CASE THIS IS ARTICLE REPORTS A B6 PATIENT WHO WAS IMPLANTED WITH A RIGHT SIDE TEXTURED SILICONE IMPLANT DEVICE MANUFACTURER UNKNOWN THE ARTICLE ADDITIONALLY PROVIDES THAT PATIENT EXPERIENCED SEROMA AND DISRUPTED IMPLANT TREATMENT REPORTED AS IMPLANT REMOVAL AND DEXAMETHASONE HIGH-DOSE ARACYTINE OXALIPLATIN DHAOX FOLLOW-UP FOUND NO EVIDENCE OF DISEASE|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176965|62446267|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6153187|61697755|N|1||B4 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH BREAST IMPLANT SURGERY INCLUDE REOPERATION IMPLANT REMOVAL INFECTION HEMATOMASEROMA BACTERIAL BIOFILM INFECTION DETECTED IN BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE-CELL LYMPHOMAÂ¿ 137 6 1659-1669 BY HONGHUA HU PHD KHALID JOHANI AHMAD ALMATROUDI KAREN VICKERY PHD BVSC BRUCE VAN NATTA MD MARSHALL E KADIN MD GARRY BRODY MD MARK CLEMENS MD CHAN YOON CHEAH MD STEPHEN LADE MD PREETI AVINASH JOSHI MDPHD H MILES PRINCE MDPHD ANAND K DEVA BSCMED MBBS MS PUBLISHED JUNE 2016|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/07/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5350320|35251015|D|1||ALCL CASE REPORT B6 WOMAN WHO UNDERWENT BREAST IMPLANTATION 8-9 YEARS AGO IN CENTRAL ASIA AND THEN AUGMENTATION IN 2011 SHE FIRST NOTICED SWELLING AND PAIN AROUND B6 2015 OF HER RIGHT BREAST WHICH WAS FOUND TO HAVE A FLUID COLLECTION AT B6 ED AND WAS REFERRED TO B6 FOR FURTHER WORKUP MAMMOGRAPHY B6 2015 WAS BIRADS 2 SHOWING ONLY FLUID COLLECTIONS AS NOTED ON US AT B6 FLUID ANALYSIS FROM ASPIRATION B6 2015 SHOWED BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA|SILICONE BREAST IMPLANT||01/04/2016||||Y|*||0HP|FTR|1.0||SILICONE BREAST IMPLANT|||||||nan|||||||True
5912356|53436714|N|1||IN RESPONSE TO FDA REPORT NUMBER B4 THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING PHYSICIAN INFORMATION AND PERMISSION TO CONTACT HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK SALINE IMPLANT|UNK SALINE IMPLANT|08/29/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5697379|46493992|N|1||MEDWATCH SENT TO THE FDA ON 06032016 LITERATURE CITATION HART ALEXANDRA M LECHOWICZ MARY JO PETERS KENDALL K HOLDEN JEANNINE CARLSON GRANT W Â¿BREAST IMPLANTÂ¿ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA REPORT OF 2 CASES AND REVIEW OF THE LITERATUREÂ¿ AESTHETIC SURGERY JOURNAL 2014 VOL 346 884-894 FIRST PUBLISHED ONLINE 01AUG2014 THE CORRESPONDING AUTHOR HAS DECLINED TO PROVIDE ALLERGAN FURTHER INFORMATION REGARDING EVENT PRODUCT PRODUCT RETURN OR PATIENT DETAILS THE EVENTS OF SEROMA AND ALCL ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE LABELING BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL POTENTIAL ADVERSE EVENTS THAT MAY OCCUR WITH SALINE-FILLED BREAST IMPLANT SURGERY INCLUDE REOPERATION PAIN WRINKLING ASYMMETRY IMPLANT PALPABILITYVISIBILITY IMPLANT REMOVAL CAPSULAR CONTRACTURE CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT DISPLACEMENTMIGRATION IMPLANT DEFLATION SCARRING INFECTION HEMATOMASEROMA BREASTFEEDING COMPLICATIONS IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS AND LYMPHADENOPATHY|UNK SALINE IMPLANT|UNK SALINE IMPLANT|06/03/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5697379|46493993|D|1||THE FOLLOWING JOURNAL ARTICLE WAS REVIEWED Â¿BREAST IMPLANTÂ¿ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA REPORT OF 2 CASES AND REVIEW OF THE LITERATUREÂ¿ THE AUTHORS REPORTED THAT A PATIENT HAD UNDERGONE BILATERAL BREAST AUGMENTATION 16 YEARS EARLIER 425-CC TEXTURED ROUND SALINE IMPLANTS WERE PLACED SUBGLANDULARLY THE MANUFACTURER OF THE IMPLANTS WAS NOT KNOWN PATIENT PRESENTED WITH ACUTE ENLARGEMENT OF THE RIGHT BREAST ULTRASONOGRAPHY SHOWED A FLUID COLLECTION AROUND THE RIGHT INTACT BREAST IMPLANT ULTRASOUND-GUIDED FLUID ASPIRATION SHOWED CD30+ ALKÂ¿ ALCL THE CELLS WERE POSITIVE FOR CD45 CD5 CD4 BUT FAILED TO EXPRESS CD34 CD20 CD68 OR CD10 THE PATIENT UNDERWENT BILATERAL CAPSULECTOMIES AND IMPLANT REMOVAL APPROXIMATELY TWO MONTHS AFTER PRESENTATION IMMEDIATELY AFTER REMOVAL THE IMPLANTS AND CAPSULES WERE EXAMINED FOR MALIGNANCY FLOW CYTOMETRY CYTOGENETIC ANALYSIS AND IMMUNOHISTOCHEMICAL STAINING FAILED TO IDENTIFY ANY UNIQUE CELL POPULATIONS THE PATIENT DID NOT RECEIVE ANY ADDITIONAL TREATMENT AND WAS FREE OF DISEASE AT PATIENTS 15-MONTH FOLLOW-UP VISIT PATIENT CONTINUES TO BE MONITORED CLOSELY BECAUSE OF CHRONIC PAIN IN THE AFFECTED BREASTÂ¿|UNK SALINE IMPLANT|UNK SALINE IMPLANT|06/03/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5725674|47409581|N|1||MEDWATCH SENT TO FDA ON 06152016 B4 THESE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT DEVICE SERIAL OR LOT NUMBER WAS NOT AVAILABLE EXACT IMPLANT DATE COULD NOT BE SPECIFIED THE DEVICE WILL NOT BE RETURNED DEVICE LABELING ADDRESSES BASED ON INFORMATION REPORTED TO FDA AND FOUND IN MEDICAL LITERATURE A POSSIBLE ASSOCIATION HAS BEEN IDENTIFIED BETWEEN BREAST IMPLANTS AND THE RARE DEVELOPMENT OF ANAPLASTIC LARGE CELL LYMPHOMA ALCL A TYPE OF NON-HODGKINÂ¿S LYMPHOMA WOMEN WITH BREAST IMPLANTS MAY HAVE A VERY SMALL BUT INCREASED RISK OF DEVELOPING ALCL IN THE FLUID OR SCAR CAPSULE ADJACENT TO THE IMPLANT ALCL HAS BEEN REPORTED GLOBALLY IN PATIENTS WITH AN IMPLANT HISTORY THAT INCLUDES ALLERGANÂ¿S AND OTHER MANUFACTURERSÂ¿ BREAST IMPLANTS YOU SHOULD CONSIDER THE POSSIBILITY OF ALCL WHEN YOU HAVE A PATIENT WITH LATE ONSET PERSISTENT PERI-IMPLANT SEROMA IN SOME CASES PATIENTS PRESENTED WITH CAPSULAR CONTRACTURE OR MASSES ADJACENT TO THE BREAST IMPLANT WHEN TESTING FOR ALCL COLLECT FRESH SEROMA FLUID AND REPRESENTATIVE PORTIONS OF THE CAPSULE AND SEND FOR PATHOLOGY TESTS TO RULE OUT ALCL IF YOUR PATIENT IS DIAGNOSED WITH PERI-IMPLANT ALCL DEVELOP AN INDIVIDUALIZED TREATMENT PLAN IN COORDINATION WITH A MULTI-DISCIPLINARY CARE TEAM BECAUSE OF THE SMALL NUMBER OF CASES WORLDWIDE THERE IS NO DEFINED CONSENSUS TREATMENT REGIMEN FOR PERI-IMPLANT ALCL|UNK SALINE IMPLANT|UNK SALINE IMPLANT|06/15/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5725674|47409582|D|1||VOLUNTARY MEDWATCH 5061844 REPORTED ALCL BREAST IMPLANT ASSOCIATED SIDE UNSPECIFIED DEVICE DESCRIPTION PROVIDED AS MCGHAN TEXTURED BREAST IMPLANT SALINE FOLLOW-UP WITH HEALTH PROFESSIONAL REPORTS Â¿AUGMENTATION OF MCGHAN TEXTURED SALINE IMPLANT 360 CC IMPLANTED SUB MUSCULARÂ¿ ULTRASOUND FOUND Â¿CONTIGUOUS WITH THE MEDIAL ASPECT OF THIS PATIENTÂ¿S LEFT BREAST IMPLANT THERE APPEARS TO BE AN ELLIPTICAL FLUID COLLECTIONÂ¿AREAS OF DENSE SHADOWING ARE SEEN WITHIN THE TWELVE OÂ¿CLOCK RAY OF THE LEFT BREAST THESE CORRESPOND WITH PREVIOUSLY IDENTIFIED BENIGN APPEARING CALCIFICATIONS WITHIN THIS REGION OF THE LEFT BREASTÂ¿ PHYSICIAN REFERRAL NOTE DESCRIBES A Â¿BREAST MASSÂ¿ THAT THE PHYSICIAN BELIEVES IS A Â¿INFLAMMATORY RESPONSE TO A BREAST IMPLANT IN THE LEFT BREASTÂ¿ ULTRASOUND OF THE LEFT BREAST STATES Â¿PALPABLE LUMP IN THE LEFT BREAST SWELLINGITCHING ALONG THE SURGICAL SCARÂ¿ FINDINGS STATE Â¿SMALL BENIGN OIL CYSTS AGAIN IMAGED AT THE 1100 AND 1200 POSITIONS OF THE LEFT BREAST BENIGN THERE IS FLUID ABOUT THE PERIPHERY OF THE IMPLANTÂ¿ OPERATIVE REPORT STATES Â¿PATIENT WHO PRESENTED TO MY OFFICE WITH SWELLING AND DISCOMFORT OF THE LEFT BREAST PATIENT WAS DIAGNOSED WITH A LEFT BREAST SEROMA WE SENT IT FOR CULTURE AND CYTOLOGY BOTH OF WHICH WERE NEGATIVEÂ¿ DEVICE WAS REMOVED AND NOT REPLACED PATIENT HAD Â¿CAPSULECTOMY AND BIOPSYÂ¿ IN ADDITION TO CHEMOTHERAPY ADDITIONAL OPERATIVE REPORT FOLLOWING PRIOR DEVICE REMOVAL DETAILS REMOVAL OF A Â¿LEFT BREAST MASS CHEST WALL MASSÂ¿ DESCRIBED AS Â¿VERY LARGE IT WAS OVER 3 CM IT WAS VERY HARD FAIRLY WELL CIRCUMSCRIBEDÂ¿ SURGICAL PATHOLOGY REPORT NOTES Â¿LARGE CELLS ARE POSITIVE FOR CD30Â¿NEGATIVE FOR ALK1Â¿ DIAGNOSIS PROVIDED AS Â¿BREAST IMPLANT Â¿ ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ ALCL DIAGNOSIS OCCURRED APPROXIMATELY 5 MONTHS AFTER EXPLANT SURGERY|UNK SALINE IMPLANT|UNK SALINE IMPLANT|06/15/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5821949|50447305|D|1||A B6 WOMAN WITH BREAST IMPLANTS ADMITTED TO OUR DEPARTMENT DUE TO SUDDEN UNILATERAL RIGHT BREAST ENLARGEMENT AND DISCOMFORT BREAST AUGMENTATION WAS DONE 11 YEARS PREVIOUSLY WITH SUBGLANDULAR PLACEMENT OF ALLERGAN TEXTURIZED PROSTHESES THROUGH THE INFRAMAMMARY APPROACH THE BREAST AUGMENTATION WAS DONE ELSEWHERE DESPITE OUR EFFORTS TO GET INFO ABOUT THE IMPLANT FROM THE PLASTIC SURGEON THAT HAD IMPLANTED THE DEVICE WE HAVE NO SERIAL NUMBER OR PRODUCT CODE THE PT HAD NO FURTHER INFO AN ULTRASOUND AND MAMMOGRAPHY IMAGES WHICH WERE DONE 4 MONTHS EARLIER WERE NORMAL THE WOMAN DENIED ANY HISTORY OF BREAST TRAUMA PRODROMAL ILLNESS PAIN PURULENT DRAINAGE LOCAL SIGN OF INFECTION NIGHT SWEATS WEIGHT LOSS POOR APPETITE OR FEVER AT PHYSICAL EXAMINATION BREAST ASYMMETRY WAS OBVIOUS THE RIGHT BREAST WAS SWOLLEN FIRM AND SENSITIVE TO DEEP PALPATION THE LEFT BREAST WAS NORMAL NO SIGN OF LOCAL INFECTION WERE OBSERVED IN B6 2015 AN ANAPLASTIC LARGE CELL LYMPHOMA WAS FOUND IN THE PERIPROSTHETIC FLUID AND FIBRINOID DEPOSITS WITHIN THE PERIPROSTHETIC CAPSULE OF THE RIGHT BREAST THE LEFT BREAST WAS WITHOUT ANY CLINICAL LAB IMAGING OR HISTOPATHOLOGICAL EVIDENCE OF DISEASE ON B6 2015 THE PT UNDERWENT BILATERAL TOTAL CAPSULECTOMY AND IMPLANT REMOVAL NOW MORE THAN A YEAR AFTER THE PT IS DISEASE FREE CT PET SCANS INCLUDING A RECENT SCAN DO NOT SHOW ANY SIGNS OF THE LYMPHOMA|ALLERGAN SILICONE TEXTURED BREAST IMPLANT||07/24/2016||||Y|*||0HP|FTR|1.0||ALLERGAN SILICONE TEXTURED BREAST IMPLANT|||||||ALLERGAN|||||||True
